第六届中国医药创新与投资大会

China BioMed Innovation and Investment Conference

CBIIC

路演项目审核专家委员会

Expert Review Committee

蒋华良
JIANG Hualiang

中国科学院院士、中国药促会 2015-2016 年度会长
中国科学院上海药物研究所研究员
Academician of Chinese Academy of Sciences, 2015-2016 Annual Chairman of PhIRDA, Professor of Shanghai Institute of Materia Medica, Chinese Academy of Sciences

蒋建东
JIANG Jiandong

中国药促会 2017-2018 年度会长
中国医学科学院药物研究院院长
2017-2018 Annual Chairman of PhIRDA, President of Institutes of Pharmaceutical Sciences, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College

李　佳
LI Jia

中国科学院上海药物研究所所长
新药研究国家重点实验室主任
Director of Shanghai Institute of Materia Medica, Chinese Academy of Sciences
Director of State Key Laboratory of Drug Research

石远凯
SHI Yuankai

中国药促会第二届药物临床研究专业委员会副主任委员
中国医学科学院肿瘤医院副院长
Vice-Chairman of 2rd PhIRDA Clinical Trial Research Specialty Committee
Vice President of Cancer Hospital, Chinese Academy of Medical Sciences

霍　勇
HUO Yong

中国药促会心血管药物临床研究专业委员会主任委员
北京大学第一医院心内科及心脏中心主任
Chairman of PhIRDA Clinical Research on Cardiovascular Drugs Specialty Committee, Director of Cardiology and Heart Center, Peking University First Hospital

李　进
LI Jin

中国药促会抗肿瘤药物临床研究专业委员会主任委员
同济大学附属东方医院肿瘤医学部主任
Chairman of PhIRDA Clinical Research on Oncology Drugs Specialty Committee
Director of Department of Medical Oncology, Shanghai East Hospital, Tongji University

纪立农
JI Linong

中国药促会糖尿病与代谢性疾病药物临床研究专业委员会主任委员
北京大学人民医院内分泌科主任
Chairman of PhIRDA Clinical Research on Diabetes and Metabolic Diseases Specialty Committee
Director of Endocrinology and Metabolism Department, Peking University People's Hospital

陈晓光
CHEN Xiaoguang

中国药促会药物研发专业委员会委员
中国医学科学院药物研究所药理室主任
Member of PhIRDA Drug R&D Specialty Committee
Director, Department of Pharmacology, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College

何如意
HE Ruyi

中国药促会国际创新药物监管专业委员会主任委员
荣昌生物首席医学官、国投创新医疗健康首席科学家
前国家食品药品监督管理总局药品审评中心首席科学家
Chairman of PhIRDA International Regulatory Science Specialty Committee,CMO of RemeGen, CMO of SDIC,
Former Chief Scientist of CDE, CFDA

胡　欣
HU Xin

中国药促会医药政策专业委员会主任委员
北京医院药学部主任药师
Chairman of PhIRDA Medicinal Policy Specialty Committee
Chief Pharmacist, Department of Pharmacy, Beijing Hospital

崔一民
CUI Yimin

中国药促会药物临床研究专业委员会主任委员
北京大学临床药理研究所所长
Chairman of PhIRDA Clinical Trial Research Specialty Committee Director of Institute of Clinical Pharmacology, Peking University, PUICP

杨大俊
YANG Dajun

中国药促会药物研发专业委员会主任委员
亚盛医药董事长兼 CEO
Chairman of PhIRDA Drug R&D Specialty Committee,
Chairman of the Board & CEO of Ascentage Pharma

王印祥
WANG Yinxiang

中国药促会药物研发专业委员会副主任委员
加科思董事长兼 CEO
Vice-Chairman of PhIRDA Drug R&D Specialty Committee
Chairman of the Board of Jacobio Pharma

房健民
FANG Jianmin

中国药促会药物研发专业委员会副主任委员
荣昌生物 CEO 兼首席科学官
Vice-Chairman of PhIRDA Drug R&D Specialty Committee CEO & CSO of RemeGen

关于大会
ABOUT CBIIC

大会将聚焦并探讨我国医药产业及全球医药研发新动态、投融资领域热点话题。为投资人和路演汇报人提供面对面交流洽谈，实现零距离无障碍沟通，深度对话碰撞出更多商机，创造更多商业价值。

2021 CBIIC will focus on China’s pharmaceutical industry, explore the new trends of global pharmaceutical R&D and hot issues in investment and financing circle. In this event, participants, investors and roadshow speakers will have face-to-face communication and negotiation to seek potential opportunities and commercial values for further collaboration.

目 录 · CONTENTS



参会企业和人数逐年增长
Participants and companies are increasing every year



大会简介 »»»

Introduction of CBIIC

中国医药创新与投资大会（以下简称“创投大会”）是由中国医药创新促进会(以下简称“中国药促会”)于2016年发起创办的医药界与投资界高端对话平台。创投大会始终坚持以“推动社会资本与医药创新相结合，提高医药创新能力”为宗旨，聚焦产业政策、全球医药研发趋势和投融资动向，为业界领袖、专家、学者以及国内外医药创新企业和投资人，搭建权威、专业、多维度的对话沟通平台，深入探讨创新发展新趋势、共商投资合作新战略。

2016-2020年中国药促会先后携手中国证券业协会、中国医疗器械行业协会、香港交易所、中国医院协会、蓝迪国际智库、艾美达医药咨询等机构成功举办了五届创投大会，累计参会人员超过12000余人次，4900余家国内外医药相关企业、投资机构参与，500余项国内外创新项目通过路演展示，1对1洽谈邀约累计收到15000次洽谈请求，达成1600场商务洽谈，被誉为“亚太地区最受关注的医药创新与投资合作平台”。

为推动新时代、新格局下全球医药创新发展和全球资本与医药创新的深入合作，促进医药创新活力充分释放与创新成果及时、高效转化，共话医药创新发展与资本融合新未来，第六届创投大会定于2021年9月25日−27日在苏州工业园区举办。

一、贯彻推动医药创新理念，多种专场设置满足不同参会者需求

第六届创投大会将继续贯彻打通医药创新投融资渠道，围绕医药创新热点问题，深度聚焦科技创新成果和全球投融资新动态、新趋势，分享我国最新医药产业政策，全面探讨全球医药创新发展趋势。大会设置多个热门领域路演专场，开设临床数据全球首发、大数据+智慧医疗、AI+生物医药以及投资人经验分享、融资并购和医药政策论坛等近二十场业内翘首以盼、特色鲜明的主题论坛。针对相关话题展开座谈，以拓宽资本对接创新领域范围，为更多创新项目寻求融资搭建高水准对话平台，助力我国医药行业核心创新能力提升，推动创新成果走向国际。

二、国家权威机构全力支持，全球顶尖机构深入合作

本届创投大会将继续与相关政府部门、国内外知名机构深入合作，邀请行业领袖、顶级专家学者热议全球医药创新及投融资政策和发展趋势，助力我国医药产业创新转化能力提升。

历届大会均得到了国内外权威机构的大力支持，包括：中国医学科学院、中国中医科学院等学术权威机构；加拿大、荷兰、澳大利亚等驻华使领馆；美国癌症研究基金会、日本制药工业协会等国际组织；香港中资证券业协会、加拿大多伦多证券交易所等国际金融机构。此外，摩根大通（J.P. Morgan）连续多届作为独家国际金融机构赞助商为大会提供全方位鼎力支持。

三、商务洽谈邀约，深度对话加速项目与资本零距离

为促进国内外医药创新与投资界的有效交流与精准合作，增强投融资精准对接，本届创投大会将持续为参会企业提供商务洽谈在线邀约服务，搭建零距离沟通平台——“一对一企业商务洽谈邀约系统”。投资人和路演汇报人可通过邀约系统寻找潜在客户、合作伙伴，在线向对方发起邀请，与会期间可与对方实现面对面洽谈，实现零距离无障碍沟通，深度对话碰撞出更多商机，实现更多商业价值。

四、国内外媒体积极关注，见证创新与投资的融合

自 2016 年以来，创投大会得到包括国际顶级学术杂志《Nature》、人民网、健康报、中国医药报、国际金融报、医药经济报在内的数十家国内外著名杂志和权威传统媒体支持；同时吸引了包括 PharmaBoardroom、界面、36 氪、财新传媒等新媒体和医药财经类行业媒体参会，并对大会实时报道，共同见证创新与投资的融合。

在各方的共同协作与鼎力支持下，创投大会正在逐步成为解读中国医药和投融资政策、展示国内外医药创新成果和引领投资新动向的具有广泛国际影响力、权威性、多元化的成果转化及权威合作交流平台，逐渐成为亚太地区最具影响力的年度品牌盛会。创投大会将继续在社会资本与医药创新发展历程中发挥引领作用，创造更加科学、更富吸引力的医药创新投资环境，为我国经济社会发展、满足临床用药需求、打造健康中国贡献力量。

The China BioMed Innovation and Investment Conference (CBIIC), as an annual grand conference to promote the communication between pharmaceutical industry and investment industry, was established and initiated by China Pharmaceutical Innovation and Research Development Association (PhIRDA) in 2016. To promote the linkage between social capital and pharmaceutical innovation and improve the innovation capability of pharmaceutical industry, the CBIIC focuses on China's latest policies in pharmaceutical industry, explore the new trends of global pharmaceutical R&D and hot issues in investment and financing circle. The CBIIC was built as an authorized, comprehensive, professional and international high level platform for the industry leaders, experts, scholars, domestic and foreign pharmaceutical innovation enterprises and investors to learn the trend of innovation and discuss new investment channels and innovative cooperation strategies.

Established by PhIRDA, the CBIIC was successively co-hosted by Securities Association of China (SAC), China Association for Medical Devices Industry (CAMDI), Hong Kong Exchanges and Clearing Limited (HKEX) and Chinese Hospital Association (CHA), Research and Development International (RDI), iMeta Health Information Consulting Co., Ltd.(iMeta) from 2016 to 2020. By the end of 2020, the CBIIC has attracted over 12,000 participants, 4,900 domestic and foreign pharmaceutical enterprises and investment institutions. Over 500 innovative projects at home and abroad have made roadshows in these events. The One-on-One Partnering System received over 15000 meeting requests and completed1600 business negotiations. The CBIIC received extensive attention and was praised as the "most popular cooperation platform for pharmaceutical innovation and investment in Asian-Pacific region".

To promote the in-depth cooperation between global capital and pharmaceutical innovation in the new era and new pattern, facilitate the release of vitality of pharmaceutical innovation and timely transformation of unmet clinical needs, jointly discuss the future of pharmaceutical innovation and capital, PhIRDA will host the 2021 CBIIC in Suzhou Industrial Park on September 25-27, 2021.

I.Implement the Pharmaceutical Innovative Concept and Set Various Parallel Sessions

The 2021 CBIIC will further open financing channel for pharmaceutical innovation, focus on China's latest policies in pharmaceutical industry, explore the new trends of global pharmaceutical R&D and hot issues in investment and financing circle, share opinions on China's latest pharmaceutical industry policies and the trend of global pharmaceutical innovation. The 2021 CBIIC will include almost 20 fascinating and excellent parallel sessions including Clinical Trial Data Release, WIT MED + Big Data, Artificial Intelligence (AI) + BioMed, and forums for Investors' Experience Sharing, Financing M&A, Latest Drug Policy Sharing, etc. The discussions on related topics will broaden the capital connection and innovation fields, build a high-level dialogue platform for more innovative projects to seek investment and partners, enhance the core innovation capacity of China's pharmaceutical industry, and drive domestic innovation to the global market.

II.Great Supports from National Authorized Institutions & In-depth Cooperation with Global Top Leading Organizations

The 2021 CBIIC will make further cooperation with government departments and well-known institutions around the world, and invite KOLs in pharmaceutical industry and leading experts to discuss policies and trends of global pharmaceutical innovation and financing to improve China's capability on transformation and innovation in pharmaceutical industry.

Since its establishment, the CBIIC has received great support from prestigious institutions in China and around the world, including Chinese Academy of Medical Sciences, China Academy of Chinese Medical Sciences and authorized academic institutions; Canada, the Netherlands, Australia and other embassies and consulates in China; National Foundation for Cancer Research (NFCR), Japan Pharmaceutical Manufacturers Association (JPMA) and international organizations; Chinese Securities Association of Hong Kong (CSAHK), TMX Group Limited and global financing institutions. Moreover, J.P. Morgan supports the CBIIC as the exclusive international financial institution sponsor for several times.

III.One-on-One Partnering System Provides Close Communication between Projects and Investors

To facilitate effective communication and precise cooperation between domestic and foreign pharmaceutical innovators and investors and bridge the investment and financing, the 2021 CBIIC will continue to offer a better and more diverse platform for project presentation and communication. The One-on-One Partnering System will be provided for participants. Investors and roadshow speakers could propose an invitation in this system easily and efficiently. In this event, participants will have face-to-face communication and negotiation to seek potential opportunities and commercial values for further collaboration.

IV.Great Attention from Domestic and Global Medias and Witness the Integration of Innovation and Investment

Since 2016, the CBIIC was supported by over ten well-known magazines and traditional medias at home and abroad, including top leading international academic journal Nature, people.cn, JKB.com.cn, China Pharmaceutical News, IFNEWS.com Medicine Economic Reporter, and attracted new medias and healthcare financial medias including PharmaBoardroom, Jiemian.com, 36 Kr, Caixin Media, to make real-time report of the event and witness the integration of innovation and investment.

Under the great support of all parties, the CBIIC is gradually becoming an international, authoritative, diversified communication platform to interpret policies on drug and financing and investment circle, present pharmaceutical innovative achievements at home and abroad, lead new investment trends. As the most influential annual grand conference in Asia-Pacific region, the CBIIC will make social capital playing a leading role in the development of pharmaceutical innovation, create a more scientific and attractive investment environment and contribute to China's economic and social development to meet the clinical needs and advance the pursuit of Healthy China.

会议组织机构
Conference Organization

主办单位

- 中国医药创新促进会
- 香港交易所
- 蓝迪国际智库
- 艾美达（北京）医药信息咨询有限公司

Hosts

- China Pharmaceutical Innovation and Research Development Association (PhIRDA)
- Hong Kong Exchanges and Clearing Limited (HKEX)
- Research and Development International (RDI)
- iMeta Health Information Consulting Co., Ltd.

特别支持单位

深圳证券交易所

上海证券交易所

Special Supporter

Shenzhen Stock Exchange (SZSE)

Shanghai Stock Exchange (SSE)

金融机构

- 华泰证券股份有限公司

Financial Institute Supporter

- Huatai Securities Co., Ltd.

协办单位 Co-Organizers

齐鲁制药集团有限公司	Qilu Pharmaceutical Group Co., Ltd.
先声药业集团有限公司	Simcere Pharmaceutical Group Limited
西安杨森制药有限公司	Xian Janssen Pharmaceutical Ltd.
上海复星医药（集团）股份有限公司	Shanghai Fosun Pharmaceutical (Group) Co., Ltd

支持单位 Supporters

丹麦外交部丹麦投资促进局	Invest in Denmark, Ministry of Foreign Affairs
新加坡经济发展局	Singapore Economic Development Board (EDB)
中关村股权投资协会	Zhongguancun Private Equity & Venture Capital Association (ZVCA)
美国癌症研究基金会	National Foundation for Cancer Research (NFCR)
日本制药工业协会	Japan Pharmaceutical Manufacturers Association (JPMA)
香港生物医药创新协会	HK Bio-Med Innotech Association (HKBMIA)
BioCentury	BioCentury
香港贸易发展局	Hong Kong Trade Development Council (HKTDC)
中国外商投资企业协会药品研制和开发行业委员会	China Association of Enterprises with Foreign Investment R&D-based Pharmaceutical Association Committee (RDPAC)
米内网	MENET

简版日程

Agenda (Brief)

2021 年 9 月 22 日
云路演专场

2021 年 9 月 23 日
国际云路演专场 –– 丹麦

2021 年 9 月 25 日（上午）大会开幕式 (B301)				
2021 年 9 月 25 日（下午）				
分会场 1 (A102-104)	**分会场 2 (A105-107)**	**分会场 3 (A108-110)**	**(A210)**	**(A211)**
临床数据全球首发专场 张钊 18813075508	医药数字化及创新疗法论坛 马超 13811939139	非上市公司专场 王亚男 13810051328	深交所创业板专题座谈会（单独报名审核） 马超 13811939139	港交所闭门会 杨沅霖 18511990895

2021 年 9 月 26 日（上午）				
分会场 1 (A102-104)	**分会场 2 (A105-107)**	**分会场 3 (A108-110)**	**分会场 4 (A203-205)**	**分会场 5 (A206-208)**
上市公司专场 马骏一 15710071471	非上市公司专场 王亚男 13810051328	以临床价值为导向的源头创新助推中国医药国际化论坛 阮欣欣 13301026263	科创板论坛 马超 13811939139	资本市场创新服务论坛 肖飞 13716679934
2021 年 9 月 26 日（下午）				
大数据 + 智慧医疗专场 杨沅霖 18511990895	非上市公司专场 王亚男 13810051328	罕见病专场 孙潭霖 18810723869	人工智能与生物医药专场 吴洋 13718138324	创新研发服务专场 张志娟 15810110185

2021 年 9 月 27 日（上午）			
分会场 1 (A102-104)	**分会场 2 (A105-107)**	**分会场 3 (A108-110)**	**分会场 4 (A203-205)**
上市公司专场 马骏一 15710071471	创新药基础研究与成果转化路演专场 肖飞 13716679934	投资人经验分享论坛 马超 13811939139	医疗器械专场 李捷 18911348940
2021 年 9 月 27 日（下午）		
分会场 1 (A102-104)	**分会场 2 (A105-107)**	**分会场 3 (A108-110)**
政策分享论坛 张志娟 15810110185	非上市公司专场 王亚男 13810051328	投资并购论坛 肖飞 13716679934

September 22 Afternoon
Virtual Roadshow

September 23 Afternoon
Virtual International Roadshow-Denmark

September 25 Morning (Opening Ceremony B301)				
September 25 Afternoon				
Parallel Session 1 (A102-104)	**Parallel Session 2 (A105-107)**	**Parallel Session 3 (A108-110)**	**(A210)**	**(A211)**
Clinical Trial Data Release ZHANG Zhao 18813075508	Digitalization in Pharma and Innovative Therapy Forum MA Chao 13811939139	Non-Listed Company Roadshow WANG Yanan 13810051328	Reform of the ChiNext Seminar MA Chao 13811939139	PhIRDA & HKEX Closed Door Meeting Yang Yuanlin 18511990895

September 26 Morning				
Parallel Session 1 (A102-104)	**Parallel Session 2 (A105-107)**	**Parallel Session 3 (A108-110)**	**Parallel Session 4 (A203-205)**	**Parallel Session 5 (A206-208)**
Listed Company Roadshow MA Junyi 15710071471	Non-Listed Company Roadshow WANG Yanan 13810051328	Original Innovations from Unmet Clinical Needs Promote China Pharmaceutical Globalization Forum RUAN Xinxin 13301026263	SSE STAR Market Forum MA Chao 13811939139	Capital Market Innovation Services Forum XIAO Fei 13716679934
September 26 Afternoon				
WIT-MED + Big Data Roadshow YANG Yuanlin 18511990895	Non-Listed Company Roadshow WANG Yanan 13810051328	Rare Diseases and Orphan Drugs Roadshow SUN Tanlin 18810723869	Artificial Intelligence (AI) + BioMed Roadshow WU Yang 13718138324	R&D Service Company Roadshow ZHANG Zhijuan 15810110185

September 27 Morning			
Parallel Session 1 (A102-104)	**Parallel Session 2 (A105-107)**	**Parallel Session 3 (A108-110)**	**Parallel Session 4 (A203-205)**
Listed Company Roadshow MA Junyi 15710071471	Fundamental Research & Transformation of New Drugs Roadshow XIAO Fei 13716679934	Investors' Experience Sharing Forum MA Chao 13811939139	Medical Devices Roadshow LI Jie 18911348940
September 27 Afternoon			
Parallel Session 1 (A102-104)	**Parallel Session 2 (A105-107)**	**Parallel Session 3 (A108-110)**	
Policy Sharing Forum ZHANG Zhijuan 15810110185	Non-Listed Company Roadshow WANG Yanan 13810051328	Financing M&A Forum XIAO Fei 13716679934	

22日 云路演专场 Virtual Roadshow

15:00-15:15 **项目 1：立足全球、面向全球：新一代抗体药物研发引领者**
Project 1: In Global and For Global: Pioneering Next Generation Biologics
Hugh Davis
CEO of Biosion

15:15-15:30 **项目 2：儿科肿瘤学的新疗法**
Project 2: New Therapies for Pediatric Oncology
Ricardo Garcia
CEO of Oncoheroes Biosciences Inc.

15:30-15:45 **项目 3：利用蛋白质调控领域的创新平台技术开发新的治疗多肽**
Project 3: Developing novel therapeutic peptides using innovative platform technologies in Protein Manipulation
马克思·施耐德 Max Cynader
CEO of Primary Peptides

15:45-16:00 **项目 4：骨新生：专注于骨科疾病创新疗法**
Project 4: Biobone BV: Focus on providing innovative therapy in bone diseases
Christoph Ladel
CSO of Biobone BV

16:00-16:15 **项目 5：开发创新的癌症靶向免疫疗法**
Project 5: Developing Innovative Targeted Immunotherapies for Cancer
Guy Yachin
Board Member of Stromatis Pharma

16:15-16:30 **项目 6：日本成立最早最大 CRO 公司分享肿瘤学解决方案的重要性**
Project 6: Sharing the importance of the Oncology Solutions by the First and Largest CRO in Japan
Takashi Asahi
Corporate Director of CMIC

16:30-16:45 **项目 7：运用新型抗体文库开发针对几乎所有靶点的治疗药物**
Project 7: Developing Therapeutics Against Virtually Any Target with New Antibody Libraries
杨敦杰 Jay Yang
Business Development Manager of Twist Bioscience

23日 国际云路演专场 -- 丹麦
Virtual International Roadshow--Denmark

主持人：殷　莺，丹麦投资促进局高级投资经理
Moderator: Margaret YIN, Senior Investment Manager of Invest in Denmark

15:00-15:15
开场报告：丹麦和它的生命科学产业集群
Opening Speech: Denmark-and the Danish Life Science Cluster
Rasmus Beedholm-Edsen
Special Advisor Life Science of Invest in Denmark

15:15-15:30
项目 1：PokeAcell– 针对实体瘤的新型多靶点 T 细胞疗法
Project 1: PokeAcell-Breaking Solid Tumor Escape- with ImmPACT
Anne R. Scordt
CEO of PokeAcell

15:30-15:45
项目 2：Antag Therapeutics– 一种治疗肥胖症的新方法
Project 2: Antag Therapeutics-A Novel Treatment for Obesity
Alexander Hovard Sparre-Ulrich
CEO of Antag Therapeutics

15:45-16:00
项目 3：治疗慢性疼痛和听力障碍的不同方法
Project 3: A Different Approach to Treating Chronic Pain and Hearing Loss
Torsten M. Madsen
CEO of Hoba Therapeutics

16:00-16:15
项目 4：Initiator– 治疗勃起功能障碍（ED）的全新治疗方案
Project 4: Initiator-A Novel Treatment Paradigm for the Treatment of Erectile Dysfunction (ED)
Claus Elsborg Olesen
CEO of Initiator Pharma

16:15-16:30
项目 5：Meabco– 通过治疗 – 连接生命
Project 5: Meabco-Access to Treatment-Access to life
Stig Lofborg
CEO of Meabco

大会开幕式（主会场）
Opening Ceremony (Main Conference)
2021/9/25

第一阶段：致辞
Session I: Welcome Remarks
主办方致辞
Welcome Remarks by Hosts
主持人：任晋生，中国医药创新促进会 2020-2021 年度会长、先声药业董事长兼 CEO
Chair: REN Jinsheng, 2020-2021 Annual Chairman of PhIRDA, CEO and Chairman of the Board of Simcere Pharmaceutical Group

08:30-08:45

李　燕 LI Yan
中国医药创新促进会会长、齐鲁制药集团总裁
Chairman of PhIRDA, President of Qilu Pharmaceutical Group

欧冠升 Nicolas Aguzin
香港交易所集团行政总裁
Chief Executive Officer of HKEX

苏州市政府领导
Senior Official of Suzhou Municipal Government

特别支持单位致辞
Welcome Remarks by Special Supporter

08:45-08:50

沙　雁 SHA Yan
深圳证券交易所党委副书记、总经理
Deputy Secretary of the Party Committee, President and CEO of Shenzhen Stock Exchange

第二阶段：主旨演讲
Session II: Keynote Speeches
主持人：李　佳，中国医药创新促进会候任会长、中国科学院上海药物研究所所长、新药研究国家重点实验室主任
Chair: LI Jia, Chairman-elected of PhIRDA, Director of Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Director of State Key Laboratory of Drug Research

08:50-09:05

张洪刚 ZHANG Honggang
国家科技部重大专项司副司长
Deputy Director-General of Department of Major Science and Technology Project, Ministry of Science and Technology
主旨报告 1：面向人民生命健康，科技创新支撑生物医药产业高质量发展
Keynote Speech 1: Scientific and Technological Innovation Supports the High-quality Development of the Pharmaceutical Industry for People's Life and Health

09:05-09:30

蒋华良 JIANG Hualiang
中国科学院院士、中国医药创新促进会 2015-2016 年度会长、中国科学院上海药物研究所研究员
Academician of Chinese Academy of Sciences, 2015-2016 Annual Chairman of PhIRDA, Professor of Shanghai Institute of Materia Medica, Chinese Academy of Sciences
主旨报告 2：AI 助力药物研发
Keynote Speech 2: AI Empowers Drug Research and Discovery

09:30-09:55

周思源 ZHOU Siyuan
国家药品监督管理局药品审评中心副主任
Deputy Director of Center for Drug Evaluation, National Medical Products Administration
主旨报告 3：以临床价值为导向的药物研发与科学监管
Keynote Speech 3: Clinical Value-Oriented Drug R&D and Scientific Administration

09:55-10:20

宋瑞霖 SONG Ruilin
中国医药创新促进会执行会长
Executive President of PhIRDA
主旨报告 4：中国医药创新发展回顾与展望
Keynote Speech 4: Review and Prospect of the Development of Pharmaceutical Innovation in China

10:20-10:45

张继强 ZHANG Jiqiang
华泰证券研究所副所长、总量研究负责人、固定收益首席分析师
Managing Director and Chief Fixed Income Analyst of Huatai Securities Research Institute
主旨报告 5：新“KPI”下的宏观形势
Keynote Speech 5: Macroeconomic Conditions under the New "KPI"

第三阶段：专题讨论
Session III: Panel Discussions
专题讨论 1：医药创新产业发展
Panel 1: Trends on Pharmaceutical Innovation Industry
主持人：陈启宇，中国医药创新促进会 2012-2013 年度会长、复星国际执行董事兼联席 CEO
Moderator: CHEN Qiyu, 2012-2013 Annual Chairman of PhIRDA, Executive Director and Co-CEO of Fosun International

10:45-11:25

赵白鸽 ZHAO Baige
十二届全国人大外事委员会副主任、中国社会科学院“一带一路”国际智库专家委员会主席、
蓝迪国际智库专家委员会主席
Vice Chair of the 12th NPC Foreign Affairs Committee of the People's Republic of China, Chair of the Advisory Committee of BRI International Think Tank, CASS, Chair of Advisory Committee of RDI

蒋华良 JIANG Hualiang
中国科学院院士、中国医药创新促进会 2015-2016 年度会长、中国科学院上海药物研究所研究员
Academician of Chinese Academy of Sciences, 2015-2016 Annual Chairman of PhIRDA, Professor of Shanghai Institute of Materia Medica, Chinese Academy of Sciences

何如意 HE Ruyi
中国医药创新促进会国际创新药物监管专业委员会主任委员、荣昌生物首席医学官、
国投创新首席科学家，原 CDE 首席科学家
Chairman of PhIRDA International Regulatory Science Specialty Committee, CMO of RemeGen, CMO of SDIC, Former Chief Scientist of CDE

李振福 LI Zhenfu
德福资本董事长兼 CEO
Chairman and CEO of GL Capital

薛　群 James XUE
中国医药创新促进会药物研发专业委员会副主任委员、北海康成制药有限公司创始人、董事长兼 CEO、
中国罕见病联盟副理事长
Vice-Chairman of PhIRDA Drug R&D Specialty Committee, Founder, Chairman of the Board, Director and CEO of CANbridge, Vice Director of the China Alliance for Rare Diseases

专题讨论 2：投资与医药创新发展
Panel 2: Investment and Pharmaceutical Innovation Development
主持人：宋瑞霖，中国医药创新促进会执行会长
Moderator: SONG Ruilin, Executive President of PhIRDA

11:25-12:05

康　韦 KANG Wei
中国外商投资企业协会副会长、RDPAC 执行总裁
Vice Chair of CAEFI, Managing Director of RDPAC

房健民 FANG Jianmin
中国医药创新促进会药物研发专业委员会副主任委员、荣昌生物 CEO 兼首席科学官
Vice-Chairman of PhIRDA Drug R&D Specialty Committee, CEO and CSO of RemeGen

王印祥 WANG Yinxiang
中国医药创新促进会药物研发专业委员会副主任委员、北京加科思新药研发有限公司董事长兼 CEO
Vice-Chairman of PhIRDA Drug R&D Specialty Committee, Chairman and CEO of Jacobio Pharmaceuticals

代　雯 DAI Wen
华泰证券研究所 A+H 医药行业首席分析师
Head of China/HK Healthcare, Huatai Securities

鲍海洁 Christina BAO
香港交易所董事总经理、市场拓展联席主管
Managing Director, Co-Head of Sales & Marketing of HKEX

陈　飞 CHEN Fei
礼来亚洲基金管理合伙人
Managing Partner of Lilly Asia Ventures

25日 临床数据全球首发专场（分会场 1）
Clinical Trial Data Release (Parallel Session 1)

第一阶段 Phase I

主持人：杨大俊，中国药促会药物研发专业委员会主任委员、亚盛医药董事长兼 CEO

Moderator: YANG Dajun , Chairman of PhIRDA Drug R&D Specialty Committee、Chairman of the Board & CEO of Ascentage Pharma

13:30-13:45 **项目 1: 绿原酸作用靶点发现与抗肿瘤作用**

Project 1: Target Discovery and Anti-tumor Effect of Chlorogenic Acid

陈晓光 CHEN Xiaoguang

中国药促会药物研发专业委员会委员、中国医学科学院药物研究所药理室主任

Member of PhIRDA Drug R&D Specialty Committee, Director, Department of Pharmacology, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College

13:45-14:00 **注射用绿原酸治疗复发胶质母细胞瘤 I/II 期临床试验进展汇报**

Evaluation of Chlorogenic Acid for Injection in the Treatment of Recurrent Glioblastoma

李文斌 LI Wenbin

中国药促会脑神经药物临床研究专委会副主任委员兼秘书长、首都医科大学附属北京天坛医院肿瘤综合治疗中心主任

Vice-Chairman & Secretary-General of PhIRDA Clinical Research on Cranial Nerve Drugs Specialty Committee, Director of Cancer Center, Beijing Tiantan Hospital, Capital Medical University

14:00-14:25 **项目 2: 派安普利单抗治疗前线化疗失败鼻咽癌的多中心 II 期注册临床研究**

Project 2: A Multicenter, Phase II Trial of Penpulimab in the Treatment of Metastatic Nasopharyngeal Carcinoma after the Failure of Previous Chemotherapy

胡超苏 HU Chaosu

复旦大学附属肿瘤医院主任医师、教授、博士生导师

Chief Physician, Professor, Doctoral Supervisor, Fudan University Shanghai Cancer Center

14:25-14:50 **项目 3: 全球首创糖尿病在研新药 Dorzagliatin 糖尿病缓解 DREAM 研究结果**

Project 3: Dream Study Result Release for the First Time, First-In-Class Antidiabetic Investigational Drug Dorzagliatin's Lasting Effect in Diabetes Remission

马建华 MA Jianhua

南京医科大学附属南京医院内分泌科主任、主任医师，教授，博士生、博士后导师

MD, PhD, Professor. Advisor of Doctoral and Postdoctoral Research. Director of Department of Endocrinology, Nanjing First Hospital

14:50-15:15 **项目 4: 幼儿轮状病毒感染急性腹泻新药 HY1002 的 I 期临床试验结果**

Project 4: Phase I Clinical Trial Results of HY1002, A New Generation of Acute Diarrhea Caused by Rotavirus Infection in Children

秦志杰 QIN Zhijie

武汉禾元生物科技股份有限公司首席医学官

CMO, Wuhan Healthgen Biotechnology Corp.

第二阶段 Phase II

主持人：张　丹，中国药促会药物研发专业委员会副主任委员、俄罗斯工程院外籍院士、昆翎医药联合创始人兼首席战略官

Moderator: ZHANG Dan , Vice-Chairman of PhIRDA Drug R&D Specialty Committee, Foreign Academician of Russian Academy of Engineering, Co-founder and Chief Strategy Officer of ClinChoice

15:15-15:40 **项目 5: HTD1801 改善二型糖尿病合并脂肪肝患者心血管代谢的临床 2 期试验结果**

Project 5: Phase 2 Trial Results of HTD1801 Improving Cardiometabolic Risk Factors in Subjects with Type 2 Diabetes and Fatty Liver Diseases

刘利平 LIU Liping

深圳君圣泰生物技术有限公司创始人兼首席执行官

Founder&CEO, Shenzhen HighTide Biopharmaceutical Ltd.

15:40-16:05 **项目 6: 糖尿病创新药苏帕鲁肽的 I 期 II 期临床数据汇报**

Project 6: Pharmacokinetics, Pharmacodynamics and Clinical Efficacy of Supaglutide, a Novel Weekly Dosing GLP-1 Based Therapy

王庆华 WANG Qinghua

国家特聘专家、上海银诺医药技术有限公司董事长兼 CEO

State Specially Recruited Experts, CEO & General Manager of Innogen Pharmaceutical Technology Co., Ltd.

16:05-16:30 **项目 7: SHR0302 JAK1 抑制剂治疗斑秃的 II 期临床试验结果**

Project 7: Positive Topline Phase 2 Results for SHR0302, a Selective JAK1 Inhibitor, for Treatment of Patients with Alopecia Areata

王　敏 WANG Min

瑞石生物医药公司创始人兼首席执行官

Co-Founder & CEO of Reistone Biopharma

16:30-16:55 **项目 8: PI3K β/δ 双重抑制剂 CVL237 在 B 细胞淋巴瘤患者的 1 期临床试验和布鲁顿酪氨酸激酶耐药的潜在治疗**

Project 8: First in Human Phase I Study of PI3K Dual β/δ Inhibitor CVL237 in Patients with B Cell Lymphoma and Potential Treatment for Bruton Tyrosine Kinase Resistance

张　虹 Helena ZHANG

甫康药业首席医学官

Chief Medical Officer, Convalife

16:55-17:20 **项目 9: 晚期实体肿瘤新药 PENAO 的首个人体 I 期临床试验**

Project 9: The First-in-Human Phase I Clinical Trial of PENAO in Advanced Solid Tumors

贾正虎 JIA Zhenghu

贝罗尼集团副总裁

Vice President of Beroni Group Limited

25日 医药数字化及创新疗法论坛（分会场 2）
Digitalization in Pharma and Innovative Therapy Forum (Parallel Session 2)

13:30-13:35 **中国医药创新促进会医药数字化及创新疗法专业委员会介绍**
Introduction of PhIRDA Digital Medicine and Innovative Therapy Committee

孙　喆 SUN Zhe
中国医药创新促进会医药创新数字化推进办公室主任
Director, Pharmaceutical Innovation Digitalization Promotion Office(PhIRDA)

13:35-13:40 **领导致辞**
Welcome Remarks by Officials

宋瑞霖 SONG Ruilin
中国医药创新促进会执行会长
Executive President of PhIRDA

第一阶段 Phase I
主持人：谷成明，赛诺菲大中华区医学部负责人
Moderator: GU Chengming, Greater China Medical Head, Sanofi

13:40-14:10 **主旨报告 1：数字疗法的产业思考**
Keynote Speech 1: The Clinical and Commercial Value of Digital Tx

吴　淳 WU Chun
BCG 高级全球合伙人及董事总经理
Managing Director & Senior Partner, Boston Consulting (Shanghai) Co., Ltd.

14:10-14:40 **主旨报告 2：数字疗法的认知神经科学基础**
Keynote Speech 2: The Cognitive and Neural Basis of Digital Therapy

薛　贵 XUE Gui
北京师范大学认知神经科学与学习国家重点实验室教授
Principal Investigator at State Key Laboratory of Cognitive Neuroscience and Learning in China

14:40-15:10 **主旨报告 3：智能自动化：生命科学的工业革命**
Keynote Speech 3: Intelligent Automation: Industrial Revolution in Life Science

王承志 WANG Chengzhi
北京镁伽科技有限公司首席科学家
Chief Scientist, Megarobo Technologies Co.

15:10-15:40 **主旨报告 4：你们真的相信 VR 吗**
Keynote Speech 4: Do You Really Believe in VR

郭镕恺 GUO Rongkai
前肯尼索州立大学终身教授、VR+ 行为学科学家
Tenured Associate Professor, Kennesaw State University & VR + Behavior Scientist

15:40-16:10 **主旨报告 5：分子表型组大数据，亟待挖掘的精准医疗新宝藏**
Keynote Speech 5: Uncover the Precision Medicine Trove from the Sea of Phenotypical Data

成晓亮 CHENG Xiaoliang
江苏品生医疗科技集团有限公司总裁
President, Jiangsu QLife Lab Technology Group Co., Ltd.

16:10-16:40 **主旨报告 6：多组学数据挖掘，开启新药差异化研发的全新时代**
Keynote Speech 6: Application of AI Based Multi-Omics & Clinical Data Mining: A New Era for Drug R&D

季序我 JI Xuwo
普瑞基准科技创始人兼首席执行官
Founder & CEO of Precision Scientific

第二阶段 Phase II

16:40-17:10

主题讨论：BT 与 IT 的碰撞与融合，中国新机遇
Panel : New Opportunities in China:The Integration of BT and IT

主持人：谷成明，赛诺菲大中华区医学部负责人
Moderator: GU Chengming, Greater China Medical Head, Sanofi

嘉　宾： 季序我　普瑞基准科技创始人兼首席执行官
Panelists: JI Xuwo, Founder & CEO of Precision Scientific
孙　巍　无疆脑智科技创始人、董事长
SUN Wei, Founder and Chairman, Infinite Brain Technologies (IBT)
严庆隆　海纳亚洲创投合伙人
Ryushi Shinagawa, Partner, Susquehanna International Group
成晓亮　江苏品生医疗科技集团有限公司总裁
CHENG Xiaoliang, President, Jiangsu QLife Lab Technology Group Co., Ltd.

25日 非上市公司专场（分会场 3）
Non-Listed Company Roadshow (Parallel Session 3)

主持人：杨烨辉，国联证券医药行业负责人 / 所长助理
Moderator: YANG Yehui , Head of Medical Industry/ Assistant Director, Guolian Securities

13:30-14:00 **开场报告**
Keynote Speech
创新药企业投融资的趋势和展望
The Investment Trend and Prospect of Innovative Drug Enterprises

杨烨辉 YANG Yehui
国联证券医药行业负责人 / 所长助理
Head of Medical Industry/ Assistant Director, Guolian Securities

14:00-14:20 **项目 1: 亚洲干细胞 ™ 干细胞药物研发、注册申报及转化应用**
Project 1: Stem Cell Drug Research, Development, Registration, Application and Transformation Application

齐念民 QI Nianmin
上海泉生生物科技有限公司董事长
Chairman, Asia Stem Cell Regenerative Pharmaceutical Co., Ltd.

14:20-14:40 **项目 2: 针对呼吸系统及相关疾病的 FIC 小分子原创新药研发**
Project 2: R&D of FIC Small Molecue Drugs for Respiratory System and Related Disease

程云锋 Jerry CHENG
杭州维坦医药科技有限公司创始人 & 首席执行官
Founder & CEO, Hangzhou Westan PharmTech Co., Ltd.

14:40-15:00 **项目 3: 下一代 CDK 抑制剂：高选择性 CDK7 抑制剂的研发**
Project 3: Next Generation CDK Inhibitors: Development of A Highly Selective CDK7 Inhibitor

李铭曦 LI Mingxi
上海湃隆生物科技有限公司总裁
President, GT Apeiron Therapeutics

15:00-15:20 **项目 4: 治疗阿尔兹海默症的新概念、新机制、新结构的小分子化合物 50561**
Project 4: A Novel First in Concept Small Molecular 50561 for Treatment of Alzheimer's Disease

马伟伟 MA Weiwei
北京卓凯生物技术有限公司总经理
General Manager, Beijing Joekai Biotechnology Co., Ltd.

15:20-15:40 **项目 5: 一种可协同调动 NK、DC、T 细胞的全新的肿瘤免疫疗法**
Project 5: A New Immunotherapy Which Can Harness NK, DC and T Cells Synergistically

杜小波 DU Xiaobo
重庆勉弈生物技术有限公司联合创始人
Cofounder, Chongqing mianyi Biotechnology Co., Ltd.

15:40-16:00 **项目 6: 澳宗生物：CNS 药物研发拓荒者**
Project 6: Auzone: Pioneer of Central Nervous System (CNS) Drugs

周 意 ZHOU Yi
苏州澳宗生物科技有限公司总经理 / 首席执行官
General Manager/CEO, Suzhou Auzone Biological Technology Co., Ltd.

16:00-16:20 **项目 7: 新型干眼症药物**
Project 7: New Drug for Dry Eye Disease

王正旺 David WANG
北京海洁海斯健康科技有限公司总经理
G.M, BEIJING H&H

16:20-16:40 **项目 8: 一种治疗脊髓性肌萎缩症（SMA）的创新药物候选物**
Project 8: An Innovative Drug Candidate for the Treatment of Spinal Muscular Atrophy (SMA)

李季男 LI Jinan
深圳瑞健同壹生物技术有限公司首席科学家
CSO, Shenzhen Ruijian Tongyi biotech company Co., Ltd.

16:40-17:00 **项目 9: 靶向离子通道治疗纤维肌痛的无成瘾性创新药物研发**
Project 9: The Development of Non-Addictive Drug for the Treatment of FibromyAlgia by Targeting Ion Channels

丁 强 DING Qiang
上海璃道医药科技有限公司副总经理（生物药理总监）
Vice-general manager (Director of Biological Pharmacology), Shanghai Leado Pharmatech Co., Ltd.

17:00-17:20 **项目 10: 改良型制剂 LH1037 的项目介绍**
Project 10: Introduction of the optimized formulation LH1037

丁 栋 DING Dong
江苏领航生物科技有限公司药理总监
Director of Pharmacology Department, Jiangsu Linghang Bio-technology Co., Ltd.

17:20-17:40 **项目 11: 用于治疗消化道癌的 CDH17/CD3 双特异性抗体新药和 mRNA 非病毒 CDH17 CAR-NK/T 治疗方法的研发和产业化（商业化）**
Project 11: Development and Industrialization (Commercialization) of New CDH17/CD3 Bispecific Antibody (BsAb) Drug and mRNA non-viral CDH17 CAR-NK/T Therapy for the Gastrointestinal Cancer

陆满晴 John LUK
艾贝乐医药科技有限公司首席执行官
CEO, Arbele Limited

26日 上市公司专场（分会场 1）
Listed Company Roadshow (Parallel Session 1)

主持人：杜　舟，华平投资副总监
Moderator: Joe DU , Associate Director of Warburg Pincus

08:30-09:00

开场报告
Keynote Speech
挖掘专利数据，助力新药研发
Mining patent data, Assisting drug discovery

胡元佳 HU Yuanjia
澳门大学中药质量研究国家重点实验室医药信息中心副主任
Deputy Director of University of Macau, Medical Informatics Center, State Key Laboratory of Quality Research in Chinese Medicine

09:00-09:25

项目 1: 歌礼制药新药研发管线介绍与肿瘤脂质代谢最新研发进展
Project 1: update for the pipeline of Ascletis Pharma Inc. and the interoduction of Patients with Recurrent Glioblastoma

吴劲梓 WU Jinzi
歌礼制药有限公司创始人、董事会主席兼首席执行官
Founder、Chairman and CEO of ASCLETIS PHARMA INC.

09:25-09:50

项目 2: 研发、合作多点突破，创新产品线价值显现
Project 2: Various Breakthroughs in R&D and Cooperation, Innovative Efforts Start to Generate Value

杨　亮 Allen YANG
绿叶制药投资者关系与公共关系副总裁
Vice President of Investor Relations and Public Relations of Luye Pharma

09:50-10:15

项目 3: 华领医药未来研发管线展望
Project 3: Introduction of future pipeline——Hua Medicine

陈　力 CHEN Li
华领医药董事长、首席执行官、创始人、首席科学官
Executive Director, Chief Executive Officer, Founder and Chief Scientific Officer of Hua Medicine

10:15-10:40

项目 4: 新赛生，新动能
Project 4: A New SciClone with New Momentum

郭晓宁 GUO Xiaoning
赛生药业控股有限公司副总裁，研发负责人兼首席医学官
Vice President, Head of R&D and CMO of SciClone Pharmaceuticals (Holdings) Limited

10:40-11:05

项目 5: 贝达的创新与发展
Project 5: From One to Unlimited: Betta's Innovation and Development

吴灵犀 WU Lingxi
贝达药业股份有限公司董事长助理兼董事会秘书
Chairman Assistant & Board Secretary of Betta Pharmaceuticals Co., Ltd.

11:05-11:30

项目 6: 亚盛医药 专注细胞凋亡研发创新药物
Project 6: Ascentage Pharma Group-Advancing Therapies That Restore Apoptosis

杨大俊 YANG Dajun
中国药促会药物研发专业委员会主任委员、亚盛医药董事长兼 CEO
Chairman of PhIRDA Drug R&D Specialty Committee、Chairman of the Board & CEO of Ascentage Pharma

11:30-11:55

项目 7: 远大医药 – 打造国际一流的肿瘤核素诊疗创新平台
Project 7: GP(HK) builds up a world-leading innovation platform for oncology diagnosis and treatment

周　超 Frank ZHOU
远大医药健康控股有限公司行政总裁
Chief Executive Officer of China Grand Pharmaceutical and Healthcare Holdings Limited

26日 非上市公司专场（分会场 2）
Non-Listed Company Roadshow (Parallel Session 2)

主持人：贺菊颖，中信建投证券医药行业首席分析师
Moderator: HE Juying, Head of Healthcare Equity Research, China Securities

08:30-08:55 **项目 1: 来凯医药——专注于肿瘤与肝病领域的突破性新药研发**
Project 1: Laekna Therapeutics——Focus on Developing New Ground-Breaking Innovative Therapies to Treat Cancer and Iiver Diseases

顾祥巨 Justin Gu
来凯医药首席科学馆
Chief Scientific Officer, Laekna Therapeutics

08:55-09:20 **项目 2: 徐诺药业——专注于开发抗肿瘤靶向创新药**
Project 2: Xynomic Pharmaceuticals——Developing Innovative Targeted Anti-Tumor Therapeutics

徐英霖 Mark XU
徐诺药业（南京）有限公司董事长兼首席执行官
Chairman & CEO, Xynomic Pharmaceuticals (Nanjing) Co., Ltd.

09:20-09:45 **项目 3: 嘉越医药——创新实现临床价值**
Project 3: JOYO Pharma——Create Unmet Needs Through Innovation

李永国 LI Yongguo
广州嘉越医药有限公司董事长、首席科学官
Chairman & Chief Scientific Officer (CSO), Guang Zhou JOYO Pharma Co., Ltd.

09:45-10:10 **项目 4: 眼科创新药企的“双引擎”战略定位思考**
Project 4: "Dual-Engine" Strategic Positioning of Innovative Ophthalmic Company

胡海迪 Eddy WU
极目峰睿（上海）生物科技有限公司创始人、首席执行官及董事
Founder, CEO & Board Director, Arctic Vision (Shanghai) Biotechnology Co., Ltd.

10:10-10:35 **项目 5: 博安生物——全球化生物药创新企业**
Project 5: Boan Biotech——Global Innovative Biopharmaceutical Company

姜 华 Sammy JIANG
山东博安生物技术股份有限公司首席执行官
CEO, Shandong Boan Biotechnology Co., Ltd.

10:35-11:00 **项目 6: 宁丹新药——中枢神经领域创新药研发引领者**
Project 6: Neurondawn Pharmaceutical——Leading CNS Drug Discovery and Development

王 鹏 WANG Peng
南京宁丹新药技术有限公司首席执行官
CEO, Neurondawn Pharmaceutical Co., Ltd.

11:00-11:25 **项目 7: 不依赖抗原的 OX40 信号可以改善 CAR-T 细胞的持久性和细胞毒性**
Project 7: Antigen-Independent OX40 Signaling Improves the Persistence and Cytotoxicity of CAR-T Cells

杨选明 YANG Xuanming
上海隆耀生物科技有限公司首席科学家
Chief Scientist, Shanghai Longyao Biotech Co., Ltd.

11:25-11:50 **项目 8: 亿一生物的国际化创新之旅**
Project 8: Evive's Global Journey

李 染 Emma LI
亿一生物制药（北京）有限公司高级财务总监
Senior Finance Director, Evive Biotech (Beijing) Co., Ltd.

主持人：杜向阳，西南证券股份有限公司医药行业首席分析师
Moderator: DU Xiangyang, Chief Analyst of Healthcare Group, Southwest Securities

13:30-13:55 **项目 1：吸入制剂技术在呼吸系统给药领域的研究和产业化**
Project 1: Research and Industrialization of Inhalation Preparation Technology in the Field of Respiratory Drug Delivery

陈永奇 CHEN Yongqi
深圳瑞思普利生物制药有限公司董事长
Chairman, Shenzhen Resproly Bio-Pharmacy Co., Ltd.

13:55-14:20 **项目 2：源头创新多肽抗感染抗肿瘤药物研发**
Project 2: Source Innovation R&D of Anti-Infective and Anti-Cancer Drugs

陈育新 CHEN Yuxin
江苏普莱医药生物技术有限公司董事长
Chairman, Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd.

14:20-14:45 **项目 3：慢性乙型肝炎新合并疗法：植物新药 BEL-X**
Project 3: Novel Combination Treatment for Chronic Hepatitis B: Botanical New Drug BEL-X

李清源 LEE Chingyuan
贝尔克斯生技股份有限公司商务长
Chief Business Officer, BELX Bio-Pharmaceutical Corporation

14:45-15:10 **项目 4：活体生物药 (LBPs) 开发及卷曲乳杆菌临床研究**
Project 4: Live Biotherapeutic Products (LBPs) Development of Lactobacillus Crispatus

黎志良 Julius LI
苏州欧赛微科生物医药科技有限公司联合 CEO
Co-CEO, Suzhou OSWK Bio-Pharm Co., Ltd.

15:10-15:35 **项目 5：创新思维更好满足临床需求**
Project 5: Innovative Thinking to Better Meet Medical Needs

陈兆荣 Rong CHEN
百奥赛图（北京）医药科技股份有限公司副总经理兼临床部首席医学官
Deputy General Manager and Chief Medical Officer, Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

15:35-16:00 **项目 6：启德医药 —— 创新生物偶联药物的开拓者**
Project 6: GeneQuantum —— A Pioneer in Innovative Bioconjugate Drug Development

Sunny WANG
启德医药科技（苏州）有限公司首席商务官 & 知识产权副总裁
CBO & VP, IP Management of GeneQuantum Healthcare (Suzhou) Co., Ltd.

16:00-16:25 **项目 7：聚焦冷肿瘤向热肿瘤转换，开创新一代癌症免疫治疗**
Project 7: Revolutionizing Cancer Therapy by Turning "Cold" Tumors into "Hot" Tumors with A Systemic Immuno-Oncology Approach

秦续科 Steve CHIN
科望（上海）生物医药科技有限公司首席医学官
CMO, Elpiscience Biopharma Co., Ltd.

16:25-16:50 **项目 8：下一代抗感染新药的研发**
Project 8: Develop the Next Generation of Anti-Infectious Drugs

周 毅 ZHOU Yi
辉诺生物医药科技（杭州）有限公司首席科学官
CSO, Phaeno Therapeutics Co., Ltd.

16:50-17:15 **项目 9：具有全球商业价值的痛风和其它创新药物的研发**

Project 9: Development of A Potent and Safe Gout Drug ABP-671 and Other Programs

金文卿 Adam JIN

江苏新元素医药科技有限公司执行副总裁

Executive Vice President, Jiangsu Atom Bioscience & Pharmaceutical Co., Ltd.

17:15-17:40 **项目 10：基于非天然氨基酸插入定点偶联技术的创新药研发先行者**

Project 10: R&D Pioneer of Innovative Drug Based on Unnatural Amino Acid-Introduced Site Specific Conjugation Technology

夏　钢 XIA Gang

浙江新码生物医药有限公司首席科学官

CSO, Novocodex Biopharmaceuticals Co., Ltd.

26日 以临床价值为导向的源头创新助推中国医药国际化论坛（分会场 3）

Original Innovations from Unmet Clinical Needs Promote China Pharmaceutical Globalization Forum (Parallel Session 3)

主持人：何如意，荣昌生物首席医学官、国投创新首席科学家，原 CDE 首席科学家
Moderator: HE Ruyi , CMO of RemeGen, CMO of SDIC, Former Chief Scientist of CDE, CFDA

08:30-08:55 **主旨报告 1：对创新药物未满足的临床需求的一点思考**
Keynote Speech 1: Opportunities and Challenges of Innovative Drugs – Unmet Clinical Demands

温　弘 WEN Hong
上海生物医药基金合伙人
Partner of Shanghai BioPharma Fund

08:55-09:20 **主旨报告 2：药物递送系统作为源头创新在未满足临床需求中的个案分析**
Keynote Speech 2: Case Studies on Innovative Drug Delivery System towards Unmet Clinical Needs

魏晓雄 Jim WEI
汉都医药创始人、首席医学官
Founder and CMO of Shanghai WD Pharmaceutical Co., Ltd

09:20-09:45 **主旨报告 3：创新医疗器械临床评价的科学设计及监管**
Keynote Speech 3: Scientific Design and Regulation of Novel Medical Devices

胡云富 HU Yunfu
泛生子首席医学官
CMO of Genetron Health

09:45-10:10 **主旨报告 4：mRNA 疫苗的临床设计及监管考量**
Keynote Speech 4: Clinical Study Design and Regulatory Considerations of mRNA Vaccines

门宇欣 Angela MEN
浙江海昶生物医药首席医学官
CMO of Zhejiang Haichang Biotech

10:10-10:35 **主旨报告 5：创新药临床试验期间药物安全警戒及中美差异**
Keynote Speech 5: Pharmacovigilance During New Drug Clinical Trials and the U.S.-China Gap

丁洪流 DING Hongliu
北京卡替医疗副总裁
Vice President of Chineo

10:35-11:00 **主旨报告 6：从 Aducanumab 治疗 AD 的新药获批，看 FDA 新药审批标准的改变**
Keynote Speech 6: New Trends in FDA New Drug Approvals - Case Study of Aducanumab for AD Therapy

何如意 HE Ruyi
荣昌生物首席医学官、国投创新首席科学家，原 CDE 首席科学家
CMO of RemeGen, CMO of SDIC, Former Chief Scientist of CDE, CFDA

11:00-12:00 **主题讨论：从临床开发角度讨论医药源头创新**
Panel : Original Innovations from Clinical Study Design

主持人：陈少羽，美国安诺波特律师事务所驻上海代表处管理合伙人
Moderator: CHEN Shaoyu , Managing Partner of Arnold & Porter LLP Shanghai Office

嘉　宾： 温　弘 上海生物医药基金合伙人
Panelists: WEN Hong, Partner of Shanghai BioPharma Fund
魏晓雄 汉都医药创始人、首席医学官
Jim WEI, Founder and CMO of Shanghai WD Pharmaceutical Co., Ltd
胡云富 泛生子首席医学官
HU Yunfu, CMO of Genetron Health
丁洪流 北京卡替医疗副总裁
DING Hongliu, Vice President of Chineo

26日 科创板论坛（分会场 4）
SSE STAR Market Forum (Parallel Session 4)

第一阶段 Phase I

主持人：林云峰，德诺资本管理合伙人

Moderator: Kevin LIN, Managing Partner, DNV Capital Limited

08:30-09:00 **主旨报告 1：科创板制度和当前运行情况介绍**

Keynote Speech 1: Introduction of the STAR Market System and Operation

卢雄鹰 LU Xiongying

上海证券交易所发行上市服务中心副总经理

Deputy General Manager, Offering & Listing Center, Shanghai Stock Exchange

09:00-09:30 **主旨报告 2：资源配置前移，君实以终为始**

Keynote Speech 2: Capital Market Enabled Junshi to Accelerate the Achievement of Its Unwavering Goal

陈英格 Inger CHEN

上海君实生物医药科技股份有限公司董事会秘书

Board Secretary , Shanghai Junshi Biosciences

09:30-10:00 **主旨报告 3：拥抱生物医药投资的科创时代**

Keynote Speech 3: Embrace the Age of Biotech Innovation

柳　丹 LIU Dan

鼎晖投资合伙人

Partner, CDH Investments

10:00-10:30 **主旨报告 4：科创思维下的生物医药企业资本运作服务**

Keynote Speech 4: Capital Operating of Biotech Company in STAR Market

廖逸星 LIAO Yixing

华泰联合证券投资银行大健康行业部联席主管

Co-head of Investment Banking Department Healthcare Division, Huatai United Securities

10:30-11:00 **主旨报告 5：科创板 or 18A: 创新药企业上市路径选择中的法律视角**

Keynote Speech 5: STAR Market or 18A: Legal Perspective of Listing Venue Selection by Bio-tech Companies

陶旭东 TAO Xudong

君合律师事务所合伙人

Partner, JunHe LLP

第二阶段 Phase II

11:00-12:00 **主题讨论 1：科创板助力生物医药产业创新发展**

Panel 1: SSE STAR Market Supports the Innovation and Development of Biomedicine

主持人：廖逸星，华泰联合证券投资银行大健康行业部联席主管

Moderator: LIAO Yixing, Co-head of Investment Banking Department Healthcare Division, Huatai United Securities

嘉　宾： 李　宁　上海君实生物首席执行官

Panelists: LI Ning, CEO of Shanghai Junshi Biosciences Co., Ltd.

唐艳旻　启明创投投资合伙人

Amy TANG, Venture Partner, Qiming Venture Partners

张　军　中信证券投行委医疗健康组执行总经理

Jon ZHANG, Executive Director, Investment Banking, Healthcare and Life Science Group, Citic Securities

李　英　汉坤律师事务所生物医药部部长

LI Ying, Director, Life Sciences and Healthcare Department, Han Kun Law Offices

巫　荟　泉创资本董事总经理

Marietta WU, Managing Director, Quan Capital

26日 资本市场创新服务论坛（分会场 5）
Capital Market Innovation Services Forum (Parallel Session 5)

主持人：肖　慧，安永华明会计师事务所（特殊普通合伙）审计服务合伙人
Moderator: Grace XIAO, Assurance Partner, Ernst & Young Hua Ming LLP

08:30-09:15

主题报告 1: 中国后疫情时代医药行业展望
Keynote Speech 1: The Outlook of China's Pharmaceutical Industry in the Post-Covid-19 Era

毛　化 Fred MAO
弗若斯特沙利文咨询公司合伙人
Partner, Frost & Sullivan

09:15-10:00

主题报告 2: 生物科技企业上市财税关注重点
Keynote Speech 2: IPO Accounting Issues for Biotech and Pharmaceutical Companies

杨淑娟 Jane YANG
安永北京主管合伙人 & 大中华区政府及公共服务事业部主管合伙人
Beijing Chief Managing Partner and Government&Pulic Service Market Segment Leader of Greater China
Assurance Partner,Ernst&Young Hua Ming LLC

10:00-10:45

主题报告 3: 波动市场下的价值之“锚”——医疗行业资本运作趋势展望
Keynote Speech 3: The "anchor" of value in fluctuating market -- Prospect of capital operation trend of medical indust

高　元 GAO yuan
华泰联合大健康部主管兼业务四部主管，董事总经理
Managing Director, Head of healthcare department, Huatai United Securities

主持人：费　凡，安永大中华区生命科学与医疗健康行业联席主管合伙人，华中地区审计部副主管审计服务主管合伙人
Moderator: Felix FEI, Ernst & Young, Health Science and Wellness Sector Co-leader, Greater China, Deputy Assurance Leader, China Central Partner, Assurance

10:45-11:30

圆桌讨论 1: 港交所拟引入 SPAC 机制：机遇与挑战
Pane 1: HKEX's SPAC Proposal: Opportunities and Challenges

高　元 GAO yuan
华泰联合大健康部主管兼业务四部主管，董事总经理
Managing Director, Head of healthcare department, Huatai United Securities

毛　化 Fred MAO
弗若斯特沙利文咨询公司合伙人
Partner, Frost & Sullivan

张晓夏 Sarah ZHANG
香港交易所环球上市服务部副总裁
Vice president,Global Issuer Services HKEX

裘育敏 Benjamin QIU
尚珹资本合伙人
Partner, Advantech Capital

宿　骅 SU Hua
安永帕特农大中华区生命科学与医疗保健行业主管合伙人
Life Science and Healthcare Practice Leader, EY Parthenon China

11:30-12:15

圆桌讨论 2: 北交所上市规则解读
Pane 2: Interpretation of IPO rules of Beijing Stock Exchange

诸　斌 Raymond ZHU
安永税务与商务咨询合伙人
Tax & Business Advisory Partner of EY

高元 GAO yuan
华泰联合大健康部主管兼业务四部主管，董事总经理
Managing Director, Head of healthcare department, Huatai United Securities

毛　化 Fred MAO
弗若斯特沙利文咨询公司合伙人
Partner, Frost & Sullivan

傅扬远 FU Yangyuan
嘉源律师事务所高级合伙人
Senior partner, JIA YUAN LAW OFFICES, Senior partner

26日 大数据 + 智慧医疗专场（分会场 1）
WIT-MED + Big Data Roadshow (Parallel Session 1)

主持人：黄蕴靖，香港交易所环球上市服务部 经理
Moderator: Kathy HUANG, Associate of Global Issuer Services, Markets, HKEX

13:30-14:30 **主题讨论：智慧医疗的下一个时代机遇**
Panel: Digital Healthcare: Next Generation Opportunities

主持人：鲍海洁，香港交易所董事总经理、市场拓展联席主管
Moderator：Christina BAO, Managing Director, Co-Head of Sales & Marketing of HKEX

嘉　宾：裘加林 微脉技术有限公司 董事长 &CEO
Panelists: Alin CHOW, Chairman & CEO of Weimai Technology Co., Ltd.
谭　铮 南京智精灵科技有限公司董事长
TAN Zheng, Chairman of Nanjing Wispirit Technology Co., Ltd.
徐济铭 医渡科技集团联合创始人、开心生活科技（HLT）CEO
XU Jiming, Co-founder of YIDU TECH Group, CEO of Happy Life Technology (HLT)
戚　飞 君联资本执行董事
QI Fei, Executive Director of Legend Capital

14:30-14:55 **主题报告 1: 智慧医疗产业新篇章：基建、盈利、服务供给变革**
Keynote Speech 1:New Chapter of the Smart Medical Industry: Infrastructure, Profitability, And the Reform Of Service Supply

王晓岑 Rachel WANG
明日联合医疗产业基金管理合伙人
Managing Partner of Mananacare United Industrial Fund

14:55-15:20 **主题报告 2: 数字智能赋能创新药研发，加速新药上市**
Keynote Speech 2: Digital Intelligence Empowers the R&D and Launch of Innovative Drugs

赵　璐 ZHAO Lu
太美医疗科技董事长兼 CEO
Chairman & CEO of Taimei Technology

15:20-15:45 **主题报告 3: 人工智能在微生态药物研发中的应用**
Keynote Speech 3:Application of Artificial Intelligence in Research and Development of Microecological Drugs

谭　验 TAN Yan
深圳未知君生物科技有限公司 CEO 兼创始人
CEO & Co-founder of Shenzhen Xbiome Biotech Co., Ltd.

15:45-16:10 **主题报告 4: 腔镜手术机器人技术浅析与产业进展**
Keynote Speech 4:States of the Art and Perspectives of Keyhole and Endoscopic Surgical Robots

徐　凯 XU Kai
北京术锐技术有限公司创始人兼董事长
Founder & Chairman of Beijing Surgerii Tech Co. Ltd.

16:10-16:35 **主题报告 5:D2D 医生网络在肿瘤新药推广中的巨大前景**
Keynote Speech 5:Great Potential of Doctor-to-Doctor Network in the Promotion of New Drugs

李　宇 LI Yu
和缓医疗 CEO
CEO of HH-MEDIC

16:35-16:55 **项目 1:miRNA 技术平台以及机器学习算法在癌症早筛领域的应用**
Project 1:Combing miRNA Detection Platform and Machine-learning Methods for Cancer Early Detection

邹瑞阳 ZOU Ruiyang
觅瑞私人有限公司首席技术官、联合创始人 & 中国区总裁
CTO, Co-Founder & President of China of MIRXES PTE LTD

16:55-17:15

项目 2: 基于人工智能与生物物理的大分子和多特异性分子药物理性设计与开发
Project 2: Macromolecule and Multispecific Molecules' Rational Design by AI and Biophysics

陈　航 Michael CHEN
北京星亢原生物科技有限公司联合创始人 &CEO
Cofounder & CEO of neoX Biotech

17:15-17:35

项目 3: 数据智能赋能医疗健康创新
Project 3:Healthcare Innovation Driven by Data Intelligence

刘立宇 LIU Liyu
生命奇点（北京）科技有限公司 CEO
CEO of Gennlife (Beijing) Technology Co., Ltd.

17:35-17:55

项目 4: 隐私计算赋能智慧医疗，推动医药数据生态建设
Project 4:Privacy Computing Enable Smart Medicine, Promote Eco-System of Digital Medicine

夏　平 XIA Ping
翼帆数字科技（苏州）有限公司董事长兼首席科学家
Chairman & CSO, Clippers DigiTech, Co., Ltd.

26日 罕见病专场（分会场 3）
Rare Diseases and Orphan Drugs Roadshow (Parallel Session 3)

第一阶段 Phase I

主持人：张爱华，南京医科大学附属儿童医院副院长

Moderator: ZHANG Aihua , Vice President, Children's Hospital of Nanjing Medical University

13:30-13:35 **开幕致辞**

Keynote Speech

李林康 LI Linkang

全国罕见病诊疗协作网办公室副主任、国家卫健委罕见病诊疗与保障专家委员会副主任委员兼办公室主任、中国医院协会副会长、中国罕见病联盟执行理事长

Deputy Director of the National Collaboration Network of Rare Diseases Diagnosis and Treatment , Deputy Director and Office Director of the National Health Commission's Disease Diagnosis and Protection Experts, Vice President of the Chinese Hospital Association, Executive Director of the China Alliance for Rare Diseases

13:35-13:55 **主旨报告**

Keynote Speech

罕见病药物临床研发指导原则的几点思考

Thoughts on the Guideline of the Orphan Drug Clinical Research Development

艾 星 AI Xing

国家食品药品监督管理局药品审评中心化药临床一部主审审评员

Chief Reviewer, Medical Review Department I, Center for Drug Evaluation of the National Medical Products Administration

13:55-14:15 **主旨报告**

Keynote Speech

罕见病药物创新生态构建的思考

Thoughts on the Construction of Rare Disease Ecosystem in China

薛 群 James XUE

中国医药创新促进会药物研发专业委员会副主任委员、北海康成制药有限公司创始人、董事长兼 CEO、中国罕见病联盟副理事长

Vice-Chairman of PhIRDA Drug R&D Specialty Committee, Founder, Chairman of the Board, Director and CEO of CANbridge, Vice Director of the China Alliance for Rare Diseases

14:15-15:00 **主题讨论**

Panel

中国罕见病药物研发创新之路

The Road of Orphan Drug R&D in China

主持人：李林康，全国罕见病诊疗协作网办公室副主任、国家卫健委罕见病诊疗与保障专家委员会副主任委员兼办公室主任、中国医院协会副会长、中国罕见病联盟执行理事长

Moderator: LI Linkang , Deputy Director of the National Collaboration Network of Rare Diseases Diagnosis and Treatment , Deputy Director and Office Director of the National Health Commission's Disease Diagnosis and Protection Experts, Vice President of the Chinese Hospital Association, Executive Director of the China Alliance for Rare Diseases

嘉 宾：艾 星 AI Xing

国家食品药品监督管理局药品审评中心化药临床一部主审审评员

Panelists: Chief Reviewer, Medical Review Department I, Center for Drug Evaluation of the National Medical Products Administration

张爱华 ZHANG Aihua

南京医科大学附属儿童医院副院长

Vice President, Children's Hospital of Nanjing Medical University

薛 群 James XUE

中国医药创新促进会药物研发专业委员会副主任委员、北海康成制药有限公司创始人、董事长兼 CEO、中国罕见病联盟副理事长

Vice-Chairman of PhIRDA Drug R&D Specialty Committee, Founder, Chairman of the Board, Director and CEO of CANbridge, Vice Director of the China Alliance for Rare Diseases

陈智胜 Chris CHEN（线上）

药明生物首席执行官

CEO, WuXi Biologics

第二阶段 Phase II

主持人：刘　洋，中国医药创新促进会项目合作部主任

Moderator: LIU Yang , Director of Project Co-operation, PHIRDA

15:00-15:20 **项目 1: 基因编辑疗法在罕见病领域的发展现状和潜力**

Project 1: The Development and Potential of Gene Editing Therapies for Rare Diseases

袁鹏飞 YUAN Pengfei

博雅辑因首席技术官

CTO, EdiGene

15:20-15:40 **项目 2: 单靶点全球首创新药开发：通过靶向 TSP-1 阻断 TGF-β 激活**

Project 2: Developing Single-Target First-in-Class Treatment through Blocking TGF-β Activation by TSP-1 Technology

韦沂均 WEI Yijun

成都惠泰生物医药有限公司首席执行官

CEO, Chengdu Huitai Biomedical Co., Ltd.

15:40-16:00 **项目 3: 以患者为中心的中国孤儿药研发策略**

Project 3: Research and Development Strategy of Patient Centered Orphan Drugs in China

谢生荣 Ron XIE

上海柯西医药科技发展有限公司总经理

General Manager, Shanghai Cauchy Medical Technology Development Co., Ltd.

16:00-16:20 **项目 4: 以患者为中心，探索“药品 + 科技”的中国罕见病商业模式**

Project 4: Drug+Technology: a Patient-Centric Business Model for Rare Disease in China

向　宇 Shawn XIANG

琅钰集团首席执行官

CEO, RareStone Group

16:20-16:40 **项目 5: 罕见，但不罕治：管控式供药，我们在路上**

Project 5: Winhealth Pharma, Bringing Real Impact to the Rare

郝景辉 Oliver HAO

香港维健医药集团有限公司联席首席执行官

Co-CEO, Hongkong WinHealth Pharma Group Co., Ltd.

16:40-17:00 **项目 6: 罕见病患者长期用药依从性的解决办法**

Project 6: Compliance Plays Key Role in Long-Term Medication of Rare Diseases

蒋　鑫 JIANG Xin

北京科信必成医药科技发展有限公司创新总监

Director, Pipeline&Strategy of CoSci Med-Tech Co., Ltd.

26日 人工智能与生物医药专场（分会场 4）
Artificial Intelligence (AI) + BioMed Roadshow (Parallel Session 4)

主持人：邓周宇，中银国际证券研究部执行董事、医疗 & 消费行业负责人、医药生物行业首席分析师
Moderator: DENG Zhouyu, Executive Director of Research Department, Chief Analyst of Pharmaceutical and Biological Industry and Leader of Medical & Consumer Research Group of BoC International (China) Co., Ltd.,

13:30-13:45 **开场报告：AI 新药研发概览 – 洞见行业发展，把握投资先机**
Keynote Speech : An Overview of AI New Drugs R&D - Insight into Development of AI Industry, Grasp Investment Opportunities
邓周宇 DENG Zhouyu
中银国际证券研究部执行董事、医疗 & 消费行业负责人、医药生物行业首席分析师
Executive Director of Research Department, Chief Analyst of Pharmaceutical and Biological Industry and Leader of Medical & Consumer Research Group of BoC International (China) Co., Ltd.,

13:45-14:10 **项目 1：以 AI 先进技术赋能药物研发创新**
Project 1: Advanced AI technology enables drug research and development innovation
谭文康 Ronald Tam
深圳晶泰科技有限公司首席财务官
CFO, xtalpi.inc

14:10-14:35 **项目 2：First-in-Class 变构小分子研发平台与管线布局**
Project 2: First in Class Allosteric Molecules: Platform and Pipeline in Drug Discovery
沈倩诚 SHEN QIancheng
上海宇道生物技术有限公司首席执行官
CEO, Nutshell Biotech (Shanghai) Co., Ltd.

14:35-15:00 **项目 3：基于 MicroED 的结构 +AI 计算新药发现平台**
Project 3: MicroED based AI+Structure Drug Discovery Platform
刘磊峰 LIU Leifeng
苏州青云瑞晶生物科技有限公司创始人 &CEO
Founder & CEO, ReadCrystal Technology Co.

15:00-15:25 **项目 4：基于人工智能的药物分子设计：潜在价值和目前的问题**
Project 4: AI-based Drug Design: potential values and current issues
吴国胜 WU Guosheng
康龙化成（北京）新药技术股份有限公司副总裁
Vice President, Pharmaron

15:25-15:50 **项目 5：香港生物节律研究院有限公司 ––– 高发癌症 居家早筛**
Project 5: HK Bio-Rhythm R&D Company Limited ----- Home-based Pre-screening of Cancer
吴　军 WU Jun
香港生物节律研究院有限公司中国区首席执行官
CEO, Mainland China, HK Bio-rhythm R&D Company Limited

15:50-16:15 **项目 6：AI 时代的小分子创新药设计与开发**
Project 6: Novel Drug Design in The AI Era
张宏波 ZHANG Hongbo
北京望石智慧科技有限公司 CEO 助理 & 药化总监
CEO Assistant & Director of Medicinal Chemistry, Beijing StoneWise Technology Co., Ltd

26日 创新研发服务专场（分会场 5）
R&D Service Company Roadshow (Parallel Session 5)

主持人：刘　熠，中国医药创新促进会创新研发服务专委会秘书长
Moderator: LIU Yi, Secretary-General of the Innovation R&D Services Specialty Committee

13:30-14:00 **主旨报告 1：以临床价值为导向的审评审批新进展及其 CRO 的机遇与挑战**
Keynote Speech 1: Latest Progress of the Clinical Value Oriented IND and NDA Review , Opportunities and Challenges to CRO

常建青 CHANG Jianqing
泰格医药政策法规事务副总裁
Vice President of Regulatory Policy, Hangzhou Tigermed Consulting Co., Ltd.

14:00-14:20 **项目 1：MiniPDX® 赋能精准医疗和新药研发**
Project 1: MiniPDX® for Precision Medicine and New Drug R&D

闻丹忆 WEN Danyi
上海立迪生物技术股份有限公司董事长兼 CEO
President & CEO, Shanghai LIDE Biotech. Co., Ltd.

14:20-14:40 **项目 2：助力中国国际化创新**
Project 2: Advance China's Internationalization Innovation

闫　慧 Angela YAN
缔脉生物医药科技（上海）有限公司中国区总裁
China President, dMed Biopharmaceutical Co., Ltd.

14:40-15:10 **项目 3：真实世界研究中的生物统计师**
Project 3: Biostatiscian in Real World Study

赵建民 ZHAO Jianmin
国信医药科技（北京）有限公司副总裁兼首席统计官
VP, GX Pharma Technology(Beijing)Co., Ltd.

15:10-15:30 **项目 4：CRO 如何助力药企的国际化发展策略**
Project 4: How CRO Assist Strategical Globalization and Development of Pharmaceutical Companies

戴学东 DAI Xuedong
上海美迪西生物医药股份有限公司国际研发服务部执行副总裁
Executive Vice President Head of International Discovery Service Unit of Shanghai Medicilon Inc.

15:30-15:50 **项目 5：临床 CRO 的技术创新赋能药物研发**
Project 5: Innovation of Clinical CRO Empowering Drug Development

熊金城 Jason XIONG
润东医药研发（上海）有限公司商务发展负责人
BBD, Rundo International Pharmaceutical Research & Development Co., Ltd.

15:50-16:10 **项目 6：为创新药出海赋能，国际多中心临床的全球战略合作伙伴**
Project 6: Next Generation Global Clinical CRO- Strategic Partner with Emerging Biotech Companies

付　萌 Amanda FU
锐得麦医药创始人兼首席执行官
Founder & CEO, Redbud Medicine Co., Ltd.

16:10-16:40 **主旨报告 2：创新药大环境下 CDMO 企业的机遇和挑战**
Keynote Speech 2: Opportunities and Challenges of CDMO Enterprises under the Environment of Innovative Drugs

李原强 LI Yuanqiang
浙江九洲药业股份有限公司首席科学官
CSO, Zhejiang Jiuzhou Pharmaceutical Co., Ltd.

16:40-17:00

项目 7：伴随诊断助力肿瘤新药研发
Project 7: Companion Diagnostics Facilitate Development of Innovative Oncology Therapeutics

董正伟 Harvey DONG
厦门艾德生物医药科技股份有限公司业务拓展部高级总监
Senior Director of Business Development, Amoy Diagnostics Co., Ltd.

17:00-17:20

项目 8：端到端的 CDMO 服务助力基因细胞治疗药物研发
Project 8: End-to-end CDMO Services Help Gene Cell Therapy Drug Discovery

孔令洁 KONG Lingjie
苏州博腾生物制药有限公司首席技术官
CTO, Porton Biologics Ltd.

17:20-17:40

项目 9：北大生物——为您打入欧美日市场的生物大使
Project 9: Peking University Biologics——"Biologics Ambassador" to China, Japan, USA, and Europe

陈晋宇 Wayne TAN
北大未名（合肥）生物制药有限公司首席执行官
CEO, Peking University V-Ming (Hefei) BIologics Co., Ltd.

张安雷 Alan CHANG
泰宏科學有限公司首席执行官兼创始人
CEO & Founder of Taron Solutions Limited

27日 上市公司专场（分会场 1）
Listed Company Roadshow (Parallel Session 1)

主持人：罗佳荣，广发证券发展研究中心生物医药行业首席分析师
Moderator: LUO Jiangrong , Chief Analyst of Healthcare Sector at GF Securities

08:30-08:55 **项目 1: 创新技术平台引领差异化优势产品线**
Project 1: Highly Innovative Technology Platform Drives Differentiated Product Portfolio

陈颖颖 CHEN Yingying
和铂医药控股有限公司 CFO
CFO of Harbour BioMed

08:55-09:20 **项目 2: 可负担的创新 值得信赖的品质**
Project 2: Reliable Quality, Affordable Innovation

李鑫磊 Gino LI
上海复宏汉霖生物技术股份有限公司首席财务官兼副总裁
Chief Financial Officer and Vice President of Shanghai Henlius Biotech,Inc.

09:20-09:45 **项目 3: 苑东生物创新和国际化之路**
Project 3: Easton Biopharma Pursuing Innovation and internationalization

陈 洪 CHEN Hong
成都苑东生物制药股份有限公司研发中心总经理
President of R & D Center of Chengdu Easton Biopharmaceuticals Co., Ltd

09:45-10:10 **项目 4: 信达：打造全球化的创新生物制药企业**
Project 4: Innovent: the strategy of global Innovation and globalistaion

奚 浩 Ronnie Ede
信达生物制药集团执行董事兼首席财务官
Executive Director and Chief Financial Officer of Innovent Biologics

10:10-10:35 **项目 5: 前沿生物 – 抗病毒新药的自主创新与国际化**
Project 5: Frontier-Independent innovation and internationalization of new antiviral drugs

邵 奇 SHAO Qi
前沿生物药业（南京）股份有限公司高级副总经理、首席财务官
SVP and CFO of Frontier Biotechnologies Inc.

10:35-11:00 **项目 6: 根植免疫，创新超越**
Project 6: Immunology and Innovation for Transformational Medicines

申华琼 Joan SHEN
天境生物科技（上海）有限公司首席执行官
CEO of I-Mab Biopharma.Co.Ltd

11:00-11:25 **项目 7: 和黄医药：以临床需求为导向的新药研发策略**
Project 7: HUTCHMED : R&D strategy focused on clinical needs

苏慰国 SU Weiguo
和黄医药（中国）有限公司执行董事、首席科学官
Executive Director & Chief Scientific Officer of HUTCHMED (China) Limited

11:25-11:50 **项目 8: 维亚生物 全球创新药研发及生产一站式平台**
Project 8: Viva Biotech, One-stop Platform for Global Innovative Drug R&D and Production

任德林 Derek REN
维亚生物执行董事兼总裁
Executive Director and President of Viva Biotech (Shanghai) Co., Ltd

27日 创新药基础研究与成果转化路演专场（分会场 2）

Fundamental Research & Transformation of New Drugs Roadshow (Parallel Session 2)

主持人：李　明，滬港中科国际生物科技有限公司首席执行官
Moderator: LI Ming , CEO, ZSHK Laboratories Limited

08:30-09:00 **开场报告：分子靶向药物研究的进展与布局**
Keynote Speech: Advances and Layout of Molecular Targeted Therapies

张　翱 ZHANG Ao
上海交通大学药学院院长
Dean, College of Pharmaceutical Sciences, Shanghai Jiao Tong University

09:00-09:20 **项目 1: 广州百暨——引领全球 AML 细胞治疗**
Project 1: Guangzhou Bio-gene leads the world in AML cell therapy

罗　敏 LUO Min
广州百暨基因科技有限公司总经理
CEO, Guangzhou Bio-gene Technology Co., Ltd.

09:20-09:40 **项目 2: 创新治疗性降压疫苗**
Project 2: Innovative Therapeutic Antihypertensive Vaccine

廖玉华 LIAO Yuhua
武汉华纪元生物技术开发有限公司总经理、首席科学家 /CEO/CSO
Wuhan Huajiyuan Biotechnologies Develop CO.,LTD

09:40-10:00 **项目 3: 免疫细胞疗法于肿瘤治疗未来之路**
Project 3: Immune cell therapy in the future of tumor therapy

贺小宏 HE Xiaohong
南京北恒生物科技有限公司董事长
CEO, Nanjing Bioheng Biotech Co., Ltd.

10:00-10:20 **项目 4: FIC 肿瘤免疫双靶点小分子和多靶点激酶的开发**
Project 4: Development of FIC Immunoncology bispefic small molecue and muti-spefic kinase inhitor

肖　凯 Carl XIAO
泰励生物科技有限公司副总裁
VP, Tyligand Bioscience

10:20-10:40 **项目 5: AAV 基因治疗产品的研发和产业化**
Project 5: R&D and industrialization of AAV gene therapy products

李新燕 LI Xinyan
方拓生物科技（苏州）有限公司总裁
President, Frontera Therapeutics, INC.

10:40-11:00 **项目 6: 抗缺血再灌注损伤新药 SR-01**
Project 6: New drug SR-01 against ischemia-reperfusion injury

姜宝红 JIANG Baohong
中科院上海药物研究所研究员
Professor, Shanghai institute of material medica

11:00-11:20 **项目 7: 抗抑郁 1.1 类化学创新药**
Project 7: The 1.1 class of chemically innovative medicine of antidepressant

黄成钢 HUANG Chenggang
中科院上海药物研究所研究员
Researcher, Shanghai Institute of Materia Medica, Chinese Academy of Sciences

11:20-12:00

讨论环节：探索创新药 – 基础研究成果转化的中国模式
Panel: Explore New Drugs-Chinese Model of Fundamental Research & Transformation

主持人：李　明，滬港中科国际生物科技有限公司首席执行官
Moderator: LI Ming , CEO, ZSHK Laboratories Limited

嘉　宾：张　翱 ZHANG Ao
Panelists: 上海交通大学药学院院长
Dean, College of Pharmaceutical Sciences, Shanghai Jiao Tong University

宋瑞霖 SONG Ruilin
中国医药创新促进会执行会长
Executive President of PhIRDA

王印祥 WANG Yinxiang
北京加科思新药研发有限公司董事长
Chairman & CEO, Jacobio Pharmaceuticals Co., Ltd.

叶崴涛 Tony Ye
醴泽资本管理合伙人
Managing Partner of LYZZ Capital.

27日 投资人经验分享论坛（分会场 3）
Investors' Experience Sharing Forum (Parallel Session 3)

第一阶段 Phase I

主持人： 李凯军，醴泽资本管理合伙人

Moderator: Kevin LI, LYZZ Capital Advisors Ltd & Managing Partner

08:30-09:00 **主旨报告 1：创新、责任、科技：中国生物医药产业的投资趋势**

Keynote Speech 1: Innovation, Responsibility, Technology: the Trend of Investment in China's Biotech Industry

陆潇波 LU Xiaobo
红杉资本中国基金合伙人
Partner, Sequoia China

09:00-09:30 **主旨报告 2：投资机构如何赋能被投企业**

Keynote Speech 2: How PE Can Empower Portfolio

施 珑 Leo SHI
华平投资合伙人
Managing Director, Warburg Pincus

09:30-10:00 **主旨报告 3：坚定做好生物医药行业"挖井人"**

Keynote Speech 3: Persistently Promote the Development of Biomedical Industry

朱晋桥 ZHU Jinqiao
倚锋资本董事长
Chairman, Efung Capital

10:00-10:30 **主旨报告 4：药品跨境交易新模式及其挑战**

Keynote Speech 4: Cross-border Drug Deals: New Models and Challenges

朱 敏 ZHU Min
汉坤律师事务所合伙人
Partner, Han Kun Law Offices

第二阶段 Phase II

10:30-11:15 **主题讨论 1：创新药企投资价值与二级市场股票价格的差异分析**

Panel 1: Differential Analysis between the Investment Value of Innovative Pharmaceutical Companies and the Stock Price in Secondary Market

主持人：胡雪峰，南京和润资本董事长、中国药促会投资专委会秘书长

Moderator: HU Xuefeng, Secretary General, Investment Committee of China Pharmaceutical Innovation and Research Development Association(PhIRDA)

嘉 宾：张 莉 齐济投资创始合伙人
Panelists: Lily ZHANG, Founding Partner, TTM capital
陶 峰 博远资本创始合伙人
TAO Feng, Founding Partner, BioTrack Capital
李凯军 醴泽资本管理合伙人
Kevin LI, LYZZ Capital Advisors Ltd & Managing Partner
林 亮 礼来亚洲基金合伙人
Stephen LIN, Partner, Lilly Asia Ventures
周成曜 汉坤律师事务所合伙人
Aaron ZHOU, Partner, Han Kun Law Offices

11:15-12:00

主题讨论 2：医药创新数字化投资趋势展望与策略分享

Panel 2: Prospects and strategy sharing of digital medicine investment trends

主持人：孙　喆，中国医药创新促进会医药创新数字化推进办公室主任

Moderator: SUN Zhe, Director, Pharmaceutical Innovation Digitalization Promotion Office(PhIRDA)

嘉　宾：王　淮　线性资本创始人兼首席执行官

Panelists: Harry WANG,Founder and CEO, Linear Capital

陈　刚　洲嶺资本管理合伙人

Jack CHENi, Managing Partner, LYFE Capital

张　楠　时节创投管理合伙人

ZHANG Nan, Managing Partner, Momentum Venture

严庆隆　海纳亚洲创投合伙人

Ryushi Shinagawa, Partner, Susquehanna International Group

陈志行　大钲资本合伙人

CHEN Zhixing, Partner, Centurium Capital

27日 医疗器械专场（分会场 4）
Medical Devices Roadshow (Parallel Session 4)

主持人：郑　薇，国联证券医药首席分析师
Moderator: ZHENG Wei , Chief Analyst of pharmaceutical Industry of Guolian Securities

08:30-08:50

开场报告
Keynote Speech
中国医疗器械本土创新趋势
Innovation journey for China MedTech

李　平 LI Ping
碧迪医疗大中华区副总裁及中国欧盟商会医疗器械委员会医用耗材工作组副主席
Vice President of BD Greater China&the company's highest representative working with Government affairs team to develop market access strategies on payment and reimbursement issues

08:50-09:10

项目 1: 新型纳米晶片透皮技术的开发和产业化
Project 1: Development of Novel Nanochip-based Transdermal Drug Delivery Technology and its Clinical Applications

徐　百 XU Bai
苏州纳生微电子有限公司董事长
Chairman of Suzhou Nasheng Microelectronics Ltd.

09:10-09:30

项目 2: 聚焦生殖健康，提供完整普惠的 IVD 产品
Project 2: Highlight reproductive health, offer intact and inclusive IVD products

张海川 ZHANG Haichuan
赛雷纳（中国）医疗科技有限公司创始人 / 董事长 / 总经理
Founder/Chairman/CEO of Celula (China) Medical Technology Co., Ltd.

09:30-09:50

项目 3: 分子 POCT 诊断技术平台的发展：我们需要什么？我们在做什么？
Project 3: The development of molecular POCT diagnostic technology platform: what do we need? What are we doing?

尤其敏 YOU Qimin
杭州优思达生物技术有限公司创始人 / 首席科学家
Foundr/Chief Scientific Officer of Ustar Biotechnologies (Hangzhou) Ltd.

09:50-10:10

项目 4: 瑞华康源智慧管理解决方案
Project 4: Rivamed Intelligent management solutions

万颖瑜 Sean WAN
浙江瑞华康源科技有限公司首席技术官
CTO of Zhejiang Rivamed Science & Technology Co., Ltd.

10:10-10:30

项目 5: 贝罗尼黄病毒四联鉴别诊断试剂盒 CII-ArboViroPlex rRT-PCR assay
Project 5: Beroni's Flavivirus Detection Kit -- CII-ArboViroPlex rRT - PCR assay

杨　劼 YANG Jie
贝罗尼集团精准医疗国际研究中心副总裁
Vice President of International R&D Center for Precision Medicine of Beroni Group

10:30-10:50

项目 6: 无创智能心血管检测系统
Project 6: Non-invasive hemodynamic system for cardiovascular screening

何　峰 Victor Ho
瑞脉医疗集团副总裁及董事
Vice President and Director of Sramek Group Inc.

10:50-11:10

项目 7: 新一代多重分子微流控即时诊断平台
Project 7: Sample in- Result out ——the next generation of syndromic testing platform

方彬彬 FANG Binbin
币冠（上海）生物科技有限公司首席执行官
CEO of Day6 Shanghai Biotech Co., Ltd.

11:10-11:30 **项目 8: 新一代可视喉罩系统及高精度多功能便携输液泵**
Project 8: Next Generation Video Laryngeal Mask System and High Accuracy Multi-function Ambulatory Infusion Pump

牛　伟 NIU Wei
长沙迈吉尔医疗科技有限公司联合创始人及商务副总裁
Co-Founder & Commercial VP of Changsha Magill Medical Technology Co., Ltd.

11:30-11:50 **项目 9: 眼视光全套创新医疗器械解决方案**
Project 9: VisionX - An emerging leader in China's vision care devices market

李笑微 LI Xiaowei
艾康特医疗科技有限公司创始人及首席执行官
Founder & CEO of VisionX

11:50-12:10 **项目 10: 基于机器学习的宿主免疫分析技术：诊断感染的新方法**
Project 10: Host immune analysis technology based on machine learning: a new method for diagnosing infections

马　林 MA Lin
英赛诊断首席运营官兼总经理
Insightmatix Diagnosis COO & General Manager

27日 政策分享论坛（分会场 1）
Policy Sharing Forum (Parallel Session 1)

第一阶段 Phase I

主持人：冯　岚，中国医药创新促进会秘书长

Moderator: FENG Lan, Secretary-General of PhIRDA

13:30-14:00 **主旨报告 1：中国新，全球新——机遇与挑战**

Keynote Speech 1:The Opportunities and Challenges in Drug Innovation: First in Class or First in China

李　靖 Jin LI

药渡经纬信息科技（北京）有限公司董事长、联合创始人

Founder and Chair of Pharmacodia

14:00-14:30 **主旨报告 2：以临床价值为导向的抗肿瘤药物临床研发及审评报告**

Keynote Speech 2: Clinical Value-oriented Anti-tumor Drug Clinical Research and Development and Review Report

杨志敏 YANG Zhimin

国家药品监督管理局药品审评中心化药临床一部部长

Leader of the Medical Review Department I, Centre for Drug Evaluation (CDE), China National Medical Products Administration (NMPA)

14:30-15:20 **主题讨论：科学监管赋能医药创新**

Panel : Scientific Regulation Empowers Pharmaceutical Innovation

主持人：宋瑞霖，中国医药创新促进会执行会长

Moderator: SONG Ruilin, Executive President of PhIRDA

嘉　宾： 李　靖　药渡经纬信息科技（北京）有限公司董事长、联合创始人

Panelists: Jin LI, Founder and Chair of Pharmacodia

杨志敏　国家药品监督管理局药品审评中心化药临床一部部长

YANG Zhimin, Leader of the Medical Review Department I, Centre for Drug Evaluation (CDE), China National Medical Products Administration (NMPA)

赵　维　山东大学临床药学系主任

ZHAO Wei, Director of the Department of Clinical Pharmacy, Shandong University

申华琼　天境生物科技（上海）有限公司首席执行官

Joan SHEN, CEO of I-Mab Biopharma Co., Ltd.

第二阶段 Phase II

主持人：俞　卫，上海创奇健康发展研究院执行院长

Moderator: YU Wei, Executive Director,China Healthcare Innovation Platform Academy

15:20-15:50 **主旨报告 1：创新药物临床价值体现的重要性**

Keynote Speech 1: The Importance of the Clinical Calue Demonstration for Innovative Drugs

宣建伟 XUAN Jianwei

中山大学药学院医药经济研究所所长

Director of Health Economics Research Institute, Sun Yat-sen University

15:50-16:10 **主旨报告 2：商业健康保险与医药创新融合发展的思考**

Keynote Speech 2: Commercial Health Insurance and Access of Innovative Medicine

韩世明 Samuel HAN

波士顿咨询合伙人

Partner of Boston Consulting Group

16:10-17:00 **主题讨论：满足临床需求，回归临床价值**

Panel :Satisfy Clinical Needs and Return to Clinical Value

主持人：俞　卫，上海创奇健康发展研究院执行院长

Moderator: YU Wei, Executive Director,China Healthcare Innovation Platform Academy

嘉　宾： 宣建伟　中山大学药学院医药经济研究所所长

Panelists: XUAN Jianwei, Director of Health Economics Research Institute, Sun Yat-sen University

李怡平　药明巨诺联合创始人、董事长兼首席执行官

James LI, Co-founder, Chairman and Chief Executive Officer, JW Therapeutics

韩世明　波士顿咨询合伙人

Samuel HAN, Partner of Boston Consulting Group

27日 非上市公司专场（分会场 2）
Non-Listed Company Roadshow (Parallel Session 2)

主持人：何风志，北康医疗投资管理有限公司总经理
Moderator: HE Fengzhi, General Manager, Beikang Healthcare

13:30-13:55 **项目 1: COVID-19 表位肽疫苗 CoVac501 研发**
Project 1: Development of CoVac501, A Multiple Epitope Peptide Vaccine for COVID-19

宫丽崑 GONG Likun
中国科学院上海药物研究所课题组长，教授
PI, Professor, Shanghai Institute of Materia Medica

13:55-14:20 **项目 2: 利用组合技术平台 开发全球新一代的抗肿瘤小分子药物**
Project 2: Utilizing Integrated Technology Platforms to Develop Next-Generation Cancer Therapeutics

王奎锋 WANG Kuifeng
勤浩医药（苏州）有限公司创始人 &CEO
Founder & CEO, Suzhou Genhouse Bio Co., Ltd.

14:20-14:45 **项目 3: 创新点亮生命——维昇药业 TransCon 技术平台产品研发进展**
Project 3: Innovation Brings Light to Life —— VISEN Pharma Innovative Pipeline Development Leveraging TransCon Technology

卢安邦 Pony LU
维昇药业 CEO
CEO, VISEN Pharmaceuticals

14:45-15:10 **项目 4: 皮卡佐剂在创新性疫苗中的应用**
Project 4: Application of PIKA Adjuvant in Innovative Vaccines

邵 辉 SHAO Hui
依生生物首席执行官
CEO, YishengBio

15:10-15:35 **项目 5: 英派药业——小分子，大影响：打造全球领先的合成致死机制产品组合**
Project 5: IMPACT Therapeutics——Small Molecule, Big Impact: Building Leading Global Synthetic Lethality Product Pipeline

包 骏 BAO Jun
英派药业总裁兼首席执行官
President & CEO, Impact Therapeutics

15:35-16:00 **项目 6: 基于膜蛋白胞内滞留技术的通用型 CAR-T：平台技术开发及临床探索**
Project 6: Allogeneic CAR-T Platform Based on Intracellular Retention of Membrane Proteins: Technology Development and Clinical Investigation

李 俊 LI Jun
苏州方德门达新药开发有限公司总经理
General Manager, Suzhou Fundamenta Therapeutics Inc.

16:00-16:25 **项目 7: 无疆科技——专注于脑科学研究和中枢神经疾病干预的数字疗法**
Project 7: Beijing Infinite Brain Technologies——Aims to Provide Digital Curative Solutions for Central Nervous System (CNS) Diseases

张类波 Angela ZHANG
北京无疆脑智科技有限公司首席运营官
COO, Beijing Infinite Brain Technologies

16:25-16:50 **项目 8: 用于治疗复发难治多发性骨髓瘤及其他多种肿瘤的新一代蛋白酶体抑制剂的研发**
Project 8: Development of A New Generation of Proteasome Inhibitors for the TreatMent of Relapsed and Refractory Multiple Myeloma and Other Tumors

仲为栋 ZHONG Weidong
宁波圣健生物医药科技有限公司商务总监
Business Development Director, Ningbo Shengjian Biopharmaceutical Tech. Co., Ltd.

27日 投资并购论坛（分会场 3）
Financing M&A Forum (Parallel Session 3)

主持人：李安民，久银控股董事长
Moderator: LI Anmin, President, EagleHoldings Co., Ltd

13:00-13:20 **开场致辞**
Keynote Speech

王少杰 Jason WANG
中关村股权投资协会会长
President of Zhongguancun Private Equity & Venture Capital Association (ZVCA)

13:20-13:50 **报告 1：全球项目交易经验分享 – 跨国药企角度**
Keynote Speech1：Global transactions case sharing – from MNC perspective

王　昕 Cynthia WANG
法国施维雅业务拓展及许可总监
BD & Licensing Director, Les Laboratories Servier

13:50-14:20 **报告 2: 创新医药和智慧医疗的中国商业化之路**
Keynote Speech2：Commercialization of innovative drug and digital therapy in China

Leo L. Han
夸克中国 /GDCC 中国中心首席执行官
CEO,Quark Venture China/GDCC

14:20-14:50 **报告 3: 立足临床需求缺口，发掘全球创新价值**
Keynote Speech3：Based on umet clinical need,explore global innovation value

王　飞 WANG Fei
三生制药集团首席财务官
CFO,3SBio Inc.

14:50-15:30 **主题讨论：生物医药投资逻辑的变化与思考**
Panel: Changes and Thoughts of the investment logic of biotech

主持人：吕　东 高瓴资本董事总经理
Moderator：Dong Lyu, MD, Hillhouse Capital

嘉　宾：易　琳 德福资本董事总经理
Panelists: Cherry YI, Managing Director,GL Capital Group
姜　华 山东博安生物技术股份有限公司首席执行官
Sammy JIANG, CEO, Shandong Boan Biotechnology Co., Ltd.
张彦涛 泰励生物科技董事长
Tony ZHANG, CEO, Tyligand Bioscience
王　翀 再鼎医药执行副总裁
Jonathan WANG, Executive Vice President, Business Development, Zai Lab



● 参会企业规模逐年扩大
Scale of participating companies is expanding every year



主办方介绍 »»»

Introduction of 2021 CBIIC Hosts

中国医药创新促进会

中国医药创新促进会（原名“中国医药工业科研开发促进会”，简称“中国药促会”），英文名称：China Pharmaceutical Innovation and Research Development Association（PhIRDA），成立于 1988 年，是经国家民政部登记注册的非营利性全国性 4A 级社会组织。

中国药促会秉承“创新、产业化、国际化”的宗旨，以临床需求为导向，长期致力于“产学研用资”紧密结合，促进医药行业创新发展，已经成为集医药创新研发型企业、科研机构、临床研究机构、创新服务机构和医药投资机构所组成的医药创新产业化促进平台，目前有会员单位 155 家。中国药促会已成立了药物研发、药物临床试验研究、医药政策、医药创新投资、创新研发服务、心血管药物临床研究、国际创新药物监管、抗肿瘤药物临床研究、脑神经药物临床研究、医药企业合规、糖尿病与代谢性疾病药物临床研究专业委员会，形成了以创新为核心，以促进创新为目标的涵盖药物研发、生产、使用以及投融资的全链条组织构架，并作为国际药品制造商协会联合会（IFPMA）的成员继续拓展国际交流渠道。

中国药促会工作内容主要包括：一是，开展医药政策研究，为我国医改事业、完善药物政策和医药产业发展建言献策；二是，通过举办各种论坛、发布会、大型会议等活动，促进会员单位乃至整个医药产业的相互交流、创新发展；三是，通过与国内外医药行业协会、企业、科研机构和外国驻华使馆合作，推动国际医药产业的多方位、多维度合作交流，为会员单位搭建国际交流平台；四是，践行国家创新驱动发展战略指导精神，为会员单位拓宽医药创新投融资渠道、搭建合作平台，推动社会资本加大对初创及研发型企业自主创新项目的投入，营造更有吸引力的医药创新投资环境；五是，为会员单位提供医药信息搜集、整理、评价服务，包括编辑每日《医药信息简报》、每周《国际医药产业发展动态与研发信息简报》等内部电子刊物以及中国药促会官方网站、微信公众号等服务平台。

中国药促会将围绕办会宗旨，不断拓展服务内涵和外延，做好政府与会员企业的桥梁和纽带，维护会员合法权益，加强行业自律，推动我国医药产业的创新和可持续发展，为加快我国经济社会发展、保障人民群众健康不断做出贡献！



PhIRDA

Founded in 1988, China Pharmaceutical Innovation and Research Development Association (PhIRDA), formerly named China Pharmaceutical Industry Research and Development Association, is registered as a non-profit 4A social organization by the Ministry of Civil Affairs of China at national level.

PhIRDA has been exerting great effort on "academia-industry-investment collaboration", which centers on the principle of "innovation, industrialization, internationalization", and persists in innovation to achieve unmet clinical requirements. As a platform facilitating the industrialization of pharmaceutical innovation, PhIRDA currently has 155 members mainly consists of pharmaceutical R&D enterprises, research institutions, clinical institutions, R&D Services companies and investment institutions focusing on pharmaceutical innovation. Moreover, PhIRDA has established the following Specialty Committees: Drug R&D, Clinical Trial Research, Medicinal Policy, Pharmaceutical Innovation Investment and Innovation R&D Services, Clinical Research on Cardiovascular Drugs, International Regulatory Science, Clinical Research on Oncology Drugs, Clinical Research on Cranial Nerve Drugs, Ethics and Business Compliance, Clinical Research on Diabetes and Metabolic Diseases, forming a fully functional organization structure focusing on innovation, aiming to promote the development of innovation, covering the whole industrial chain, including drug R&D, manufacturing, using, investment and capital market. PhIRDA is also a member of International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) to continuously broaden channels of international collaboration.

Major work of PhIRDA includes: first, to conduct policy researches, propose valuable suggestions on healthcare reform and the development of pharmaceutical industry; second, to promote communication and innovative development of our members and even the whole pharmaceutical industry through forums, press-conferences, summits, etc.; third, to make efforts to establish an international exchange platform for our members through cooperation with foreign embassies and foreign associations to stimulate comprehensive communication between China and foreign countries in pharmaceutical field; fourth, to practice the guiding spirits of national innovation-driven development strategy, to broaden the investment and financing channels of pharmaceutical innovation, to build the cooperation platform for our members, and to promote social capitals to pay more attention on investment in innovative projects of start-up and R&D enterprises to create a more attractive environment of pharmaceutical innovation and investment; fifth, to improve the website and WeChat official account of PhIRDA and provide collecting, arranging, revising service of pharmaceutical information, which includes the following internal e-magazines such as the daily Pharmaceutical Information Brief, the weekly International Pharmaceutical Development Tendency and Research Information Brief.

PhIRDA will center on our principle, continuously expand services, build a bridge between the government and our members, maintain legitimate rights and interests of members, strengthen self-discipline, promote healthy development of Chinese pharmaceutical industry, making constant contributions to the greater economic development of the country and public health.

香港交易所

香港交易及结算所有限公司（香港交易所）是世界主要的交易所集团之一，业务范围包括股票、大宗商品、衍生产品、定息及货币产品。香港交易所是全球领先的新股融资中心，也是香港唯一的证券及衍生产品交易所和结算所营运机构，为国际投资者提供进入亚洲最活跃市场的渠道。

香港交易所透过全资子公司伦敦金属交易所（LME）和 LME Clear Limited，运营全球领先的工业金属交易市场。2018 年，香港交易所在中国深圳设立的前海联合交易中心（QME）开业，迈出大宗商品业务发展的又一步。

香港交易所是与中国内地市场互联互通的先行者。2014 年，香港交易所推出沪港通机制，让国际投资者可以通过香港直接投资中国内地股市；沪港通开启的互联互通机制先后于 2016 年及 2017 年拓展至深港通及债券通。

HKEX

Hong Kong Exchanges and Clearing Limited (HKEX) is one of the world's major exchange groups, and operates a range of equity, commodity, fixed income and currency markets. HKEX is the world's leading IPO market and as Hong Kong's only securities and derivatives exchange and sole operator of its clearing houses, it is uniquely placed to offer regional and international investors access to Asia's most vibrant markets.

HKEX is also the global leader in metals trading, through its wholly owned subsidiaries, The London Metal Exchange (LME) and LME Clear Limited. This commodity franchise was further enhanced with the launch of Qianhai Mercantile Exchange (QME), in China, in 2018.

HKEX launched the pioneering Shanghai-Hong Kong Stock Connect programme in 2014, further expanded with the launch of Shenzhen Connect in 2016, and the launch of Bond Connect in 2017.

蓝迪国际智库

蓝迪国际智库在新型全球化和第四次产业革命的浪潮 中应运而生，相关项目于 2015 年 4 月正式启动，旨在推动“一 带一路”倡议的研究与实践。蓝迪国际智库自运行以来，以问题导向、需求导向、项目导向和结果导向为原则，在智库研究、国际合作以及促进“一带一路”建设等方面开展了大量工作。目前 , 已经建立了完善的智库网络、国际网络、城 市网络和企业网络。

智库网络：汇聚国内外专业智库、学界及企业等各领域专家学者的力量，聚焦“一带一路”所涉及到的国际热点和关切的议题，充分发挥咨政建言、理论创新、舆论引导、社会服务、公共外交等重要功能。组织开展高层交往、智库研讨、能力建设和专题研究，围绕“一带一路”相关问题，在 深入调研的基础上形成高质量报告，向中央及地方政府建言献策，相关报告及政策均有效的转化为有关部委和地方政府政策措施，对中国企业“走出去”起到重大指导作用。

国际网络：形成了统筹国内外政党、政府、议会、智库、 企业、金融机构、社会组织、媒体和国际多双边机构等各方战略合作伙伴及支持机构的服务体系，以国际战略委员会、重点国家双主席制度和国际分支网络为组织支撑，以多、双边高层交往为重要纽带，以企业合作为载体，促进“一带一路”建设。

城市网络：助力地方经济社会高质量发展，为地方发展创新思想、集聚智慧、储备人才。着力提升地方政府决策的科学化、民主化和法治化水平，积极开展城市综合经济研究和产业研究，为城市建设与产业发展提供智力支持。蓝迪国际智库与珠海、青岛、宁波、苏州、南宁、保定、湘潭、青 海省、海南省等地方政府展开密切合作，建立起“智库 + 城 市”服务网络，成功打造蓝迪国际智库专家高层咨询会系列品牌活动，为地方经济社会高质量可持续发展出谋划策。

企业网络：整合了包括能源、制造、农林牧渔、信息、服务、文化、贸易物流、基建、医药、房地产、金融、园区、 港口、矿业、商会协会、培训等众多行业骨干企业或机构团队。通过建立法律服务、政策研究、技术标准、信息服务、金融支持、文化与品牌、能力建设七大专业服务组，积极组织政府、企业和行业资源，带领企业抱团出海，为企业参与“一带一路”建设提供了大量系统性的服务和支持。

蓝迪国际智库获得了国内外相关机构的认可。2016 年欧洲对外关系委员会发布《分析中国: 中国兴起百家智库》研究报告，将蓝迪国际智库作为中国新型智库建设中的范例，称“蓝迪国际智库已拥有系统的对话交流及合作机制”，同年，“一带一路百人论坛”通过系统性公开信息分析，将蓝迪国际智库评选为年度“一带一路”优秀智库；2017 年 2 月， 蓝迪国际智库加入中联部牵头的“一带一路”智库合作联盟理事会，2019 年 12 月 , 蓝迪国际智库荣获“一带一路”智库合作联盟理事会年度优秀理事单位品牌活动奖；2019 年 , 蓝迪国际智库获得巴基斯坦“卓越新月奖”国家荣誉勋章；2020 年，蓝迪国际智库与国家发改委城市和小城镇改革发展中心、民盟中央经济委联合申报的重大课题《“一带一路”城市合作发展研究》荣获国家发展和改革委员会优秀研究成果奖。



RDI

Research and Development International (RDI) emerged in the waves of the New Globalization and the 4th Industrial Revolution. Aimed at promoting BRI researches and practices, its relative projects was launched in April 2015. RDI has contributed great efforts to think tank research, international cooperation and the B&R construction based on the "Problem-oriented, Demand-guided, Project-focused, Result-based" principle. By far, it has established its well-structured think tank network, international network, city network and enterprise network.

Think tank network: it has brought together experts and scholars from professional think tanks, academia and enterprises at home and abroad to provide consultation and advice, carry out theoretical innovation, guide public opinion, provide social service, promote public diplomacy, with its focus on international hot spot issues and concerns relative to the B&R construction. It organizes high-level exchanges and think tank symposiums, builds capacity and launches mono-graphic studies. It formulates high-quality reports based on in-depth investigations and surveys on the B&R-related issues and provides suggestion and advice to the central and local governments. Its reports and policy suggestions have been effectively adopted as policies and measures by relevant ministries, commissions and local governments, which has provided significant guidance to help the Chinese enterprises "Go Global".

International network: it has formed a service system coordinating strategic partners and supporting organizations at home and abroad, including political parties, governments, parliaments/NPC, think tanks, enterprises, financial institutions, social organizations, media and multilateral/bilateral international organizations. With the organizational support of RDI Strategy Committee, dual-chairman system of key countries and international branch networks, it takes bilateral and multilateral high-level exchanges as important linkages and enterprise cooperation as carrier to promote the B&R construction.

City network: it innovate ideas, pool wisdom and cultivate talents to help cities achieve economic and social development with high quality. It makes efforts to improve the scientific, democratic and legal level of local government decision making, actively carry out urban comprehensive researches on urban economy and industry, and provides intellectual support for urban construction and industrial development. It has carried out close cooperation with the governments of Zhuhai, Qingdao, Ningbo, Suzhou, Nanning, Baoding, Xiangtan, Qinghai Province, Hainan Province, etc., established a "Think Tank + City" service network, successfully held a series of high-level consultative conference which now represents one of its brand event, so as to provide suggestions and plannings for the high-quality and sustainable development of local economy and society.

Enterprises network: it has integrated many backbone enterprises of multiple sectors, including energy, manufacturing, agriculture, forestry, animal husbandry, fishery, information, service, culture, logistics, infrastructure, pharmaceutical, real estate, finance, park, mining, training and institutions like chambers of commerce. By establishing seven professional service systems, i.e. legal service, policy research, technological standard, information service, financial support, culture and brand, and capacity building, RDI allocates resources of government, enterprise and industry to group enterprises to "Go Global" and provides systematic services and supports to enterprises for their participation in the B&R construction.

RDI has gained recognition from relevant institutions at home and aboard. "China Analysis - A Hundred Think Tanks Blooming in China", a research report released by the European Council on Foreign Relations (ECFR) in August 2016 hails RDI as an example of China's new think tanks and states that "RDI has established systematic mechanisms for dialogues, exchanges and cooperation." It was selected as the 2016 "Excellent B&R Think Tank" after a systematic and open information analysis by the Belt and Road 100 at the end of December 2016 and was elected a member institution of the Council of Silk Road Think Tank Association under the International Department of the Central Committee of the CPC in February 2017. It was conferred upon the "Brand Activity Award" by the Council of Silk Road Think Tank Association in December 2019. It was granted "Hilal-i-Imtiaz" Pakistan Civil Award in 2019. The Report entitled "Research on the Cooperation and Development of Cities along the B&R" won the "2019 Award for Excellent Research Achievements of National Development and Reform Commission" jointly drafted by RDI, China Center for Urban Development of National Development and Reform Commission, and the Central Economic Committee of China Democratic League in 2020.

艾美达医药咨询

艾美达（北京）医药信息咨询有限公司成立于 2014 年，是一家专业的医药行业咨询服务提供商，同时也是医药产业链资源整合服务商。公司依托强大的医药行业国内外资源，以国家产业政策对市场的影响为导向，医药卫生行业大数据为基础，通过专业的数据分析，结合药物经济学和市场准入流程，利用学术活动平台为医药企业提供市场解决方案。

同时，公司致力于将产业政策与真实世界的数据挖掘深度结合，洞悉行业政策对市场的影响，通过专业的研究提供前瞻性的市场分析，为企业提供技术和政策咨询服务。

公司拥有专业权威的医药行业政策研究团队，市场分析调研团队，强大的平台活动策划团队，依托丰富的行业资源，为创新医药企业和产品提供产业链整体解决方案。

2016 年，公司携手中国医药创新促进会发起并创立了医药界与投资界高端对话平台——中国医药创新与投资大会（以下简称“创投大会”）。创投大会平台立足国内医药创新领域，联合美国港澳台地区、欧洲、日本、澳大利亚、港澳台地区等优秀创新生物医药科技企业、研究机构、投资机构及生物医药上下游服务企业，并建立了密切联系和业务合作关系。

历届会议我们本着展示前沿创新项目和技术，汇聚全球创新医药领域重量级专家学者，解读创新医药产业热点话题为目标，积极鼓励并创造参会者之间充分的交流分享机会，促进医药创新活力充分释放与创新成果及时、高效转化。受到国内外产业界与投资界高度关注和广泛好评，被誉为“亚太地区最受关注的医药创新与投资合作平台”。

前瞻思维，引领企业战略。资源整合，缔造品牌价值。艾美达以权威的政策解读、精准的调研分析、丰富的行业资源、专业的服务团队、强大的整合能力为您带来高品质的服务。

iMeta

Established in 2014, iMeta (Beijing) Health Information Consulting Co., Ltd.(iMeta) is a professional consulting provider and a service provider offering integrated resource in pharmaceutical industry chain. Relying on domestic and global rich resource in pharmaceutical industry, taking national industrial policies as guide and on the basis of big data from medical and health industry for professional data analysis, iMeta combines market access with pharmacoeconomic and fully utilizes academic platform to provide technical service and market solutions for pharmaceutical enterprises.

Meanwhile, iMeta is committed to in-depth integration of industrial policies and real world data. With the insight into the impact of industrial policies on the market, iMeta could provide enterprises with technical and policy consulting services based on its forward-looking market analysis through professional research.

iMeta has professional and authoritative teams on pharmaceutical industry policy research, market analysis, and a strong platform event planning. Relying on its rich industry resources, iMeat could provide innovative pharmaceutical enterprises and products with overall industrial chain solutions.
In 2016, iMeta and China Pharmaceutical Innovation and Research Development Association (PhIRDA) initiated and established a high-end dialogue platform between pharmaceutical industry and the investment --the China BioMed Innovation and Investment Conference (CBIIC). Based on pharmaceutical innovation industry in China, CBIIC has collaborated and established close contact and partnership with outstanding innovative pharmaceutical technology enterprises, research institutes, investment institutions and biopharmaceutical upstream and downstream service enterprises in the United States, Europe, Japan, Australia, Chinese Hong Kong, Macao and Taiwan.

In previous sessions, iMeta has demonstrated cutting-edge innovative projects and technologies, gathered experts and scholars in tglobal pharmaceutical innovation industry around the world. With the purpose of well-interpreting the hot topics of the innovative pharmaceutical industry, iMeta has actively encouraged and created ocommunication opportunities forparticipants, and facilitate the release of vitality of pharmaceutical innovation and timely transformation of unmet clinical needs. CBIIC has received high recognition and appreciation from pharmaceutical industry and investment at home and abroad, being praised as "the most popular dialoguage between pharmaceutical innovationand investment in the Asia-Pacific Region".

With corporate strategy led by forward thinking and brand value generated from integrated resources, iMeta could offer high-quality services based on our authoritative policy interpretation, precise research and analysis, rich industry resources, professional team and strong integration capabilities.

特别支持单位

Special Supporter

深圳证券交易所

深圳证券交易所于 1990 年 12 月 1 日开始营业，是经国务院批准设立的全国性证券交易场所，受中国证监会监督管理。深交所履行市场组织、市场监管和市场服务等职责，主要包括：提供证券集中交易的场所、设施和服务；制定和修改本所的业务规则；审核、安排证券上市交易，决定证券暂停上市、恢复上市、终止上市和重新上市；提供非公开发行证券转让服务；组织和监督证券交易；组织实施交易品种和交易方式创新；对会员进行监管；对证券上市交易公司及相关信息披露义务人进行监管；对证券服务机构为证券上市、交易等提供服务的行为进行监管；设立或者参与设立证券登记结算机构；管理和公布市场信息；开展投资者教育和保护；法律、行政法规规定的以及中国证监会许可、授权或者委托的其他职能。

深交所是实行自律管理的会员制法人，现有 119 家会员和 3 家特别会员。在所党委统一领导下，深交所治理架构包括：一是会员大会，为权力机构。二是理事会，对会员大会负责，下设战略发展、会员自律管理、市场风险、上市培育、技术发展、薪酬财务、上诉复核、创业板股票发行规范等 8 个专门委员会。三是经理层，负责日常管理工作，下设上市、纪律处分等 2 个专门委员会，设有技术管理、上市公司监管、产品与参与人管理、培育发展、风险管理等 5 个专业管理委员会。四是监事会，为监督机构。五是设 29 个部室和 5 家下属机构。

深交所立足服务实体经济和国家战略全局，经过 30 年的发展，初步建立起板块特色鲜明、监管规范透明、运行安全可靠、服务专业高效的多层次资本市场体系，市场规模不断扩大，市场功能稳步增强，吸引力和影响力持续提升，多项指标位居世界前列，正成长为全球最具活力的新兴市场。截至 2020 年 12 月末，深交所共有上市公司 2354 家，总市值 34.2 万亿元；挂牌债券（含资产支持证券）7954 只，挂牌面值 2.5 万亿元；挂牌基金 487 只，资产净值 2669 亿元；沪深 300ETF 期权平稳运行，累计成交 7877 万张，成交面值 3.5 万亿元。2020 年，深市各类证券成交总额达 162.2 万亿元，股票融资额 5638 亿元，固收产品融资额 1.85 万亿元。

深交所坚持以习近平新时代中国特色社会主义思想为指导，准确把握新发展阶段，深入贯彻新发展理念，积极推进构建新发展格局，坚持稳中求进工作总基调，按照“建制度、不干预、零容忍”方针和“四个敬畏、一个合力”要求，紧抓服务粤港澳大湾区和中国特色社会主义先行示范区发展机遇，深化金融供给侧结构性改革，提高直接融资比重，发挥市场枢纽作用，构建更加适应创新资本形成的市场体系、制度体系、产品体系、监管风控体系、双向开放体系、数字化体系和交易所治理体系，促进科技、资本和实体经济的高水平循环，奋力建设优质创新资本中心和世界一流交易所，为打造一个规范、透明、开放、有活力、有韧性的资本市场贡献积极力量。

SZSE

Shenzhen Stock Exchange (SZSE), established on 1st December, 1990, is a self-regulated legal entity under the supervision of China Securities Regulatory Commission (CSRC). It also organizes, supervises securities trading and performs duties prescribed by laws, regulations, rules and policies. Its main functions include providing the venue and facilities for securities trading, formulating operational rules, receiving listing applications and arranging securities listing, organizing and supervising securities trading, supervising members; regulating listed companies, managing and disseminating market information and other functions as approved by the CSRC.

SZSE is committed to developing China's multi-tiered capital market system, serving national economic development and transformation and supporting the national strategy of independent innovation. The SME Board was launched in May 2004. The ChiNext market was inaugurated in October 2009. In 2021, SZSE starts preparation for the merger between the Mainboard and the SME Board. Thus SZSE has basically put in place a framework of multi-tiered capital market comprising the Main Board and the ChiNext market. SZSE's products cover equities, mutual funds and bonds. The product lines include A-shares, B-shares, indices, mutual funds (including ETFs and LOFs), fixed income products (including SME collective bonds and asset-backed securities), and diversified derivative financial products (including warrants and repurchases). SZSE plays an increasingly important role in supporting the real economy and transforming the nation's economic growth model.

Since 2001, SZSE has signed MOUs with more than 50 major stock exchanges and financial institutions in the world and enhanced cross-border cooperation and communications. It has also taken an active part in international securities organizations. SZSE is a member of both the World Federation of Exchanges (WFE) and the Asian and Oceanian Stock Exchanges Federation (AOSEF). It is also an affiliate member of the International Organization of Securities Commissions (IOSCO).

特别支持单位

Special Supporter

上海证券交易所

上海证券交易所（以下简称上交所）成立于 1990 年 11 月 26 日，同年 12 月 19 日开业，受中国证监会监督和管理，是为证券集中交易提供场所和设施、组织和监督证券交易、实行自律管理的会员制法人。

上交所致力于创造规范、透明、开放、有活力、有韧性的市场环境，主要职能包括：提供证券集中交易的场所、设施和服务；制定和修改上交所业务规则；按照国务院及中国证监会规定，审核证券公开发行上市申请；审核、安排证券上市交易，决定证券终止上市和重新上市等；提供非公开发行证券转让服务；组织和监督证券交易；组织实施交易品种和交易方式创新；对会员进行监管；对证券上市交易公司及相关信息披露义务人进行监管，提供网站供信息披露义务人发布依法披露的信息；对证券服务机构为证券发行上市、交易等提供服务的行为进行监管；设立或者参与设立证券登记结算机构；管理和公布市场信息；开展投资者教育和保护；法律、行政法规规定的及中国证监会许可、授权或者委托的其他职能。

经过 30 年的快速成长，上交所已发展成为拥有股票、债券、基金、衍生品 4 大类证券交易品种、市场结构较为完整的证券交易所；拥有可支撑上海证券市场高效稳健运行的交易系统及基础通信设施；拥有可确保上海证券市场规范有序运作、效能显著的自律监管体系。依托这些优势，上海证券市场的规模和投资者群体也在迅速壮大。

截至 2020 年末，沪市上市公司家数达 1800 家，总市值 45.5 万亿元；2020 年全年股票累计成交金额 84.0 万亿元，日均成交 3456 亿元，股票市场筹资总额 9152 亿元；债券市场挂牌 20378 只，托管量 13.2 万亿元，现货成交 11.5 万亿元；基金市场上市只数达 373 只，累计成交 10.8 万亿元；衍生品市场全年累计成交 7167 亿元。沪市投资者开户数量已达 27550 万户。

经过 30 年发展，目前上交所已经成为全球第三大证券交易所和全球最活跃的证券交易所之一。截至 2020 年底，上交所 IPO 数量及融资金额均位列全球第一；股票成交金额超过 75 万亿元，在全球交易所中排名第四。

SHANGHAI STOCK EXCHANGE

Shanghai is Mainland China's first city to see the emergence of stocks, stock trading and stock exchanges. Stock trading started in Shanghai as early as the 1860s. In 1891, the Shanghai Share Brokers Association, an early form of stock exchange, was established in Shanghai. Later in the 1920s, with the founding of the Shanghai Securities Goods Exchange and the Shanghai Chinese Securities Exchange, Shanghai emerged as the financial center of the Far East, where both Chinese and foreign investors could trade stocks, bonds, and futures. In 1946, the Shanghai Chinese Security Exchange was renamed the Shanghai Securities Exchange Co., Ltd. Later in 1949, all securities trading venues were closed down.

Since 1980, China's securities market has grown in tandem with the reform and opening up of the country and the development of the socialist market economy. In 1981, the offering of treasury bonds was resumed. In 1984, stocks and enterprise bonds were issued in Shanghai and other regions. On November 26, 1990, the Shanghai Stock Exchange (the Exchange) was established, and on December 19 of the same year, it started formal operations.

Under the strong leadership of the CPC Central Committee and the State Council and the direct guidance of the CSRC, along with fervent support from all sectors of society, the Exchange makes it its mission to serve the nation's reform and development initiatives. In line with the principles of rule by law, regulation, self-discipline and compliance, the Exchange has been committed to creating a transparent, open, reliable and efficient marketplace and fulfilling its frontline role in market organization, oversight and development over the past 20 plus years.

嘉宾介绍 »»»
Introduction of Guests

任晋生
中国医药创新促进会 2020-2021 年度会长、先声药业董事长兼 CEO

REN Jinsheng
2020-2021 Annual Chairman of PhIRDA, CEO and Chairman of the Board of Simcere Pharmaceutical Group

先声药业创始人，麦考瑞大学经济学硕士，高级经济师。转化医学与创新药物国家重点实验室主任，中国医药创新促进会 2020-2021 年度会长，全国五一劳动奖章获得者，国家科学技术进步二等奖，中国医药行业十大领军人物。

Founder of Simcere Pharmaceutical Group Limited, earning his master's degree of Economics at Macquarie University, Senior Economist. Director of State Key Laboratory of Translational Medicine and Innovative Drug Development, 2020-2021 Annual Chairman of PhIRDA, the winner of the National May 1st Labor Medal,Second Prize of National Science and Technology Progress award, one of Top Ten Leaders in China's pharmaceutical industry.

李　燕
中国医药创新促进会会长、齐鲁制药集团总裁

LI Yan
Chairman of PhIRDA, President of Qilu Pharmaceutical Group

李燕，中欧国际工商管理学院工商管理硕士、高级工程师，现任齐鲁制药集团有限公司总裁。担任第十三届全国人大代表，中国医药创新促进会候任会长、中国医药企业管理协会轮值会长、中国药学会理事等。荣获全国劳动模范、全国三八红旗手、全国优秀企业家、中国医药经济年度人物等荣誉。

李燕专心专注医药产业发展，集团连续多年跻身中国医药工业百强榜前十强。建立中美联动五大研发中心，主导实施创新驱动战略，“十四五”期间预计将有 10-12 个创新药物上市。大力实施精品战略和国际化战略，集团是国内唯一一家同时向欧、美、英、日、澳大利亚法规市场出口制剂的药企，18 个产品在当地市场占有率第一。李燕累计提交全国两会建议 30 余项，推动法规政策完善和医药产业高质量发展。

With a certificate of MBA at CEIBS and title of senior engineer, Ms. Yan Li currently serves as the President and CEO of Qilu Pharmaceutical Group, Co., Ltd. Ms. Li also serves as deputy of the Thirteenth National People's Congress, designate chairman of China Pharmaceutical Innovation and Research Development Association, rotating chairman of the China Pharmaceutical Enterprises Association, council member of Chinese Pharmaceutical Association. Honors awarded to Ms. Li include but not limited to National Model Worker, National March 8th Red Banner Pace-setter, National Outstanding Entrepreneurs, Person of the Year for the Chinese Pharmaceutical Economy.

By dedicating her service to the motherland and laying the cornerstone to success of the enterprise through industrial development, Ms. Li concentrates her attention to focus on development of the pharmaceutical industry, and leads the Group as one of the top 10 enterprises among the Top 100 Chinese Pharmaceutical Industry for multiple consecutive years. Ms. Li managed to implement the innovation-driven strategy and lead to build and improve 5 major R&D centers connecting China and the US, with 10-12 innovative drugs to be developed and launched to the Chines market within the 14th Five-Year Plan. Ms. Li is also a practitioner of the strategy of product excellence and internationalization, Qilu is the only pharmaceutical enterprise in China that exports to the regulatory markets of Europe, the United States, Britain, Japan and Australia at the same time, with 18 products ranking first in the local market share. As a deputy of the National People's Congress, Ms. Li has filed over 30suggestions covering people's livelihood and high quality development of the pharmaceutical industry, pushing the regulation and policy improvement in such fields.

欧冠升
香港交易所集团行政总裁

Nicolas Aguzin
Chief Executive Officer of HKEX

欧冠升于 2021 年 5 月 24 日加入香港交易所为集团行政总裁，此前为摩根大通私人银行国际市场首席执行官，于 2012 年起在香港工作。2013 年至 2020 年，欧冠升为摩根大通亚太区首席执行官，负责领导该行在区内 17 个市场的业务，期间掌管摩根大通一些重要的业务拓展，包括成为少数在中国内地提供全方位服务的国际银行之一，其中全资拥有一家于当地注册的商业银行、控股一家证券公司、一家资产管理公司和一家期货及期权公司。他担任亚太区首席执行官一职的同时，还负责亚太区的投资银行部门。在欧冠升领导下，摩根大通成为亚太区领先的投资银行之一。

欧冠升于 1990 年加入摩根大通出任金融分析师，1990 年至 2005 年期间在纽约和布宜诺斯艾利斯出任多个职位，并于 2005 年出任拉丁美洲首席执行官。2008 年至 2009 年他担任拉丁美洲首席执行官和拉丁美洲投资银行主管时，更兼任巴西地区高级主管 。

欧冠升拥有美国宾夕法尼亚大学沃顿商学院经济学士学位，精通西班牙语、葡萄牙语和英语。

Nicolas Aguzin joined HKEX as Chief Executive Officer on 24 May 2021 from J.P. Morgan, where he was most recently Chief Executive Officer of J.P. Morgan's International Private Bank. Mr Aguzin has been based in Hong Kong since 2012.

From 2013 to 2020, Mr Aguzin was CEO, J.P. Morgan, Asia Pacific where he was responsible for all the firm's business across 17 markets. Mr Aguzin presided over some of the firm's major expansion efforts during the period, including establishing itself in China as one of the few international financial institutions with a full range of services and capabilities; including a fully-owned locally incorporated commercial bank, a majority-owned securities company, an asset management company and a futures and options company. Concurrent with his Asia CEO role, Mr Aguzin also ran J.P. Morgan's Investment Banking division in Asia. During his tenure the bank rose to become one of the leading investment banks in the Asia Pacific region.

Mr Aguzin joined J.P. Morgan in 1990 in Buenos Aires as a financial analyst. Between 1990 and 2005, he held a variety of roles in New York and Buenos Aires, and in 2005 he was appointed as CEO, Latin America. In 2008 and 2009, in addition to his responsibilities as CEO, Latin America and Head of Latin America Investment Banking, he served as Senior Country Officer for Brazil.

Mr Aguzin holds a bachelor degree in Economics from the Wharton School of the University of Pennsylvania in the US and is fluent in Spanish, Portuguese and English.

沙　雁
深圳证券交易所党委副书记、总经理

SHA Yan
Deputy Secretary of the Party Committee, President & CEO of Shenzhen Stock Exchange

沙雁女士于 2013 年 5 月起先后任中国证监会上市公司监管二部副主任，上市公司监管部副主任，证券基金机构监管部副主任、主任。2020 年 6 月起任深圳证券交易所党委副书记、总经理。

Ms. SHA Yan has served various roles in China Securities Regulatory Commission (CSRC) since May 2013 , including Deputy Director of the Listed Companies Supervision Department II , Deputy Director of Listed Companies Supervision Department, and Deputy Director and later Director of the Department of Fund and Intermediary Supervision. She assumed office of President & CEO of SZSE Since June 2020.

李　佳
中国医药创新促进会候任会长、中国科学院上海药物研究所所长、新药研究国家重点实验室主任

LI Jia
Chairman-elected of PhIRDA, Director of Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Director of State Key Laboratory of Drug Research

1992 年毕业于浙江医科大学药学系，1994 年进入中国科学院上海药物研究所攻读博士学位，2000 年获理学博士学位。作为主要发明人参与研发 15 个候选 1 类新药进入系统临床前研究，其中 10 个候选 1 类新药实现转移转化，6 个候选 1 类新药进入临床研究。已授权国际国内发明专利 141 项，申请 82 项。发表 SCI 论文 460 余篇，总引用超过 10000 次。获得国家杰出青年科学基金资助，入选国家百千万人才工程、国家中青年科技创新领军人才、国家“万人计划”科技创新领军人才。曾获得中国青年科技奖、国家科技进步二等奖、上海市科技进步一等奖。

Prof. Jia Li graduated from the Department of Pharmacy, Zhejiang Medical University in 1992. He entered Shanghai Institute of Materia Medica Chinese Academy of Sciences in 1994 and obtained the doctorate of science in 2000. Prof. Li has led 15 undergoing pre-clinical studies. Ten drug candidates have been successfully transferred to domestic pharmaceutical companies. Six drug candidates entered phase I clinical trial. Prof Li is the co-inventor of 223 patents (with 141 already issued). Prof. Li has published 460 SCI papers, >10000 total citations. Prof Li has been supported by the National Science Foundation for Distinguished Young Scholars, selected as one of the leading talents in Science and Technology innovation of the National Project of Tens of Millions of Talents, National Young and Middle-aged Leading Talents in Science and Technology Innovation, and National "Ten Thousand Talents Plan" leading Talents in science and technology innovation. Prof. Li has won the China Youth Science and Technology Award, the second prize of national Science and Technology Progress, and the first prize of Shanghai Science and Technology Progress.

周思源
国家药品监督管理局药品审评中心副主任

ZHOU Siyuan
Deputy Director of Center for Drug Evaluation, National Medical Products Administration

周思源，国家药品监督管理局药品审评中心副主任。1982 年 9 月 -1990 年 7 月，在同济医科大学公共卫生学院学习，获得医学学士、医学硕士学位。1990 年 8 月 -2006 年 1 月，在国家药品审评中心工作，历任临床组审评员、化药及生物制品室临床组组长、审评管理与协调部副部长、审评管理与协调部部长。2006 年 1 月 -2015 年 5 月，历任国家食品药品监督管理局行政受理服务中心副主任、局办公室综合处副处长、国家食品药品监管总局人事司干部处处长。2015 年 5 月 - 现在，先后任国家食品药品监督管理总局药品审评中心副主任、国家药品监督管理局药品审评中心副主任。2017 年 7 月，任国家药品监督管理局 ICH 工作办公室主任，为国家药品监督管理局 ICH 大会和管委会代表，同时为 ICH 管委会新议题分委会委员、ICH 指导原则实施分委会委员。2017 年，兼任国家药典委第十一届药典委员会执行委员会委员；中国药学会第 24 届理事会理事。

ZHOU Siyuan, Deputy Director of the Center for Drug Evaluation (CDE), NMPA. 1982-1990 Master of Medicine, School of Public Health, Tongji Medical University.1990-2006 Reviewer of CDE Clinical Group; Principal of Clinical Group, Division of Chemical Drugs and Biological Products, CDE; Deputy Director of the Department of Drug Review and Evaluation and Coordination, CDE. Director of the Department of Drug Review and Evaluation and Coordination, CDE. 2006-2015 Deputy Director of the Division of General Affairs, General Office and Deputy Director of the Department of Administrative Acceptance Service Center of CFDA, Director of Division of Personnel, Department of Human Resources, CFDA. 2015-Present, Deputy Director of CDE, CFDA, Deputy Director of CDE, NMPA. Since 2017, Director of ICH China Office, NMPA representative in ICH Assembly and Management Committee, Member of ICH New Topic, Member of Implementation of ICH Guidelines. 2017, Member of the 11th Executive Committee of Chinese Pharmacopoeia Commission, Member of the 24th Board of Chinese Pharmaceutical Association.

宋瑞霖
中国医药创新促进会执行会长

SONG Ruilin
Executive President of PhIRDA

宋瑞霖，现任中国医药创新促进会执行会长、全国政协参政议政人才库特聘专家、农工党中央参政议政咨询专家；先后取得中国政法大学法学学士、中欧国际工商学院工商管理硕士和中国药科大学社会与管理药学博士学位；澳大利亚悉尼大学访问学者。曾长期在国务院法制办公室从事卫生与药物政策、法律研究并负责卫生医药领域的法律、法规起草和审查工作；近年来，在完善我国药品审评审批制度改革、医保报销制度改革和医药创新政策方面做出了重要贡献。

现担任的其他社会职务：中国药科大学国家药物政策与产业发展研究中心执行副主任、上海交通大学客座研究员、香港联交所生物科技咨询小组成员、中国罕见病联盟副理事长、中国药学会理事、中国药师协会理事、白求恩公益基金会理事。

Mr. Song Ruilin is the Executive President of China Pharmaceutical Innovation and Research Development Association (PhIRDA), Expert of the Talent Pool for State Affairs of Chinese People's Political Consultative Conference (CPPCC) and Expert for State Affairs of Central Committee of Chinese Peasants and Workers Democratic Party. He is also L.L.B. of China University of Political Science and Law, EMBA of China Europe International Business School, Doctor of Social and Administrative Pharmacy of China Pharmaceutical University and Visiting Scholar of the University of Sydney. Mr. Song had served in the Legislative Affairs Office at State Council of China for a long time, engaging in health and drug policy, legal studies and in charge of law making and reviewing in the areas of pharmaceutical and healthcare industry. He has made great contribution in optimizing the reform of drug review and approval system, medical insurance reimbursement system and making policies for pharmaceutical innovation in China.

Currently, Mr. Song also undertakes several social positions, such as Executive Deputy Director of the Research Center of National Drug Policy & Ecosystem of China Pharmaceutical University, Guest Research Professor of Shanghai Jiao Tong University,Biotech Advisory Panel Member of the Stock Exchange of Hong Kong Limited, the Vice President of China Alliance for Rare Disease (CARD), Director of Chinese Pharmaceutical Association (CPA), Director of Chinese Pharmacists Association and Director of Bethune Charitable Foundation .

张继强
华泰证券研究所副所长、总量研究负责人、固定收益首席分析师

ZHANG Jiqiang
Managing Director and Chief Fixed Income Analyst of Huatai Securities Research Institute

毕业于复旦大学，数量经济学专业硕士。 2018 年 10 月加入华泰证券研究所，目前任研究所副所长、总量研究负责人及固收首席、董事总经理。此前曾就职于中金公司，从事固定收益研究，曾任中金公司固定收益研究负责人、董事总经理。

张继强曾率领团队获得新财富最佳分析师殊荣，其中 2020、2019、2017 年获得第一名；2020 年财新 II 分析师评选宏观经济第一名，十大最受欢迎分析师；2015-2017、2019 年获得《证券市场周刊》水晶球奖债券研究的第一名。此外，张继强先生本人获得《财资》（The Asset）杂志 2018 年中国地区最佳本币债券研究分析员第一名。张继强先生主张简洁、有力的逻辑框架，报告风格逻辑性强、接地气。

Mr. Zhang obtained Master of Quantitative economics in Fudan University. He joined Huatai Securities Research Institute as Managing Director and Chief Fixed Income Analyst from 2018. Prior to that, he worked as Head of Fixed Income Research and Managing Director in China International Capital Corporation.

He has led the team won the First Prize of New Fortune Best Research Award in 2017, 2019, and 2020; the Institutional Investor All China Macro Economics Research Team and the Top 10 most popular analyst; the First Prize of Crystal Ball Awards for Chinese Sell-Side Analysts in 2015-2017, 2019. In addition, Mr. Zhang was awarded the First Best Fixed Income Research Analyst in China by The Asset in 2018. He advocates concise, powerful, logical research framework, which is also easy-to-understand for the investors.

陈启宇
中国医药创新促进会 2012-2013 年度会长、复星国际执行董事兼联席 CEO

CHEN Qiyu
2012-2013 Annual Chairman of PhIRDA, Executive Director and Co-CEO of Fosun International

陈启宇，48 岁，本公司执行董事兼联席首席执行官。陈先生于 2020 年 2 月获委任为本公司联席首席执行官。陈先生于 1994 年加入本集团，截至报告期末亦出任复星医药（香港联交所及上交所上市）非执行董事，复宏汉霖（香港联交所上市）非执行董事兼董事会主席，国药控股（香港联交所上市）非执行董事兼副董事长，New Frontier Health Corporation（纽约证券交易所上市－股份代号：NFH）联席董事长，Gland Pharma Limited（孟买证券交易所及印度国家证券交易所上市－股分代号：GLAND）董事、三元股份（上交所上市）及本集团内其他公司之董事。截至报告期末，陈先生为中国医药物资协会会长、中国医药创新促进会副会长、上海市生物医药行业协会名誉会长兼监事长。

Chen Qiyu, aged 48, is an Executive Director and Co-CEO of the Company. Mr. Chen was appointed as the Co-CEO of the Company in February 2020. Mr. Chen joined the Group in 1994 and as at the end of the Reporting Period, he has also been a non-executive director of Fosun Pharma (listed on the Hong Kong Stock Exchange and the SSE), a non-executive director and chairman of Shanghai Henlius (listed on the Hong Kong Stock Exchange), a non-executive director and vice chairman of Sinopharm (listed on the Hong Kong Stock Exchange), a co-chairman of New Frontier Health Corporation (listed on the New York Stock Exchange with stock code NFH) , a director of Gland Pharma Limited (listed on the BSE Limited and National Stock Exchange of India Limited with stock code GLAND), Sanyuan Foods (listed on the SSE) and various companies within the Group. Mr. Chen was a director of Dian Diagnostics Group Co., Ltd. (listed on the Growth Enterprise Market Board of the Shenzhen Stock Exchange with stock code 300244), a non-executive director of BabyTree (listed on the Hong Kong Stock Exchange). As at the end of the Reporting Period, Mr. Chen has been the chairman of China Medical Pharmaceutical Material Association, a vice chairman of China Pharmaceutical Innovation and Research Development Association, the honorary chairman and chief supervisor of Shanghai Biopharmaceutics Industry Association, the vice council chairman of Shanghai Society of Genetics and a member of the 13th Shanghai Standing Committee of the Chinese People's Political Consultative Conference. Mr. Chen was a member of the 12th Shanghai Standing Committee of the Chinese People's Political Consultative Conference. Mr. Chen was awarded the "Best Entrepreneurial Leader" under Golden Kirinbest Hong Kong Stock Value Ranking by Sina Finance, "Shanghai Excellent Constructor of Socialism with Chinese Characteristics from Non-public Sector" and "Shanghai Outstanding Entrepreneur". Mr. Chen received a bachelor's degree in genetics from Fudan University in 1993 and an EMBA degree from China Europe International Business School in 2005.

赵白鸽
十二届全国人大外事委员会副主任、中国社会科学院“一带一路”国际智库专家委员会主席、蓝迪国际智库专家委员会主席

ZHAO Baige
Vice Chair of the 12th NPC Foreign Affairs Committee of the People's Republic of China, Chair of the Advisory Committee of BRI International Think Tank, CASS, Chair of Advisory Committee of RDI

赵白鸽为中华人民共和国十二届全国人大外事委员会副主任委员、中国社会科学院“一带一路”国际智库专家委员会主席、蓝迪国际智库专家委员会主席。致力于“一带一 路”倡议的有效实施，积极向党中央、国务院建言献策，组建了由政府、智库、企业共同组成的“一带一路”平台，为中国参与新型全球化建设发挥了重要的作用。她积极参与促进中外国际交流，推动中欧绿色和智慧城市交流合作与模式创新，为城市发展寻找新方向。 2019 年，赵白鸽获得巴基斯坦政府授予的“ 卓越新月奖 ”国家荣誉勋章，2020 年受聘为全国政协参政议政人才库特聘专家。

Baige Zhao is the Vice Chair of the 12th NPC Foreign Affairs Committee of the People's Republic of China, Chair of the Advisory Committee of BRI International Think Tank, CASS, Chair of Advisory Committee of RDI. Baige Zhao has been dedicated to effectively implementing the BRI, offering advice to the government, and participating in the establishment of the BRI platforms co-organized by the government, think tanks and enterprises, which fulfill an important role for China to participate the new type of globalization. She actively participates in the promotion of international exchanges between China and foreign countries, promotes China-EU green and smart city exchanges and cooperation and model innovation, and seeks new directions for urban development. In 2019, Baige Zhao was granted “Hilal-iImtiaz” Pakistan Civil Award by Pakistani Government. In 2020, Baige Zhao was appointed as member of the Distinguished Experts Group of the CPPCC National People’s Political Consultative Conference.

蒋华良
中国科学院院士、中国医药创新促进会 2015-2016 年度会长、中国科学院上海药物研究所研究员

JIANG Hualiang
Academician of Chinese Academy of Sciences, 2015-2016 Annual Chairman of PhIRDA, Professor of Shanghai Institute of Materia Medica, Chinese Academy of Sciences

蒋华良，1987 年毕业于南京大学化学系，获得有机化学学士学位；1992 年于华东师范大学化学系获得物理化学硕士学位；1995 年于中国科学院上海药物研究所获得药物化学博士学位。目前担任 J. Med. Chem. 副主编和其他 5 种国际学刊的编委。曾任国家 863 计划专家组成员、国家重大基础研究计划“蛋白质科学重大基础研究计划”专家组成员、现任国家自然科学基金委“生物大学分子动态修饰与化学干预”重大研究计划专家组组长。

蒋华良主要从事药物科学基础研究和新药发现。系统发展了药物作用靶标发现和药物设计理论计算新方法，为新药研究提供工具，获得国际同行和工业界广泛应用。设计高效探针分子，深入阐明和确证了一系列新靶标的作用机制和药理功能。针对肺动脉高压、精神分裂症和阿尔茨海默症等国内目前尚无自主知识产权新药的重大疾病，与他人合作进行新药开发研究，数个候选新药进入临床研究或获得临床批件，并实现技术转化。曾获得国家自然科学二等奖、国家科技发明二等奖、何梁何利科技创新奖等奖项。

Dr. Hualiang Jiang obtained his bachelor's degree from the Department of Chemistry, Nanjing University in 1987. He received his master’s degree in Physical Chemistry from East China Normal University in 1992. In 1995, he obtained his Ph.D. degree in Medicinal Chemistry from Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences (CAS). He was a member of scientific committees of several major research programs in China, such as 863 National High Technology Program, National Basic Research Program, and Major Research Project of National Natural Science Foundation of China. He also serves as Associate Editor of Journal of Medicinal Chemistry and editorial board members of several journals such as The Journal of Biological Chemistry.

Dr. Jiang's has been engaged in the establishment of the innovative drug research platform by integrating target discovery and drug design methods and technologies. He developed a series of new methods for drug target discovery and drug design, which have been widely used and drawn a great deal of attention from the research community. Targeting several diseases such as pulmonary hypertension, schizophrenia, erectile disorder and Alzheimer’s disease, Dr. Jiang and his co-workers obtained a number of drug candidates by using computational drug design, organic synthesis and drug development technologies. Some compounds have entered into phase I or II clinical trial. Over the years, Dr. Jiang has received the Natural Science Award of China, the National Award for Technological Invention, the Science and Technology Progress Prize from Ho Leung Ho Lee Foundation, etc.

何如意
中国药促会国际创新药物监管专业委员会首任主任委员、荣昌生物首席医学官、国投创新首席科学家，原 CDE 首席科学家

HE Ruyi
Chairman of PhIRDA International Regulatory Science Specialty Committee, CMO of RemeGen, CMO of SDIC, Former Chief Scientist of CDE

何如意博士曾担任美国 FDA 新药审批办公室消化系统及罕见病药物审评部临床审评官，代理副主任；在 FDA 具有 17 年临床审评审批经验，起草多个 FDA 的工业指南及产品的临床评价指南等。负责审批了许多新药临床试验申请和新药上市申请。何如意博士 2016 年 7 月加入中国食品药品监督管理局药品审评中心，作为中国 CFDA 首位从海外引入的高级人才，担任首席科学家。在中国 CDE 期间，组织参与审评审批制度改革及技术指南撰写研讨工作。何如意博士毕业于中国医科大学。于 1988 年 3 月赴美，在美国国家卫生研究院（NIH）从事临床研究。他在美国的 Howard 大学医学院完成内科住院医师工作，目前持有美国多个州的执业医师证书。

Dr. Ruyi He was the Chief Scientist at the Center for Drug Evaluation at the Chinese Food and Drug Administration (CFDA). Dr. He joined CFDA in July 2016, after having worked at the US Food and Drug Administration (FDA) for more than 17 years. He participated CFDA drug review and evaluation system reform in the recent years.Dr. Ruyi He joined the US Center for Drug Evaluation and Research (CDER) at the US FDA in 1999 as a Medical Officer in the office of New Drug. He was the Acting Deputy Director in the division of GI and Inborn error Drug Products. He chaired several working groups that were tasked with drafting and finalizing guidelines for industry. Dr. Ruyi He has received many awards since he joined the FDA.Dr. Ruyi He received his medical degree from China Medical University. He completed his intern and residency training in Internal Medicine at Howard University Hospital in Washington, DC. He received his clinical and research training at the National Institutes of Health (NIH) in Bethesda, Maryland. He is a licensed, board-certified physician in several States in the America.

李振福
德福资本董事长兼 CEO

LI Zhenfu
Chairman and CEO of GL Capital

李振福是德福资本的创始人、董事长兼首席执行官。自 2004 年至 2010 年间，他曾担任诺华中国区总裁。在此之前，他曾在美国贝思佳集团公司工作长达 11 年，担当投资、咨询和管理等数项职务。在贝思佳集团的最后五年，他在美国吉时公司就任商务公司总裁。李振福是中国企业家俱乐部理事成员，美国百人会会员，美国伊利诺伊理工学院国际董事会成员，中华慈善总会荣誉副会长，大自然保护协会中国理事会理事成员。

李振福在北京航空航天大学获得理学士，在美国伊利诺斯技术研究院获得理学硕士。

Jeffrey is the founder and Chairman & CEO of GL Capital Group, a leading health care private equity firm in China. He was the Country President of Novartis China during 2004 - 2010. Prior to that, he worked for the Pritzker family in a number of positions of investment, advisory and general management for 11 years. Jeffrey is a member of China Entrepreneur Club, a member of Committee of 100, a member of International Board of Overseas of Illinois Institute of Technology. He is an honorary Vice Chairman of China Charity Federation, a member of China Advisory Board of The Nature Conservancy, and an independent director of Shanghai Pharma.

Jeffrey has BS from Beijing University of Aeronautics and MS from Illinois Institute of Technology.

薛　群
中国医药创新促进会药物研发专业委员会副主任委员、北海康成制药有限公司创始人、董事长兼 CEO、中国罕见病联盟副理事长

James XUE
Vice-Chairman of PhIRDA Drug R&D Specialty Committee, Founder, Chairman of the Board, Director and CEO of CANbridge, Vice Director of the China Alliance for Rare Diseases

薛群 博士，北海康成制药有限公司创始人，董事会主席、董事兼首席执行官；中国医药创新促进会药物研发专业委员会副主任委员；中国罕见病联盟副理事长、上海罕见病基金会副主任；北京大学医学部－密歇根大学医学院联合研究所领导委员会委员；TERMEER 基金会导师。薛群博士在医疗及制药公司拥有超过 22 年的丰富经验，曾任美国健赞公司（Genzyme）高管及健赞中国区第一任总经理，是一位兼具国际视野和多年本土实战经验的创业家和复合型管理者。他于 2012 年创立的北海康成，是一家立足中国、专注于罕见疾病的全球领先生物制药公司，致力于研究、开发和商业化变革性疗法。

James Xue, Ph.D., Founder, Chairman of the Board, Director and CEO, CANbridge Pharmaceuticals Inc. Dr. Xue is the Vice Chair of the R&D committee of the China Pharmaceutical Innovation and Research Development Association (PhIRDA), Deputy director general of the China Alliance for Rare Disease, Deputy director of the Shanghai Foundation for Rare Disease. He has also been a member of the Leadership Council of the Joint Institute of Peking University Health Science Center and University of Michigan Medical School, and a mentor of the TERMEER Foundation.

Dr. Xue has over 22 years of experience in medical and pharmaceutical companies. He has been a former Genzyme executive and the founding general manager of Genzyme China. He is an entrepreneur and compound manager with international vision and years of local practical experience. Established in 2012, CANbridge is a leading China-based, global rare disease-focused biopharmaceutical company committed to the research, development, and commercialization of transformative therapies.

房健民
中国医药创新促进会药物研发专业委员会副主任委员、荣昌生物 CEO 兼首席科学官

FANG Jianmin
Vice-Chairman of PhIRDA Drug R&D Specialty Committee, CEO and CSO of RemeGen

加拿大戴豪斯大学生物学博士，美国哈佛大学医学院博士后，专注癌症研究。

荣昌生物制药（烟台）股份有限公司联合创始人、首席执行官兼首席科学官；迈百瑞国际生物医药有限公司创始人、董事长。同济大学生命科学和技术学院教授、博导，山东省“泰山学者”、国家“重大新药创制”科技重大专项总体专家组成员。

房健民教授的研究主要是针对肿瘤和自身免疫疾病等重大疾病的新药研发，多项研究成果发表于 Nature Biotechnology，PNAS，Cancer Research，Molecular Therapy 等，有 40 多项发明专利，包括多个抗体药物全球专利，是泰它西普（RC18）、纬迪西妥单抗（RC48）、RC28、康柏西普等的发明者。

Professor Fang Jianmin got his PhD in Biology from Dalhousie University and worked as a post-doctoral fellow focusing on cancer research at Harvard Medical School.

He is the co-founder, CEO, and CSO of RemeGen Co., Ltd. and the founder and chairman of MabPlex International Ltd. In addition, Dr. Fang serves as professor and PhD supervisor at School of Life Science and Technology of Tongji University.Dr. Fang was recognized as Taishan Scholar by the Shandong Provincial Government and member of the scientific expert committee of the National Major Scientific and Technological Project for “Major Drug Innovations” of China.

Dr. Fang has been committed to the drug innovations for major diseases of tumor and autoimmune, and his research results have been published in Nature Biotechnology, PNAS, Cancer Research, and Molecular Therapy, etc. As the inventor of Telitacicept (RC18), Disitamab vedotin (RC48), RC28, and Conbercept, he owns more than 40 invention patents, including several global patents for antibody-based drug.

王印祥
中国医药创新促进会药物研发专业委员会副主任委员、北京加科思新药研发有限公司董事长兼 CEO

WANG Yinxiang
Vice-Chairman of PhIRDA Drug R&D Specialty Committee, Chairman and CEO of Jacobio Pharmaceuticals

北京加科思新药研发有限公司，任董事长兼 CEO。

1999 年毕业于美国阿肯色大学医学院，1999-2003 在耶鲁大学分子生物物理和生物化学系从事博士后研究。

2003 年回国创建贝达药业有限公司，任总裁兼首席科学家，主持了中国第一个有自主知识产权的靶向抗癌药凯美纳（埃克替尼）在中国的上市，该项目获国家科技进步一等奖和国家专利金奖；2013 年和美国安进在中国组建贝达安进制药有限公司 , 任总经理；2015 年创建北京加科思新药研发有限公司，任董事长兼 CEO。

中国药促会新药研究专业委员会第二届主任委员；中国药学会肿瘤药物专业委员会副主任委员；中关村企业家顾问委员会委员。

Jacobio Pharmaceuticals Co., Ltd,serving as the Chairman & CEO.

Dr. Yinxiang Wang was graduated from the University of Arkansas for Medical Sciences in 1999,and served as a postdoctoral research fellow at the Department of Molecular Biophysics and Biochemistry of Yale University from 1999 to 2003.

He returned to China in 2003 and founded Betta Pharmaceuticals,and served as the President and CSO of Betta Pharmaceutiacals,developed Icotinib Hydrochloride (Conmana®),a new molecular entity (NME) for lung cancer. This novel drug is the first small molecule anticancer drug that is completely developed in China and approved by CFDA in 2011.The project won the 1st prize of National Science , the gold medal of WIPO-SIPO Award; Betta formed JV with Amgen (Amgen-Betta Pharmaceuticals) in 2013 and Dr. Wang served as GM.

In 2015, he founded Jacobio Pharmaceuticals in Beijing and serving as the Chairman & CEO.

Dr. Wang is the second chairman, New Drug R&D Committee of China Pharmaceutical Innovation and Research Development Association (PHIRDA); Associate Chairman, Oncology Drug Clinical Research Committee of Chinese Pharmaceutical Association;Member of Zhongguancun Entrepreneur Advisory Committee.

鲍海洁
香港交易所董事总经理、市场拓展联席主管

Christina BAO
Managing Director, Co-Head of Sales & Marketing of HKEX

鲍海洁女士，现担任香港交易所董事总经理及市场拓展联席主管，为拟到香港上市的全球发行人提供服务，并推动香港交易所战略项目发展。鲍海洁女士于 2016 年加入香港交易所，曾担任行政总裁办公室总管，负责香港交易战略项目推动和业务综合管理。在加入香港交易所前，鲍女士自 2001 年起曾在平安银行和深圳发展银行担任不同管理职位，包括曾任深圳发展银行董事长兼行政总裁办公室总管，负责战略专案、投资者关系和公共关系管理。鲍女士曾全面负责深圳发展银行和平安银行的两行整合项目。两行整合完成后，鲍女士担任了平安银行零售网络金融事业部总裁等职务。

鲍女士于北京大学获取工商管理硕士学位（金融系）。

Ms Christina BAO, Managing Director, is currently the Co-Head of Sales & Marketing at HKEX.

Ms Bao joined HKEX in 2016 as the Chief of Staff, reporting to the CE of HKEX. She was responsible for the planning and oversight of the Group's strategic projects.

Prior to joining HKEX, Christina held a number of senior positions at Ping An Bank (previously at Shenzhen Development Bank, which merged with Ping An Bank in 2010) since 2001. At Shenzhen Development Bank, she served as the Chief of Staff to the Chairman and CEO from 2005 until 2010, and was responsible for the bank's strategic projects, Investor Relations and Public Relations. After the merger and integration of the two banks, she headed Retail e-Banking, Service & Marketing, and the Retail e-Finance Strategic Business Unit for Ping An Bank.

Ms Bao received her Master of Business Administration (Finance, General) from the Peking University of Mainland China.

陈　飞
礼来亚洲基金管理合伙人

CHEN Fei
Managing Partner of Lilly Asia Ventures

陈飞博士是礼来亚洲基金管理合伙人，负责礼来亚洲基金的投资决策并参与全面管理礼来亚洲基金。陈飞博士自 2009 年起先后投资了贝达药业 (300558.SZSE)、微芯生物 (688321.SHSE)、荣昌生物 (09995.HKSE) 等标杆性的中国创新药物研发企业以及英派药业、科州药业、益方生物、博雅辑因、亘喜生物 (GRCL.US)、艾力斯医药 (688578.SHSE)、迪哲医药、宜明昂科、康乃德生物 (CNTB.US)、科济药业 (02171.HKSE)、新码生物、普方生物等极具潜力的创新药物研发企业，和博瑞生物 (688166.SHSE)、兴齐眼药 (300573.SZSE)、欧米尼医药、华威医药、奥翔药业 (603229.SHSE) 等行业领先的专科药品企业以及品驰医疗、微泰医疗、鹏远基因、华脉泰科、沛嘉医疗 (09996.HKSE)、亚辉龙生物 (688575.SHSE)、熙华检测、世和基因、丰凯医疗、徕瑞医疗、华大因源、颐坤生物、新羿生物、新光维医疗等创新医疗器械体外诊断和研发外包企业。

陈飞博士拥有复旦大生物学学士学位和复旦大学医学分子遗传学博士学位。他同时也是美国百华协会（BayHelix）成员。

Fei Chen, Ph.D., is a Managing Partner with Lilly Asia Ventures (LAV) and responsible for LAV's investment decision and fund management. Since 2009 Dr. Chen's investments list includes leading Chinese biotech companies such as Betta Pharma (300558.SZSE), Chipscreen Bio (688321.SHSE), RemeGen (09995.HKSE), Impact Therapeutics, Kechow Pharma, Inventis Bio, Edigene, Gracell Bio (GRCL.US), Allist (688578.SHSE), Dizal, ImmuneOnco, Connect (CNTB.US), CARsgen, NovoCodex, and Profound etc., leading Chinese specialty pharms such as BrightGene (688166.SHSE), Sinqi Eye (300573.SZSE), Omni, Huawei, Ausun Pharma (603229.SHSE) etc., and leading medtech/IVD/CRO companies such as Pins, Microtech, Singlera Genomics, Purcutek, Peijia (09996.HKSE), YHLo Bio, Xihua Scientific, Geneseeq, Forqaly, LavaMed, BGImNGS, Virtue Dx, TargetingOne, and Scivita etc.

Dr. Chen holds a Ph.D. in molecular genetics and a Bachelor's degree in biology from Fudan University, he is a member with BayHelix Group.

杨大俊
中国药促会药物研发专业委员会主任委员、亚盛医药董事长兼 CEO

YANG Dajun
Chairman of PhIRDA Drug R&D Specialty Committee, Chairman of the Board & CEO of Ascentage Pharma

杨大俊博士是亚盛医药董事长兼首席执行官，同时兼任中山大学肿瘤防治中心教授及博导、中国药促会研发专委会主任委员、中科院上海药物所新药产业兼职研究员等职位。杨博士专注肿瘤学、细胞凋亡机理与新药研发近 30 年。他于 2009 年共同创办亚盛医药，并在细胞凋亡及自噬双通道调节新靶点药物开发领域内取得重大突破。亚盛医药作为全球唯一在该领域形成通道多靶点药物全布局的企业，成功将 8 项具有全球范围内“First-in-class”或“Best-in-class”类潜力原创新药推进到中国、美国、澳大利亚、欧洲多地临床开发阶段。杨大俊博士先后承担国家“863”专项、重大新药创制专项等重大科研攻关项目近 10 项。他带领团队获得江苏省及苏州重大创新团队、首届江苏省创新争先团队奖、百华协会 2017 年度研发成就奖等多项殊荣，并荣获 2018 独墅湖杯“最具影响力药物研发领军人物奖”，在原创新药研发领域拥有广泛的影响力。

Dajun Yang, Ph.D.,is the Co-Founder, Chairman of the Board, and Chief Executive Officer of Ascentage Pharma. Dr. Yang has dedicated his career to the research on apoptosis and innovative drug R&D for nearly 30 years. In 2009, he co-founded Ascentage Pharma and made major breakthroughs in the research of development of precision drugs targeting apoptosis and autophagy dual-channel regulation. Ascentage Pharma is the only company in the world that researches and develops innovative drugs targeting all of these pathways. Ascentage Pharma currently has eight potential “First-in-class” or “Best-in-class” innovative drug candidates in Phase I/II clinical developments in China, the United States, Australia and Europe. Dr. Yang has undertaken nearly ten National Science and Technology Major Projects such as the National High-tech R&D Program (the “863 Program”) and the Major Innovative Drug Developments program. The team led by Dr. Yang has won multiple awards such as the Major Innovation Team of Suzhou and Jiangsu, the First Jiangsu Innovation Competition Team Award, and the R&D Achievement of the Year 2017 from the BayHelix Group. Dr. Yang is the recipient of the 2018 “Dushu Lake Prize” for the Most Influential Leader in Drug R&D, an award widely recognized in the field drug R&D.

陈晓光
中国药促会药物研发专业委员会委员
中国医学科学院药物研究所药理室主任

CHEN Xiaoguang
Member of PhIRDA Drug R&D Specialty Committee
Director, Department of Pharmacology, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College

陈晓光博士，研究员，现为中国医学科学院药物研究所药理室主任，天然药物活性物质与功能国家重点实验室副主任。首批新世纪“百千万人才工程”国家级人选，国务院特殊津贴专家。曾获得首届 DEBIOPHARM-CCRF 中国奖一等奖。1996 年、1997 年、2001 年作为客座教授或访问学者先后到日本、瑞士、美国相关大学和研究机构从事研究工作。长期从事肿瘤分子药理学及新药创制研究。主要研究领域为抗肿瘤药物研究新靶点、信号通路抑制剂以及与免疫治疗密切相关的新药研究。发表学术论文 150 余篇；申请国内外专利 60 余项，获得授权专利 40 项，主编研究生教材 3 部，主持多个创新药物的研发。作为项目总负责人已完成 5 个 1 类化药的成果转化，转让总额近 5 亿元人民币， 所研发的小分子肿瘤免疫治疗新药在国内外处于领先地位。在小分子新药的基础研究、新药创制与开发中取得显著成绩。

Xiaoguang Chen, Director of Pharmacology Department of IMM, CAMS&PUMC, Deputy Director of the State Key Laboratory of Active Substances in Natural Medicines. She was elected as Millions of Talent Projects National candidates and awarded the State Council Special allowance. She has won the first prize of the first DEBIOPHARM-CCRF China Award. In 1996, 1997, and 2001, she worked as a visiting professor or visiting scholar in related universities and research institutions in Japan, Switzerland, and United States. Her major is in the research of cancer molecular pharmacology and new drug development. Her main research areas are new targets for anti-tumor drug research, signaling pathway inhibitors, and new drug research closely related to immunotherapy. She has published more than 150 academic papers, applied for more than 60 domestic and foreign patents, obtained 40 authorized patents, edited 3 postgraduate textbooks and developed several innovative medicines. As the head of the project, she has completed 5 patent transfers of Class 1.1 new drugs with a total package of nearly 500 million RMB. The new drug for small molecule cancer immunotherapy she has developed is at the leading position in china and abroad. She has made significant achievements in basic research and R&D of small molecule drugs.

李文斌
中国药促会脑神经药物临床研究专委会副主任委员兼秘书长
首都医科大学附属北京天坛医院肿瘤综合治疗中心主任

LI Wenbin
Vice-Chairman & Secretary-General of PhIRDA Clinical Research on Cranial Nerve Drugs Specialty Committee
Director of Cancer Center, Beijing Tiantan Hospital, Capital Medical University

李文斌，主任医师、教授，博士生导师，首都医科大学附属北京天坛医院肿瘤综合治疗中心主任，国家健康医疗大数据（首医）研究院院长助理，首都医科大学肿瘤学系主任，中国药促会脑神经药物临床研究专业委员会副主委，中国医师协会脑胶质瘤专业委员会常委，中国抗癌协会期刊出版部部长，脑胶质瘤专业委员会副主委兼秘书长，《Signal Transduction and Targeted Therapy》和《Cancer Biology & Medical》编委，《中国卫生标准管理》总编辑，《医学参考报神经肿瘤专刊》主编，北京市中西医双领军专家，2020 年国之名医优秀风范，美国南佛罗里达大学名誉研究员。善长颅内恶性肿瘤的化疗和药物临床试验研究。主持两项国家十三五重点创新药物 I 期临床试验。美国 GBM AGILE 国际多中心临床试验中国总协调人。

Wenbin Li, Chief physician, Professor, Doctoral supervisor, Director of Cancer Center of Beijing Tiantan Hospital affiliated to Capital Medical University, Assistant to the Dean of National Institute of Health Data Science at Capital Medical University, Director of Department of Clinical Oncology at Capital Medical University, Vice chairman of Clinical Research on Cranial Nerve Drugs Specialty Committee of China Pharmaceutical Innovation and Research Development Association, Standing Committee of Society for Neuro-Oncology of China, Director of Department of Journal and Publishing of China Anti-Cancer Association, Vice chairman of the Society of Neuro-Oncology of China Anti-Cancer Association, Editorial board member of《Signal Transduction and Targeted Therapy》and《Cancer Biology & Medical》, Editor-in-chief of《China Health Standard Management》, Chief editor of《Medical Reference》, Leading Talent of Beijing Traditional Chinese and Western Medicine, The famous doctor of China--Excellent demeanor in 2020, Honorary Research Fellow of University of South Florida of America. He was dedicated to chemotherapy for malignant tumors and clinical trial for drugs, and leaded 2 first-in-class drugs clinical trials of National Science and Technology Major Project. China General coordinator for international multicenter clinical trial-GBM AGILE.

胡超苏
复旦大学附属肿瘤医院主任医师，教授，博士生导师

HU Chaosu
Chief Physician, Professor, Doctoral Supervisor, Fudan University Shanghai Cancer Center

胡超苏教授为复旦大学附属肿瘤医院主任医师，教授，博士生导师，放射治疗中心副主任，鼻咽癌首席专家。胡教授分别于 1994 年和 2004 年在美国 William Beaumont 医院放射治疗科和 MD Anderson 肿瘤中心放射治疗科进修。从事肿瘤的放射治疗及综合治疗工作 30 余年，对鼻咽癌等头颈部肿瘤的放射治疗及综合治疗具有丰富的临床经验。发表论文 130 余篇，主编或参与编写多部书籍及教材，组织或参与多项全球或全国多中心前瞻性临床研究。并获得教育部、核工业部，上海市、中国抗癌协会科技奖等。现任中国临床肿瘤学会头颈肿瘤专家委员会候任主委，中国临床肿瘤学会鼻咽癌专家委员会副主任委员，中国抗癌协会鼻咽癌专业委员会前任主任委员等社会职务。

Professor Chaosu Hu worked as the chief physician, professor, doctoral supervisor of Fudan University Shanghai Cancer Center, he is the deputy executive director of the radiation therapy center and the chief expert on nasopharyngeal carcinoma. Professor Hu studied at William Beaumont Hospital in 1994 and MD Anderson cancer center in 2004. He has been devoted to tumor radiation and systemic therapy for over 30 years while maintaining profound knowledge and experience on the treatment of head and neck cancer, especially nasopharyngeal carcinoma. Professor Hu has published over 130 articles, worked as the chief editor taking part in editing multiple books and teaching materials. He has also organized and taken part in multiple global and national multi-center prospective clinical trials. Professor Hu has won many prizes and awards from the Ministry of education, Ministry of nuclear industry, Shanghai municipal and Chinese Anti-Cancer Association, etc. He is also a key member of many medical associations, such as the president-elect of CSCO experts committee on head and neck cancer, vice president of CSCO experts committee on nasopharyngeal carcinoma, former president of CACA experts committee on nasopharyngeal carcinoma, etc.

马建华
南京医科大学附属南京医院内分泌科主任、主任医师，教授，博士生、博士后导师

MA Jianhua
MD, PhD, Professor. Advisor of Doctoral and Postdoctoral Research. Director of Department of Endocrinology, Nanjing First Hospital

马建华博士，南京医科大学附属南京医院（南京市第一医院）内分泌科主任，南京市糖尿病防治中心主任，主任医师，南京医科大学教授，博士生、博士后导师。

现任中华医学会糖尿病学分会常委，中国医师协会内分泌代谢科医师分会委员，中华糖尿病学会 β 细胞学组组长，江苏省中西医结合学会内分泌学分会主任委员，江苏省医学会内分泌学分会候任主任委员，南京医学会内分泌学分会主任委员。

中华糖尿病杂志、医学研究生学报、国际内分泌代谢杂志、Diabetes 中文版编委、Endocrine Reviews 中文版编委。参与指南、专家共识编写 9 部，参编中文专著 12 部，英文专著 1 部，中文核心期刊 300 余篇，SCI 收录 70 余篇。

南京市中青年行业学科带头人，南京市 213 人才工程培养对象，南京市好市民。

Jianhua Ma, MD, PhD, Professor and Director at Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University. He is also an advisor of Doctoral and Postdoctoral research and a Director of Nanjing Diabetes Prevention and Treatment Center.

At present, Dr. Ma is a member of Standing Committee and a Team Leader of β-Cell Cytology Investigation Group at Chinese Diabetes Society (CDS), a committee member of Chinese Endocrinologist Association (CEA). Dr Ma holds a position of Current President at Jiangsu Endocrinology Society of Integrated Chinese and Western Medicine, President-elect of Jiangsu Endocrinology Society, Current President of Nanjing Endocrinology Society.

Dr. Ma serves as an editorial board member of Chinese Journal of Diabetes, Journal of Medical Postgraduates, International Journal of Endocrinology and Metabolism, Diabetes (Chinese Version) and Endocrine Reviews (Chinese Version). He participated in the writing and editing of 9 guidelines and expert consensus, 12 Chinese monographs and 1 English monograph. He has published more than 300 papers in Chinese core journals, with additional more than 70 papers indexed by SCI.

Dr. Ma is also awarded as Academic Leader of Nanjing Young and Middle-Aged Industry, Training Object of Nanjing 213 Talent Project and Nanjing Good Citizen.

秦志杰
武汉禾元生物科技股份有限公司首席医学官

QIN Zhijie
CMO, Wuhan Healthgen Biotechnology Corp.

秦志杰博士，山东医学院（现山东大学齐鲁医学院）临床医学专业，中国科学院与日本関西医科大学联合培养博士，美国加利福尼亚大学博士后，通过美国医师协会 Board 资格获 ECFMG 认证医学博士。先后担任美国加利福尼亚大学圣克鲁斯分校研究员、美国 TOSK 制药公司临床研究科学家、AnaSpec 生物公司资深科学家和企业发展策划专家、美国 ReLIA Diagnostic 公司医学和市场总监、丹诺医药（苏州）有限公司临床医学副总裁。秦志杰博士具有小分子和抗体蛋白大分子新药研发、FDA 临床试验申报（IND）和临床试验的实验设计和管理经验。2021 年 2 月加入武汉禾元生物科技股份有限公司，担任首席医学官，并指导公司 HY1001 重组人白蛋白和 HY1002 重组人乳铁蛋白项目的临床 II 期试验。

QIN Zhijie, MD., PhD., finished his medical school course at Shandong Medical College (current the Shandong University Qilu Medical School). He then completed his doctoral work at the Institute of Biophysics at Chinese Academy of Sciences, and Kansai Medical University in Japan, in biochemistry, biophysics, and molecular biology. He has been extensively trained in biomedicine at the University of California at Santa Cruz working as a postdoctoral researcher and succeeded the USMLE (US Medical License Examinations) and obtains the Certificate of Medical Degree from ECFMG in United States. From there he has worked as a senior scientist at TOSK, a start-up pharmaceutical firm, to develop new small molecular drugs in oncology. After TOSK, he jointed a biotech company named AnaSpec working as a senior scientist in antibody development and left as a manager of Antibody department. Later, Dr. Qin joined ReLIA Diagnostic as Director of Marketing and Clinical Medicine. In 2018, Dr. Qin jointed TenNor Pharmaceutics at Suzhou as Vice President of Clinical Development to take charge in the clinical studies of their novel anti-microbe products, and successfully conducted Phase 1 and Phase 2 studies internationally. In 2021, Dr. Qin jointed Wuhan Healthgen in the role of Chief Medical Officer to lead the clinical study team.

张　丹
中国药促会药物研发专业委员会副主任委员、俄罗斯工程院外籍院士
昆翎医药联合创始人兼首席战略官

ZHANG Dan
Vice-Chairman of PhIRDA Drug R&D Specialty Committee,
Foreign Academician of Russian Academy of Engineering,
Co-founder and Chief Strategy Officer of ClinChoice

张丹博士是中国医药创新促进会理事，曾任中国医药创新促进会药物研发专业委员会主任委员，现任创新研发服务专业委员会副主任委员。曾任美中生物医药科技协会（CBA）会长，美中药物专业协会（SAPA）执行董事，百华协会（Bayhelix）董事。现任国家“十三·五”重大新药创制计划责任专家，并参与国家药品监督管理局药审中心的技术指南制订和新药临床评审及药审人员培训工作。目前担任国际 ICH E19 IFPMA 专家委员会组长，NMPA ICH 工作组专家。

张丹博士于 1981-1984 年在北京大学生物系医预科就读，并在 1984-1989 年在北京协和医科大学学习临床医学并获医学博士学位，之后先后在哈佛大学公共卫生学院，宾州大学沃顿商学院等院校进修医院管理，经济学及金融学等，获公卫硕士、医院管理硕士及在读金融学博士。

Dr. Zhang is a member of grant review committee for National Drug Development Fund of China, and is also a consultant for the National Medical Products Administration (NMPA). He is a member of ICH E19 Expert Working Group. He is also chairing the committee of Pharmaceutical R&D, China Pharmaceutical Industry Research and Development Association. Dr. Zhang is also a senior consultant for the Chinese Academy of Medical Sciences and Peking Union Medical College. He was a member of the Expert Committee on New Drug R&D for the Ministry of Science and Technology of China. Dr. Zhang was the former board of director for the Sino-American Pharmaceutical Association (SAPA) and was the former president of Chinese Biopharmaceutical Association-USA (CBA). Dr. Zhang is chairing the government relationship committee of Bayhelix - an organization hosting senior executives from life science organizations in USA and China.

Dr. Zhang received his pre-med training from Peking University and received M.D. from Peking Union Medical College. He then went to the Harvard School of Public Health and received MPH in health policy and management. Then he went to the Wharton Business School of the University of Pennsylvania, where he obtained his master’s degree in healthcare management in 1998.

刘利平
深圳君圣泰生物技术有限公司创始人兼首席执行官

LIU Liping
Founder&CEO, Shenzhen HighTide Biopharmaceutical Ltd.

刘利平博士为君圣泰创始人及首席执行官，全面负责公司的运营、资金募集、指导药物的研究及开发等。她作为发明人开发的治疗糖尿病的药物获得美国 FDA 批准上市，且参与了 10 多个新药注册申报，申请和授权的发明专利超过 100 个。刘博士拥有丰富的药物研发经验，对慢性肝病、胃肠道及代谢类疾病的复杂病因及发病机理形成了独到的见解。

刘博士于 1994 年获得南开大学高分子化学与物理博士学位，之后赴加拿大多伦多大学及病童医院 Dr.Charles Deber 实验室从事博士后研究。2006 年刘博士获得了美国约翰霍普金斯大学凯利商学院授予的 MBA 学位。刘博士在行业及商界获得多项殊荣，其中分别包括知名行业及商业媒体评选的“Biotech 15 人”、“2021 年值得关注的女性创业领袖”、“十大创新科学家”等。

Liping Liu is the founder and CEO of HighTide, who is fully responsible for HighTide’s daily operation, fundraising, leading drug research and development, etc.She is a named inventor of an FDA approved diabetes drug and was involved with over 10 IND submissions and 100+ international patent applications and issuance. Through her extensive drug research and development experience, Dr. Liu has formed insights and perspectives on the complex etiology and pathogenesis of chronic liver, gastrointestinal and metabolic diseases.

Dr. Liu received her doctoral degree from Nankai University in 1994, completed post-doctoral training in University of Toronto, and received MBA degree from Johns Hopkins University Carey Business School in 2006.Dr. Liu has received many awards in the industry and business circles, including “Top 15 Biotech Leaders” “2021 Top 30 Female Entrepreneurs to Watch” and “Top 10 Innovative Scientists” selected industry and business media.

王庆华
国家特聘专家，上海银诺医药技术有限公司董事长兼 CEO

WANG Qinghua
State Specially Recruited Experts, CEO & General Manager of Innogen Pharmaceutical Technology Co., Ltd.

博导，复旦大学特聘教授，华山医院内分泌科教授，复旦大学内分泌糖尿病研究所副所长。十二五、十三五国家科技“重大新药创制”项目负责人，还担任 CDE 药审、国家重大专项、NSFC 重点基金、国家创新人才及人才基金包括长江学者，杰青等评审评专家。他的团队注重胰岛生理、β 细胞再生的机制研究 , 致力于糖尿病转化医学。王博士是苏帕鲁肽等糖尿病创新药的首要发明人，目前还兼任加拿大圣米高医院胰岛生理实验室主任，担任多种国际科研和奖励基金的评委（包括美国 NIH，JDRF，英国 MRC，加拿大 CIHR）和多个国际前沿科学期刊的编委，兼任瑞典 Diamyd Medical 公司的科学医学顾问。

Doctoral advisor, Distinguished Professor of Fudan University, Professor of Endocrinology Department of Huashan Hospital, Deputy head of Fudan University Institute for endocrine and diabetes. Project leader of National Major Scientific and Technological Special Project for “Significant New Drugs Development” during the Twelfth Five-year Plan Period and the Thirteenth Five-year Plan Period. Professor Wang also served as an evaluation expert in CDE drug review, national major special projects, NSFC Key Fund, National Innovation Talent and Talent Fund, including Cheung Kong Scholars Programme, The National Science Fund for Distinguished Young Scholars. His team focuses on islet physiological function, β cell regeneration mechanisms, and is dedicated to diabetes translational medicine. Professor Wang is currently the Director of islet Physiology Laboratory at St. Michael's Hospital in Canada, a judge of a variety of international research and awards funds (including NIH, JDRF, MRC, CIHR) and member of editorial board of several international scientific journals, as well as a scientific medical consultant at Diamyd Medical.

王　敏
瑞石生物医药公司创始人兼首席执行官

WANG Min
Co-Founder & CEO of Reistone Biopharma

王敏博士是瑞石生物医药公司的 CEO，瑞石医药立足中国上海张江从事全球医药开发。

王博士具有 20 多年在大型跨国制药公司工作的经验并持有高级领导职位。她组建过多个完整的药物临床开发团队，包括临床开发、医学事务和法规事务，药品安全和医学信息、项目管理等团队。在她的领导下共获得大约 20 个新药和新适应症在中国和加拿大的快速批准上市，同时她也参与多个公司新药技术产品转让及合作成功项目。

王敏毕业于重庆第三军医大学获医学学士和硕士学位，后就读加拿大多伦多大学并获临床生物化学的博士学位。在中国工作 10 多年期间，曾担任拜耳中国 / 香港医学事务副总裁，葛兰素史克上海研发中心中国药品开发部副总裁， 和日本武田制药亚洲 / 上海开发中心副总裁及总经理，领导负责全球新药在中国和亚洲的临床开发和上市。

Dr. Min Wang Irwin is the CEO of Reistone Biopharma which is incorporated in Shanghai Zhangjiang in January 2018. Most recently, Dr. Irwin worked in Qiming Venture Partners as venture partner. Dr. Irwin has brought more than 20 years' experience in RD, partnering, market access and organization development in global and China. She has established several big medical and development teams including product development, medical affairs, regulatory affairs, project management as well worked closely with company commercial teams for product lunch and life cycle management. In addition, she worked extensively with BD to complete several product licensing deals. Under her leadership, teams had successfully received NDA approval for close to 20 drugs in small molecules, biological products, medical devices and consumer healthcare products across many therapeutic areas in China and Canada.

Dr. Irwin worked at Takeda as VP, site head of Takeda Development Center Asia. She also worked in GlaxoSmithKline's R&D Center in Shanghai where she served as Vice President China Medicine Development since January 2013. Prior to joining GSK, she was with Bayer Healthcare for 13 years in China and Canada. Dr. Irwin's career also includes Clinical Science and Research with Parke-Davis and biotech startup company, Dimethaid Pharmaceutical.

Dr. Irwin has a Ph.D. in Diabetes Research from University of Toronto, a Master of Science degree in Anti-Infection after Burn Injury and a Doctor of Medicine, both from Third PLA Medical University in China.

张　虹
甫康药业首席医学官

Helena ZHANG
Chief Medical Officer, Convalife

张虹，Helena，是甫康药业首席医学官（CMO）。25 年来在中国和美国药品和医疗器械领域，从产品研发到上市的生命周期管理方面的经验。她熟悉国内创新药公司和跨国企业的运作 。她曾任昆泰大中华区首席医学管。成功主导过多项新药临床开发项目。在医学、临床运营、方案设计等方面拥有丰富经验。她曾在法国皮尔法伯制药、Parexel 等外资制药企业和 CRO 担任亚太临床和医学负责人。也曾担任中国临床肿瘤学会 (CSCO) 临床研究和药物安全委员会委员。

参加编审多本医学书籍、撰写并发表 SCI 文章，曾任 CMAO（中华医学事务）医学联络官专委会主席。张医生毕业于上海交通大学医学院并在英国卡迪夫商学院获得工商管理学硕士（MBA）。她曾在临床呼吸内科工作。在美国印第安纳州大学医学中心工作了 4 年 , 于 2006 年回国后一直从事临床研发和医学事务工作。

Helena, MD, MBA is the Chief Medical Officer (CMO) of Convalife. Dr. Zhang joined the biopharmaceutical industry in 1996 and had gained a wealth of experience on product life-cycle management both in the field of drug and medical device in China and US. She was the Chief Medical Officer for Quintiles, now IQVIA in the Greater China region. She is familiar with the operation of domestic innovative drug companies and multinational companies. She has successfully led a number of new drug clinical development projects. Her rich experiences cover medical, clinical operation and study design etc. She served as the head of clinical and medical of Asia Pacific region in MNC pharmaceutical company and CRO such as Pierre Fabre medicament and Parexel. She also served as the key board member of the clinical research and drug safety committee of the Chinese Society of Clinical Oncology (CSCO).

She wrote and published SCI papers, and served as the Chairman of Medical Science Liaison Committee, CMAO (Chinese Medical Affairs Organization). Dr. Zhang graduated from the medical school of Shanghai Jiaotong University and obtained a master of Business Administration (MBA) from Cardiff Business School in the UK. She practiced clinical medicine in the hospital. She worked in the medical center of Indiana University, US for four years and has been engaged in clinical development and medical affairs since returning home in 2006.

贾正虎
贝罗尼集团副总裁

JIA Zhenghu
Vice President of Beroni Group Limited

贾正虎博士，贝罗尼集团副总裁，暨南大学生物医学转化研究院免疫与微生态实验室主任，暨南大学国际免疫中心 PI。山东大学医学院临床医学学士，南开大学免疫学硕士、博士，暨南大学附属第一医院博士后。美国哥伦比亚大学和日本昭和大学访问学者。曾任武汉普锐医学检验实验室主任，拥有抗肿瘤新药研发及体外诊断行业近十年的管理经验。2017 年加入贝罗尼集团（OTCQX: BNIGF; NSX: BTG），担任精准医疗国际研究中心总裁，2019 年晋升为集团副总裁，成功引进 PENAO 抗肿瘤小分子药和 DC 肿瘤疫苗等项目。目前已开启全国多中心临床试验 13 个，作为企业发起人与第三方合作的医学项目超过 50 个。获省部级奖项 4 项，在国外期刊发表 SCI 文章 10 篇，已获得授权的专利 30 个。主持研发的检测试剂获批国家科技部重点专项。

Dr. Zhenghu Jia is the vice president of Beroni Group, director of Immunology and Microecology Laboratory, Biomedical Translational Research Institute, Jinan University, PI of International Immunization Center, Jinan University, bachelor of Clinical Medicine, Shandong University School of Medicine, master of Immunology and doctor of Nankai University, postdoctoral of the First Affiliated Hospital of Jinan University, visiting scholar of Columbia University and Showa University in Japan. He once served as the director of Wuhan Purui Medical Laboratory, and has nearly ten years of management experience in the research and development of new antitumor drugs and in vitro diagnosis industry. In 2017, he was hired by Beroni Group (OTCQX: BNIGF; NSX: BTG) as the president of Precision Medicine International R&D Center, and was promoted to the Group's vice president in 2019. During his tenure, he successfully introduced projects such as PENAO, an anti-tumor small molecule drug and DC tumor vaccine. At present, he has participated in 13 multi-center clinical trials nationwide, and has cooperated with third parties for more than 50 medical projects as an initiator. He has won 4 provincial and ministerial awards, has published 10 SCI articles in foreign journals, and has obtained 30 authorized patents. The detection kit which he directed was approved as a key special project by the Ministry of Science and Technology.

谷成明
赛诺菲大中华区医学部负责人

GU Chengming
Greater China Medical Head, Sanofi

谷成明博士现任赛诺菲大中华区医学部负责人，中山大学和河北大学科技学院 客座教授，罗格斯大学罗格斯商学院董事会成员，中国外商投资企业协会药品研 制和开发行业委员会 (RDPAC) 医学事务组主席，中国卫生经济学会基层卫生经济 专业委员会副主任委员，卫生费用与政策专业委员会常委，中华预防医学会慢性 病预防与控制分会副主任委员。谷博士为北京协和医院医学博士，新泽西州立大学罗格斯商学院 EMBA。有着 15 年在国内外医疗机构作为医生或访问学者的临床医疗经验和 20 年大型跨国制药 公司医学部工作经验。

Dr. Gu Chengming is working at Sanofi as Greater China Medical Head.

Dr. Gu is also professor in Sun Yat-Sen University and University of Hebei Science and Technology, Board member of Rutgers Business School, Rutgers University, Chairman of RDPAC medical group, Vice Chairman of Prevention and Control of NCD committee, Chinese Preventive Medical Association and Vice Chairman of Public Health Economic Committee, Chinese Health Economic Association.

Dr. Gu obtained his PhD from Peking Union Medical College Hospital and his EMBA from Rutgers business school, the State University of New Jersey.

孙　喆
中国医药创新促进会医药创新数字化推进办公室主任

SUN Zhe
Director, Pharmaceutical Innovation Digitalization Promotion Office (PhiRDA)

孙喆，现担任中国药促会医药创新数字化推进办公室主任，致力于推动中国医疗产业的数字化转型工作。在此之前，曾作为联合创始人创立医渡科技，并长期担任公司 CEO。同时，创立时节投资，担任管理合伙人，具有十多年的医疗行业实践及投资经验。

Sun Zhe is currently the director of Pharmaceutical Innovation Digitalization Promotion Office of PhiRDA, dedicated to promoting the digital transformation of China's medical industry. Mr. Sun founded Yidu Technology as a co-founder and served as the company's CEO for a long time. At the same time, he founded Momentum Venture and has more than ten years of medical industry practice and investment experience.

薛　贵
北京师范大学认知神经科学与学习国家重点实验室教授

XUE Gui
Principal Investigator at State Key Laboratory of Cognitive Neuroscience and Learning in China

薛贵 , 北京师范大学教授，麦戈文脑研究院 PI，长江学者特聘教授，北脑学者，博士生导师。主要从事人类学习和记忆的认知及神经机制研究，包括记忆编码、提取和巩固和优化，执行功能、决策与适应性学习，以及语言和第二语言学习等。以第一作者或者通讯作者身份在 Science, PNAS, TiCS，Current Biology, eLife, Journal of Neuroscience, Cerebral Cortex 等学术刊物上发表 100 多篇具有影响力的学术论文。目前担任 Cortex 杂志副主编，《心理学报》编委。近年来主持国家自然科学基金重点项目、973 课题，中以国际合作项目等项目。获教育部自然科学一等奖（2013，2019），入选爱思唯尔中国心理学高被引学者（2019，2020）。

Dr. Xue is a Professor at Beijing Normal University, a Principal Investigator at IDG/McGovern Institute for Brain Research. He is also a ChangJiang Chair Professor and a distinguished Scholar in Chinese Institute for Brain Research, Beijing.

Dr. Xue is mainly engaged in the research on cognitive and neural mechanisms of human learning and memory, including memory coding, extraction, consolidation and optimization, executive function, decision-making and adaptive learning, language and second language learning. As the first author or corresponding author, Dr. Xue has published more than 100 academic papers in high-impact journals such as Science, PNAS, TiCS, Current Biology, eLife, Journal of Neuroscience, Cerebral Cortex, etc. He is currently the Deputy Editor in Chief of the journal Cortex and serves on the editorial board of Journal of Psychology. In recent years, Dr. Xue has taken a leading role in National Science Foundation key projects, 973 Projects, and many international collaborative projects between China and Israel. Dr. Xue has won the first prize in natural science given by the Ministry of Education in 2013 and 2019, and was selected as Elsevier's highly cited scholar in Chinese psychology in 2019 and 2020.

王承志
北京镁伽科技有限公司首席科学家

WANG Chengzhi
Chief Scientist, Megarobo Technologies Co.

王承志博士毕业于北京大学医学部。先后在美国密苏里大学癌症研究中心、北京生命科学研究所（NIBS）和中科院生物物理所从事肿瘤靶向治疗、基因表达调控等研究工作。进入产业界后先后在知名创新药 CRO 和药企从事新药研发和临床试验相关工作。现担任镁伽科技生命科学事业部副总裁和首席科学家。

Dr. Cheng-Zhi Wang was graduated from Peking University Health Science Center. He then did tumor targeted therapy and gene regulation research at the Cancer Research Center of Missouri University (USA), the National Institute of Biological Sciences (NIBS) and the Institute of Biophysics of the Chinese Academy of Sciences. After shifting to the industry, Dr. Wang has successively engaged in innovative drug R&D and clinical trials in well-known CROs and pharmaceutical companies. Dr. Wang is currently the Vice President of the Life Science Business Unit and Chief Scientist of Megarobo.

郭镕恺
前肯尼索州立大学终身教授、VR+ 行为学科学家

GUO Rongkai
Tenured Associate Professor, Kennesaw State University & VR + Behavior Scientist

郭镕恺博士从事虚拟现实 (VR)/ 增强现实 (VR) 康复研究十余年。他在科研中专注于 VR/AR 中的人机交互和用户体验，尤其是对特殊人群的设计。他进行了世界上第一项关于 VR 如何影响具有行动障碍的人群的基础研究。自 2010 年以来，郭博士和 Dr. John Quarles 发现了行动障碍人群对虚拟环境的反应与健康人群的差异，并开始提出针对无障碍虚拟环境设计的通用指南。郭博士针对视觉障碍人群的研究调查获得了美国国家科学基金会的科研基金。

郭博士曾带领团队为 Marmon 集团（巴菲特 Berkshire Hathaway 持有）旗下铁路服务公司设计开发了一系列安全培训环境，为建筑公司设计开发了 VR 安全知识测评系统，为当地电力公司设计开发了 VR 货车检测训练环境。郭镕恺博士的工作和实验室曾多次被美国多家当地媒体报道。

Dr. Rongkai Guo has been researching the VR for rehabilitation for more than ten years. His expertise primarily focuses on Human-Computer Interactions and User Experiences in VR/AR, especially for the special populations. He conducted the FIRST basic research study IN THE WORLD that formally investigated how VR impacts persons with mobility impairments. Since 2010, Guo and Quarles have discovered that persons with mobility impairments have different reactions to a virtual environment than healthy persons and have begun to derive generalizable guidelines for accessible virtual environment design, which has been published in peer-reviewed scholarly journals. Dr. Guo also investigated if/how people with visual impairments experience the AR environment differently, funded by the National Science Foundation in the US.

In addition, Dr. Guo led a team that designed and developed a series of safety training environments for a rail service company under Marmon Group, which held by the Berkshire Hathaway Group, a VR safety knowledge evaluation system for a construction company, a VR truck inspection environment for a local power company. His works and lab have been reported by multiple local media many times in the USA.

成晓亮
江苏品生医疗科技集团有限公司总裁

CHENG Xiaoliang
President, Jiangsu QLife Lab Technology Group Co., Ltd.

成博士从事质谱技术应用开发 20 年，是国际知名的代谢组学和质谱技术领域的科学家，也是世界领先的 Qchip 高通量质谱芯片技术发明人之一。曾就职于美国伯克利国家实验室，他的团队已开发出数十种应用于临床诊断、药物筛选的技术，其中一项高通量质谱芯片筛选技术入选获评 2013 年科技界奥斯卡奖（R&D 100 Awards），同年被诺维信和欧洲科学联盟评选获得第一届青年科学家奖（Novozymes Scientist Award）。成博士团队建立了目前全球领先的前沿蛋白质组 X 代谢组学临床转化平台，也是目前全球范围内唯一成熟的，可商业化的临床蛋白质组 x 代谢组临床转化平台。成博士及其团队在 Lancet, Nature, Cell, PNAS 等顶级杂志发表论文 100 余篇、专利 150 余项。成博士同时也是中国临床质谱研究与产业联盟常务副理事长。

Dr. Cheng has dedicated to developing mass spectrometry technology and its clinical application for nearly two decades. He is an internationally renowned scientist in the field of metabolomics and clinical mass spectrometry technology and one the co-inventors of Qchip – the world-leading high-throughput mass spectrometry chip technology. He used to work at the Mass Spectrometry Technology Innovation Center of the Lawrence Berkeley National Laboratory, one of the top three mass spectrometry technology centers around the world. Dr. Cheng and his team have developed hundreds of technologies and patents for the screenings of early-diagnosis of diseases, drug development, and enzyme activity engineering. He was the only Chinese winner of the R&D 100 Awards (known as the “Oscar of Science and Technology”) in 2013. Dr. Cheng and his team have published over 100 peer-reviewed articles in such top academic journals as Lancet, Nature, Cell, and PNAS, obtained over 150 patents. Dr. Cheng also serves as the Vice Chairman of the Chinese Clinical Mass Spectrometry Research and Industry Union.

季序我
普瑞基准科技创始人兼首席执行官

JI Xuwo
Founder & CEO of Precision Scientific

季序我博士，普瑞基准科技创始人 &CEO。

普瑞基准深度挖掘海量多组学数据，支持药企打造创新、差异化的研发管线。公司建立了国际领先水准的 AIBERT 平台，整合多组学、生物信息学和 AI 算法，获得对肿瘤及其治疗的分子机制的深入理解，从而支持新药的关键研发决策（全新靶点评估、适应症选择、生物标志物发现、耐药机制研究和联用方案探索等），并提供中心实验室检测、伴随诊断开发等整体服务，已与数十家国内外一流药企和 biotech 公司合作，助力多个在研新药的开发。季博士 2007 年在北京大学获得生物信息学博士学位，论文发表在 Nucleic Acid Research, Nature Communications 等一流学术刊物。

Dr. Ji Xuwo, founder & CEO of Precision Scientific. Precision Scientific is an innovative translational medicine company, using multi-omics & clinical data mining application to support pharmaceutical companies innovation pipelines building. The company has developed AIBERT, an cutting-edge AI technology , which integrates multi-omics, bioinformatics, and AI algorithms to gain an in-depth understanding of the molecular mechanisms of caner, thereby supporting decision-making for new drugs R&D (target evaluation, indication selection, biomarker discovery, research on drug resistance mechanism, and rational design of drug combination, etc.), and provide integrated services such as central laboratory testing and companion diagnostic development. It has established numerous collaborations with top global pharma and biotech companies. Dr. Ji obtained his Ph.D. degree in bioinformatics from Peking University in 2007. His research achievements were published in high impact journals such as *Nucleic Acids Research and Nature Communications*.

孙　巍
无疆脑科技创始人、董事长

SUN Wei
Founder and Chairman, Infinite Brain Technologies (IBT)

孙巍博士是无疆脑科技创始人。他在创立无疆脑科技前，曾是数智匠人创投（一家专注于投资中国“数据驱动的服务”型初创公司的天使投资基金）和厚新健投（一家专注于投资中国医疗健康领域的私募股权基金）的合伙人。此前，他曾担任厚生投资的执行董事，负责厚生投资旗下基金在科技和健康领域的投资。在加入厚生投资之前，孙博士在博斯公司的中国办公室，帮助世界五百强和中国领先的企业制定战略和提升运营管理能力，并协助它们通过并购和投资获得快速成长。此前，孙博士在美国学习和工作 10 年，曾服务于晨星公司和拉克斯资本，并参与两家美国高科技企业的创立；孙博士在美国罗切斯特大学获得生物医学工程博士，并拥有美国芝加哥大学商学院的 MBA 学位，以及天津大学的电气工程学士和英语学士学位。

Dr. Wei Sun is the Founder of Infinite Brain Technologies (IBT). Before founding IBT, he was a partner of Hosencare Brothers and funding partner of Digital Craftsman Venture Partners. He also had led the investment efforts of Hosen Capital in technology and healthcare. Prior to the investment roles, Dr. Sun worked with Booz & Co., helping fortune 500 and leading Chinese companies to grow in China and overseas. Before returning to China, He had many years of product management and startup experience in the US, where he worked with Morningstar as well as served as founding members of two technological startups. Dr. Sun received his PhD in Biomedical Engineering from the University of Rochester, MBA with honor from The University of Chicago Booth School of Business, and BS in Electrical Engineering and BA in English from Tianjin University.

严庆隆
海纳亚洲创投合伙人

Ryushi Shinagawa
Partner, Susquehanna International Group

严庆隆（Ryushi Shinagawa）在医疗行业及投资领域有近 10 年的从业经验，主导 / 参与 Finch Therapeutics（FNCH），晶泰科技、心诺普、立达融医、智云健康、望石智慧、奈特瑞等多家公司的投资和投后管理工作。在加入 SIG 之前，他曾职于复星集团及海航集团从事医疗投资和运营。

严庆隆拥有北京大学光华管理学院工商管理硕士，Brandeis University 哲学学士 & 经济学学士。

Ryushi Shinagawa has over 10 years of investment experience in healthcare sector, leading/participating in the investment and post-investment management of Finch Therapeutics (FNCH), XtalPi, Synaptic Medical, Leader Medical, Cloud of Wisdom, Stonewise, and Netrain etc. Before joining SIG, he worked in Fosun Group and HNA Group, participated in their respective healthcare investments. Ryushi Shinagawa received MBA from Guanghua School of Management Peking University. He also holds Bachelor of Philosophy and Bachelor of Economics from Brandeis University.

吴　淳
BCG 高级全球合伙人及董事总经理

WU Chun
Managing Director & Senior Partner, Boston Consulting (Shanghai) Co., Ltd.

BCG 全球资深合伙人兼董事总经理
BCG 医疗健康大中华区负责人
吴淳博士是波士顿咨询公司（BCG）全球资深合伙人兼董事总经理，BCG 医疗健康的大中华区负责人。她一直为多家跨国公司和本土企业提供战略和运营咨询服务，涵盖医疗行业改革影响及发展战略；新产品研发，技术平台升级；业务发展（并购、合资和授权引进）；和数字化升级。
吴淳博士现致力于医疗大数据的搭建和人工智能技术的应用开发。她一直协助政府和业内机构搭建医疗数据平台和生物样本库，以及数据应用开发。
吴淳博士拥有北京大学生物化学学士学位和耶鲁大学遗传学博士学位。
BCG Senior Partner and Managing Director
Leader of BCG Health Care Practice in Greater China
Dr. Chun Wu is a Senior Partner and Managing Director of Boston Consulting Group. She leads BCG's Health Care Practice in Greater China. Dr. Wu has served various multinational and local pharma clients on strategic and operational topics, covering healthcare reform impact and growth strategy; R&D, especially new technology platforms; commercial excellence; business development (M&A, JV and in/out-licensing); and digital transformation.
Dr. Wu dedicated significant time in big data and AI in healthcare. She has supported government and industry players to build HC database and biobank, as well as data application development.
Dr. Wu holds a B.S. degree in biochemistry from Peking University and a Ph.D. degree in Genetics from Yale University.

薛　冰
汉坤律师事务所 合伙人

XUE Bing
Partner of Han Kun Law Offices

薛冰律师于 2010 年加入汉坤律师事务所。薛律师主要从事私募股权和风险投资、兼并和收购、资本市场、外商直接投资等业务。薛律师曾代表众多的投资基金、跨国公司、国有企事业单位、初创及成长型公司、上市公司和科研机构处理各种法律事务；薛律师的业务领域涉及众多行业，包括高新技术、电子科技、生命医药、环境技术、电信、互联网、广告、能源、教育、房地产和财富管理等。薛律师在中国税务合规及税收规划相关法律服务领域还有着丰富的实践经验。
在加入汉坤前，薛律师曾先后在普华永道的税务法律部门从事中国税务法律及商务咨询工作，德恒律师事务所从事资本市场与公司投融资法律业务。薛律师还曾于 2013 年在一家总部位于深圳的投资机构担任并购咨询部门的执行总裁。
Mr. Xue joined Han Kun in 2010. His practice focuses on venture capital and private equity investment, mergers and acquisitions, capital markets transactions, and foreign direct investment. Mr. Xue has represented and provided legal services to numerous investment funds, multinational companies, state-owned enterprises, start-ups and emerging companies, public companies, and research institutions in relation to their various PRC legal matters, covering the high-tech, electronic technology, life science and pharmaceutical, environmental technology, telecommunications, internet, advertising, energy, education, real estate, and wealth management industries. Mr. Xue also has solid knowledge of and practice experience with China tax compliance and tax planning-related legal services.
Before joining Han Kun, Mr. Xue practiced tax and law with PricewaterhouseCoopers and DeHeng Law Offices. In 2013, he served as CEO of a Shenzhen-based buyout firm and was responsible for M&A transactions.

朱　坚
君合律师事务所 合伙人

James ZHU
Partner, JunHe LLP

朱坚博士是君合律师事务所的合伙人，负责知识产权业务和硅谷分所。

朱坚博士的执业领域包括一系列广泛的技术行业（主要为生命科学、生物制药、能源、材料科学、医疗仪器和电子行业）内的知识产权申请、意见书、分析与战略、诉讼和技术许可服务。

作为中国与世界的桥梁，朱坚博士代表国际客户在中国获得或维护其专利权。朱坚博士为国际客户进入中国市场时提供战略专利咨询，进行复杂的尽职调查并分析评估知识产权风险，通过诉讼和行政手段以保护客户知识产权。

在加入君合之前，朱坚博士曾在美国博钦律师事务所（Perkins Coie LLP）工作 8 年，并于 2008 年成为美国博钦律师事务所洛杉矶办事处合伙人并兼任该所的北京代表处的执行合伙。在投身法律职业前，朱坚博士还曾任安泰克国际公司，一家位于硅谷的创业公司的创始人和首席法律顾问，主导其融资、法律和业务开发活动。90 年代初，朱坚博士曾是默克公司的科学家。

Dr. James J Zhu is a partner at JunHe and the head of the firm's intellectual property group and the Silicon Valley office by splitting his time between the US and China.

James' practice includes patent procurement, opinion, analysis & strategy, litigation and technology licensing. He primarily focuses on life sciences, material sciences, medical devices, and electronics.

James represents international clients to obtain and enforce their patent rights in China. In particular, James helps international clients to prosecute their patent rights, design intellectual property (IP) strategies for their market entry into China, conducts complex IP due diligence and risk analysis in business transactions, and enforces or defends IP rights by leading litigation or invalidation effort.

Prior to JunHe, James spent eight years at Perkin Coie LLP, became a partner in Perkins Coie's Los Angeles Office and then the Managing Partner of Perkins Coie's Beijing Office. Prior to his advancement in law, James was a co-founder & General Counsel of GanTech International, a Silicon Valley start-up where he spearheaded fund-raising, legal and business development activities. In the early 90s, James was a researcher at Merck & Co.

杜　舟
华平投资副总监

Joe DU
Associate Director of Warburg Pincus

杜舟，华平投资副总监，其在医药医疗领域具有深厚的研究、投资经验及行业资源。

在加入华平投资之前，杜舟先生曾任中国平安人寿（601318.SH/2318.HK）组合投资经理（Portfolio Manager）、医药战投主管分析师；三胞集团首席战略官、副总裁、市值管理总经理。

杜舟先生亦曾任申万宏源证券（000166.SZ/6806.HK）医药行业首席分析师、医疗大健康行业负责人。中国水晶球最佳分析师评选第一名。中国非公立医疗机构协会投融资分会委员、中央电视台首席看市金牌特邀嘉宾。其主要覆盖 A 股及 A+H 股在医药大健康行业的龙头上市公司，在医药行业二级市场有深厚的研究经验与行业资源，具有深厚的市场影响力。

杜舟先生亦曾从事投资银行、战略咨询及美国生物医学研发工作；其拥有美国密歇根大学工商管理硕士（MBA）及生物医学硕士（M.S.）的双学位。

Associate Director, WARBURG PINCUS

Mr. Du is the Associate Director at WARBURG PINCUS, focusing on China healthcare research and investments.

Prior to joining WARBURG PINCUS, Mr. Du worked as Portfolio Manager, Lead Analyst of Healthcare Strategic Investments at PINGAN LIFE INSURANCE (601318.SH/2318.HK); and Chief Strategy Officer, Vice President at SANPOWER GROUP.

Also, Mr. Du worked as the Head of China Healthcare Research, Chief Healthcare Equity Research Analyst at SHENWAN HONGYUAN SECURITIES (000166.SZ/6806.HK), covering leading healthcare and pharmaceutical companies in A-Share and A+H Share stock market in China, with extensive research experience and industry resources in China healthcare sector. He ranked No.1 in Crystal Ball Awards (China Sell-Side Analysts Survey).

Mr. Du also worked in investment banking and management consulting industry in China, as well as biomedicine R&D in the United States. He holds a MBA degree from University of Michigan Ross School of Business, and a M.S. degree in Biomedicine from University of Michigan, Ann Arbor.

胡元佳
澳门大学中药质量研究国家重点实验室医药信息中心副主任

HU Yuanjia
Deputy Director, University of Macau, Medical Informatics Center, State Key Laboratory of Quality Research in Chinese Medicine

胡元佳博士是澳门大学中药质量研究国家重点实验室医药信息中心副主任，博士生导师。胡博士开展医药专利与复杂系统分析超过 15 年，创建医药技术扫描与专利价值评估模型，建立基于复杂系统的药物开发平台，近年来积极推动医药科技成果转化，在 Nature Biotechnology, Briefings in Bioinformatics, Pharmacological Research 等国际期刊发表学术论文 150 余篇。胡博士也是世中联网络药理学专委会副秘书长，中国药理学会网络药理学专业委员会委员，国家药物政策与医药产业经济研究中心项目研究员，国家知识产权公共服务平台金融创新试点平台政策指导专家。胡博士于 2001 年获中国药科大学药事管理学士学位，2008-2009 赴奥地利研究中心访问研究，2009 年获澳门大学生物医药博士学位。

Dr. Yuanjia Hu is PhD Supervisor and Deputy Director at Medical Informatics Center of the State Key Laboratory of Quality Research in Chinese Medicine, University of Macau. Dr. Hu has researched medical patents and complex system for more than 15 years, initiatively established models of medicinal technological scanning and patent valuation, built up drug development platform based on complex system, actively impelled the transformation of medicinal scientific and technological achievements in the recent years, and published more than 150 academic articles in peer-reviewed journals, e.g., Nature Biotechnology, Briefings in Bioinformatics, and Pharmacological Research. Dr. Hu is also Deputy Secretary-General and Executive Council Member in Specialty Committee on Network Pharmacology of WFCMS, Commissioner of the Commission on Network Pharmacology in Chinese Pharmacological Society, Project Researcher in the Research Center of National Drug Policy & Ecosystem, and Policy Expert in Financial Innovation Pilot Platform of State Intellectual Property Operation Public Service Platform. Dr. Hu received B.Sc. degree of Pharmacy Administration from China Pharmaceutical University in 2001, studied in Austrian Institute of Technology during 2008-2009, and achieved Ph.D. degree in Biomedical Sciences from the University of Macau in 2009.

吴劲梓
歌礼制药有限公司创始人、董事会主席兼首席执行官

WU Jinzi
Founder,Chairman and CEO of ASCLETIS PHARMA INC.

吴劲梓博士，国家级领军人才，歌礼创始人、董事会主席兼首席执行官，于 2013 年 4 月创办歌礼。歌礼是一家拥有三个上市产品的研发驱动型创新生物科技公司。2018 年 8 月，在吴博士带领下，歌礼（1672.HK）成为香港交易所全球首家成功上市的未盈利生物医药企业，融资 4 亿美元。在吴博士的领导下，歌礼已发展成为一体化平台型公司，涵盖了从新药发现和开发直到生产和商业化的完整价值链。在吴博士带领下，歌礼致力于开发脂肪性肝炎、肿瘤脂质代谢与口服检查点抑制剂、病毒性肝炎和艾滋病相关创新药，满足国内外患者需求。

吴博士拥有超过 20 年在跨国企业和生物科技企业的新药研发、GMP 生产和商业化的经验。创立歌礼前，吴博士曾担任美国葛兰素史克（GSK）研发部门的副总裁。他还曾先后在美国诺华（Novartis）、美国安进（Amgen）/Immunex 和加拿大 Ambrilia 等制药公司研发部门担任高级科学家、副总裁等职位。吴博士在美国亚利桑那大学获得癌症生物学博士学位。

Dr. Jinzi J. Wu is Founder, Chairman and CEO of Ascletis which was founded in April 2013. Ascletis is an innovative R&D driven biotech with three commercial products. Led by Dr. Wu, Ascletis (1672.HK) became the first pre-revenue biotech listed on the Hong Kong Stock Exchange in August 2018 and raised US$400M. Under his leadership, Ascletis has developed a fully integrated platform covering the entire value chain from discovery and development to manufacturing and commercialization. Under his leadership, Ascletis is committed to developing and commercializing NASH, cancer lipid metabolism and oral checkpoint inhibitors, viral hepatitis and HIV/AIDS related innovative drugs for unmet medical needs in China and Globally.

Dr. Wu has more than 20-year experience covering R&D, GMP manufacturing and commercialization in Big Pharma and biotech. Prior to founding Ascletis, he was Vice President at GSK R&D in USA. He also held various R&D positions from Sr. Scientist to Vice President at Novartis, Immunex/Amgen and Ambrilia in USA and Canada. Dr Wu obtained his PhD in Cancer Biology from University of Arizona.

杨　亮
绿叶制药投资者关系与公共关系副总裁

Allen YANG
Vice President of Investor Relations and Public Relations of Luye Pharma

杨亮先生现任绿叶制药投资者关系与公共关系副总裁，负责集团投资者关系与品牌管理工作。杨亮先生毕业于武汉大学，具有十余年 500 强跨国公司财经传播与品牌管理工作经验，曾任职于欧莱雅（中国）、礼来制药。

Mr. Yang Liang (Allen Yang) is currently the Vice President of Investor Relations and Public Relations, Luye Pharma, responsible for investor relations and branding management. Allen graduated from Wuhan University, and has over 10 years of experience in financial communication and branding management for top 500 multinational companies including Loreal China and Eli Lilly.

陈　力
华领医药董事长、首席执行官、创始人、首席科学官

CHEN Li
Executive Director, Chief Executive Officer, Founder and Chief Scientific Officer of Hua Medicine

陈力博士，华领医药技术（上海）有限公司董事长、首席执行官、创始人，首席科学官。陈力博士曾任罗氏研发中国有限公司首席科学官，拥有 20 多年新药研发创新及管理经验，是 55 件授权发明专利和 138 件发明专利申请的发明人，并发表 60 多篇科学论文。

陈力博士于 2011 年成立华领医药，以“患者为先、创新为本、良药为民”为宗旨，运用“中西合璧、联合创新”的新药研发运营模式和“高标准、高质量、创造高价值”的经营理念，在 5 年内华领医药的糖尿病全球原创新药 HMS5552 成功取得中美临床试验批件、完成四个临床 I 期和临床 II 期 POC 试验，并在 2017 年全球率先启动同类产品 III 期临床试验和药品上市计划，实现全球首创、中国首发。在此期间，成功完成 2 亿美元融资和中国新药创新公司建设。华领医药已于 2018 年 9 月于港交所上市。

Dr. Li Chen, Founder, Executive Director, Chief Executive Officer, and Chief Scientific Officer. Li received his PhD at Iowa State University and joined Roche R&D center in USA in 1992. With 18 years at Roche, Li advanced his career from a medicinal chemist to the head of High Throughput Technology, and later CSO of Roche China R&D Center with a membership at Roche Research Leadership Team. He is an inventor of 35 granted patents and an author with over 60 publications.

Li leads Hua Medicine a clinical stage biotech company whose mission is to bring personalized diabetes medicines to patients in China and worldwide. He is a pioneer in collaborative innovation in China and advanced Hua Medicine with an operation principle of high standards, high quality and create high value. Hua Medicine leverages global resources to develop GKA and completed 6 clinical studies in China and USA, in which the HMS5552, a novel GK PAM demonstrated desirable safety and efficacy profiles together with an improvement of beta cell function in Chinese T2DM patients. Under his leadership, Hua Medicine completed successfully a POC study and initiated China NDA enabling process. During this period, Hua Medicine raised 200M USD and established the leading position of Hua Medicine in China biotech industry.

郭晓宁
赛生药业副总裁，研发负责人兼首席医学官

GUO Xiaoning
Vice President, Head of R&D and CMO of SciClone Pharmaceuticals (Holdings) Limited

郭晓宁博士现任赛生药业副总裁、研发负责人兼首席医学官，全面负责公司管线产品的研发和上市后产品的生命周期管理。
郭晓宁博士毕业于中科院上海药物研究所，获得药理学博士学位。后赴美国，在肿瘤综合医院和癌症中心 Roswell Park 癌症研究所任研究员。2007 年回国，进入全球 TOP10 的跨国药企从事研发工作，先后加入阿斯利康创新研发中心和美国强生制药公司，负责转化医学项目、临床 I 期到 III 期的项目开发和 portfolio 管理。之后，郭晓宁博士加入科文斯医药研发公司，担任亚太区临床开发高级总监、科学医学顾问负责人，负责项目全球临床开发战略的制定和规划。郭晓宁博士积累了从临床前药物开发包括生物标记物研究到转化医学到临床开发不同阶段的药物研发的丰富经验。加入赛生药业前，郭晓宁博士任职交晨生物的副总经理兼首席医学官，负责临床开发和法规注册部门。

Dr. Xiaoning Guo is currently the vice President, Head of R&D and Chief Medical Officer of SciClone Pharmaceuticals (Holdings) Limited. He is fully responsible for R&D of pipeline drug candidates and life cycle management of post-market products.
Dr. Guo graduated from Shanghai Institute of Materia Medica, Chinese Academy of Sciences with a PhD in pharmacology. Later, he went to the United States and worked as a research affiliate at Roswell Park Cancer Institute, a National Comprehensive Tumor Hospital and Cancer Center. In 2007, Dr. Guo came back to China and joined MNCs including Astrazeneca and Johnson & Johnson to in charge of translational medicine project, clinical Phase I to III project development and portfolio management. After a couple of years, Dr. Guo joined Covance as a senior Director, Clinical Drug Development Leader in Asia Pacific region, responsible for the development and implement of the global development strategy of the project. Dr. Guo has accumulated extensive experience in different stages of drug development from preclinical including biomarker research to translational medicine to clinical development. Before joining SciClone Pharmaceuticals, Dr. Guo served as deputy General Manager and Chief Medical Officer of General Regeneratives, co., Ltd., responsible for clinical development and regulatory affairs department.

吴灵犀
贝达药业股份有限公司董事长助理兼董事会秘书

Wu Lingxi
Chairman Assistant & Board Secretary of Betta Pharmaceuticals Co., Ltd.

北京大学金融学硕士。曾就职于国泰君安证券有限责任公司、瑞银证券有限责任公司、华泰联合证券有限责任公司，长期从事投资银行业务，具有保荐代表人资格和丰富的境内外 IPO、股权再融资、并购、债券融资等资本运作经验。
Master in Finance from Peking University, Sponsor Representative. Wealth of experience in A-share IPOs and overseas IPOs, equity refinancing, mergers and acquisitions, bond financing and other capital operation. Prior to joining Betta, Mr. Wu has dedicated to investment banking business at GTJA (GUOTAI JUNAN SECURITIES), UBS (UBS Securities Co. Limited) and HUATAI UNITED SECURITIES.

周　超
远大医药健康控股有限公司行政总裁

Frank ZHOU
Chief Executive Officer of China Grand Pharmaceutical and Healthcare Holdings Limited

周超先生，目前担任远大医药健康控股有限公司行政总裁一职。周先生服务中国远大超过 8 年，任职期间担任多项投资并购项目重要职务，投资并购经验丰富。周先生自二零一九年四月起担任远大医药行政副总裁，并担任中国远大集团若干联营公司的董事，其中包括于美国 NASDAQ 上市的 OncoSec Medical Inc. (NASDAQ:ONCS)。周先生加盟远大医药前，曾担任中国远大集团有限责任公司的法律安全管理总部法务经理、高级法务经理及业务总监。周先生拥有中国海洋大学法律本科学位及中国对外经济贸易大学国际经济法硕士学位。

Mr. Zhou Chao, currently serves as the Chief Executive Officer of China Grand Pharmaceutical and Healthcare Holdings Limited. Mr. Zhou has served China Grand Enterprises Incorporation for more than 8 years. During his tenure, he played key roles in several M&A projects, and has rich M&A experience. Mr. Zhou has been the executive deputy officer of China Grand Pharmaceutical and Healthcare Holdings Limited since April 2019, and is also a director of certain associated companies of the Group, including OncoSec Medical Inc., a company listed on NASDAQ in the United States (NASDAQ:ONCS). Prior to joining the Company, Mr. Zhou has been the legal manager, senior legal manager and business director of the department of legal security management of China Grand Enterprises Incorporation. Mr. Zhou holds a bachelor's degree in Law School from of Ocean University of China and a master's degree in international economic law from University of International Business and Economics of China.

罗佳荣
广发证券发展研究中心生物医药行业首席分析师

LUO Jiangrong
Chief Analyst of Healthcare Sector at GF Securities

罗佳荣，广发证券发展研究中心生物医药行业首席分析师，曾任申银万国证券研究所有限公司生物医药首席分析师，近十年医药行业二级市场研究经验，带领团队获得 2019 年东方财富最佳分析师生物医药行业第一名，新财富最佳分析师第五名；2018 年中国保险资产管理业最受欢迎卖方分析师第三名；2017 年中国保险资产管理业最受欢迎卖方分析师第三名，新财富最佳分析师第 5 名。对创新药、生物药、创新疫苗、CRMO、医药流通等细分子行业有相对完备的跟踪和覆盖，对恒瑞医药、药明康德、长春高新、通策医疗等行业龙头公司有长期的研究。毕业于上海财经大学财务管理硕士，南京大学化学系本科。

Luo Jiarong is the chief analyst of Healthcare Sector at GF securities, was formerly the chief analyst of Healthcare Sector at SWS Research. He has almost ten-year equity research experience in pharmaceutical industry in secondary market, and led team into winning the first place in 2019 Eastmoney Best Analyst in Biological & Pharmaceutical Industry, the fifth in 2019 New Fortune Best Analyst, the third in 2018 IAMAC Most Popular Sell-Side Analyst, the third in 2017 IAMAC Most Popular Sell-Side Analyst, and the fifth in 2017 New Fortune Best Analyst. He has relatively complete following and coverage in sub-industries including innovative drugs, biological drugs, innovative vaccines, CRMO, medicine circulation, and has long-term research experience in leading enterprises such as Hengrui Medicine, Changchun High-tech, WuXi AppTec, and so on. He obtained the master degree in financial management from Shanghai University of Finance and Economics, and bachelor degree in chemistry from Nanjing University.

陈颖颖
和铂医药首席财务官

CHEN Yingying
CFO of Harbour BioMed

陈博士在金融和医疗行业拥有累计超过 20 年的职业经验和卓越成就。加入和铂医药前，陈博士曾任广发投资（香港）有限公司及民生商银国际控股有限公司的董事总经理及医疗投资负责人。在此之前，她曾任职过多家投资银行，包括瑞银、苏格兰皇家银行和德意志银行，为医疗领域客户提供服务。陈博士早期职业生涯亦曾担任辉瑞公司全球研发中心研究科学家。

陈博士拥有美国明尼苏达大学化学工程博士学位、密西根大学工商管理硕士学位、迈阿密大学化学和工程物理理科学士学位。

Dr. Chen has accumulated over 20 years of experience and exceptional achievement in the financial and healthcare industries. Prior to joining the Group, Dr. Chen served as Managing Director and Head of Healthcare Investments at GF Investments (Hong Kong) Company Limited and CMBC International Holdings Ltd. Prior to that, she worked at multiple investment banks, including UBS, Royal Bank of Scotland and Deutsche Bank AG, where she served clients in the healthcare sector. In the earlier stage of her career, she had also worked as a research scientist at Pfizer Inc.'s global R&D center.

Dr. Chen holds a PhD degree in Chemical Engineering from University of Minnesota, an MBA degree from University of Michigan, and bachelor of science degrees in Chemistry and Engineering Physics from Miami University.

李鑫磊
上海复宏汉霖生物技术股份有限公司 首席财务官兼副总裁

Gino LI
Chief Financial Officer and Vice President of Shanghai Henlius Biotech,Inc.

公司首席财务官兼副总裁，负责公司上市投资管理、市值管理及财务运营管理。在加入复宏汉霖之前，李鑫磊先生任职复星医药副总裁兼投资者关系与资本发展部总经理。李鑫磊先生于 2004 年获四川大学理学学士学位（药学专业），于 2006 年获英国哈德兹菲尔德大学理学硕士学位，于 2016 年获复旦大学 – 香港大学工商管理学硕士学位。

Mr. Gino Li, Chief Financial Officer and Vice President, is responsible for listing investment management, market value management and financial operation management. Previously, Mr. Li served as vice president and the general manager of investor relations and capital development department of Fosun Pharma. Mr. Li obtained a Bachelor of Science degree in Pharmacy from Sichuan University in 2004, a Master of Science degree from the University of Huddersfield in the U.K. in 2006, and a master's degree from the IMBA Programme of Fudan University – Hong Kong University in 2016.

陈　洪
苑东生物研发中心总经理

CHEN Hong
President of R & D Center of Easton Biopharma

现任成都苑东生物制药股份有限公司副总经理，研发中心总经理。河北省“百人计划”医药专家和外专局特聘专家。以及四川省“千人计划”医药专家。他 1996 年获得美国 Cleveland State University 分析化学博士学位。之后又在全球心脏方面最著名的 Cleveland Clinic Foundation 做了两年生物医药博士后研究。拥有 25 年在美国 Adolor、J&J、Teva 和 Nexgen Pharma 和以岭药业丰富的工作和管理经历；曾担任过全球最大仿制药公司 Teva 的分析和技术服务总监以及美国 Nexgen Pharma 的研发总监和高级总监，以岭研究院副院长。亲自领导和参与 30 多个新药和仿制药的研发，其中一个一类新药（Entereg）和 17 个 ANDA 固体和液体制剂产品获得美国 FDA 批准和 3 个固体一致性评价获得中国 CDE 批准上市。现负责苑东生物创新药，改良型新药和仿制药研发和国际制剂注册申报 . 有着丰富的团队建设、项目管理、国际认证、研发质量体系建立、制剂注册申报的经验。曾经出版，演讲和展示了 113 篇在药物研发，生物医学方面的科学论文。

Dr. Chen is currently the Vice President of Easton Biopharmaceuticals and the President of the R&D Center. He has been honored the "Hundred/Thousand Talents Program" medical expert by both Hubei and Sichuan Province. He received his Ph.D. in analytical chemistry from Cleveland State University in 1996. He then spent two years in biomedical postdoctoral research at the Cleveland Clinic Foundation, the world's most famous cardiology clinic center. He has 25 years of working and management experience in Adolor, J&J, Teva and Nexgen Pharma in the United States and Yiling, Easton Pharma in China. He has served as Director of Analytical and Technical Services of Teva, the world's largest generics company, and R&D Director and Senior Director of Nexgen Pharma, USA, R&D Vice President of Yiling Pharma. Directly led and participated in the development of more than 30 new drugs and generics, including a Class 1 new drug (Entereg), 17 ANDA solid and liquid products approved by the US FDA and 3 products approved through Consistency evaluation by China CDE. He is responsible for the research and development of new, 505b2, generic drugs and ANDA registration of Easton Biopharmaceutical. Dr. Chen has extensive experience in team building, project management, GMP certification, establishment of R&D quality system and ANDA filings. He has published, lectured and presented more than 113 scientific papers in drug discovery and biomedical science.

奚　浩
信达生物制药集团执行董事兼首席财务官

Ronnie Ede
Executive Director and Chief Financial Officer of Innovent Biologics

奚浩先生是信达生物集团的执行董事兼首席财务官，2017 年加入集团后负责集团财务、投资者关系、基金、渠道和信息技术管理。
奚浩先生在医疗行业内有超过 25 年丰富的工作经验。 在加入信达生物前，从 2011 年至 2016 年，担任百盛国际有限公司的首席财务官。2009 年至 2011 年，担任迈瑞医疗国际有限公司的执行董事兼首席财务官。
从 2006 年至今，奚浩先生也担任迈瑞医疗国际有限公司（深圳上市）的独立非执行董事，2015 年至今担任东瑞制药（控股）有限公司（香港上市）的独立非执行董事。
奚浩先生拥有夏威夷大学工商管理学士、华盛顿大学 MBA，新加坡特许会计师公会资深会员及深圳证券交易所认证的 A 股独立董事。

Mr. Ronald Ede is the Executive Directors & Chief Financial Officer for Innovent Biologic Inc. Joined since 2017, Mr. Ede is responsible for finance, investor relations, fund, channel management and information technology of the Group.
Prior to joining the Group, from 2011 to 2016, Mr. Ede was the chief financial officer of Biosensors International Ltd. and from 2009 to 2011, he was the executive director and chief financial officer of Mindray Medical International Limited.
Mr. Ede is also an independent non-executive director for Mindray Medical International Limited (a listed company on the Shenzhen Stock Exchange with stock code: 300760) since 2006, and Dawnrays Pharmaceutical (Holding) Ltd. (a company listed on the Hong Kong Stock Exchange with stock code: 2348) since 2015, respectively.
Mr. Ede received his bachelor of business administration degree from University of Hawaii in December 1984 and master of business administration degree from University of Washington in December 1988. Mr. Ede is a fellow member of the Institute of Singapore Chartered Accountants and an A-Share independent director certified by the Shenzhen Stock Exchange.

邵　奇
前沿生物药业（南京）股份有限公司高级副总经理、首席财务官

SHAO Qi
SVP and CFO of Frontier Biotechnologies Inc.

1980 年出生，中国国籍，硕士研究生学历。
2006 年 3 月至 2012 年 10 月任巴斯夫（中国）有限公司财务主管；
2012 年 10 月至 2015 年 12 月任大陆汽车投资（上海）有限公司高级财务经理；
2015 年 12 月至 2016 年 3 月任南京前沿生物有限责任公司副总经理兼财务总监；
2016 年 3 月至 2021 年 2 月任前沿生物药业（南京）股份有限公司副总经理兼财务总监；
2021 年 2 月至今任前沿生物高级副总经理、首席财务官。

Born in 1980, Chinese nationality, master degree.
From March 2006 to October 2012, he served as Supervisor in Finance Department of Basf (China) Ltd., Co;
From October 2012 to December 2015, he served as Senior Finance Manager of Continental Automotive Holding Co.,Ltd;
From December 2015 to March 2016, he served as Vice President and Finance Director of Nanjing Frontier Biotechnologies Co.,Ltd;
From March 2016 to February 2021, he served as vice president and Finance Director of Frontier Biotechnologies Inc..
Since February 2021, he has been the Senior Vice President and Chief Financial Officer of Frontier Biotechnologies Inc..

申华琼
天境生物科技（上海）有限公司首席执行官

Joan SHEN
Chief Executive Officer of I-MAB Biopharma Co., Ltd.

申华琼博士毕业于美国印第安纳大学医学院，获得生命科学博士学位，并曾在该院所担任临床兼职教授一职。除此之外，她还完成了内分泌学、心理药理学和临床药理学的博士后研究。由于她的杰出科学贡献，获得了多项研究补助金，并已经发表了 30 多篇出版物。同时她也是拥有美国处方权的执照医生。
申华琼博士的制药人生涯始于美国礼来公司，在这之后她曾在惠氏，辉瑞，恒瑞和强生担任高管职位。在辉瑞，她曾担任临床开发负责人一职。在恒瑞，她曾任职首席医学官，在她的领导下，恒瑞建立了中国本土药企最大规模的创新临床团队，成功开拓了在澳洲及美国的临床试验。在强生，申博士曾任职中国临床开发负责人，负责所有中国开展的临床项目，在她的带领下强生中国多个新药成功获批，药品包含斯耐瑞，司美匹韦胶囊，伊布替尼，欣普尼和喜达诺。
申华琼博士曾当选 RDPAC 研发核心工作组的预备主席。当选过中国药物临床评价研究专业委员会委员之一。新近更被北京大学聘为客座教授。

R&D is led by Joan Huaqiong Shen, MD, PhD, CEO of I-Mab. Dr. Shen is a US board-certified physician and holds a PhD in life sciences from Indiana University School of Medicine, where she was appointed as an adjunct professor in the department of psychiatry. She also completed fellowships in endocrinology, psychopharmacology and clinical pharmacology. Her scientific contributions have led to multiple research grant awards and more than 30 publications.
Dr. Shen's pharmaceutical career began at Eli Lilly & Company, after which she held executive positions at Wyeth, Pfizer, Jiangsu Hengrui Medicine and Johnson & Johnson. She was the clinical head at Pfizer China and the Chief Medical Officer at Jiangsu Hengrui Medicine, where she built the largest clinical team among Chinese domestic pharma companies and established successful clinical trials in China, the US and Australia. At J&J, Dr. Shen served as China Development Head and oversaw all clinical development programs in China, including multiple innovative drugs that were approved by China NMPA, such as Sirturo, Olysio, Imbruvica, Simponi, and Stelara.
Dr. Shen serves as co-chair of the R&D-based Pharmaceutical Association in China's (RDPAC) core R&D team, sits on the China New Drug Research Evaluation Executive Committee, and is currently a guest professor at the Beijing University Clinical Research Institute.

苏慰国
和黄医药（中国）有限公司执行董事、首席科学官

SU Weiguo
Executive Director & Chief Scientific Officer of HUTCHMED (China) Limited

苏慰国博士自 2017 年起担任和黄医药的执行董事、2011 年起担任首席科学官。自加入和黄医药以来，他领导了所有药物研发，包括作为研发创新平台的关键领导人策划科学策略，同时负责发掘管线中的每一种小分子候选药物。苏博士于 2005 年加入和黄医药，此前他供职于辉瑞美国中央研究院工作。2017 年，他获得中国医药创新促进会（PhIRDA）授予“最具影响力的药物研发领军人物”奖。2021 年 1 月，在第十三届健康中国论坛上被评为中国十大医药产业人物（国内版）。他于 1982 年在上海复旦大学取得化学理学学士学位，并在哈佛大学师从诺贝尔奖得主 E. J. Corey 教授，在其指导下于 1988 年取得化学博士学位并从事博士后研究。

Dr. Su has been an Executive Director of HUTCHMED since 2017 and has been Chief Scientific Officer since 2011. He has headed all drug discovery and research since he joined HUTCHMED, including master-minding the company’s scientific strategy, being a key leader of the Innovation Platform, and responsible for the discovery of each and every small molecule drug candidate in the company’s pipeline. Prior to joining HUTCHMED in 2005, Dr. Su worked with Pfizer's U.S. research and development organization.

In 2017, he was granted the prestigious award by the China Pharmaceutical Innovation and Research Development Association (PhIRDA) as one of the Most Influential Drug R&D Leaders in China. In January 2021, he was awarded as one of the Top 10 Pharmaceutical Industry Figures in Mainland China on the 13th Health China Forum.

Dr. Su received a Bachelor of Science degree in Chemistry from Fudan University in Shanghai in 1982 and completed a Ph.D. and Post-Doctoral Fellowship in Chemistry at Harvard University in 1988 under the guidance of Nobel Laureate Professor E. J. Corey.

任德林
维亚生物执行董事兼总裁

Derek REN
Executive Director and President of Viva Biotech (Shanghai) Co., Ltd

任德林博士 2009 年 5 月加入维亚生物科技（上海）有限公司，先后担任公司副总裁、总经理等职位，目前为本公司的执行董事兼总裁，全面负责集团的 CRO 业务。任博士拥有十多年的 CRO 行业经验和十多年国际大药企的工作经验。加入维亚生物之前，任博士自 1998 年起先后在美国 Warner-Lambert 制药公司、辉瑞全球研究与发展中心先后担任研究员、高级研究员、资深科学家、和新药研发项目主持人。主要研究方向包括药物新靶点确认、高效药物筛选方法建立、前导活性化合物筛选确任、候选临床前药效研究等。他 1996 年毕业于美国密西根州立大学取得动物科学博士学位，随后在美国密西根州立大学生物化学系做了两年博士后研究，曾在国际科学期刊发表约近 20 篇研究论文，研究方向涵盖糖尿病、肥胖症和炎症性疾病领域。

Dr. Ren joined Viva Biotech (Shanghai) Co., Ltd. in May 2009 and successively served as the company's vice president and general manager. He is currently the company's executive director and president, mainly responsible for the overall management of the company CRO business. Dr. Ren has ten plus years of CRO industry experience and over ten years of work experience in major international pharmaceutical companies. Prior to joining Viva Biotech, Dr. Ren has served as a senior scientist, principle scientist and drug discovery project leader in Warner-Lambert Pharmaceuticals and Pfizer Global Research and Development Center since 1998, focusing on new drug target validation, bioassay development, lead active compound screening and confirmation, and preclinical drug candidate discovery, etc. Dr. Ren received his Ph.D. in Michigan State University in animal science major in 1996, and then did two-year postdoctoral research in the Department of Biochemistry of Michigan State University. He has published about 20 research papers in international scientific journals, and his research interests cover diabetes, obesity and inflammatory diseases.

杨烨辉
国联证券医药行业负责人 / 所长助理

YANG Yehui
Head of Medical Industry/ Assistant Director, Guolian Securities

中山大学硕士，曾就职于江中药业研发部，默沙东市场销售部，招商证券、华泰证券研究所，2016 年加盟天风证券。有超过 14 年的医药行业从业 + 投资研究工作经验，作为团队成员参评获得 2011 年新财富第三名，2012 年新财富第四名，2013 年新财富入围，2014 年新财富第二名，2017 年带队参评新财富入围。

Master of Sun Yat-sen University, once worked in Jiangzhong Pharmaceutical R & D Department, Merck East Market Sales Department, China Merchants Securities, Huatai Securities Research Institute, joined Tianfeng Securities in 2016. More than 14 years of experience in the pharmaceutical industry and investment research, as a team member to participate in the 2011 new wealth third place, 2012 new wealth fourth place, 2013 new wealth finalist, 2014 new wealth second place. In 2017, he led the team to participate in the new wealth and shortlisted.

贺菊颖
中信建投证券医药行业首席分析师

HE Juying
Head of Healthcare Equity Research, China Securities

中信建投证券医药行业首席分析师，复旦大学管理学硕士，10 年以上医药卖方研究从业经验，善于前瞻性把握细分赛道机会，公司研究深入细致，负责整体投资方向判断。

2020 年度新浪财经金麒麟分析师医药行业第七名、新财富最佳分析师医药行业入围、万德最佳分析师医药行业第四名等荣誉。2019 年 Wind“金牌分析师”医药行业第 1 名。2018 年 Wind“金牌分析师”医药行业第 3 名，2018 第一财经最佳分析师医药行业第 1 名。2013 年新财富医药行业第 3 名，水晶球医药行业第 5 名。

Head of Healthcare Equity Research at China Securities, holds a master degree from Fudan University in management with more than 10 years' experience in sell-side healthcare equity research, skilled at seizing opportunities in different subdivisions with a forward-looking strategy, proficient in conducting comprehensive and in-depth company research, responsible for overall judgement of investment direction with strong macro view.

In 2020, Sina Finance “Jin Qilin Analyst” for Healthcare Industry (ranked 7th), New Fortune “Best Analyst” for Healthcare Industry (shortlisted), Wind “Best Analyst” for Healthcare Industry (ranked 4th). In 2019, Wind “Gold Analyst” for Healthcare Industry (ranked 1st). In 2018, Wind “Gold Analyst” for Healthcare Industry (ranked 3rd), YICAI “Best Analyst” for Healthcare Industry (ranked 1st). In 2013, New Fortune “Best Analyst” for Healthcare Industry (ranked 3rd), Capital Week “Crystal Ball Awards for Sell-Side Analysts” for Healthcare Industry (ranked 5th).

杜向阳
西南证券股份有限公司医药行业首席分析师

Du Xiangyang
Chief Analyst of Healthcare Group, Southwest Securities

西南证券医药行业首席分析师，中科院博士生，遗传学硕士，7 年医药行业研究经验。之前重点研究创新药及产业链（CRO/CDMO）、生物制品（疫苗、血制品、重组蛋白等）、医药流通（药店和分销）等多个子版块，具有丰富的产业资源。2020 年 3 月加入西南证券，曾任职于兴业证券、光大证券、国联证券。作为首席，带领团队获得多项荣誉：Wind 金牌分析师：2020 年最佳分析师医药生物行业第 1 名；水晶球：2020 年最佳分析师医药生物行业入围，公募机构榜单第 6 名。作为团队核心成员，连续获得新财富：2019、2018、2017 年最佳分析师医药生物行业第 1 名。

Du Xiangyang is the Chief Analyst of healthcare group at Southwest Securities. He has over 7 years of research expertise in healthcare sector and has developed strong industry connections. Prior to joining in Southwest Securities in Mar. 2020, he worked in China Industrial Securities, Everbright Securities, and Guolian Securities, covering brand-name medicines, CRO&CDMOs, biological products and distribution. He holds a master's degree in Genetics and studied for a PhD degree in Chinese Academy of Sciences. As a Chief Analyst, he has won many awards, including the 1st place of Wind Gold Medal Analyst in 2020, nomination as the Best Analyst in Crystal Ball Awards 2020, the 6th place in the Mutual Fund Institution List. As a senior analyst, he has won the 1st place of New Fortune Best Analyst in 2017, 2018 and 2019.

何风志
北康医疗投资管理有限公司总经理

HE Fengzhi
General Manager, Beikang Healthcare

何风志，北康医疗投资公司总经理。兼任被投企业董事：北京莱尔生物科技公司董事、海南中和药业董事等。同时兼任诚泰保险独立董事。北康医疗投资为北控集团旗下上市公司北京健康（HK.02389）联合产业合作伙伴，专注于医疗健康领域股权投资的市场化的专业机构。核心合作伙伴包括北京健康、大健康产业方和地方政府引导基金等。主要投资的项目 CDMO 领域烟台迈百瑞生物、四川康德赛医疗（肿瘤疫苗创新研发企业）、北京莱尔生物（循环肿瘤细胞 CTC）及河北森朗生物（Car-T 细胞治疗）等。

Mr. He Fengzhi, the General Manager of Beikang Healthcare, also works as the director of fund's portfolio which include Beijing Cyttel bio, Hainan Zhonghe Pharmaceutical etc. and the independent director of Champion Property & Casualty Insurance.

As the joint-industry partner of the listed company Beijing Health(HK.02389)which is affiliated to Beikong Group, Beikang Healthcare is a professional and market-oriented fund focusing on equity investment in the health-care area, with its primary partners including Beijing Health, enterprises in big health industry, government guide fund etc. Its invested enterprises include: Mabplex in CDMO, Cunde Bio (an innovative company engaged in research and development of tumor and vaccine medication), Beijing Cyttel (a leading company in treating circulating tumor cells), Senlang Bio (a company in curing CAR-T cells) etc.

魏晓雄
上海汉都医药科技有限公司创始人、首席医学官

WEI Xiaoxiong
Founder and Chief Medical Officer of Shanghai WD Pharmaceutical Co., Ltd

魏晓雄博士有近 10 年时间服务于美国 FDA 药物评审中心（CDER）临床药理部，之后在美国临床 CRO 公司 Medpace 工作 10 年。他曾在美国国立卫生研究院癌症研究所从事博士后工作，并首次发现 5- 氟尿嘧啶人体毒性反应的药物遗传学基础。魏晓雄博士 1983 年毕业于浙江医科大学（现为浙江大学医学院）并在中国完成了内科学 / 心脏内科临床专业培训，1989 年获 Merck 国际临床药理奖学并在美国华盛顿大学医学中心接受临床药理的专业培训，1995 年获美国爱达荷州立大学博士学位。

Dr. Xiaoxiong Wei worked as a senior reviewer in the Office of Clinical Pharmacology at CDER/ FDA for nearly 10 years, and then worked at Medpace, a US clinical CRO company as senior Medical Director for 10 years. Dr. Xiaoxiong Wei graduated from Zhejiang Medical University (Zhejiang University School of Medicine) in 1983 and completed his internal medicine/cardiology training in China. He received fellowship training in clinical pharmacology at the University of Washington School of Medicine affiliated Boise VA Medical Center in 1989. He was a postdoctoral fellow at the National Cancer Institute of NIH and discovered the pharmacogenetic basis of 5-fluorouracil human toxicity for the first time.

温　弘
上海生物医药基金合伙人

WEN Hong
Partner of Shanghai Healthcare Capital

温弘博士在药物研发尤其转化医学领域有杰出成就和丰富经验。2018 年到 2020 年，回国任丽珠医药集团首席科学家。2013 年到 2018 年，担任美国 FDA 科研领头人和资深审评，负责法规制定，复杂药物综合审评，药物上市后调查及 NDA/ANDA/DMF/CP/CC 审评。也负责相关领域的科研项目立项，审核，指导。在加入 FDA 之前，在美国医药工业（诺华和惠氏）的 11 年中，主持或参与了 32 个临床阶段药物的研发和申报，有 9 个新药已获得批准上市（其中多个年销售额超过 10 亿美元）。温弘博士于 2002 年获得美国普度大学药学博士。发表超过 100 篇论文 / 专利 / 学术专著 / 报告。在 FDA 多次获奖，也得到诺华的最高科学奖“Novartis Leading Scientist”。

Hong has extensive experiences in drug R&D especially translation medicine. From 2018 to 2020, he served as the CSO of Livzon Pharmaceuticals Group, a public traded company in both Hong Kong and Mainland China. From 2013 to 2018, he was a scientific lead and senior reviewer for the US FDA, responsible for FDA Guidance development, complex drug product reviews, and post-marketing Investigations, as well as numerous drug reviews. Prior to joining FDA in 2013, Hong has worked 11 years in pharmaceutical industry (Novartis and Wyeth), and led and contributed to the development of 32 new drug candidates at clinical stage, of which nine NDA approvals in Europe and USA. In 2002, he received his Ph.D. in Industrial and Physical Pharmacy from Purdue University. In addition to “Novartis Leading Scientist” award, the highest scientific recognition of Novartis, Hong has been recognized multiple times at the US FDA.

胡云富
泛生子首席医疗官

HU YunFu
CMO of Genetron Health

胡云富博士在医疗器械、医药研发领域，拥有二十余年企业管理及政府监管经验：在 BD、葛兰素史克、Metabolon 公司先后共有 10 年工作经验，随后 11 年就职于美国 FDA。作为首席医疗官加入泛生子前，胡云富博士担任美国 FDA 医疗器械和放射健康中心 / 体外诊断和放射健康办公室分子遗传学与病理学部副主任，其领导的团队负责监管癌症分子诊断（液体活检、癌症早筛、病程监测、微小残留病等）、伴随诊断、基因检测、人工智能解剖学和细胞学病理设备。胡云富博士曾 10 次获得 FDA 局级奖励，8 次获得医疗器械和放射健康中心级集体成就奖。

Dr. Hu has more than two decades of experience in medical product development and regulations including 2 years at Becton Dickson, 6 years at GlaxoSmithKline, 2 years at Metabolon and 11 years at US FDA. Prior to joining Genetron Health as the Chief Medical Officer in April, 2020, Dr. Hu was the Deputy Director of the Division of Molecular Genetics and Pathology in the Office of In Vitro Diagnostics and Radiological Health, Center for Devices and Radiological Health, FDA. His team was responsible for regulating molecular oncology diagnostic products (liquid biopsy, early cancer screening, course detection, micro-residual disease, etc.), companion diagnostics, gene testing, artificial intelligence in anatomical and cytological pathology devices. Hu received 10 agency-level awards and eight center-level achievement awards at FDA.

门宇欣
海昶生物首席医学官

Angela MEN
CMO of Haichang Biotech

门宇欣博士 2003 年加入美国食品药物管理局（FDA），历任药审中心（CDER）临床药理高级、特级审批官和药物审批小组负责人职位，主要负责肿瘤和神经药物 IND/NDA/BLA 审批。在近 18 年的药物监管生涯中，她亲自负责审批了 2000 多个新药试验申请和 30 多个新药上市申请。她曾于 FDA 获得五十余奖项并领导了许多与药审相关的研究项目，获得了 12 个 FDA 科研基金，主导了数个 FDA 指南的制定，并多次担任学术会议的组织者或讲员。她同时担任联邦亚太裔美国人委员会（FAPAC）会员和社区拓展部门的助理主席，积极参与和推动各项亚太裔活动。门博士毕业于天津医科大学，获得临床医学学士学位后于天津第二附属医院任神经内科医生并参与药物一期临床试验。赴美后于弗吉尼亚州立大学药学院获得制药科学博士学位，期间做为 PI 完成一期临床试验。现任海昶生物首席医学官。

Dr. Angela Yuxin Men joined the US Food and Drug Administration (FDA) Center for Drug Evaluation (CDER) in 2003 and has served as senior, master clinical pharmacology reviewer and Team Leader for oncology and neurology IND/NDA/BLA evaluations. During her almost 18 years drug regulatory tenure, she was responsible for approving more than 2,000 new drug applications at IND stage and more than 30 at NDA/BLA stage. She has won more than fifty awards from the FDA and received 12 intramural grants to conduct research projects and led development of several FDA guidelines. She also actively served as an organizer or lecturer for many scientific conferences. She is a member of the Federal Asian Pacific American Council (FAPAC), an assistant chairman of the Community Outreach committee, and has been actively participating and promoting various Asian Pacific American activities. Dr. Men graduated from Tianjin Medical University. After obtaining a bachelor's degree in clinical medicine, he worked as a neurologist in Tianjin Second Affiliated Hospital and participated Phase I clinical trials. Later, she obtained her Ph.D. in pharmaceutical science from School of Pharmacy, Medical College of Virginia, Virginia Commonwealth University in US, during which he completed a phase 1 clinical trial as a PI. Currently, Dr. Men is a Chief Medical Officer in Haichang Biotech.

丁洪流
北京卡替医疗副总裁

DING Hongliu
Vice President of Chineo

丁博士现任北京卡替医疗副总裁，负责项目管理和法规事务工作，领导公司细胞治疗产品管线推进，质量体系建设，非临床及临床研究开发策略制定，产品注册申报等工作。旅美期间在美国麻省大学和哈佛大学从事医学研究，并在 FDA 担任资深评审专家近 10 年，负责药物安全审评。回国后曾就职于上海复宏汉霖生物技术公司和驯鹿医疗，在免疫和细胞治疗的产品开发以及国内国际临床试验开展和注册申报领域积累了多方位的企业实际操作和管理经验。

Dr. Ding is currently the vice president of Beijing Chineo Medical in charge of project management and regulatory affairs, leading the company's cell therapy product pipeline advancement, quality system construction, non-clinical and clinical study design and development, and regulatory application of products. During his stay in the United States, he engaged in medical research at the University of Massachusetts and Harvard University, and served as a senior review expert in the FDA for nearly 10 years, responsible for drug safety review. After returning to China, he worked for Shanghai Henlius Biotechnology Co., Ltd. and IASO Biotherapeutics. He has accumulated multi-faceted corporate practical operation and management experience in the areas of the development of immune and cell therapy products, domestic and international clinical trials, and regulatory affairs.

陈少羽
美国安诺波特律师事务所驻上海代表处管理合伙人

CHEN Shaoyu
Managing Partner of Arnold & Porter LLP Shanghai Office

陈少羽律师是美国安诺波特律师事务所驻上海代表处管理合伙人，律所总部在美国首都华盛顿，拥有超过 1000 名律师，在美国、欧洲和亚洲共有 13 个办公室，为客户提供全球性的法律服务。

陈律师曾经在美国 FDA 马里兰总部担任助理首席律师（2000-2004），以及在美国安进公司加州总部担任高级法律顾问（2006-2010）。陈律师毕业于北京大学，目前持有美国首都华盛顿的律师执照。

陈律师精通中美两国的药品和医疗器械的监管法律，拥有 20 年的丰富经验，擅长为制药企业和医疗器械公司在中国和美国的业务活动提供法律服务，通过解决各种重大法律问题，帮助公司制定关键战略方向和实施方案，力图符合中美医药的监管要求，避免遭到执法处罚，使得企业得以顺利发展，开展投资并购，许可合作，研发注册，生产销售，投标定价，药物警戒等核心业务。

陈律师还经常凭借他在美国 FDA 的工作经验，提供公益服务，帮助中国政府的医药监管部门以及生命科学领域的学术机构深入了解美国 FDA 监管体制，以求扬长避短，加速中国与世界接轨，早日成为医药强国。

Andrew Shaoyu Chen is the managing partner of the Shanghai office of Arnold & Porter LLP, which is a large international law firm headquartered in Washington DC, with over 1000 attorneys providing full legal services from 13 offices located in the US, Europe, and Asia.

Mr. Chen has 20 years of experience in food and drug law, including serving in the US Food and Drug Administration (2000-2004) in Rockville, Maryland, as Assistant Chief Counsel, and Amgen (2006-2010) in Thousand Oaks, CA, as Senior Counsel. Mr. Chen was born and grew up in China, graduated from Peking University, and received attorney license from Washington DC.

Leveraging this very unique experience, Mr. Chen has been effectively assisting life sciences companies doing business in China and the US, ranging from Fortune 500 to midsize and small startups, to help them resolve the most challenging legal and regulatory issues.

Mr. Chen has also been actively assisting, on a pro bono basis, the China National Medical Products Administration (NMPA, formerly known as CFDA and SFDA) and various academic organizations to better understand the US FDA framework, and help the NMPA to further reform and align with the leading international regulatory systems.

林云峰
德诺资本管理合伙人

Kevin LIN
Managing Partner, DNV Capital Limited

林云峰先生拥有中欧国际工商管理学院（CEIBS）EMBA 学位、英国兰卡斯特大学（Lancaster University）金融学硕士及中国人民大学经济学学士学位。同时，林先生是微软 MCSE 认证工程师，并于 2016 年荣获投资中国的“全球最佳跨境早期投资人”奖项、2016 年入选胡润人物榜“最佳跨境投资人 Top20”。

在创立德诺资本以前，林先生任职鼎晖投资，负责华南区的创投业务，后加入创东方投资基金任管理合伙人。林先生早年在华为总裁办工作，参与了《华为基本法》的制定。1999 年加入涌金集团，担任董事长魏东的助理。2003 年林先生任职中兴通讯投资部，主导了亚洲、非洲和北美地区的多个投资项目，并担任了多家公司的董事职务。

林先生在金融及战略投资方面拥有 20 多年的丰富经验，曾主导投资了医疗健康、创新科技、TMT 行业的一系列项目，包括：普利制药（300630.SZ）、美国 Vessix 高血压治疗、启明医疗人工心脏瓣膜（2500.HK）、海创药业、Broncus 肺癌检测、以色列 HumanExtensions 手术机器人（TASE:HUMX）、美国 Sorrento 生物制药（NASDAQ: SRNE）、北海康成生物制药、世和基因、应流股份（603308.SH）、伯特利（603596.SH）、晶科电子（836789.SZ）等。

Mr. Lin owns an EMBA Degree from China Europe International Business School (CEIBS), a Master Degree in Finance from Lancaster University and a Bachelor Degree in Economics from Renmin University of China.

Before founding DNV Capital, Mr. Lin was the partner of CDF Capital. Previously, he served in CDH investments and was responsible for the VC business in South China. While working for ZTE investment department, he was in charge of multiple investment projects in Asia, Africa and North America.

Mr. Lin has 20 years of rich experience in financial and strategic investment areas. He has led investment in a series of projects in the Healthcare, Innovative Technology, TMT and Consumer Goods industry, including Poly Pharm (300630.SZ), Vessix Vascular Inc., Venus Medtech (Hangzhou) Inc., Hinova, Broncus, Sorrento (SRNE. NASDAQ), Geneseeq, CANbridgepharma, Yingliu Electromechanical (603308.SH) , APT Electronics (836789.SZ) and Opzoon (600701.SH)

卢雄鹰
上海证券交易所发行上市服务中心副总经理

LU Xiongying
Deputy General Manager, Offering & Listing Center, Shanghai Stock Exchange

经济学博士，现任上海证券交易所发行上市服务中心副总经理，长三角 G60 科创走廊联席办公室副主任，上海股交中心董事，科创板筹备组成员。

Doctor of Economics, currently the deputy general manager of the Offering & Listing Service Center, Shanghai Stock Exchange, the deputy director of the joint office of the Yangtze River Delta G60 Science and Technology Corridor, the director of the Shanghai Stock Exchange Center, and a member of the STAR Market Preparatory Group.

陈英格
上海君实生物医药科技股份有限公司 董事会秘书

Inger CHEN
Board secretary , Shanghai Junshi Biosciences

陈英格于 2017 年 4 月加入君实生物，于 2017 年 4 月至 2018 年 1 月担任证券事务代表，自 2018 年 1 月起担任君实生物董事会秘书。陈女士在职期间协助公司董事会完成多次募资以及相关证券市场工作，其中包括公司两地的 IPO 上市，以及一次 H 股再融资。

陈女士于 2014 年 7 月在中国上海中医药大学获得药学学士学位，并于 2015 年 11 月在英国伦敦大学学院获得药物设计理学硕士学位。陈女士自 2017 年 11 月起取得全国中小企业股份转让系统董事会秘书资格，自 2019 年 10 月起取得上交所科创板董事会秘书资格。

Inger Chen joined Junshi Biosciences in April 2017 and was a securities affairs representative of the Company from April 2017 to January 2018. Ms. Chen has served as the secretary of the Board since January 2018. During her tenure, Ms. Chen assisted the board of directors of Junshi Biosciences in completing several capital raisings and stock market affairs, including the company's dual IPOs(A+H) and one H-share placing.

Ms. Chen obtained her bachelor's degree in pharmacy from Shanghai University of Traditional Chinese Medicine, the PRC in July 2014 and her master's of science degree in drug design from University College London, the United Kingdom in November 2015. Ms. Chen has obtained the qualification of NEEQ secretary of the Board since November 2017, and obtained the qualification of board secretary of the Shanghai Stock Exchange STAR Market since October 2019.

柳　丹
鼎晖投资合伙人

LIU Dan
Partner, CDH Investments

柳丹博士现任鼎晖投资创新与成长基金合伙人，负责健康医疗领域的投资，代表项目包括：成都先导 (688222.SH)、天境生物 (IMAB.O)、和铂医药 -B(2142.HK)、九强生物 · 迈新生物 (300406)、集萃药康、新格元生物、齐碳科技等。

在加入鼎晖投资前，柳博士曾在 Bain & Company 从事大健康领域和大消费领域的管理咨询业务。期间，他服务并负责过多个大型跨国医药和器械企业的战略项目。

柳丹博士在科研、商业、管理、咨询、投资等多领域拥有约十五年健康医疗行业相关经验。

柳丹博士同时担任多个政府、行业协会理事和高级专家，及多个省市级科技和人才项目的审评专家。获评“2021 第五届医疗健康投资卓悦榜 40 Under 40. 年度医疗健康投资人”、“2020-2021 未来医疗 100 强 . 年度青年投资人”。

Dr. Dan Liu joined CDH in 2015, focusing on global Healthcare investments. Prior to this position, he worked at Bain & Company, providing management consulting services to multinational biopharmaceutical companies, healthcare providers and private equity firms.

Dan Liu is the Partner of Venture and Growth Capital for Healthcare at CDH Investments, covering fields of Biotech, Pharmaceuticals, Medtech and Diagnostics. In this role, he is responsible for deal sourcing, execution, transaction and portfolio management. His biopharma investment portfolio includes HitGen (688222.SH), I-MAB (IMAB.O), Harbour-B (2142.HK) etc.

Prior to this position, Dr. Liu worked at Bain & Company, serving in management consulting leadership team and formulating strategies for multinational biopharmaceutical companies, healthcare providers and private equity firms.

Dr. Liu is a seasoned scientist, consultant and investor with around 15 years of experience in Healthcare Sector.

廖逸星
华泰联合证券投资银行大健康行业部联席主管

LIAO Yixing
Co-head of Investment Banking Department Healthcare Division, Huatai United Securities

廖先生毕业于北京大学，获得医学硕士，医学、经济学双学士学位

曾负责或参与了荣昌集团整体资本运作，分拆荣昌生物 H 股 + 科创板 IPO；药明集团整体资本运作，分拆药明康德 A 股 +H 股 IPO、A+H 再融资；爱尔眼科整体资本运作，先后完成了两次再融资、一次重大资产重组；石药集团整体资本运作；康诺亚港股 IPO、三生制药分拆三生国健科创板 IPO、开拓药业港股 IPO、奥赛康药业借壳上市等项目。

在境内外发行上市、资产分拆、企业融资等方面具有丰富的资本运作经验。

Mr. Liao graduated from Peking University with a master's degree in medicine and a double bachelor's degree in medicine and economics

He was responsible for the spun off of Rongchang group, the H-share IPO and the A-share IPO of Remegen(9995.HK); the A-share and H-share IPO of WuXi AppTec(603259.SH/2359.HK); the follow on and the major asset restructuring of Aier(300015.SZ); Capital operation of CSPC(1093.HK); H-share IPO of Keymed(2162.HK); Spin off of 3SBio(1530.HK) and some other projects.

He has rich capital operation experience in the A-share and H-share IPO, asset spin off and enterprise financing.

陶旭东
君合律师事务所合伙人

TAO Xudong
Partner, JunHe LLP

陶旭东律师现为君合律师事务所资深合伙人、医药医疗业务部负责人，拥有超过 25 年为各类医药医疗企业提供从上市前架构重组、私募融资、股权激励、在国内 A 股及香港、纽交所、纳斯达克等主要境内外资本市场上市以及上市后各类资本运作的实战经验。

陶律师近期作为项目主要负责人参与的项目包括：(1) 首家采用科创板第五套标准上市的企业——苏州泽璟；(2) 国内肿瘤早筛香港上市第一股——诺辉健康；(3) 国内首家继纳斯达克、香港主板之后在科创板第 3 上市的企业——百济神州 (进行中)；(4) 西南地区首家科创板上市企业——成都先导，另有十几单创新药与创新医疗器械、CRO 企业在国内科创板、创业板、香港主板、纳斯达克的项目正在进行中。

Mr. Xudong Tao is a senior partner of JunHe LLP and head of Life Science Practice. He has over 25 years of experience advising various types of pharmaceutical and medical device companies in pre-IPO restructuring, private equity financing, employee equity incentive, IPO and listing on SSE, SZSE, HKEX, NYSE and NASDAQ, and post-IPO compliance and transaction services.

The most recent representative deals of Mr. Tao include: (a) the first STAR-listing company adopting Criteria 5 – Suzhou Zelgen; (b) the first HKSE-listing cancer-screening company – New Horizon; (c) the first company seeking for 3rd listing on STAR (following NASDAQ and HKSE listing) – Beigene (ongoing); (d) the first company of west-south China listed on STAR-Chengdu Hitgen. In addition to the above, Mr. Tao is representing over 10 bi-tech and innovative medical device companies seeking for listing at STAR, ChiNext, HKEX and NASDAQ.

李　宁
上海君实生物首席执行官

LI Ning
CEO of Shanghai Junshi Biosciences Co., Ltd.

李宁博士现任君实生物首席执行官。加入君实生物前任赛诺菲集团副总裁兼亚洲区药政与医学政策主管，在新药研发，临床研究与药品科学审评领域拥有丰富的经验。曾就职于美国食品与药品管理局（FDA），历任审评员、资深审评员、审评主管及分部主任等职。参与了多个技术指南委员会，担任过数十个创新药上市许可申请及数百个临床研究申请的主审和主管专业的复审终审。加入 FDA 前，曾任教于美国爱荷华大学医学院内科系及上海医科大学（现复旦大学医学院）。

李宁博士获得美国爱荷华大学医学院硕士、博士学位，上海医科大学医学硕士，医学学士等学位；发表临床试验、药物开发相关学术论文 30 余篇。

李宁博士还同时担任美国国立卫生研究院（NIH）药物科研基金评审委员会委员，美国国立卫生研究院科研基金评审特别委员会（Special Panel）成员，及美国约翰霍普金斯（Johns Hopkins）大学和北京大学兼职教授等职，并于 2020 年起担任上海证券交易所科创板股票上市委员会委员。

Ning Li is currently the Chief Executive Officer at Shanghai Junshi Biosciences. Before he joined Junshi Biosciences, Dr. Li had been appointed as Vice President and Head of Region Asia and China Regulatory Affairs and Medical Policy in Sanofi. He has extensive experience and expertise in clinical research and medical product evaluation. Dr. Li worked at US Food and Drug Administration previously as a regulatory reviewer and held various positions from Oncology drug team reviewer, senior reviewer/expert reviewer, senior GCP medical reviewer to team leader, branch chief with increasing responsibilities. Dr. Li was a member of multiple technical committees and the lead or medical reviewer for dozens of new drug applications (NDA) and over 200 investigational new drug applications (IND). Prior to his US FDA career, Dr. Li served on the faculty of Internal Medicine Department at University of Iowa and Shanghai Medical University (Fudan University).

Dr. Li obtained his medical degree from Shanghai Medical University (Fudan University) and a doctorate degree from University of Iowa. He has published more than 30 scientific papers in the area of clinical trial methodology.

Dr. Li is a member of Cooperative Drug Development Grants Review Committee, NIMH, NIH and Special Emphasis Panel NIDR, NIH, an adjunct faculty member at Johns Hopkins University and Peking University. He has served as a member of the Shanghai Stock Exchange Science and Technology Innovation Board Stock Listing Committee since 2020.

唐艳旻
启明创投投资合伙人

Amy TANG
Venture Partner, Qiming Venture Partners

沈阳药科大学获得学士、中科院硕士、长江商学院 EMBA 硕士。现任启明创投医疗健康投资合伙人。

唐女士加入启明前，在晨兴创投工作 13 年 (2002-2015)，担任晨兴北京办公室总经理。在此期间，独立投资并在董事会层面管理超过 20 家早期生物医药公司。 其中大部分均已通过上市或并购途径成功退出，回报丰厚。加入晨兴之前，唐女士在葛兰素史克工作七年，其中五年做新药注册，两年做产品经理。

在启明工作期间，投资项目包括神州细胞，义翘神州，加科思，科州，克睿基因，和其瑞等公司。

Amy earned her master's degree in Chinese Academy of Sciences and a bachelor's degree from Shen Yang Pharmaceutical University. Amy is also a graduate of EMBA course of Cheung Kong Graduate School of Business (CKGSB).Ms. Amy Tang is a Venture Partner at Qiming Venture Partners.

Amy previously worked in Morningside Ventures for 13 years (2002~2015). in charge of its Beijing office. Amy invested and managed dozens of early stage biotech portfolios during this period. Up till now, most of the investments have exited via IPOs or M&A with multiple returns.

Prior to joining Morningside, Amy worked in GSK as a regulatory manager for five years and product manager for two years. She had participated in the investment on Sino Cell Tech, Sino Biological, Jacobio Pharma, KeChow Pharma, Cure Genetics and Hope Medicines.

张　军
中信证券投行委医疗健康组执行总经理

Jon ZHANG
Executive Director, Investment Banking, Healthcare and Life Science Group, Citic Securities

张先生现任中信证券投行委医疗健康组执行总经理，立项委员会委员，投资决策委员会委员，拥有逾 10 年的医疗健康行业投资银行与投资经验，先后为以岭药业、步长集团、甘李药业、绿叶制药、三生药业、金域医学、艾德生物、联影医疗、泰格医药、国药集团、益丰药房、康宁医院、博瑞医药、艾力斯等数十家知名客户提供融资、境内外上市、并购重组等全方位服务。在企业战略咨询、资本策略选择、交易结构设计、交易高效执行、行业资源整合等方面拥有丰富的经验。

Mr. Zhang is the current executive director and member of the Project Establishment Committee and the Investment Decision Committee of the Healthcare Group of CITIC Securities. He has over 10 years of investment banking and investment experience in the healthcare field, and has successively provided all-round services including financing, IPO in domestic and overseas market and M & A, for dozens of well-known companies, such as Yiling Pharmaceutical, Buchang Pharma, Gan & Lee Pharmaceuticals, Luye Pharma Group, 3SBio Group, Kingmed Diagnostics, AmoyDx, United Imaging Healthcare, Tigermed, Sinopharm, Yifeng Pharmacy, Kangning Hosptical, BrightGene Bio-Medical Technology, Allist Pharmaceutical technology etc. He has rich experience in enterprise strategic consulting, capital strategy selecting, transaction structure designing, efficient transaction executing, and industry resources integrating.

李　英
汉坤律师事务所生物医药部部长

LI Ying
Director, Life Sciences and Healthcare Department, Han Kun Law Offices

李英博士的专长包括专利申请、无效和诉讼、专利检索、专利交易以及其他与知识产权相关的咨询。她在为国内和跨国客户提供法律服务方面拥有丰富的经验，曾协助许多行业领先的客户在中国获得专利。在加入汉坤之前，李博士曾在中国国际贸易促进委员会专利商标事务所工作 16 年，其中有 9 年担任团队负责人。

李博士的业务涵盖专利挖掘和布局、撰写申请、答复审查意见、现有技术检索、FTO 检索和分析等。她在用 STN 等数据库进行化学小分子药物和包括核酸以及蛋白质在内的生物大分子的检索方面经验丰富。她曾代表许多客户在国家知识产权局和各地法院审理的多起专利无效和行政诉讼案件中取得过胜利成果。她多次在大型复杂案件中担任主要办案人和组织者，凭借优秀的诉讼结果和出色的沟通能力获得了客户的广泛认可和信任。

Dr. Li's expertise covers patent prosecution, invalidation and litigation, patent searches, patent transactions, and other IP-related counseling. She has extensive experience in providing a range of legal services to both domestic and multinational clients and has assisted many industry-leading clients in obtaining patents in China. Prior to joining Han Kun, Dr. Li practiced for 16 years with CCPIT Patent and Trademark Law Office, where she was a group leader for 9 years.

Dr. Li's practice covers a variety of legal services, such as patent mining, drafting and responding to office actions, prior art searches, freedom-to-operate (FTO) searches and analysis, and consulting. Additionally, Dr. Li has extensive experience using the STN database in FTO searches related to small molecule drugs and biological macro-molecules such as proteins and nucleic acids. Dr. Li has successfully represented many clients before the China National IP Administration and the courts in various patent invalidation and administrative litigation cases. She has taken charge of many large and complex cases and is widely recognized and trusted by her clients for obtaining excellent results and for her excellent communication skills.

巫　荟
泉创资本董事总经理

Marietta WU
Managing Director, Quan Capital

巫荟博士现任泉创资本董事总经理。巫博士不仅专长于临床药物和医药研发，同时在金融和创业方面有丰富的经验。作为再鼎医药（纳斯达克：ZLAB；港交所：09688）的联合创始人，巫博士曾任该公司的首席运营官一职。巫博士现同时兼任礼邦医药、Crescendo Biologics、典晶生物、健新原力、迈杰转化医学、琅钰集团、泽纳、Zidan 的董事，也曾担任科越医药的董事。过去十多年间，她活跃于生命科学产业的跨国风险投资以及价值创造领域。巫博士曾任职于博乐集团，担任博乐基金董事总经理，负责博乐集团在大中华区的业务。在投身医疗健康投资行业之前，巫荟博士曾任职于美国礼来公司和爱德华生命科技公司。

巫荟博士先后在上海交通大学医学院（曾名：上海第二医科大学）、俄亥俄州医学院、密歇根大学商学院取得了医学学士、医学科学博士以及工商管理硕士学位。

Dr. Marietta Wu is Managing Director of Quan Capital, a life sciences venture fund with offices in China & US, and deep expertise in cross-border value creation and global investments. She is a founding member of Zai Lab (NASDAQ: ZLAB; HKEX: 09688) and served as COO and Director of the company prior to Quan Capital. Dr. Wu represents Quan Capital on the board of Alebund Biotech, Crescendo Biologics, Eluminex Biosciences, Innoforce, MEDx Translational Medicine, RareStone Group, Zenas Biopharma and Zidan Medical, and was a Director of Kira Pharmaceutical. Over the past decade, Dr. Wu has been active in cross-border ventures and value creation in the life sciences industry. She was Managing Director at Burrill & Company, leading Burrill's investments and operation in Greater China. Prior to her focus on healthcare investments and company building, Dr. Wu held various roles with increasing responsibilities at Edwards Lifesciences and Eli Lilly & Company.

Dr. Wu received her medical degree from Shanghai Jiaotong University School of Medicine (formerly Shanghai Second Medical University), a Ph.D. in Medical Sciences from Medical College of Ohio, and an MBA from the University of Michigan Ross School of Business.

傅扬远
嘉源律师事务所 高级合伙人

FU Yangyuan
Senior partner, JIA YUAN LAW OFFICES

傅律师现为嘉源律师事务所高级合伙人，融资业务联席负责人，主要负责境内外资本市场业务及私募股权投资业务，领域涵盖医疗健康、半导体集成电路、装备制造、新材料等。傅律师拥有超过 15 年资本市场法律服务经验，参与过数十家企业境内外上市项目及众多私募股权投资项目，医疗健康相关代表业绩包括：泰格医药 A 股及 H 股上市项目、泰格医药分拆方达控股港股上市项目、惠泰医疗 A 股 IPO 项目、亚虹医药 A 股 IPO 项目、微创机器人 H 股 IPO 项目、捍宇医疗 H 股 IPO 项目、国药控股 H 股 IPO 项目等。傅律师毕业于上海财经大学法学和武汉理工大学，现为上海市律师协会证券业务研究委员会委员。

Ms Fu is currently the senior partner and co-head of the financing business of Jiayuan Law Offices. She is mainly responsible for domestic and overseas capital market business and private equity investment, covering medical and health, semiconductor integrated circuits, equipment manufacturing, new materials, etc. Ms Fu has more than 15 years of experience in legal services in the capital market, and has participated in dozens of domestic and overseas listing projects and numerous private equity investment projects. Her representative projects in medical and healthcare include: Tigermed A-share and H-share listing projects, Tigermed spin-off the Hong Kong stock IPO project of Frontage Holdings, the A-share IPO project of APT Medical and Asieris Medical, the H-share IPO project of MicroPort MedBot, Hanyu Medical, Sinopharm Group etc. Ms Fu graduated from Shanghai University of Finance and Economics and Wuhan University of Technology. She is currently a member of the Securities Committee of the Shanghai Bar Association.

毛　化
弗若斯特沙利文咨询，合伙人

Fred MAO
Partner, Frost & Sullivan

毛化先生负责弗若斯特沙利文大中华区的医疗咨询服务，项目服务对象包括医药、医疗器械及医疗服务三大板块的多家中国及国际领先的企业，掌握了丰富的产业经验，长期受邀参加中国医疗领域的顶级会议并担任演讲嘉宾。通过投融资服务、IPO 行业咨询服务、研发管线的开发策略咨询、商业尽调及市场准入等多种项目类型，毛先生深入了解中国医药市场的前沿动态，积累了丰富的专业知识。毛先生持有上海交通大学硕士学位。

Mr. Mao takes charge of the healthcare consulting service of Frost & Sullivan in Greater China. He possesses a wealth of industry experience in three major healthcare sectors including pharmaceuticals, medical devices and healthcare services, covering a number of clients that are leading companies in the field, in China or around the globe. He has been frequently invited to participate and speak at top-level conferences of China's healthcare industry. At the same time, he keeps abreast with the dynamics of China market and accumulates a wealth of professional knowledge through investment and financing services, industry consulting services for IPO, strategic consulting for pipeline development, commercial due diligence, market access, as well as other projects. Mr. Mao holds a master's degree from Shanghai Jiaotong University.

杨淑娟
安永华明会计师事务所（特殊普通合伙）、安永北京主管合伙人，
安永大中华区政府及基础设施市场主管合伙人、审计合伙人

Jane Yang
Managing Partner, Beijing office,
Government & Infrastructure Market Segment Leader Greater China
Assurance Partner
Ernst & Young Hua Ming LLP

杨淑娟女士拥有逾 25 年的审计经验，目前是安永北京主管合伙人、大中华区政府及基础设施市场主管合伙人，同时还兼任中国人民大学商学院客座教授及会计专业硕士企业导师、财政部政府会计准则咨询委员会委员及 PPP 专家委员等职。杨女士曾于 2012 年至 2016 年四年间连任中国证监会并购重组审核委员会审核委员。

杨女士对审计大型国有企业，民营企业及中外合资企业等均有丰富的项目管理经验，所审计的公司覆盖各种行业，主要包括制药及生物科技业、消费品制造业、大型制造业、建筑业及零售业。杨女士在协助中国企业在 A 股及海外上市审计和财务报告方面有丰富经验，她曾成功协助沈阳三生、甘李药业、百得利汽车、中国圣牧、中国通号、中国铁建、铁建高新装备、西部矿业及京客隆在内的众多企业成功在香港及国内上市，并协助株洲时代新材顺利完成海外并购。她目前还担任华润医药和中国建筑年度审计及多个生物医药企业，包括依生生物、三叶草生物、北海康成生物医药等的 IPO 审计项目的负责合伙人的工作。

Ms Jane Yang has over 25 years of audit experience. She is the Managing Partner of Beijing office and the Government & Infrastructure Market Segment Leader of EY Greater China. She is also a guest professor and an enterprise coach for MPACC students of Renmin University of China, a Ministry of Finance PPP Center Expert and a member of Ministry of Finance Government Accounting Standards Consultancy Committee. Ms Yang was a member of China Security Regulation Committee (CSRC) Merge & Acquisition Review Committee during the period from 2012 to 2016.

Ms Yang has rich experience in the audit and project management of a number of state owned companies, privately owned companies as well as multinational joint ventures. Industry coverage ranged from pharmaceuticals and biotech science, consumer products industrial products, construction, mining and retail. She also has extensive audit experience in sizable Chinese engagements with domestic and overseas listing/listed company financial reporting requirements. Ms Yang has assisted her audit client including 3SBio Inc., Gan&Lee Pharmaceutical Co.,Ltd., BetterLife Holding Limited, China Shengmu Organic Milk Limited, China Railway Signal & Communication Corporation Limited, China Railway Construction Corporation Limited, CRCC High Tech Equipment Corporation Limited, West Mining Co.,Ltd. and Beijing Jingkelong Co., Ltd.in successfully completing IPO in Hong Kong and Mainland China. She also assisted in the completion of overseas acquisition by Zhuzhou New Times Materials Co., Ltd.. She is the partner in charge of annual audit of China Resource Pharmaceutical Group Ltd.,and China State Construction Engineering Corporation Limited and a number of IPO audit engagements of biotech companies currently, including YishengBio Co., Ltd, Clover Biopharmaceuticals Ltd., CANbridge Pharmaceuticals Inc., etc.

高　元
华泰联合大健康部主管兼业务四部主管，董事总经理

GAO Yuan
Managing Director, Head of healthcare department, Huatai United Securities

高先生毕业于浙江大学竺可桢学院及法学院，2006 年入职华泰证券投资银行部，拥有超过 15 年的投资银行业务经历（其间 2011 年 9 月 -2012 年 9 月在南京经济开发区挂职党委副书记）。

高先生从业期间主持及参与了数十家企业首发上市及融资并购业务，被评为新财富 2020 年度最佳保荐人，2017 年以来大健康部连续获得新财富医疗健康领域最佳投行。

从业期间服务的主要客户及代表性项目有：作为签字保荐代表人完成迈瑞医疗 A 股 IPO，融资金额 59 亿元，为核准制下创业板最大规模 IPO，2020 年作为签字保荐代表人完成药明康德 A+H 再融资项目，合计融资金额约 130 亿元；荣昌生物科创板 IPO、石药集团红筹回归 A 股、奥赛康药业重组上市、爱尔眼科产业并购及非公开发行、艾迪药业科创板首发上市、诺唯赞科创板上市、雅克科技首发上市、国科微首发上市、江南嘉捷首发上市等，具有突出的投资银行保荐业务能力，特别是在医疗健康行业领域具有丰富资本运作经验。

Mr. Gao graduated from Chu Kochen Honors College and Law School of Zhejiang University. He joined Huatai United Securities in 2006 and has more than 15 years of investment banking experience (During the period from September 2011 to September 2012, he served as deputy secretary of the Party Committee in Nanjing Economic Development Zone.).

During his career, Mr. Gao presided over and participated in dozens of companies' initial public offerings and mergers and acquisitions. He was entitled as the best sponsor representative of New Fortune in 2020. Since 2017, the Healthcare Division has continuously won the best investment bank in the healthcare field of New Fortune.

The main clients and representative projects Mr. Gao served and participated are as following: completed Mindray Bio-medical's A-share IPO as the sponsor representative, with a financing amount of 5.9 billion yuan, which is the largest IPO under the qualification approval system for the GEM, completed WuXi AppTec's A+H refinancing project as the sponsor representative in 2020, with a total financing amount of about 13 billion yuan, RemeGen's IPO, CSPC Pharma Red Chip Return to A Shares, ASK Pharma's reorganization and listing, Aier Eye Hospital Industry M&A and non-public offering, Aidea Pharmaceutical and Vazyme's IPO on the SSE STAR Market, Yoke Technology's IPO, Goke Microelectronics' IPO, SJEC's IPO, etc.

Mr. Gao has outstanding investment bank sponsoring capabilities. Especially, he has rich experience in capital operation in the healthcare field.

费　凡
安永大中华区生命科学与医疗健康行业联席主管合伙人
华中地区审计部副主管、审计服务主管合伙人

Felix FEI
Ernst & Young
Health Science and Wellness Sector Co-leader, Greater China
Deputy Assurance Leader, China Central Partner, Assurance

费凡先生现任安永大中华区生命科学与医疗健康行业联席主管合伙人及审计服务主管合伙人。负责对客户提供高质量、一体化的审计、税务、咨询及财务交易服务。

费凡先生现任安永中区审计服务副主管，协助主管合伙人领导审计部门在中区的市场活动和运营。

费凡先生专注于服务生命科学与医疗健康领域的客户，包括生物科技、制药、医药流通、医疗器械及医疗服务等行业。其在零售及消费品及汽车行业也有丰富的经验。

费凡先生一直专注服务民企的收购重组、资本募集及上市；对于中国、香港、国际及美国会计准则及公司架构重组、兼并收购有深刻认识和丰富的实际操作经验。其职业生涯中成功帮助多家民企在各主要资本市场成功上市。

费凡先生是中国注册会计师资深执业会员，上海安泰经济与管理学院导师委员会副主任委员、会计硕士和审计硕士项目导师。

Felix is the co-leader of Great China Health Science and Wellness Sector, leading EY Great China's assurance, tax, advisory and transaction services for life science clients.

Felix is the deputy assurance leader of China Central. He assists assurance leadership team to drive marketing strategy and operational excellence.

Felix has 20 years' experience in providing assurance service to clients in life science, consumer products and automotive industry sectors.

Felix also specialized in providing exceptional services to private-owned companies' IPOs. Focus on China domestic, US and Hong Kong capital market.

Felix is also a guest lecturer of Shanghai Jiao Tong University's Master of Professional Accountants ("MPACC") Program and a deputy director of the Career Mentor Committee of Antai Economics and Management Colleague of Shanghai Jiao Tong University.

宿　骅
安永帕特农大中华区生命科学与医疗保健行业主管合伙人

SU Hua
Life Science and Healthcare Practice Leader, EY Parthenon China

宿骅先生是安永帕特农大中华区生命科学与医疗保健行业主管合伙人，拥有超过 15 年的专业服务经验，专注于中国制药与医疗器械领域业务。

他在制药、医疗器械、医院规划、交易战略、标的筛选、尽职调查等多个领域有着丰富的项目经验，为各大制药与医疗器械企业提供咨询服务以及跨境并购支持，议题涉及企业战略、成长战略、投资组合管理、品牌、新产品发布及市场进入策略、以及商业尽调和估值等。

宿骅先生拥有清华大学和欧洲商学院 EMBA 学位，拥有麻省理工学院、新加坡国立大学、韩国国立大学等多个硕士学位，及上海交通大学三个工学学士学位

Hua is leader for Life Science and Healthcare Practice in EY Parthenon China, with over 15 years of experiences in management consulting focusing on pharmaceutical and medical device industry in China.

He is experienced in serving all of the major pharma and device companies, covering their corporate strategy, growth strategy, portfolio, branding, new product launch and market access. His core expertise include pharma, medical device, hospital planning, deal strategy, target screening, and commercial due diligence.

Hua holds two EMBAs from Tsinghua Univ and Instead, several Master Degrees from MIT, NUS, Korean National Univ, and Triple Bachelor from JiaoTong University.

裘育敏
尚珹资本合伙人

Benjamin QIU
Partner, Advantech Capital

裘育敏先生现任尚珹资本合伙人。尚珹资本由于剑鸣先生于 2016 年 1 月成立，关注创新驱动的成长型投资机会，主要投资于医疗医药健康服务业、科技与创新领域。裘育敏先生主要关注医药、医疗服务、医疗器械等行业的投资机会。

裘先生拥有逾 15 年的医疗医药投资、咨询与医院管理经验。自 2013 年加入新天域资本以来，裘先生主导投资了康宁杰瑞、东曜药业、益方生物、兴盟生物、再鼎医药、和铂医药、山东亨利药业、导明医药、泛生子医疗、瑞尔齿科、上海力康生物医疗等项目。

加入新天域资本之前，裘先生作为专注医疗产业投资的德福资本的核心团队之一，主导了温州康宁医院等项目的投资。裘先生还曾是普华永道医疗咨询服务团队的创始成员之一，早年亦在加拿大温哥华总医院供职多年。

裘先生拥有英属哥伦比亚大学 MBA 学位和华东工业大学学士学位。裘先生亦持有特许金融分析师（CFA）和美国管理会计师（CMA）证书。

Mr. Qiu is Partner at Advantech Capital, a private equity fund founded by Mr. Jianming Yu in January 2016. Advantech Capital focuses on innovation-driven growth capital, on investments in Healthcare, TMT, and E-services sectors in China. Mr. Qiu's main focus areas are Pharmaceutical, Medical Devices and Healthcare Services.

Mr. Qiu has aggregated over 15 years of experience in healthcare investment, consulting and hospital management. He joined New Horizon Capital in 2013 and has since taken a leading role in investments in AlphaMab Oncology, TOT Pharma, Synermore Biologics, InventisBio, Zai Lab, Harbour BioMed, KBP, DTRM Pharma, Arrail Dental and HealForce Biotech etc.

Before joining New Horizon Capital, Mr. Qiu worked at GL Capital, a healthcare-dedicated investment fund, where he led multiple deals including Kangning Psychiatric Hospitals Group. Mr. Qiu also worked at the PwC Healthcare Advisory Team as a founding member and at Vancouver General Hospital as a business analyst.

Mr. Qiu holds an MBA degree from the University of British Columbia and a Bachelor's degree in Engineering from the Eastern China University of Technology. He is also holder of designations of CFA (Chartered Financial Analyst) and CMA (Certified Management Accountant – US).

诸　斌
安永税务与商务咨询合伙人

Raymond ZHU
Tax & Business Advisory Partner of EY

诸斌先生是安永税务部华中区合伙人。在过去逾十九年的专业服务中，他致力于为各级政府部门、大型国有企业、全球跨国企业以及高成长民营企业提供优质的税务咨询协助。拥有丰富的服务经验。

在此期间，诸先生为客户提供过如下主要服务：IPO 上市、企业兼并、集团重组、跨境投资运作相关涉税事宜、税务咨询 / 筹划、税务申报等服务。

诸先生拥有众多行业经验，特别擅长为制造业、金融业、医药及医疗器械、分销 / 零售业、互联网行业、矿业、物流、电子商务等行业客户提供专业的税务服务。

诸斌先生担任上海市外资委外商投资咨询企业协会委员，国家会计学院特聘硕士生导师。

Raymond is a tax partner with over 19 years of Chinese and international tax experience serving Fortune 500 multinationals and private equity firms investing in China.

Raymond has led many studies that involve formulation of investment strategies, restructuring of Chinese operations, advice on merger and acquisition (including tax due diligence, tax structuring and post-deal integration), tax compliance assessment, design and implementation of cash repatriation schemes, tax negotiations and etc.

Raymond is also frequently engaged in providing advice on tax issues faced by Chinese companies listed/ to be listed in and outside China equity market. All of these assignments have created significant value to clients and have covered around parts of China including Beijing, Guangzhou, Shanghai, Shenzhen and so forth.

Raymond has worked with a wide spectrum of clients in industries with a focus on pharm & medical instruments, TMT (Technology, Media, Telecom) sector, internet, manufacturing, distribution & retailing, and electronic commerce.

黄蕴靖
香港交易所环球上市服务部经理

Kathy HUANG
Associate of Global Issuer Services of HKEX

黄蕴靖女士现任职香港交易所环球上市服务部经理，主要负责内地企业赴港上市的市场推广和拓展工作。致力与拟上市企业、政府部门以及相关业界机构保持紧密合作，为其提供最新香港资本市场动态和上市规则介绍。

黄蕴靖女士毕业于加拿大多伦多大学。加入港交所之前曾任职于加拿大皇家银行和汇丰银行，专注公募基金运营，产品研发和投后管理。

Ms. Huang is the Associate of the Global Issuer Services Department of HKEX, mainly responsible for the market promotion and education of Mainland issuers listing in Hong Kong. She maintains close cooperation with issuers, government and industry associations to provide latest updates on Hong Kong's capital market developments and listing rules.

Ms. Huang graduated from the University of Toronto, Canada. Before joining HKEX, she worked at Royal Bank of Canada and HSBC, focusing on mutual fund operation, product research and post investment management.

裘加林
微脉技术有限公司董事长 &CEO

Alin CHOW
Chairman & CEO of Weimai Technology Co., Ltd.

裘加林先生深耕医疗健康服务领域十余年，于 2015 年创办了微脉技术有限公司，现任微脉技术有限公司董事长兼 CEO。经过多年发展，公司目前已成为全国最大的本地一站式医疗健康服务平台。

裘先生是中国第一批创业板上市企业联合创始人，是国内“智慧城市”理念首创者之一，于 2010 年开始先后出版了全国第一套《智慧城市》系列丛书及《智慧医疗》专著；2013 年开始担任全国首个省级重点“智慧健康研究院”院长，是国内医疗信息服务领域领军人物之一，曾带领企业在移动医疗、区域医疗领域连续多年排名全国第一；2020 年被评为杭州市科技局、杭州日报年度创业人物；2021 年入选中国产业创新百人榜。

裘先生毕业于浙江大学管理学院，清华大学五道口金融学院 EMBA。获聘浙江大学管理学院 MBA 企业导师、浙江大学校友创业导师、浙江工业大学信息学院兼职教授。

Alin Chow, chairman and CEO of Weimai Technology Co., LTD. ,founded Weimai in 2015, having been deeply engaged in medical and health services for over 10 years. After years of development, the company has now become the largest local one-stop medical and health service platform in China.

Chow is the co-founder of the first batch of GEM listed companies and one of the pioneers of the "smart city" concept in China. Since 2010, he has published the first domestic set of "Smart City" series and "Smart Medical" monograph. Since 2013, he has served as dean of the country's first provincial-level key "Smart Health Research Institute", and is one of the leading figures in the field of medical information service in China, who has led the enterprise to rank first in the field of mobile medical and regional medical for many consecutive years. In 2020, he was awarded as entrepreneur of the Year by Hangzhou Science and Technology Bureau and Hangzhou Daily. In 2021, he was selected into the list of China's Top 100 Industrial Innovators.

Chow graduated from the School of Management of Zhejiang University and is the Finance EMBA of Tsinghua PBCSF. He was hired as MBA business mentor of the School of Management of Zhejiang University, alumni business mentor of Zhejiang University, and part-time professor of the College of Information Engineering of Zhejiang University of Technology.

谭　铮
南京智精灵科技有限公司董事长

TAN Zheng
Chairman of Nanjing Wispirit Technology Co., Ltd.

谭铮先生现担任南京智精灵科技有限公司董事长。

谭铮先生在中国生物医药行业积累了近 30 年的经验，在陕西步长制药有限公司、陕西康惠控股有限公司、武汉呵尔医疗科技发展有限公司等多家行业龙头的生物医药企业具有高级管理层的任职经历。

此外，经过多年行业内的积淀，谭铮先生创立了多家已上市或者尚在上市孵化过程中的生物医药行业公司。其中，永泰生物制药有限公司（股票代码：06978.HK）是第一家根据香港联交所《上市规则》第 18A 章申请上市的细胞免疫治疗公司；北京华诺奥美基因生物科技有限公司是北京市服务业扩大开放综合试点医疗服务业的唯一基因检测企业；而聚焦认知精神障碍数字药研发与临床认知精神诊疗服务落地转化的南京智精灵科技有限公司，则有望成为认知科学领域下一个“独角兽”企业。

Mr Tan Zheng serves as the Chairman of Nanjing Wispirit Technology Co., Ltd..

Through working as senior management in various leading biomedical companies such as Shaanxi Buchang Pharmaceutical Co., Shaanxi Kanghui Pharmaceutical Co., Ltd. and Wuhan Heer Medical Technology Development Co., Ltd., Mr Tan Zheng has accumulated almost 30 years of experience in biomedical industry in China.

With years of accumulation in the pharmaceutical industry, Mr Tan Zheng has founded a number of biomedical companies listed or in the process of listing. Immunotech Biopharm Ltd (Stock Code: 06978. HK) is the first cellular immunotherapy biopharmaceutical company listed on the Hong Kong Stock Exchange satisfying the requirements under Chapter 18A of the Listing Rules. Beijing Huanuo Aomei Gene Biotech Co. is the only gene testing enterprise in the medical service industry of Beijing's expanded and comprehensive service industry. Nanjing Wispirit Technology Co., Ltd., which focuses on R&D of digital medicine and the implementation of clinical diagnosis and treatment for cognitive disorder, is expected to become the next "unicorn" enterprise in the field of cognitive science.

徐济铭
医渡科技集团联合创始人、开心生活科技 (HLT) CEO

XU Jiming
Co-founder of YIDU TECH Group, CEO of Happy Life Technology (HLT)

清华大学－医渡云智能自动化医疗系统联合研究中心副主任，《人工智能技术在药物研发中的应用》论文的合著者，该论文于 2019 年 1 月发表于《自然－医学》。

徐济铭先生专注于搜索引擎技术、大数据技术及医疗人工智能领域已有超过 10 年的时间。

在行业率先建立医疗人工智能处理与应用平台，加速医疗行业在此领域的转化应用。

近年专注于利用人工智能技术，加速药品的临床研发和证据产生，为降低药品的研发成本和提升药品的安全性和有效性证据提供创新解决方案，带动行业进入药品临床研究的智能化和在线化时代，相关案例也被《Nature》等国外国内期刊媒体报道，带领企业和行业合作伙伴加速行业创新和进化。

Deputy Director of Tsinghua University YIDUCLOUD Joint Research Center for Intelligent and Automated Medical system , co-author of the paper "Application of Artificial Intelligence Technology in Drug Research and Development ", which was published in Nature Medicine in January 2019.

Mr. Jiming Xu has focused on search engine technology, big data technology and medical artificial intelligence for 10+ years

Mr. Jiming Xu Led the industry in establishing processing and application platform in medical artificial intelligence, accelerated the transformation and application of medical industry in this field.

Mr. Jiming Xu has focused on using artificial intelligence technology in recent years accelerating the clinical research and development of drugs and the production of evidence, providing innovative solutions to reduce the cost of drug R & D and enhance the safety of medicines and evidence of validity, promoting the industry into the era of intelligent and online in drug clinical research, related cases have also been reported in foreign and domestic journals of media such as Nature, leading enterprises and industry partners to accelerate industry innovation and evolution.

戚　飞
君联资本执行董事

QI Fei
Executive Director of Legend Capital

戚飞博士于 2014 年加入君联资本，目前担任君联资本执行董事，专注于生物技术与精准医疗、医疗服务与数字化等方向的投资。

戚飞博士主导、参与的投资项目包括 NexImmune (Nasdaq : NEXI)、百洋医药 (SZ:301015)、ETANA、嘉因生物、朗信生物、瑞博生物、T-cure、金匙基因、博恩登特、欢乐口腔、芙艾医疗、肿瘤资讯、动脉网等。

戚飞博士拥有北京大学细胞生物学博士学位及北京大学生物技术学士学位，曾任美国加州大学洛杉矶分校（UCLA）访问学者。

Dr. Qi Fei Joined Legend Capital in 2014. Now he is an Executive Director of the firm focusing on biotechnology, medical services, and digital health sectors.

Dr. Qi led or participated in investments including NexImmune (Nasdaq : NEXI), Baheal Pharmaceutical (SZ:301015), ETANA, Exegenesis, Innostellar, Ribo, T-cure, Genskey, Bondent, Enjoy Dental, Phiskin, Oncologynews, Vcbeat, etc.

Dr. Qi holds a Ph. D. degree in cell biology and a bachelor degree in biotechnology from Peking University. Prior to joining Legend Capital, Dr. Qi worked as a visiting scholar at University of California, Los Angeles (UCLA).

王晓岑
明日联合医疗产业基金管理合伙人

Rachel WANG
Managing Partner of Mananacare United Industrial Fund

王晓岑，明日医疗产业基金管理合伙人，明日医疗产业基金是专注投资新医疗科技的产业基金，由金沙江宽带共同发起，投资于大数据、大感知、人工智能、物联网等与医疗结合的项目。

曾任中电健康基金合伙人，中电健康产业基金是依托医疗健康大数据国家队中电数据发起的第一只互联网医疗的产业基金，之前曾在经纬中国工作 4 年，主要投资医疗服务以及移动医疗领域，成功投资多个知名案例。此前，任职外资咨询公司，有四年半的医药行业咨询经验，主要服务 top20 外资药企和上市公司。

参与投资和管理的项目包括中电数据、智云健康、芸泰网络、微脉、医联、倍肯、森亿、更美、新氧、云知声、艾棣维欣、安心医生、小雨伞、轻加、拓普基因、翼展、未名企鹅、太美等三十多个互联网医疗和新医疗科技项目。已上市及拟上市公司包括新氧、更美、云知声、智云健康、医联、倍肯、芸泰、艾棣维欣。投资孵化培育的独角兽企业近 10 个。

Rachel Wang, the managing partner of Mananacare United Industrial Fund. Mananacare United Industrial Fund is an industrial fund, co-sponsored by GSR Broadband, focusing on the investment in new medical technology, and majorly investing in deals that integrate healthcare with big data, big perception, artificial intelligence (AI), and Internet of things (IoT), etc.

Rachel Wang was the former partner of CLP Health Industrial Fund. CLP Health Industrial Fund is the first Internet medical industrial fund initiated by CLP Data, the national team in the healthcare big data industry. Rachel Wang also worked at MatrixPartners China for 4 years, mainly focusing on the investment in the field of medical services and mobile medical care, with many well-known deals. Prior to this, she worked at a foreign consulting company and had four and a half years of consulting experiences in the pharmaceutical industry, mainly serving top 20 foreign-funded pharmaceutical companies and listed companies.

Rachel Wang has invested in and managed more than 30 deals in the field of Internet medical and new medical technology, including CLP Data, ClouDr., Yuntai Networks, Weimai, Med Linker, Biochem group, Synyi AI, iGengmei, SoYoung, Unisound, Advaccine Biotechnology, Anxin Doctor, Xiaoyusan insurance, Light Plus, Top Gene, Wing Span, Weiming Penguin, Taimei Tech, etc. Among the companies she invested in and incubated, there are several listed and proposed listing companies, including SoYoung, iGengmei, Unisound, ClouDr., Med Linker, Biochem group, Yuntai Networks, and Advaccine Biotechnology, and nearly 10 unicorn companies.

赵　璐
太美医疗科技董事长兼 CEO

ZHAO Lu
Chairman & CEO of Taimei Technology

毕业于吉林大学分子生物学系与沈阳药科大学制药系，生物技术制药专业学士学位；复旦大学管理学院 / 台湾大学管理学院 EMBA 学位。2019 年加入第五期湖畔大学。

赵璐先生曾于上海医药集团和先灵葆雅公司从事销售管理、市场推广等工作，业绩杰出。2008 年，创立上海捷信医药科技股份有限公司，在国内患者管理领域业绩斐然，并挂牌新三板（股票代码 834294）。

2013，赵璐先生再次创建太美医疗科技。至今，公司成为生命科学产业数字化运营平台，获得众多国内外领先制药企业、医院 / 机构的青睐，多个产品市场占有率居全国第一。公司获得腾讯投资，经纬创投，元生资本，北极光创投，软银中国、凯风创投等顶尖 VC 的多轮投资。

Mr. Zhao holds the bachelor degree of biotechonolgy pharmacy from Jilin University-China / Shenyang Pharmaceutical University and EMBA from Fudan University/Taiwan University management college. Member of 2019 Hupan University.

Mr. Zhao has 10-year working experience in Shanghai Pharma Group and Schering Plough.

In 2008, Mr. Zhao established Jsure Health. With outstanding achievements in the field of patient recruitment, Jsure Health was listed on the new OTC Market (Symbol: 834294).

Mr. Zhao subsequently started Taimei Medical Technology in 2013 to develop digital operation platform in life science industry. Till now, Taimei has been obtained multiple rounds of investment from top VC such as Tencent, Matrix Partner, Genesis Capital, Northern Light, etc.

谭　验
深圳未知君生物科技有限公司 CEO 兼创始人

TAN Yan
CEO & Co-founder of Xbiome Ltd., Shenzhen, China

谭验博士在麻省理工大学和哈佛大学联合成立的博德研究所完成生物信息博士研究工作，拥有波士顿大学生物信息与计算生物学博士学位，和北京大学生物技术学士学位，其研究领域横跨生物信息学、微生物学和免疫学。

博士期间，谭验设计和完成了大量的生物信息学分析软件，并对免疫学和微生物学领域做出了创新性的贡献。其研究成果发表在 Immunity、European Journal of Immunology 等杂志上，单篇论文被 European Journal of Immunology 评为 2014 年引用最高文章之一。

2018 年谭验博士被评为深圳市孔雀人才，2019 年谭验博士受聘担任“中国科学院微生物研究所—生物工程专业硕士研究生企业导师”，担任“粤港澳肠道微生态学术联盟理事”、“中国科学院深圳先进技术研究院微生态制药联合实验室”理事长、“深圳市合成生物研究重大科技基础设施企业用户顾问委员会委员”等多项社会团体职务。

Dr. Tan has completed Ph.D. in computational biology and bioinformatics at the Broad Institute of MIT and Harvard. He hold a Ph.D. degree in computational biology and bioinformatics from Boston University and a bachelor’s degree in biotechnology from Peking University. His research field spans bioinformatics, microbiology and immunology.

During his doctoral research, he has designed and completed a number of bioinformatics analysis software, and made innovative contributions to the fields of immunology and microbiology. His work has been published in Immunity, European Journal of Immunology and other journals. Specifically the work using machine learning algorithm predicting immunity based on early stage gene expression profiles was recognized as one of the most cited articles in 2014 by European Journal of Immunology.

In 2018, Dr. Tan Was awarded as Shenzhen Peacock Talent. In 2019, Dr. Tan was appointed as "Enterprise Tutor for Postgraduates of Bioengineering Major, Institute of Microbiology, Chinese Academy of Sciences". He is also the director of "Guangdong-Hong Kong-Macao Intestinal Microecology Academic Alliance", the chairman of "Micro-ecological Pharmaceutical Joint Laboratory of Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences", and the member of "Shenzhen Synthetic Biology Research Major Science and Technology Infrastructure Enterprise User Advisory Committee".

徐　凯
北京术锐技术有限公司创始人兼董事长

XU Kai
Founder & Chairman of Beijing Surgerii Tech Co. Ltd.

徐凯，北京术锐技术有限公司创始人，上海交通大学教授、博导。基金委优青、北京市海聚特聘专家、教育部新世纪优秀人才、上海浦江人才、青年科技启明星。清华大学学士、硕士，美国哥伦比亚大学博士，曾获哥伦比亚大学最高的杰出校长奖学金和中国国家优秀自费留学生奖学金。主持国家自然科学基金项目四项，科技部重点研发计划专项项目一项，发表论文 80 余篇，获中外发明专利授权 60 余项。担任世界机器人学顶级杂志 IEEE Transactions on Robotics 副编辑，国际委标准国际专家。

Kai Xu, founder of the Beijing Surgerii Technology Co., as well as professor of Shanghai Jiao Tong University, received his B.E. and M.S. degrees from Tsinghua University, China, and Ph.D. degree with distinction from Columbia University. He received the Presidential Distinguished Fellowship, Columbia's highest fellowship in 2004, and the Chinese Government Award for Outstanding Self-Financed Students Abroad in 2008. He was selected into the Program for New Century Excellent Talents in University (NCET Program) by the Ministry of Education, China in 2009, as well as the Pujiang Scholar Program and the Rising Star Program by the Shanghai Metropolitan Government in 2011 and 2014, respectively. He was awarded the NSFC Grant for Excellent Young Scholars in 2017. He has published more than 80 scientific articles, been awarded more than 60 patents, as well as served as the Principal Investigator of more than 20 research projects, sponsored by the National Key R&D Program of China, the National Natural Science Foundation of China, etc. He currently serves as an Associate Editor for IEEE Transactions on Robotics, as well as an international expert on the ISO/TC184 representing China.

李　宇
和缓医疗 CEO

LI Yu
CEO of HH-Medic

和缓医疗 CEO 李宇先生于 2015 年创业之前拥有十年产业投资及互联网公司管理经验，曾作为高管完整经历公司创始阶段至上市后多元发展的全过程。

以 " 互联网 + 分级诊疗 " 作为切入点，通过创新的移动化视频医疗解决方案缓解 " 看病难、看病贵 " 的问题，核心产品【和缓名医】与【和缓视频医生】，致力于促进医疗发展，延长人类寿命。

Mr. Li Yu, CEO of HH-Medic Inc., had 10 years of experience in industrial investment and Internet company management before he started his business in 2015. As a senior executive, he experienced the whole process from the initial stage of the company to the diversified development after listing.

Taking "Internet + hierarchical diagnosis and treatment" as the breakthrough point, the problem of "difficult and expensive to see a doctor" can be alleviated through innovative mobile solutions, so as to promote medical development and prolonging human life.

张爱华
南京医科大学附属儿童医院副院长

ZHANG Aihua
Vice President, Children's Hospital of Nanjing Medical University

张爱华教授（二级），主任医师、博士生导师，国家杰出青年科学基金获得者，国家“万人计划”科技创新领军人才，科技部中青年科技创新领军人才，南京医科大学附属儿童医院副院长，南京医科大学儿科研究所所长，江苏省儿童重大疾病研究重点实验室主任。

张爱华教授实验室长期致力于线粒体功能、氧化应激在肾脏损伤中的研究。主持国家杰出青年科学基金、国家自然科学基金重点项目（2 项）、国家重点研发计划重大专项和 973 课题等国家级项目 10 余项。在 Sci Transl Med,PNAS、J Am SocNephrol、Kidney Int、JBC 等期刊上发表 SCI 论文 160 余篇，累积影响因子 600 余分。获批国家发明专利 10 项，相关研究成果先后获得教育部自然科学一等奖、江苏省科学技术二等奖和三等奖以及中华肾脏病青年研究者奖等。目前担任中华医学会儿科分会肾脏学组副组长、中华医学会儿科分会青年委员会副主任委员、江苏省医学会罕见病学分会主任委员、江苏省医学会儿科分会副主任委员、中国药理学会肾脏药理专业委员会常委、《American Journal of Physiology Renal Physiology》、《World Journal of Pediatrics》等 SCI 期刊编委。

Dr. Ai-Hua Zhang is Professor of Nephrology, chief physician, doctoral supervisor. He awarded the National Science Fund for Distinguished Young Scholars in 2013, the National "Ten Thousand Talents Program" Technology Innovation Leading Talents and the Young and middle-aged leading talents in science and technology innovation of the Ministry of Science and Technology. He is the vice president of Children’s Hospital of Nanjing Medical University, the Director of Institute of Pediatrics, Nanjing Medical University,and the Director of the Key Laboratory of Children's Major Disease Research of Jiangsu Province.

Dr. Zhang’s laboratory has long been interested in mitochondrial function, reactive oxygen species and kidney injury. Dr. Zhang has successfully applied for and received funding from different agencies in recent years. These include National Science Foundation for Distinguished Young Scholars of China, key project of National Nature Science Foundation,National Basic Research Program of China (973 Program), Ministry of Education, and Ministry of Science and Techology. He has published more than 160 articles in various international peer-reviewed journals, including Sci Transl Med, PNAS, Kidney Int, JBC, Am J Pathol, Am J Physiol Renal Physiol.He was authorized ten national invention patents. Related research achievements have been awarded the first prize of natural Science by the Ministry of Education, the second prize and third prize of Jiangsu Province science and technology,young investigator award of Chinese Nephrologist Association.He is the vice director of Nephrology Group, Pediatric Branch of Chinese Medical Association, the vice chairman of youth Committee of Pediatric Branch of Chinese Medical Association, the Chairman of the Rare Disease Branch of Jiangsu Medical Association,vice Chairman of the Pediatric Branch of Jiangsu Medical Association and the committee member of renal-pharmacology of Chinese Pharmacological Society.He currently serves as an Editorial Board Member for World J Pediatr, Am J Physiol Renal Physiol, Chin Med J.

李林康
中国罕见病联盟执行理事长，全国罕见病诊疗协作网办公室副主任

LI Linkang
Executive Director, China Alliance for Rare Disease.
Deputy Head, Bureau of National Rare Disease Diagnosis & Treatment Network

全国罕见病诊疗协作网办公室副主任、国家卫健委罕见病诊疗与保障专家委员会副主任委员兼办公室主任、中国医院协会副会长、中国罕见病联盟执行理事长、中国药科大学校外硕士生导师，《中国药房》杂志编委会主任委员、北京罕见病诊疗与保障学会会长等职务。
曾任国家卫生健康委员会医政医管局巡视员。

Deputy Director of the national collaboration network of rare diseases diagnosis and treatment , Deputy Director and Office Director of the National Health Commission's Disease Diagnosis and Protection Experts, Vice President of the Chinese Hospital Association, Executive Director of the Chinese Hospital Disease Alliance, Master's tutor for ex-students of China Pharmaceutical University, "Pharmacy" magazine. The director of the society, the chairman of the Beijing outpatient clinic and security committee, etc.
Served as an inspector of the Medical Administration and Hospital Administration Bureau of the National Health Commission.

陈智胜
药明生物首席执行官

Chris CHEN
CEO, WuXi Biologics

陈智胜博士现任药明生物首席执行官，在单克隆抗体、治疗性蛋白质及疫苗方面拥有 20 年以上工作经验。在陈博士领导下，药明生物自 2011 年以来已经建立起全球领先的生物药发现、开发和生产一体化平台，赋能 450 余家全球合作伙伴，包括小型初创企业和全球 20 强医药企业。作为一家香港上市公司，药明生物始终保持高速稳健发展，市值突破 600 亿美元，并作为唯一的生物技术公司入选恒生指数。公司拥有全球最大的生物药研发团队之一，员工遍布中国、美国、爱尔兰和德国，总数超过 7600 人，是中国首家也是目前唯一一家同时通过美国 FDA、欧盟 EMA、中国 NMPA、巴西 ANVISA、新加坡 HSA 检查的生物制药企业。陈博士拥有北京清华大学获化学工程以及自动化双学士学位及美国特拉华大学获得化学工程博士学位，是国际制药工程协会（ISPE）国际董事会首位亚洲成员。

Dr. Chris CHEN is the Chief Executive Officer of WuXi Biologics, a Hong Kong-listed leading global open-access biologics technology platform company. Dr. Chen's extensive experience in monoclonal antibodies (mAb), therapeutic proteins and vaccines has been recognized by industry leaders. Since 2011, Dr. Chen has built WuXi Biologics into a global contract development and manufacturing organization (CDMO) worth more than US$60 billion and has led the company to achieve steady growth. Under Dr. Chen's leadership, WuXi Biologics has assembled one of the world's largest biologics teams, with over 7,600 employees located in China, the United States, Ireland and Germany, enabling over 450 partners ranging from small firms to Top 20 global pharmaceutical companies. WuXi Biologics has also successfully completed 18+ regulatory inspections by the U.S. FDA, EMA, NMPA, ANVISA and HSA, demonstrating compliance with the highest global regulatory standards. Dr. Chen obtained bachelor's degrees in chemical engineering and automation from Tsinghua University and a Ph.D. in chemical engineering from the University of Delaware. He serves on the International Board of Directors for the International Society for Pharmaceutical Engineering (ISPE), and is the first board member from Asia.

邓周宇
中银国际证券研究部执行董事、医疗 & 消费行业负责人、医药生物行业首席分析师

Zhouyu Deng
Executive Director of Research Department, Chief Analyst of Pharmaceutical and Biological Industry and Leader of Medical & Consumer Research Group of BoC International (China) Co., Ltd.,

11 年医药行业研究经验，先后供职于国海证券、国信证券、中银国际证券。广泛覆盖：行业政策、创新药、医疗服务、医疗器械、医药流通业、中药行业、互联网医疗、商业健康险研究；并对 AI 新药研发进行过系统性研究，著有多篇 AI 新药研发系列报告。曾获得新财富最佳分析师（2014），水晶球最佳分析师（2014、2017）、金牛奖最佳分析师（2014）、金翼奖最佳分析师（2017、2018）、金融界最佳分析师（2013）、东方财富网 100 强分析师（2021）。

Zhouyu Deng, Executive Director of Research Department, Chief Analyst of Pharmaceutical and Biological Industry and Leader of Medical & Consumer Research Group of BoC International (China) Co., Ltd., has 11 years research experience in pharmaceutical industry and successively worked for Sealand Securities, Guosen Securities.

Deng has extensively covered: industry policy, innovative drugs, medical services, medicine distribution industry, TCM industry, internet medical industry and commercial health insurance research. In addition, he has conducted systematic research on the R&D of AI new drugs and written a series of relevant reports.

He has won the first place for the Best Analyst in financial industry in 2013. In 2014, Deng's team has achieved the third place in "2014 New Fortune Best Analysts", the third place for the Best Analysts of Golden Bull Awards , and the fourth place for the Best Analysts in Crystal Ball Awards.

He also got the fifth place in "2017 Crystal Ball Awards Best Analysts" (Public Offering Fund Group), and the fifth place in "Golden Wing Award Best Analysts" in 2017 and 2018.

In 2021, he was also awarded the "Top 100 Analyst of Eastmoney".

李　明
滬港中科国际生物科技有限公司 CEO

LI Ming
CEO, ZSHK Laboratories Limited

李明，滬港中科国际生物科技有限公司 CEO，从事药物临床前评价工作十余年。

在创立滬港中科公司之前，李明博士曾在中国科学院上海药物研究所从事药物安全性评价工作，主持建设中国第一家符合欧盟多国认证的 GLP 实验室工作，建设的 GLP 实验室曾支持多家国内外医药企业的研发药物在北美、英国、德国、瑞典等进行临床研究。

目前，滬港中科公司已经在深圳和苏州建立了独立的药物临床前研究评价的实验室，苏州实验室已经获得 NMPA 的 GLP 资质，在香港的同类实验室 2021 年底可投入使用。滬港中科公司致力于成为中国新药研发创新最具价值的合作伙伴。

李明先生在中国科学院上海药物研究所获得药理学博士学位，也获得了上海交通大学安泰经管学院和法国 KEDGE 商学院的 MBA 双硕士学位。

Li Ming, CEO of ZSHK Laboratories Limited, has been working in the drug preclinical evaluation industry for more than 15 years.

Before founding ZSHK Laboratories Limited, Dr. Li Ming was engaged in drug safety evaluation at Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences (CAS), and presided over the construction of China’s first GLP laboratory with an OECD certification, which has supported clinical researches conducted in countries like North America, the United Kingdom, Germany for the development of new drugs by both Chinese and foreign pharmaceutical companies.

At present, ZSHK Laboratories Limited has established independent drug pre-clinical research and evaluation laboratories in Shenzhen and Suzhou. The Suzhou laboratory has obtained the GLP qualification of NMPA. A similar laboratory in Hong Kong will be put into use by the end of 2021. ZSHK Laboratories Limited is committed to becoming the most valuable partner in China's new drug R&D and innovation.

Mr. Li Ming has obtained a Ph.D. in pharmacology from the SIMM CAS, and a dual MBA degree from Antai College of Economics and Management of Shanghai Jiaotong University and KEDGE Business School in France.

张　翱
上海交通大学药学院院长

ZHANG Ao
Dean, College of Pharmaceutical Sciences, Shanghai Jiao Tong University

张翱，上海交通大学特聘教授，博士生导师，药学院院长。2000 年在中科院上海有机化学研究所博士毕业，2001-2004 年分别在美国乔治敦大学医学中心和哈佛医学院进行博士后研究，2004-2006 年担任哈佛医学院讲师、哈佛医学院 McLean 医院药物化学研究室助理主任，曾获哈佛医学院 Alfred Pope 优秀青年奖及 Adam Cornneel 青年学者奖。

张翱教授 2006 年入选中科院“百人计划”回国加盟中科院上海药物研究所，先后获上海市浦江人才计划、上海市优秀学科带头人计划、国家杰出青年科学基金等支持，领衔的研究团队获 2018 年度科技部“创新人才推进计划”-“重点领域创新团队”称号，2019 年获中组部国家“万人计划”领军人才计划。2020 年加入上海交通大学药学院。

张翱教授研究团队主要致力于药物化学技术创新推动的新药发现研究，尤其是聚焦基于天然产物的药物化学和化学生物学研究、难靶蛋白的药物设计、分子靶向个性化药物及免疫治疗研究等领域。已发表 SCI 论文 170 余篇，申请国内国际专利 70 余项。主持研发的 2 个 1 类新药已经进入临床研究，多个候选新药正在进行临床前研究。

Ao Zhang is currently the Professor and dean of the College of Pharmaceutical Science at Shanghai Jiao Tong University. He received the Ph.D. diploma in Organic Chemistry in 2000, and then joined Georgetown University Medical Center in 2001 as a Postdoctoral Fellow. In 2002, he became a Research Investigator at McLean Hospital, Harvard Medical School, and was promoted to Instructor at Harvard Medical School in 2003 and Assistant Director of the Medicinal Chemistry Program at McLean Hospital in 2004. He was awarded Alfred Pope Young Investigator Award in 2004 and Adam Corneel Young Investigator Award in 2005 from Harvard Medical School. In 2006 he received the Hundred Talent Project award from the Chinese Academy of Sciences, and became the Professor of Medicinal Chemistry at Shanghai Institute of Materia Medica (SIMM). In 2011, he was awarded the Distinguished Young Investigator Award from Chinese Natural Science Foundation. Since May of 2020, he joined Shanghai Jiao Tong University as the Principal Investigator of the Pharm-X Center at the College of Pharmaceutical Sciences. The research interests at Professor Zhang's group include the design and synthesis of novel small molecules as structural and functional probes for the diagnosis and treatment of brain disorders and cancer by using the state-of-art medicinal chemistry strategy. He has authored or co-authored over 170 publications and 75 patents. Three new investigational drugs from his research group are now under phase I and II clinical trials, and many more candidates are in preclinical stages.

罗　敏
广州百暨基因科技有限公司，首席技术官

Min Luo
Guangzhou Bio-gene Technology Co., Ltd, CTO

罗敏博士，现任广州百暨基因科技有限公司总经理兼首席技术官。博士毕业于新加坡国立大学，曾在贝勒医学院从事博士后研究。期间在国际一级期刊发表论文多篇，包括第一作者的 Cell Stem Cell，Nature Genetics 杂志论文，论文影响因子总数达到 150，论文总引用次数超过 1500 次。回国之前在美国基因治疗企业蓝鸟生物担任高级科学家，参与了多项细胞治疗产品的临床转化研究。回国后曾获评“广州市黄埔区创新创业领军人才”。

Dr. Min Luo is the CTO of Guangzhou Bio-gene Co., Ltd. She obtained her PhD from National University of Singapore, and conducted postdoctoral research at Baylor College of Medicine. Her work has led to numerous publications in top journals such as Nature Genetics and Cell Stem Cell. She was a translational scientist at Bluebird bio in Boston before joining Guangzhou Bio-gene in 2017.

廖玉华
武汉华纪元生物技术开发有限公司总经理、首席科学家

LIAO Yuhua
CEO/CSO of Wuhan Huajiyuan Biotechnologies Develop CO.,LTD

廖玉华现为武汉华纪元生物技术开发有限公司总经理、首席科学家；华中科技大学附属协和医院二级教授；中国心衰中心联盟主席、生物靶向治疗教育部重点实验室主任。主要从事治疗性降压疫苗研究，构建短肽偶联治疗性疫苗研究技术平台，发明 ATR Qβ-001 降压疫苗、ETRQβ-002 肺动脉高压疫苗、PCSK9Qβ-003 降脂疫苗、ADRQβ-004 降压疫苗，获得国家发明专利授权 6 项，主编《心血管病免疫学》和《心脏病学》等专著 4 部，在 JACC、Hypertension、JI 等杂志发表论文 172 篇，总 IF=250, SCI 他引 1023 次；2021 年 6 月 17 日启动国际首创 HJY-ATRQβ-001 治疗性降压疫苗联合产业开发。

Liao Yuhua is the CEO and CSO of Wuhan Huajiyuan Biotechnologies Development Co., LTD. Second professor, Union Hospital affiliated to Huazhong University of Science and Technology; Chairman of Chinese Federation of Heart Failure Centers, director of Key Laboratory of Bio-targeted Therapy of Ministry of Education. Mainly engaged in the research of therapeutic antihypertensive vaccine, and constructed the research technology platform of short peptide conjugate therapeutic vaccine. Invented ATR Qβ-001 antihypertensive vaccine, ETRQβ-002 pulmonary hypertension vaccine, PCSK9Qβ-003 lipid-lowering vaccine and ADRQβ-004 antihypertensive vaccine, and obtained 6 national invention patents. He has been the chief editor of 4 monographs, including Cardiovascular Disease Immunology and Cardiology, and 172 papers have been published in JACC, Hypertension, JI and other journals, with total IF=250 and SCI cited 1023 times. On June 17, 2021, the international first joint industrial development of HJY-ATRQβ-001 therapeutic antihypertensive vaccine will be launched.

贺小宏
南京北恒生物科技有限公司创始人兼董事长、
南京北恒生物党支部书记、中国科学院细胞生物学博士

HE Xiaohong
Founder&Chairman ,Nanjing Bioheng Biotech Co., Ltd.
Party branch secretary, Nanjing Bioheng Biotech Co., Ltd.
Doctor of cell biology, China Academy of Sciences

南京北恒生物科技有限公司（以下简称“北恒生物”）成立于 2017 年，是一家专注于疾病治疗产品开发及商业化的创新型生物医药公司。2021 年 3 月北恒生物获得高瓴创投、德诚资本和八方资本等领投的 5.2 亿元 B 轮投资，目前累计完成融资近 7 亿元。

北恒生物开发的第五代“现货”通用型 CAR-T 细胞治疗产品，具有国际领先的研发水平，有望从根本上解决当前 CAR-T 治疗“成本高、时间久、生产难、个性化”的困境，实现免疫细胞治疗的可负担性和可及性。

路演题目：免疫细胞疗法于肿瘤治疗未来之路

摘要：免疫细胞治疗针对血液相关肿瘤取得瞩目疗效，现已上市产品及各机构在研产品以自体型 CART 细胞疗法开发为主。由于其个性化制备的特殊性，导致免疫细胞治疗药物可及性及高昂价格使其应用受到限制。对于未来免疫细胞疗法下一步出路，依然重点是在解决其商业化及针对更广阔市场的实体瘤方面，期待通过不同形式的通用型免疫细胞疗法及实体瘤有效性方面的突破，使免疫细胞疗法更具有市场性及服务更多患者。

Nanjing bioheng Biotechnology Co., Ltd. (hereinafter referred to as "beiheng biotechnology") was established in 2017. It is an innovative biomedical company focusing on the development and commercialization of disease treatment products.

In March 2021, bioheng biology obtained 520 million yuan of round B investment led by Hillhouse venture capital, Decheng capital and eight party capital. At present, nearly 700 million yuan of financing has been completed.

The fifth generation of "spot" universal car-t cell therapy products developed by beiheng biology have the international leading R & D level. It is expected to fundamentally solve the dilemma of "high cost, long time, difficult production and personalization" of car-t therapy and realize the affordability and accessibility of immune cell therapy.

肖　凯
泰励生物，副总裁

Carl Xiao
VP, Tyligand Bioscience

肖凯博士在医药研发和商务扩展方面拥有超过十年的从业经验。在加入泰励生物之前，他曾在上海医药（香港）投资有限公司担任商务拓展及投资并购高级副总裁职务。作为上海医药集团进军海外的过程中的一员，负责新药研发投资，商务拓展和投后管理等工作。在此期间，参与并完成了多个新药研发项目和并购相关的工作，其中成功达成了上海医药与俄罗斯最大的生物医药公司 BIOCAD 的 4 亿美金合资合作项目，并参与合资企业的初创平台搭建工作。在加入上海医药之前，肖凯博士曾就三生制药，主要负责研发商务拓展业务，主导并完成多项研发合作。加入三生制药之前，肖凯博士就职于罗氏早期研发部门（pRED），负责大分子药物的靶点筛选和抗体发现工作，参与约 40 多项 FIC 项目的全球研发工作。

肖凯博士本科毕业于广州中山大学生物技术专业，并于美国佛罗里达大学医学院获得遗传与基因组学博士学位，以及美国佛罗里达大学商学院工商管理硕士学位。

Dr. Xiao Kai has over 10 years of experience in pharmaceutical R&D and Business Development. Prior to joining Tyligand Bioscience, He held the position of Senior Vice President at Shanghai Pharmaceuticals (Hong Kong) Investment Inc. As a member of Shanghai Pharmaceutical Group's overseas expansion team, he is responsible for innovative drug's BD, investment, and alliance management. During this period, he has completed a number of new licensing & M&A projects, among which, he has successfully concluded the Shanghai Pharma and BIOCAD, Russia's largest biopharmaceutical company, a $400 million joint venture project and participated in the joint venture's start-up platform establishment. Prior to joining Shanghai Pharma, Dr. Xiao worked at 3Sbio Inc., where he was responsible for Business development, where he has completed a number of R&D licensing & collaborations. Prior to joining 3S Bio, Dr. Xiao worked at Roche pRED Center, where he was responsible for target identification and antibody discovery work and was involved in of approximately 40 FIC projects within the Roche global R&D network.

Dr. Xiao Kai graduated from Sun Yat-sen University in Guangzhou with a Ph.D. in Genetics and Genomics from the University of Florida, School of Medicine, and an MBA from the University of Florida Business School.

李新燕
方拓生物科技（苏州）有限公司 总裁

Li Xinyan
Co-founder , President of Suzhou Frontera Co., Ltd.

李新燕，现任方拓生物科技（苏州）有限公司总裁，苏州大学内科学博士，法国蒙彼利埃大学基因与细胞治疗中心访问学者。5 年临床内科工作经验， 10 年医学院教学和科研经历；领先海归创业，从事创新药物研发管理 20 年，负责创新药物的研究和开发，包括 R&D、临床前动物有效性 / 安全性评价、临床试验、注册申报、药物生产和质量控制（QC 和 QA）、政府关系、基金申报等。

作为项目负责人，组织实施了两个原创新药在中国 / 美国的研发全过程，在创新药物研发领域积累了丰富的管理和实战经验。

曾主持 CART 细胞的临床前、IIT、注册临床研究、中美注册申报等工作。

曾先后主持国家“十一五”、“十二五”“十三五”重大新药创制等多项课题。

Xinyan Li, president of Suzhou Frontera Co., Ltd., was a visiting scholar at the Gene and Cell Therapy Center of the University of Montpellier, France, and got her Internal Medicine Doctor's degree from Soochow University. Dr. Li has 5 years of clinical internal medicine work experience, 10 years of medical school teaching and scientific research experience. Then she took the lead in starting a business before an oversees returnee and engaged in innovative drug R&D management for 20 years, including R&D, preclinical efficacy/safety evaluation, clinical Trials, registration, drug production and quality control (QC and QA), government relations, fund applications, etc.

As the project leader, Dr. Li led the entire R&D process of two innovative drugs in China and U.S., and accumulated rich practical and management experience in the field of innovative drug R&D. Dr. Li presided over the pre-clinical, IIT, registered clinical research, and China and US registration of CART cell product.

As the principal investigator, Dr. Li also led a series of National Significant New Drugs Development Projects during the Eleventh, Twelfth, and Thirteenth Five-year Plan Periods.

姜宝红
中国科学院上海药物研究所研究员

JIANG Baohong
Shanghai Institute of Materia Medica, CAS. Professor

姜宝红，研究员，1992 年获沈阳药科大学药剂学学士学位，1998 获沈阳药科大学药理学硕士学位，2004 年获日本关西医科大学药理学博士学位。2006 年起就职于中国科学院上海药物研究所，从事心血管药理研究，重点研究方向为心肌梗死、主动脉夹层和主动脉瘤的发病机理和治疗药物发现。近年来在 Biomaterials, Int J Cardiol, Phytomedicine 等国际期刊上发表 SCI 论文七十余篇。申请发明专利多项，获授权发明专利四项。作为项目负责人承担国家和省部级科研课题十余项。

Jiang Baohong, as the professor in Shanghai Institute of Materia Medica, Chinese Academy of Sciences, engaged in cardiovascular pharmacology research. Professor Jiang focused in the drug development on myocardial infarction, aortic dissection and aortic aneurysm. Professor Jiang has published more than 70 SCI papers. Professor Jiang applied several patents and three patents were authorized. As the leader, she undertook more than 10 projects.

黄成钢
中国科学院上海药物研究所研究员

HUANG Chenggang
Researcher, Shanghai Institute of Materia Medica, Chinese Academy of Sciences

黄成钢博士现为中国科学院上海药物研究所二级研究员、博士生导师、研究组长、中药标准化技术国家工程实验室副主任。从事中药及复方药效物质研究，建立了系统的体内外结合中药及复方药效物质研究方法和关键技术，发现一批具有显著药效的有效成分、部位、组分及其配伍，研发现代中药；对天然产物进行结构改造，获得具有自主知识产权的新结构活性化合物，研发创新药物。近年来，主持国家基金委重点项目、国家“863”项目、国家新药创制重大专项、中科院战略性先导专项等项目。已发表 SCI 研究论文 100 多篇；申请发明专利 50 多项（授权 20 多项，包括美国和日本专利）。新药研发方面，与企业合作的部分项目已分别获国家药监局临床批件、新药证书并投产上市。

Dr. Chenggang Huang is a researcher , doctoral supervisor , principal investigator and deputy director of Traditional Chinese medicine Standardized technology in Shanghai Institute of Materia Medica, Chinese Academy of Sciences. He has been engaged in researching the pharmacodynamic substances of Chinese medicine prescriptions, and established a systemically strategy and key technology based on in vitro-in vivo integration to search effective compounds of Chinese medicine and prescriptions. With the application of this strategy, a number of pharmacodynamic ingredients, parts, components and the combinations have been found, followed by the modern Chinese medicine. New structural active compounds with independent intellectual property rights were obtained through the structural modification of natural products, followed by the development of innovative drugs. In recent years, he has been funded by key project of National Natural Science Foundation of China, the National High Technology Research and Development Program("863"Program) of China, the National Science and Technology Major Project of the Ministry of Science and Technology, Strategic Priority Research Program of Chinese Academy of Sciences, and so on. There has been more than 100 SCI research papers published, and more than 50 invention patents applied for (more than 20 patents granted, including the patents in the United States and Japan). Some of the new drug cooperating with enterprises has received the clinical approval or the new drug certificate with market operation from China Food and Drug Administration.

叶崴涛
醴泽资本管理合伙人

Tony Ye
Managing Partner of LYZZ Capital.

叶崴涛先生是醴泽资本的共同创始人及管理合伙人。他熟悉药品研发及销售的各个环节，具有丰富的医药销售、政府事务工作经验。在共同创立醴泽资本之前，他是建信资本和建信康颖基金的创始合伙人。

在此之前，他是上海医药集团抗生素事业部政府事务总监、总裁助理、营销副总裁，并分管集团政府事务。他曾任安万特医药全国政府事务总监以及拜耳（中国）有限公司区域销售经理、全国政府事务经理。叶崴涛先生参与投资的生物医药公司包括：纽脉医疗、北京利达康科技、博瑞生物、陕西康惠制药、武汉海特生物、浙江昂利康药业等。

叶崴涛先生拥有上海医科大学药物化学学位和中欧国际工商学院 EMBA 学位。

Tony Ye is the Co-Founder and Managing Partner of LYZZ Capital. He is familiar with all aspects of drug research and development and sales, and has rich experience in pharmaceutical sales and government affairs. Before co-founding LYZZ Capital, he was a Founding Partner of Jianxin Capital and Jianxin Venture Healthcare Fund. Prior to that, he was the Director of Government Affairs, Assistant President and Vice President of Marketing of the Antibiotics Division of Shanghai Pharma Group, where he was in charge of the Group's Government Affairs. He was the National Government Affairs Director of Aventis Pharmaceuticals and the Regional Sales Manager and National Government Affairs Manager of Bayer (China). Tony invested in a number of biomedical companies, including of Newmed Medical, Beijing Lida Kang Technology, Suzhou Bright-Gene Pharma, Shanxi Kanghui Pharma, Wuhan Hiteck Pharma, Zhejiang AngLiKang Pharma, among others.

Tony received a Bachelor's degree of pharmaceutical chemistry from Shanghai Medical University and an EMBA degree from China Europe International Business School.

陆潇波
红杉资本中国基金合伙人

LU Xiaobo
Partner, Sequoia China

陆潇波先生是红杉中国合伙人，专注于医疗健康行业投资，拥有超过 25 年医疗产业及投资经验，主导超过 30 个医疗项目投资，代表案例：华大基因（300676）、贝达药业（300558）、信达生物（01801 HK）、微芯生物（688321）、纳微科技（688690）、百洋医药（301015）、天智航（688277）、奥精医疗（688613）、康辰药业（603590）、数坤科技、菲鹏生物、英诺特、缔脉生物、树兰医疗、都创医药、赛乐医疗等。陆先生拥有浙江大学生物化学工程学士，清华大学国际 MBA，清华五道口金融 EMBA。

Lu Xiaobo, Partner of Sequoia China

Lu Xiaobo focuses on investments in the healthcare sector. He has more than 25 years of experience in this industry, and has led more than 30 investments, including BGI (300676), Betta Pharmaceuticals(300558), Innovent Biology(01801 HK), Chipscreen(688321), Nanomicro Technology (688690), BAHEAL Pharmaceutical Group(301015), TINAVI(688277), Allgens Medical Technology(688613), KONRUNS(603590), Shukun Technology, FAPON, INNOVITA, dMed biopharmaceutical, Shulan Health, BirdoTech, SIFARY, etc. Mr. Lu holds a bachelor's degree in Biochemical Engineering from Zhejiang University, an international MBA from Tsinghua University, and an EMBA in Finance from Tsinghua PBCSF.

朱晋桥
倚锋资本董事长

ZHU Jinqiao
Chairman, Efung Capital

倚锋资本创始人 & 董事长、清华五道口金融学院 MBA、长江商学院 EMBA、法国巴黎商学院工商管理博士（在读），香港生物医药创新协会荣誉会长、中国医药创新促进会投资专委会发起人、Bayhelix Group（百华协会）会员。

20 年投资行业耕耘，亲自主导投资多家全球顶尖生物医药企业，助力医药产业发展，荣获 2019 中国金融年度人物、2019 年度医疗健康投资人 TOP10、2020 医疗健康行业最佳投资人等荣誉。

经典投资案例：迈瑞医疗、微芯生物、前沿生物、亚盛医药、普门科技、和铂医药、和元生物、亚虹医药、华昊中天、思路迪医药、Centrexion、Apexigen 等境内外企业 。

Founder and Chairman of Efung Capital, Tsinghua PBCSF MAB, CKGSB EMBA, DBA Candidate of Paris School of Business (PSB), Honorary Chairman of HKBMIA, Sino-PhIRDA Investment Committee Sponsor, Bayhelix Group Member.

Dedicated to healthcare industry investment for 20 years, Mr. Zhu He has played a leading role in investing serval promising pharmaceutical projects, and fostered the development of healthcare industry in China. Thus Mr. Zhu was nominated for “China Finance Person of The Year 2019”, “Top 10 Healthcare Investor 2019”and “2020 Best Investor in Healthcare Industry”.

Mr. Zhu has displayed his excellent expertise in healthcare investment, his classical investment portfolios include: Mindray, Chipscreen Bioscience, Frontier Biotech, Ascentage Pharma, Lifotronic Technology, Harbour BioMed, OBiO Technology, Asieris Pharma, Biostar Technologies, 3D Medicines, Centrexion and Apexigen et al.

施　珑
华平投资合伙人

Leo SHI
Managing Director, Warburg Pincus

施珑先生于 2019 年加入华平，主要负责华平亚太区医疗健康行业的投资。自 2015 年起，施先生在淡马锡中国担任高级总监，主要负责医疗健康行业的投资业务。加入淡马锡中国之前，施先生曾在华平担任过三年投资董事。在此之前，也曾经从事过投资银行和咨询行业工作。

施先生目前担任北京美中宜和妇儿医院集团和北京高视远望科技有限责任公司的董事。

他持有复旦大学金融学士学位。

Leo Shi is based in Shanghai, joined Warburg Pincus in 2019 and focuses on investments in the healthcare sector in Asia. Prior to joining Warburg Pincus, he has been working as Senior Director at Temasek China focusing on healthcare investing since 2015. Prior to Temasek China, he was a VP at Warburg Pincus for three years and has also worked at investment banking and consulting industry. Mr. Shi is a director of Beijing Amcare Women’s and Children’s Hospital Group and Gaush Meditech Ltd.

He received a B.A. of Finance from Fudan University.

朱　敏
汉坤律师事务所合伙人

ZHU Min
Partner, Han Kun Law Offices

朱律师曾连续数年被国际权威律师评级机构 Chambers 和 Legal 500 评为生命科学和健康医疗领域以及公司合规业务领域的重点推荐律师。
朱敏律师主要的业务领域包括一般公司及商事业务、公司合规、私募股权投资、外商直接投资、兼并和收购以及公司重组。朱律师曾为众多跨国公司、外商投资企业和内资公司就它们的设立、境内外投资并购以及监管与合规事务提供法律服务。
朱律师在生命科学和健康医疗领域具有相当丰富的经验，为该领域处于各个发展阶段的公司提供各类法律服务，包括但不限于创新型企业的融资和品种许可引进、医疗健康企业的兼并收购，以及该领域的各类合规和监管事项，例如反腐败和反商业贿赂、临床试验、产品注册、营销、广告和推广以及健康医疗数据处理等。

Mr. Zhu has been consecutively recognized as a highly recommended practitioner in life sciences, healthcare, and corporate compliance by leading global legal ranking organizations such as Chambers and Partners and The Legal 500.
Mr. Zhu concentrates his practice on general corporate and commercial matters, corporate compliance, private equity investment, foreign direct investment, mergers and acquisitions, and corporate restructuring. Mr. Zhu has provided legal services for dozens of multinationals, foreign companies, and Chinese companies with respect to their establishment, domestic and overseas investments, as well as regulatory and compliance affairs.
Mr. Zhu is experienced in the life sciences and healthcare industries, and provides legal services for various companies in their different stages of development, including financing and license-in deals for start-up companies, mergers and acquisitions of healthcare companies, and various regulatory and compliance matters, such as anti-corruption and anti-bribery, clinical trials, drug and medical device registration, distribution, advertising and promotion, as well as medical and healthcare data compliance, etc.

胡雪峰
南京和润资本董事长，中国药促会投资专委会秘书长

HU Xuefeng
Secretary General, Investment Committee of China Pharmaceutical Innovation and Research Development Association (PhIRDA)

胡雪峰　中国药科大学博士，中欧国际工商管理学院 EMBA、正高级经济师。 在医药、投资领域工作近 30 年，历任南京医药（SH600713）副总裁、上海复星医药（SH600196）副总裁、中国医药集团国药控股（HK1099）江苏公司总经理、深圳高特佳投资集团副总裁，主管合伙人。现任江苏聿泉高特佳健康产业基金执行事务合伙人、安徽瑞皖高特佳健康产业基金执行事务合伙人、中国药品创新促进会投资专业委员会秘书长、北京阳光诺和药物研发公司（688621）独立董事、南京和润至成私募基金管理有限公司董事长。
分管或参与的投资案例：博雅生物（300294）、国药股份（600511）、首都在线（300846）、先声药业（02096）、阳光诺和（688621）、红日药业（300026）、智同生物、贝克生物等。

Hu Xuefeng, PhD, China Pharmaceutical University, Senior Economist, China Europe International Business School EMBA,
Previous posts: Worked in the pharmaceutical and investment fields for nearly 30 years, served as VP of Nanjing Pharmaceutical (SH600713), VP of Shanghai Fosun Pharmaceutical (SH600196), general manager of Jiangsu Company of sinopharmholding Group(HK1099), VP/Managing partner of Shenzhen GTJA Investment Group
The current:
Jiangsu Jiequan GTJA Health Industry Fund managing partner
Managing partner of Anhui Ruiwan GTJA Health Industry Fund
Secretary general of Investment Committee of China Pharmaceutical Innovation and Research Development Association (PhIRDA)
He is an independent director of Beijing Sun-Novo Pharmaceutical Research Co.,Ltd (688621)
Investment cases in charge of or involved in: Boya Biotechnology (300294), Capital Online (300846), Simcere Pharmaceutical (02096), Sun-Novo (688621), Mindray Medical (300760), Viya Biotechnology (01873), Hongri Pharmaceutical (300026), Hehe Diagnostics, Zhitong Biology, BeikeBiology, Luo Yi Biology and so on

张　莉
齐济投资创始合伙人

Lily ZHANG
Founding Partner, TTM capital

张莉，齐济投资创始管理合伙人，毕业于美国宾夕法尼亚大学沃顿商学院，专注于生物医药、医疗器械、诊断试剂及生物科技类投资。前鼎晖创新成长基金合伙人，负责医药健康领域的投资，代表项目有：和铂医药、先导药物、天境生物、福州迈新、江苏艾尔康和科望生物，多个项目带来 10 倍以上回报。曾任葛兰素史克中国投资有限公司业务发展和市场信息总监，带领跨职能团队完成多起并购、技术转移、产品分销、专利授权、原料供应和产品剥离交易。曾任美国强生公司亚太区和中国业务发展经理，负责亚洲 13 个国家的业务发展、全治疗领域的收购和授权许可项目，领导完成多个重要授权许可交易，引进具有巨大市场价值的专利新药。张莉女士是全球生命科学领域华人精英组织百华协会、美中医药开发协会、中国药促会、新药投资百人圈、沃顿商学院医疗俱乐部、BIG 等多个生命健康行业协会会员；并担任上海临港集团产业发展顾问、中科院上海巴斯德研究所产业发展顾问。

Lily Zhang, the founding managing partner of TTM capital, graduated from The Wharton School of the University of Pennsylvania, focusing on the investments of biomedicine, medical devices, medical diagnostics and biotechnology. Former partner of CDH VGC Fund, responsible for investment in the field of medicine and health. Representative projects include: Harbour BioMed, HitGen, I-MAB, MAXIM, EyeCure and Elpiscience (multiple projects bringing more than 10 times returns). She once served as the director of business development and market information of GSK-China and led the cross-functional teams to complete a number of M&A, technology transfer, product distribution, patent authorization, raw material supply and product divestiture transactions. She used to be the business development manager of Johnson & Johnson in Asia Pacific and China, responsible for business development, acquisition and licensing projects in the whole treatment field in 13 countries in Asia, leading to complete several important licensing transactions and introduce patented new drugs with great market value. Ms. Zhang is a member of many life and health industry associations, such as BayHelix, SAPA, PhIRDA, New Drug Founder Club, Wharton Business School Medical Club, BIG Club and so on; She also served as the Industrial Development Consultant of Lingang Group and Institute Pasteur of Shanghai Chinese Academy of Sciences.

李凯军
醴泽资本管理合伙人

Kevin LI
LYZZ Capital Advisors Ltd & Managing Partner

李凯军博士是醴泽资本的共同创始人及管理合伙人，他在生物医学、医疗健康投资和创业方面拥有 20 多年的专业经验。在共同创立醴泽资本之前，他曾任德同资本合伙人、HBM BioMed China 合伙人以及美国 Toucan Capita 投资经理，从事生物医药方面的风险投资。他还是昆翎医药和摩珈生物的共同创始人。李凯军博士参与投资的生物医药公司，包括 Neurelis、Qpex、Jumpcode、Onchilles、Wugen、晨泰医药、诺康生物、凯赛生物、海特生物、微芯生物、昆翎医药等。

李凯军博士拥有南开大学学士学位、美国印第安纳大学生物科学博士学位、斯坦福大学博士后。

Dr. Li is the Co-Founder and Managing Partner of LYZZ Capital. He has over 20 years of professional experience in biomedical sciences, healthcare investment and entrepreneurship. Before co-founding LYZZ Capital, Dr. Li was a Partner at DT Capital, a Partner at HBM BioMed China, and an Associate at Toucan Capital in the US, all in the field of biotech investments. Dr. Li was also a co-founder of ClinChoice and Mojia Biotech. Dr. Li invested in a number of biomedical companies, including Neurelis, Qpex, Jumpcode, Onchilles, Wugen, Alpha Biopharma, Nuokang Biopharma, Cathay Biotech, Wuhan Hiteck Biopharma, Chipscreen, ClinChoice, among others.

Dr. Li received a Bachelor's degree from Nankai University, a doctorate degree in biological sciences from Indiana University and postdoctoral training from Stanford University.

林　亮
礼来亚洲基金合伙人

Stephen LIN
Partner, Lilly Asia Ventures

在预防性疫苗、治疗性药物和体外诊断等领域完成了多个创新企业的投资以及公司孵化，包括康希诺生物、凯因科技、圣湘生物、康诺亚生物、迈博斯生物、迪哲医药、原力生命科学、典晶生物、朗信生物、科伦博泰、凌科药业和镁信健康等。 此前他先后在三九医药创建了战略规划部并领导公司战略规划与业务拓展，在默克－雪兰诺（中国）负责核心产品的市场营销，在葛兰素史克（中国）从事企业收购兼并以及产品的引进和对外授权。拥有中国药科大学化学制药学士学位和药物化学硕士学位、中欧国际工商学院 MBA 学位（金融方向）及执业药师资格。

Stephen, the Partner at Lilly Asia Ventures, led the investments in companies of vaccine, small molecule, large molecule and IVD, including CanSinoBIO, Kawin, Sansure Biotech, KeyMed Biosciences, IonovaBio, MabSpace, Dizal Pharma, Elumienx Biosciences, InnoStella Biotherapeutics, Kelun Biotech, Lynk Pharma, MediTrust Health, et al. Before that, he worked in BD function at GlaxoSmithKline (Great China), covering M&A and product licensing. Previously, he managed the marketing of a core product at Merck Serono (China). In Sanjiu Medical & Pharmaceutical, he set up and headed the Strategic Planning Department, driving corporate strategic planning and business development.

Stephen's education includes a Master of Science in Medicinal Chemistry and a Bachelor of Pharmaceutical Chemistry, both from China Pharmaceutical University. He also earned a Master of Business Administration degree (finance direction) from China Europe International Business School. A Licensed Pharmacist in China.

周成曜
汉坤律师事务所合伙人

Aaron ZHOU
Partner, Han Kun Law Offices

周成曜律师专长于跨境和境内兼并收购、私募股权投融资、风险投资、技术/知识产权授权、外商投资、合资，涉及医药、医疗设备、健康管理、高科技、保险、金融、新能源、传统能源、互联网、电信和文化娱乐等诸多行业。

周律师曾协助多家境内外知名医药企业完成旨在实现医药产品在大中华区的商业化、开发和生产的授权事宜、药品资产和权益买卖交易、药品合作研发和委托生产交易、药品经销、研发和生产、及医疗器械的授权和合资项目，并在此过程中提供全程的法律服务，包括设计交易架构、起草和修改交易文件以及主导项目谈判。

周律师有 16 年的法律执业经验，包括在顶级美国华尔街律师事务所工作 5 年、担任《财富》世界 50 强公司的亚太地区法务主管 3 年。

Mr. Aaron Zhou's practice focuses on cross-border and domestic mergers and acquisitions, private equity investment, venture capital investment, foreign direct investment (FDI), joint ventures and technology/IP licensing. Mr. Zhou's practice covers a variety of industries, including pharmaceutical, medical device, healthcare management, technology, the Internet, telecommunications, finance, insurance, clean energy, natural resources, culture and entertainment.

Mr. Zhou's experiences in the pharmaceutical and healthcare field include out-license/in-license and supply agreements for the development and commercialization of new drugs and generic drugs in greater China, sale and purchase of pharmaceutical-related assets and businesses, investments in and acquisitions of pharmaceutical and healthcare companies, joint ventures and related technology licenses, research collaboration and manufacturing services agreements, and FCPA-related and compliance matters.

Mr. Zhou has over 16 years' legal experience, including five years at Davis Polk and 3 years as the Asia Pacific legal head of a Fortune Global 50 company.

王　淮
线性资本创始人兼首席执行官

Harry WANG
Founder and CEO, Linear Capital

线性资本创始人兼 CEO，关注前沿科技解决产业升级问题项目的投资。是地平线机器人、神策数据、特赞、酷家乐、若琪、思灵机器人等公司的天使投资人。线性资本聚焦投资数据技术和人工智能 (Data Intelligence) 领域的创新项目，基金总规模约 70 亿人民币。

成立线性资本前，Harry 是 Facebook 总部中国籍第二位工程师和第一位研发经理，这段经历已经写成畅销书《打造 Facebook》。离开 Facebook 后，Harry 担任过大众点评等公司的 CEO 顾问，并在国内多个头部科技公司、技术社区做过分享交流和培训。

Harry 多次获得媒体评选的“最佳早期投资人”、“最受创业者喜爱的早期投资人”，他是美国阿斯彭学会会员（Apsen Fellow），未来论坛青年理事会第一届主席，2018 年世界经济论坛 “全球青年领袖”（Young Global Leaders）获得者。Harry 毕业于浙江大学计算机系，在斯坦福大学获得管理科学与工程专业硕士学位。

Founder and CEO at Linear Capital. He is a well-known investor focusing on the frontier technology investment which would work best for the industrial upgrading. Harry is the angel investor of Horizon Robotics, Sense Data, Tezign, Kujiale, Rokid and Agile Robotics. The total AUM of Linear Capital is around US$1B.

Prior to that, Harry was the second Chinese engineer and first R&D manager at Facebook (HQ). He is also the writer of the bestseller book Building up Facebook. Harry served as a CEO advisor in many tech companies, such as dianping.com. Harry has been granted the Best Early Investor, Most Welcomed Investor by Entrepreneurs many times. He is also a member of the Aspen Global Leadership Network, and Young Global Leader, Class of 2018, World Economic Forum. Harry owns Stanford's MS&E degree and Zhejiang University's bachelor degree of computer science.

陈　刚
洲嶺资本管理合伙人

Jack CHEN
Managing Partner, LYFE Capital

陈刚系洲嶺資本的管理合伙人。加入洲嶺資本之前，他曾先后担任艾意凯咨询 （L.E.K. Consulting）的高级顾问、维梧资本的投资总监和艾兰得（Aland）的投资总监，拥有 13 年医疗投资和咨询的工作经验。通过多年的经验累积，陈刚拥有中国当地广泛的业界资源。陈刚在西北大学凯洛格（Kellogg）管理学院取得了工商管理硕士学位（MBA），在此之前他业于复旦大学临床医学专业。

Jack Chen is a Managing Partner at LYFE Capital. He has a total of 13 years of experience in healthcare investing and consulting. Prior to joining LYFE, Jack was a Principal at VIVO Capital and before that a Senior Consultant at L.E.K. Consulting and Investment Director of Aland Investment Holdings. He has built up an extensive and connected map of local resources throughout his years in the industry. Jack obtained his MBA from Kellogg School of Management, Northwestern University and was initially trained in clinical medicine at Fudan University in Shanghai.

张　楠
时节创投管理合伙人

ZHANG Nan
Managing Partner, Momentum Venture

张楠先生拥有超过 13 年的投资银行、创业投资工作经历，曾在中信证券、德意志银行、中信银行等金融机构投资银行业务及投资业务部门任职，协助多家医疗类上市公司完成并购交易。曾于 2018 年联合创立聚明创投并募集首期基金，完成了近 20 个中早期生物医药项目投资。于 2020 年创立时节创投并完成集萃药康、博腾生物、鼎泰药研等项目。

Mr. Zhang has over 13 years' experience on investment banking and venture investment and worked for CITIC Securities, Deutsche Bank and CITIC Bank before raising his own fund. He has closed investments on over 20 early biotech ventures. He founded Momentum Venture in 2020 had invested in several influential CRO companies.

陈志行
大钲资本合伙人

CHEN Zhixing
Partner, Centurium Capital

陈志行，现任大钲资本董事总经理，拥有超过 10 年的医疗行业私募股权投资经验，曾任职于华平投资中国和中信产业投资基金（CPE）。参与了多起医疗领域投资和退出，包括泰邦生物、乐普医疗、美中宜和妇儿医院和海吉亚医疗集团等。获得清华大学金融学学士学位和管理学硕士学位。

Chen Zhixing, Managing Director of Centurium Capital, has over 12 years of private equity investment experience in China healthcare space. He worked at Warburg Pincus and CPE before joining Centurium. Mr. Chen led or participated a series of notable investment, including Taibang Biologic Group, Lepu Medical, Amcare, Hygeia Group and etc. Mr. Chen holds a B.A. in finance and an M.A. in management from Tsinghua University.

陶　峰
博远资本创始合伙人

TAO Feng
Founding Partner, BioTrack Capital

陶峰先生是博远资本创始合伙人。

博远资本是一家专注于医疗健康领域的创业投资机构，成立于 2017 年，资产管理规模接近 10 亿美元。博远资本是被创业者和投资人认可的中国领先的医疗健康领域投资机构，曾被投中、清科等评为排名前十的中国医疗健康领域投资机构。

陶峰先生拥有近 20 年中国医药企业运营、管理及投资经验。在创立博远资本前，陶峰先生在中国领先的医疗集团复星医药工作超过 15 年，任复星医药集团总裁助理和战略发展部总经理、投资总部总经理等职务。陶峰先生主导的投资案例包括山河药辅、山东威高、微医、石四药集团、倍特药业等。

陶峰先生拥有同济大学化工学士及上海财经大学工商管理硕士学位。

Mr. Tao Feng is the founding partner of Biotrack Capital("Biotrack").

Founded in 2017, with over 1 billion USD AUM, Biotrack is a dedicated healthcare venture capital firm focused on investing and incubating innovative life science companies in China. As a leading healthcare investment firm, Biotrack is widely recognized by entrepreneurs and investors and has been ranked as one of the top 10 firms in this field by professional agencies such as Chinaventure.com, Zero2IPO, etc.

Mr. Tao Feng, as an industry veteran, has spent over 20 years in managing, operating, and investing in healthcare companies in China. Before founding Biotrack, Mr. Tao Feng served at Foson Pharma Group, a Chinese leading healthcare conglomerate, for over 15 years, as Assistant to Chairman & Director of Strategy Development, Head of Fosun Group Strategy and Investment Department, etc. Mr. Tao Feng led investments in several major deals including Sunhere Pharma (300452.SZ); WEGO (01066.HK); WeDoctor; Shijiazhuang No.4 pharmaceutical; Brilliant Pharmaceutical, etc.

Mr. Tao Feng holds Bachelor's Degree in Chemical Engineering from Tongji University and an MBA from Shanghai University of Finance and Economics.

马　超
中国医药创新促进会综合部副主任

MA Chao
Deputy Director of Administrative Office, China Pharmaceutical Innovation and Research Development Association (PhIRDA)

马超，中国医药创新促进会综合部副主任。2016 年先后参与中国医药创新促进会医药创新投资专业委员会组建及中国医药创新与投资大会创办筹备工作，负责中国医药创新促进会医药创新投资专业委员会及会员单位联络工作和办公室综合业务。

马超先生曾就职于北京市市场监督管理局朝阳分局，负责企业主体登记注册、变更、改制等业务。

Ma Chao, Deputy Director of Administrative Office, China Pharmaceutical Innovation and Research Development Association (PhIRDA). In 2016, He Successively participated in the establishment of the PhIRDA Pharmaceutical Innovation Investment Specialty Committee and the preparation of CBIIC. He is responsible for the liaison of PhIRDA members and Investment Specialty Committee members, and office management.

Mr. Ma Chao used to work in Chaoyang Branch of Beijing Municipal Administration of Market Supervision and was responsible for the registration, modification, and restructuring of business entities.

李　平
碧迪医疗大中华区副总裁及中国欧盟商会医疗器械委员会医用耗材工作组副主席

Ping Li
Vice President of BD Greater China&the company's highest representative working with Government affairs team to develop market access strategies on payment and reimbursement issues

李平先生现任碧迪医疗大中华区副总裁，大中华区领导层成员之一；他同时是中国欧盟商会医疗器械委员会医用耗材工作组副主席。

作为碧迪医疗政府事务最高领导人主要负责定价、支付、报销等相关市场准入战略，负责搭建政策相关制定者，学会等合作平台。加入碧迪医疗前，他曾以市场准入总监、政府事务总监、销售经理等身份，服务于诺华制药、礼来和默沙东等公司。在此之前，他曾在医院担任外科医生 5 年。

李平先生在北京大学国家经济研究中心获得工商管理硕士学位，有超过 20 年的医疗行业从业经验。

Ping Li is the Vice President of BD Greater China, and a member of Greater China Leadership Team. Ping Li acts as the company's highest representative working with Government affairs team to develop market access strategies on payment and reimbursement issues. He is also responsible for build cooperative relationship with policy association and key policy makers on the relevant matter. Prior to joining BD, he had served Novartis Pharm, Eli Lilly and Company and MSD China by taking the role as Government Affairs Director, Government Affairs Manager, and Sales Manager.

Ping Li obtained his Executive Master of Business Administration from national economic research center of Peking University, and has served the healthcare industry for more than 20 years.

郑　薇
国联证券医药首席分析师

Zheng Wei
Chief Analyst of pharmaceutical Industry of Guolian Securities

郑薇，毕业于中国科学技术大学生物化学与分子专业。毕业后在深圳迈瑞生物医疗电子股份有限公司就职 5 年。曾在体外诊断事业部做产品研发 2 年多，后转至战略发展部 2 年多。

2015 年在华泰证券研究所医药团队任高级研究员，负责医疗器械板块；2016 年中加入天风证券 ,2017-2021 年任天风证券医药首席分析师，2021 年加入国联证券任医药首席。在医疗行业具有 12 年产投经验。

Zheng Wei, graduated from the University of Science and Technology of China with a major in Biochemistry and Molecules. After graduation, she worked in Shenzhen Mindray Bio-Medical Electronics Co., Ltd. for 5 years. She worked in the IVD Division for product research and development for more than 2 years, and then worked in the Strategy Development Department for more than 2 years.

In 2015, she served as a senior researcher in the medical team of Huatai Securities Research Institute, responsible for the medical device sector; joined Tianfeng Securities in mid-2016, served as the chief pharmaceutical analyst of Tianfeng Securities from 2017 to 2021, and joined Guolian Securities as the chief pharmaceutical analyst in 2021. She has 12-year experience in investment in the medical industry.

冯　岚
中国医药创新促进会秘书长

FENG Lan
Secretary-General of China Pharmaceutical Innovation and Research Development Association (PhIRDA)

冯岚，中国医药创新促进会秘书长。先后任职国家食品药品监督管理局信息中心，《中国新药杂志》有限公司总经理，2008 年参与建立中国药学会医药政策研究中心。兼任中国罕见病联盟副秘书长，北京大学光华管理学院健康协会副秘书长。

冯岚女士在企业管理、媒体运营、医药与卫生政策研究等方面拥有多年经验。毕业于吉林大学白求恩医学部，并在北京大学光华管理学院取得高级工商管理（EMBA）硕士学位。

Ms. Feng Lan, Secretary-General of China Pharmaceutical Innovation and Research Development Association (PhIRDA), Deputy Secretary-General of China Alliance of Rare Diseases (CARD) and Guanghua EMBA Health Association. She successively served as the Associate Editor in the Information Center of China Food and Drug Administration (CFDA), General Manager of Chinese Journal of New Drugs and participated in the establishment of the Medicinal Policy Research Center of Chinese Pharmaceutical Association in 2008.

Ms. Feng Lan is experienced in business management, media operation and medical and pharmaceutical policy research. She holds a Bachelor of Medicine in Norman Bethune Health Science Center at Jilin University and EMBA of Guanghua School of Management at Peking University.

李　靖
药渡经纬信息科技（北京）有限公司董事长、联合创始人

Jin LI
Founder and Chair of Pharmacodia

李靖博士，是中国海归留学生中成功的创业者之一。从 2006 年到现在，创办的企业包括：北京珅奥基医药科技有限公司，北京欧博方医药科技有限公司（董事长），药渡经纬信息科技有限公司（董事长）；本草资本（合伙人）；发表 30 于篇论文，申请专利 50 于件；参与并主持许多国家项目：包括：“十一五”重大新药创制课题研究；科技部支撑计划；北京海淀科委“科技专项计划”等课题研究。

新药研发在过去的二十年中，取得了巨大成就。在新的形势下，First in class 的新药研发是创新的趋势。本报告基于对中国整体药物研发的大数据分析，对创新的机会和挑战进行了策略性分析。

Dr. Jin Li, one of the most productive entrepreneur of returnees. He founded companies including Shenogen Pharma group, Orbiepharm, Pharmacodia and 3E Bioventures since 2006. He also have a strong publication track record, publishing more than 50 patents, 30+ research articles and 14 book chapters. He is also the Editor in Chief of Pharmaceutical Index which is published worldwide.

Great achievements have been made in the Drug R&D in China in the past two decades. The new drug research and development of first in class drug is an innovative trend in the future. Based on the big data analysis of China's overall drug R & D, this report makes a strategic analysis on the opportunities and challenges of innovation.

杨志敏
国家药品监督管理局药品审评中心化药临床一部部长

YANG Zhimin
Leader of the Medical Review Department I, Centre for Drug Evaluation (CDE), China National Medical Products Administration (NMPA)

杨志敏，主任药师，儿科主治医师。

现任国家药品监督管理局药品审评中心化药临床一部部长。毕业于北京大学医学部临床医学专业，1993 年进入北京大学附属人民医院儿科，从事儿科临床和科研工作。2001 年进入药品审评中心担任临床审评员，已有超过 15 年的临床审评经验。目前她所负责的部门主要承担抗肿瘤药、血液病药、糖尿病药、风湿免疫药等小分子和大分子产品的临床审评。曾在澳大利亚和美国分别接受过药品研发和评价的中长期培训。主导多个新药临床研发技术指导原则的制定，目前担任中国抗癌协会肿瘤药物临床研究专业委员会副主任委员，曾任 ICH E11a 专家组成员，目前为 ICH E6R3 专家组成员和中国 ICH 科学技术委员会委员。荣获国务院政府特殊津贴。

Zhimin Yang, chief pharmacist, pediatrics physician.

Dr Yang is the leader of the Medical Review Department I, Centre for Drug Evaluation (CDE), China National Medical Products Administration (NMPA). She graduated from Peking University Medical School, and worked as pediatrics physician in People's Hospital (affiliated with Peking University Medical School) for 8 years since 1993, she joined in CDE as medical review in 2001, now is with more than 15 years experience of medical review. Dr Yang's department is responsible for the medical evaluation of the therapeutic drugs of cancer, leukemia, diabetes, rheumatoid arthritis etc. Dr. Yang received long course system training of new drug development and review in Australia and the United States of America. She leaded multiple guidances clinical development of new drugs, and is the vice chairman of Clinical Trial Committee Chinese Anti-Cancer Association. She is the professor of ICH E11a and ICH E6R3, and a member of China Science Committee of ICH. She was awarded with special allowance of the State Concil.

赵　维
山东大学临床药学系主任

ZHAO Wei
Director of the Department of Clinical Pharmacy, Shandong University

赵维，山东大学临床药学系主任、教研室主任；山东大学临床药理研究所所长；国家药品监督管理局创新药物临床研究与评价重点实验室常务副主任；山东省千佛山医院Ⅰ期临床试验研究中心主任；国家药品监督管理局新药审评专家；欧盟药监局数据外推委员会、建模与仿真委员会常务委员、审评专家；法国药监局儿科药物评审委员会副主任；British Journal of Clinical Pharmacology 执行主编。在特殊人群药物临床试验与个体化治疗研究领域有丰富的临床和科研经验。主持 70 余项药代动力学、有效性和安全性研究；获得国家药品监督管理局药物批件、欧盟药监局药物研究计划 PIP 批件 10 余项。

Wei Zhao, Pharm.D., Ph.D., Professor of clinical pharmacist and pharmacologist currently working as the Chair of Institute of Clinical Pharmacy and Clinical Pharmacology at Shandong University, Deputy Director, NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drug, China. Prof Zhao also works also as a regulator scientist. he was nominated as a member and expert of pediatric committee in French National Agency of Medicine and Health Products Safety (ANSM) in 2015 and a member and expert of modeling & simulation and extrapolation working groups in European Medicines Agency (EMA).

俞　卫
上海创奇健康发展研究院执行院长

YU Wei
Executive Director of China Healthcare Innovation Platform Academy

俞卫，上海创奇健康发展研究院执行院长、中国卫生经济学会常务理事、《中国卫生政策》、《中国卫生经济》、《中国卫生》编委。曾任上海财经大学公共经济与管理学院教授、院长，国务院医改办政策咨询委员会委员，美国波士顿大学医学院助教授，美国联邦退役军人医疗系统卫生经济资源中心和斯坦福大学卫生政策中心研究员。主要研究领域包括卫生经济与政策分析、医疗保险支付方式、医院管理与绩效评估，在中外期刊发表论文 80 余篇，包括美国医学会期刊《JAMA》和《中国社会科学》等权威期刊。他于 1982 年获上海华东纺织工学院电气自动化学士学位，1988 和 1992 年分别获得美国克莱姆森大学经济学硕士和博士学位，1994-96 年在波士顿大学完成卫生经济学博士后研究。

Yu Wei, executive director of China Healthcare Innovation Platform Academy, executive director of China Health Economics Association, editorial board member of *China Health Policy, China Health Economy and China Health*. He was a professor and dean of the School of Public Economics and Management of Shanghai University of Finance and Economics, a member of the Policy Advisory Committee of the Medical Reform Office of The State Council, an assistant professor of Boston University School of Medicine, a researcher of the Health Economic Resource Center of the Federal Veterans Medical System and the Center for Health Policy of Stanford University. His main research areas include health economics and policy analysis, medical insurance payment methods, hospital management and performance evaluation. He has published more than 80 papers in Chinese and foreign journals, including *JAMA* and *Chinese Social Sciences*. He received a BACHELOR's degree in electrical automation from East China Textile Institute in Shanghai in 1982, a master's degree in economics from Clemson University in 1988 and a doctoral degree in economics from Clemson University in 1992, and completed postdoctoral research in health economics at Boston University from 1994 to 1996.

宣建伟
中山大学药学院医药经济研究所所长

XUAN Jianwei
Director of Health Economics Research Institute, Sun Yat-sen University

宣建伟博士在中山大学、佛罗里达大学、复旦大学等重点大学以及辉瑞、葛兰素史克等多家跨国制药公司拥有 30 多年的研究、教学和全球领导经验。宣博士领导了多个全球卫生经济和市场准入团队，并进行了具有影响力的卫生政策、卫生经济学、比较效益、结果研究、流行病学和市场准入研究，以支持循证决策过程。他的研究成果已在许多国家得到采纳，以支持制定国家医疗保健政策、设计药物报销方案和支持政府决策。宣博士拥有 30 多年工作 / 研究经验，在卫生经济、市场准入、结果研究、流行病学、药物警戒等领域发表了 140 多篇论文。他与全球 KOLs 建立了广泛的专业网络，并领导了众多全球政策论坛、咨询委员会和政府小组讨论。宣博士是多个中国政府机构的卫生经济和市场准入政策顾问。

Dr. Jianwei Xuan has more than 30 years of research, teaching, and global leadership experience at major Universities such as Sun Yat-sen University, University of Florida, Fudan University, and several multinational pharmaceutical companies such as Pfizer, GSK, etc. Jianwei has led multiple global health economic and market access teams and conducted high impact health policy, health economics, comparative effectiveness, outcomes research, epidemiology and market access research to support evidence-based decision-making processes. His research results have been adapted in numerous countries to support formulating national health care policy, designing drug reimbursement formularies, and supporting government decision making. With more than 30 years of working/research experience, Dr. Xuan also published extensively in the areas of health economic, market access, outcomes research, epidemiology, pharmacovigilance with 140+ papers. He has established an extensive professional network with global key opinion leaders and led numerous global policy forums, advisory boards, and government panel discussions. Dr. Xuan is advisor to multiple Chinese government agencies regarding health economic and market access policies.

韩世明
波士顿咨询合伙人

Samuel HAN
Partner of Boston Consulting Group

韩世明先生是 BCG 合伙人，常驻上海办公室，是 BCG 大中华区医疗健康团队核心成员，医疗支付领域核心领导团队之一。韩先生在医疗健康领域有 13 年工作经验。韩世明在药品准入与支付、医疗保险领域有丰富的经验。近期曾撰写《2020 肿瘤创新药支付报告》、《医保目录调整 - 从洞察到行动》、《美国健康保险研究》等文章。曾帮助众多国内外企业制定创新药准入策略、政策倡导策略与准入组织优化方案，帮助行业协会制定多层次医疗保障相关政策倡导建议等。加入 BCG 前，韩世明先生在一家领先的跨国制药企业工作，领导战略项目的制定和实施，以及领导核心产品的市场营销团队。韩世明先生获得浙江大学工学硕士学位，并获得华中科技大学双学士学位。

Samuel Han is BCG Partner, in Shanghai office. He is a core member of BCG Greater China Healthcare Practice. He is a member of Payer leadership team of BCG Greater China Healthcare Practice. He has been working in healthcare industry for 13 years. Mr. Han is an expert in market access, payer, healthcare insurance. He recently wrote publications of "China oncology innovative drug payment report", "From insight to action – 2020 NRDL update" and "Study and learning from US healthcare insurance market". He supported various companies in determining access strategy, and support industry associations to develop advocacy position of healthcare payment system. Prior to joining BCG, Samuel Han worked in a leading pharmaceutical companies, responsible of leading strategy and portfolio development, and marketing of core products. Mr. Han received Master Degree in Zhejiang University, and Bachelor Degree in Huazhong University of Science and Technology.

李怡平
药明巨诺联合创始人、董事长兼首席执行官

James LI
Co-founder, Chairman and Chief Executive Officer, JW Therapeutics

李怡平 药明巨诺 联合创始人、董事长兼首席执行官。

李怡平先生于 2016 年 2 月与美国巨诺公司和药明康德共同创建了药明巨诺，担任首席执行官，2020 年 10 月起任董事长。加入药明巨诺之前，李怡平曾担任美国安进副总裁及大中华区创始总经理、美国凯鹏华盈基金生命科学领域的合伙人、默沙东美国及亚太地区的多个领导职务。

James Li, Co-founder, Chairman and CEO at JW Therapeutics.

In early 2016, James Li co-founded JW Therapeutics with Juno Therapeutics and WuXi AppTec, serving as Chief Executive Officer. From Oct 2020, Dr. Li became the Chairman of the Board. Prior to JW Therapeutics, James served as Vice President and the founding General Manager, Greater China at Amgen, Partner at Kleiner Perkins Caufield & Byers life science practice, and several leadership positions across the US and Asia Pacific at Merck Co. & Inc.

李安民
北京久银投资控股股份有限公司 (833998) 董事长

LI Anmin
President, EagleHoldings Co., Ltd

中国社会科学院金融研究所博士后、教授。从事证券业务近 30 年，见证了新中国证券市场的发展历程，参与了新中国证券市场的重大变革。曾任中国人民银行广州分行金融市场证券部经理、广东华侨信托投资公司证券总部总经理、湛江证券有限公司董事兼总裁、汉唐证券有限公司董事兼常务副总裁、兴业国际信托公司总裁特别助理、华安财产保险股份有限公司副总裁、弘康人寿保险股份有限公司董事长、总裁等职务。

Li Anmin, chairman / president of EagleHoldings, he received his post-doctoral degree from Financial Research Institute of Chinese Academy of Social Sciences, He is the professor of Chinese Academy of Social Sciences, has almost 30 years' experience of security. Witnessed the development history of China's security market, took part in the significant revolution of China's security market. He was the manager of financial market and security department in Guangzhou Branch of people's bank of China, general manager of security department of Huaqiao Trust Investment Co., Ltd, Director/President of Zhanjiang Security Co., Ltd, Director/President of Hantang Security Co., Ltd, Special Assist of President of Xingye International TrustCo., Ltd, Vice President of Huaan Property Insurance, Chairman/ President of Hongkang Life Insurance.

王少杰
中关村股权投资协会会长

Jason WANG
President of Zhongguancun Private Equity & Venture Capital Association (ZVCA)

中关村股权投资协会会长、长江商学院工商管理硕士学位、新供给经济学 50 人论坛特邀研究员；上海股权托管交易中心股份有限公司第一届、第二届审核委员会、注册委员会委员。南方科技大学新兴产业研究院执行院长。

在金融投资领域有近四十年的理论与实战经验；是金融投资、企业管理方面的专家，国际投资交流合作专家。拥有广泛而深厚的政府、金融、上市公司、高新企业以及国内外数千家投资机构等方面的人脉关系、项目资源。具有丰富的证券市场以及资本市场运作经验。

President of China Zhongguancun Private Equity & Venture Capital Association (ZVCA), MBA from Cheung Kong Graduate School of Business (CKGSB), Specially Invited Researcher at Zhongguancun Huaxia New Supply-side Economist 50 Forum. Member of both the audit committee and the registration committee of Shanghai Equity Exchange Co., Ltd during its initial two years. Executive principal of the Research School of Emerging Industries at Southern University of Science and Technology.

40 years of theoretical knowledge and practical experience in the realm of finance; subject matter expert in financial investment, enterprise management and international investment collaboration. Broad and in-depth network resources with government, financial institutions, public companies, Hi-tech & innovation firms and thousands of investment firms around the world. Advanced knowledge and experience in managing operations in the security market and capital market.

王　昕
法国施维雅药厂，亚太生物创新中心，业务拓展及许可总监

Cynthia WANG
BD&Licensing Director, BioInnovation Asia, Les Laboratories SERVIER

王昕女士于 2015 年 7 月加入施维雅中国，任职业务发展总监，专注于以中国地区的业务发展；自 2020 年 4 月起，任职法国施维雅药厂亚太生物创新中心业务拓展及许可总监，致力于通过合作和共同创造推动中国及亚太地区医疗创新。

王昕女士在中国的生命健康及制药领域工作超过 20 年。加入施维雅之前，王昕女士曾经任职辉瑞中国高级业务拓展经理，负责全球疫苗业务拓展和辉瑞中国对外许可项目管理。过往任职经历还包括西安杨森，安捷伦科技，施耐德电气等公司的业务发展，新产品引进及上市准备，战略联盟管理，业务规划及运营等职能。王昕女士专注于药品业务发展领域多年，拥有丰富的项目经验，同时兼任 CHBD 协会（中国医疗健康产业 BD 协会）轮值会长。

王昕女士的教育经历包括北京大学 MBA，美国福坦姆大学国际金融硕士，北京大学医学部药学学士。

Cynthia Wang Joined Servier China as Business Development Director since July 2015.

Cynthia brings with her over 20 years of Healthcare/pharmaceutical industrial experience in China. Prior to Servier China, Cynthia worked as Senior BD manager for Pfizer in Vaccine BD global M&A projects and managing full TAs of out-licensing BD activities. Before joining Pfizer, Cynthia held a series of positions in Business Development, New Product Introduction, Product launch, Strategic Alliance Management, Business planning and Operational Management at Janssen/Johnson & Johnson, Agilent Technologies and Schneider Electric. Cynthia has broad BD network in China serving as Rotating Vice Chairman of CHBD (China Healthcare BD) organization, Cynthia has proven BD track records of closing multiple BD deals. Cynthia holds a Master of Business Administration from Peking University, a Master of Global Finance from Fordham University in NYC, a Pharmacy degree from Peking University Health Science Centre.

Leo L. Han
CEO，夸克中国 /GDCC 中国中心

Leo L. Han
CEO, Quark Venture China/GDCC

Dr.Han 在新加坡国立大学药物学院获得博士学位，在美国国立卫生研究院（NIH）完成博士后，在美国国立卫生研究院（NIH）工作 12 年，历任职员科学家，技术负责人，从事生物信息，计算机辅助药物设计和基于 WGS 的致病源检测。2021 年作为 CEO 加入 GDCC/Quark Venture China。

Dr. Han 在生物信息和计算机药物辅助设计领域发表了 60+ SCI 收录文章，10K+ 引用，在生物计算和 CADD 的近 20 年的工作经历中，利用 AI 技术 / 统计学习 / 深度学习来解决生物信息学和化学信息学问题，利用 AI/NLP/CV 来迎接多模态医疗信息的挑战，同时着重于虚拟高通量药物筛选，真实世界证据和数字化生物标记物的研究。

Dr. Han graduated from National University of Singapore and completed postdoctoral training in United States National Institutes of Health (NIH). He worked as Staff Scientist, Senior Bioinformatics Software Architect and Tech Lead at National Institutes of Health over 12 years, engaged in the biological information, computer aided drug design and pathogen detection. In 2021, he joined GDCC/Quark Venture China as CEO.

Dr. Han has published 60+ SCI articles, 10K+ citations in the field of bioinformatics and computer-aided drug design. With nearly 20 years of research experience in AI/CA-Drug Design, Dr. Han dedicate his research in utilizing AI technology to tackle the advanced bioinformatics and cheminformatics challenges, as well apply the AI/NLP/CV for multimodal medical information, virtual high throughput drug screening, Real World Evidence and the research of digital biomarkers.

王　飞
三生制药 CFO

WANG FEI
CFO, 3S Bio Inc.

王飞先生现为三生制药（HK1530）首席财务官，主要负责集团财务会计，管理监督财务申报，集团投融资活动，集团投资者关系事务。王飞先生为中国注册会计师，在审计、会计及财务管理超过 20 多年经验。曾先后担任阿斯利康制药公司中国区运营首席财务官，及呼吸，免疫，炎症事业部财务总监，港股主板上市公司执行董事及首席财务官以及多家上市公司董事职务。

王飞先生于 1999 年毕业于新疆财经大学，获管理学学士，并于 2012 年取得上海交通大学及法国马赛商学院 (现 KEDGE) 的工商管理硕士学位。

Mr. Wang Fei is now the chief financial officer of 3SBio Inc. (HK1530), mainly responsible for the corporation's financial accounting, management and supervision of financial reporting, the group's investment and financing activities and the group's investor relations.

Mr. Wang is a Chinese CPA with more than 20 years of experience in audit, accounting and financial management. He has successively served as the chief financial officer of AstraZeneca pharmaceutical company's operation in China, financial director of respiratory, immune and inflammation division, executive director and chief financial officer of listed companies on the main board of Hong Kong stocks, and the public board of several listed companies.

Mr. Wang graduated from Xinjiang University of Finance and Economics with Bachelor degree of management in 1999 and MBA from Shanghai Jiaotong University & Marseille Business School (now KEDGE) in 2012.

王　翀
再鼎医药（上海）有限公司，执行副总裁，商务拓展

Jonathan WANG
ZAI Lab, EVP, Head of Business Development

王翀先生自 2014 年起担任再鼎医药执行副总裁，负责商务拓展。加入再鼎医药之前，他曾在奥博资本担任资深投资经理，负责中国医药投资和被投公司管理。2005 年至 2011 年期间，王翀先生曾在波士顿咨询公司担任资深顾问，负责制药和医疗保健行业业务，为多家跨国公司及中国本土公司制定中国发展战略。此前，王翀先生曾就职于高盛投资银行，积累了丰富的金融交易经验。王翀先生拥有美国沃顿商学院医疗管理 MBA。

Jonathan Wang is our head of business development since 2014. Prior to joining Zai Lab, Mr. Wang was an investment professional at OrbiMed, where he was responsible for China healthcare investment and portfolio management. From 2005 to 2011, Mr. Wang worked as a consultant at the Boston Consulting Group in China, where he specialized in pharmaceutical and healthcare engagements, assisting multinational and local companies with their China strategy. Previously, Mr. Wang also gained financial transactional experience at Goldman Sachs Investment Banking. Mr. Wang received a master of business administration in healthcare management from Wharton Business School.

吕　东
高瓴资本 董事总经理

LYU Dong
Hillhouse Capital, Managing Director

吕东博士现为高瓴资本董事总经理，主要负责医疗健康领域的一级市场投资工作。在加入高瓴资本之前，曾分别于 2016-2020 年和 2011 年 −2016 年在太盟投资集团和中信产业基金工作，从事医疗健康领域投资工作超过十年。在此之前，曾在国家卫生部和国家食品药品监督管理局分别工作，负责药品的审评审批工作。吕先生持有中国药科大学博士学位，北京大学硕士学位以及北京医科大学学士学位。

Dr. Lyu Dong currently serves as the Managing Director of Hillhouse Capital. His key focus is healthcare investment on the primary market.

Prior to his current role, Dr. Lyu had served the growth fund of PAG from 2016 to 2020 and served the medical and health investment department of CITIC PE from 2011 to 2016. He has had over 10 years of experiences in healthcare investment. Dr. Lyu also had the working experiences in Ministry of Health (now as National Health Commission) and State Food and Drug Administration (now as National Medical Products Administration)

Mr. Lyu earned his Doctor's degree from Chinese Pharmaceutical University, Master's degree from Peking University and Bachelor's degree from Beijing Medical University.

易　琳
德福资本董事总经理

YI Lin
Managing Director, GL Capital

易琳女士现为德福资本董事总经理，加入德福资本 10 年，易女士主要负责德福资本一级市场投、融资业务。易女士拥有多年的医疗健康行业投资工作经验，投资领域覆盖质谱检测、第三方检测服务、眼科领域、康复领域、微创外科器械耗材、医药器械 CXO 等领域，在加入德福资本之前，易女士曾在普华永道审计部任职。易女士持有北京大学工商管理硕士学位和对外经济贸易大学学士学位。

Ms. Yi Lin is now the managing director of GL Capital. She has joined GL capital for 10 years. Ms. Yi is mainly responsible for the primary market investment and fundraising for GL Capital. Ms. Yi has many years of investment experience in the medical and health industry. Her investment fields cover mass spectrometry detection, third-party detection services, ophthalmology devises, rehabilitation equipment, minimally invasive surgical instrument consumables, medical and equipment CXO companies etc. Before joining GL Capital, Ms. Yi worked in the Audit Department of PricewaterhouseCoopers. Ms. Yi holds a master's degree in Business Administration from Peking University and a bachelor's degree from the University of International Business and Economics.

姜　华
博安生物 CEO

Sammy JIANG
CEO, Shandong Boan Biotechnology Co., Ltd.

姜华女士现任博安生物 CEO，全面负责公司的管理和运营工作。在此之前曾任职绿叶制药集团副总裁，负责集团战略发展、业务拓展，并购及合作，以及投资者关系工作。姜华女士拥有上海复旦大学世界经济系学士学位、法国马赛 KEDGE 商学院工商管理硕士学位（MBA）及比利时联合商学院工商管理博士学位（DBA），并拥有经济师资格证书。姜华女士具有多年医药相关领域的涉外合作、兼并收购和跨国管理经验。

Ms. Jiang Hua is currently the CEO of Boan biology and is fully responsible for the management and operation of the company. Before that, he worked as vice president of green leaf Pharmaceutical Group, responsible for the group's strategic development, business development, M & A and cooperation, and investor relations. Ms. Jiang Hua holds a bachelor's degree in world economics from Fudan University in Shanghai, an MBA from kedge business school in Marseille, France, and a DBA from United Business School in Belgium. She also holds the qualification certificate of economist. Ms. Jiang Hua has many years of experience in foreign-related cooperation, mergers and acquisitions and transnational management in pharmaceutical related fields.

张彦涛
泰励生物，CEO

Tony Zhang
CEO, Tyligand Bioscience

张彦涛博士是泰励生物科技的联合创始人和董事长。 他毕业于山东大学化学系，获 CGP 奖学金赴美国普度大学，师从 Ei-ichi Negishi 教授（2010 诺贝尔奖获得者）从事有机金属催化及合成化学研究，获得博士学位。曾任礼来制药 (Eli Lilly) 小分子设计与发展部门首席科学家，礼来中国研发中心首任董事总经理，及礼来全球合作研发亚太区副总裁。

张彦涛博士具有国际药厂长期的科研管理和商业拓展经验，曾主持了多个治疗领域新药项目的开发，领导建立了数个技术创新平台，所设计的多项制药工艺被成功地应用于大规模产业化生产，是业界公认的 CMC 专家。他在化学合成，金属催化，新药研发，制药制剂新技术，工艺和产品设计，及绿色化学等领域发表了 50 余篇文章和专著，获得 24 个国际专利授权。现任“有机工艺研发”(Organic Process Research and Development, 美国化学协会和英国皇家化学协会共同出版）杂志编委。张博士是礼来制药最高荣誉董事局主席奖及普度大学杰出校友奖的获得者。他担任过中美健康领域产业组织百华协会（BayHelix Group）的董事会主席，多个院校的兼职教授和机构顾问。

Tony Zhang is a co-founder and CEO for Tyligand Bioscience. He has a PhD degree from Purdue University under the direction of Professor Ei-ichi Negishi. Prior to founding Tyligand, he has served at Eli Lilly for 25 years with escalating responsibilities, including Senior Research Fellow of Small Molecular Design and Development, founding Managing Director of Eli Lilly China R&D; and Vice President of Lilly Global External R&D, Asia.

Dr. Zhang has led multi-disciplined teams in drug development across several therapeutic areas, and has published more than 60 articles and monographs in the fields of synthetic, medicinal and process chemistry, and pharmaceutical product design. He is a named inventor for 26 international patents and an editorial board member for the journal Organic Process Research and Development, co-published by the American Chemical Society and the Royal Society of Chemistry. He has served as the Chairman of the Board for the Bayhelix Group, adjunct professor or advisor for several universities, not-for-profit organizations, and venture investment firms.

肖　慧
安永华明会计师事务所（特殊普通合伙）审计服务合伙人

Grace XIAO
Assurance Partner, Ernst & Young Hua Ming LLP

肖慧女士拥有逾 15 年的审计经验，现为安永审计服务合伙人。她对审计大型国有企业，民营企业及中外合资企业等均有丰富的经验，服务的项目涉及多个行业，包括生物医药行业、汽车业、制造业、批发零售业、港口运营及物流业等。

肖女士近年专注于服务生命科学与医疗健康领域的客户，对于生物医药、医药流通、医疗器械及医疗服务等，有较为完整的理解和丰富的实操经验。

肖女士熟悉中国企业会计准则、国际财务报告准则及美国会计准则，熟悉不同资本市场的披露规定和内部控制审计的实务操作，在协助企业在不同资本市场的 IPO 审计和年报审计中积累了丰富的经验。

Ms. Grace Xiao has more than 15 years of audit experience and is now an assurance partner of Ernst & Young Hua Ming. She has rich experience in auditing state-owned enterprises, private enterprises as well as multinational joint ventures, covering industries including pharmaceuticals and biotech, automotive, manufacturing, retail and logistics industry.

Grace has focused on serving clients in life science industry in recent years. She has relatively complete understanding of biopharmaceuticals, medicine circulation, medical device and medical service industries, and has accumulated rich experience in providing relevant professional services.

Grace has rich experience in IPO audit and annual audit for clients in different markets. She is familiar with Chinese Accounting Standards, International Financial Reporting Standards and US Generally Accepted Accounting Principles, and the corresponding listing rules and internal control practice.



● 合作洽谈数量稳步增长
Number of business meetings is increasing steadily

临床数据全球首发项目介绍 »»»

Clinical Trial Data Release

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
陈晓光 CHEN Xiaoguang	中国药促会药物研发专业委员会委员、 中国医学科学院药物研究所药理室主任 Member of PhIRDA Drug R&D Specialty Committee、Director, Department of Pharmacology, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College	绿原酸作用靶点发现与抗肿瘤作用 Target Discovery and Anti-tumor Effect of Chlorogenic Acid

项目简介

通过利用带有双吖丙啶和炔基标签修饰的光亲和标记探针分子 PAL-CHA，对人恶性黑色瘤细胞 A375 线粒体中的活性蛋白进行标记，随后对标记蛋白进行酶解、质谱检测及 Uniprot 蛋白数据库查询比对，筛选到该蛋白为 ACAT1。通过一系列相互作用实验，验证了 CHA 与 ACAT1 蛋白具有直接相互作用，并进一步阐明了 CHA 通过调控 ACAT1 蛋白磷酸化发挥其抗肿瘤作用的机制，为 CHA 抗肿瘤的临床应用提供了实验依据，亦为新型抗肿瘤药物的研究与开发提供了全新的靶标。

Project Introduction

The active protein in the mitochondria from human melanoma cell line A375 was labeled by photoaffinity probe molecule PAL-CHA, modified with diacridine and alkynyl tags, and then the labeled protein was identified as ACAT1 by probe incubation, target enrichment, sample preparation, liquid chromatography-mass spectrometry (LC-MS) measurement, data processing and analysis. Through a series of interaction experiments, the direct interaction between CHA and ACAT1 protein was verified, and the anti-tumor mechanism of CHA regulating the phosphorylation of ACAT1 protein was further studied. The present study provides an experimental basis for the clinical application of CHA against tumor and a new target for the research and development of novel anti-tumor drugs.

李文斌 LI Wenbin	中国药促会脑神经药物临床研究专委会副主任委员 兼秘书长、首都医科大学附属北京天坛 医院肿瘤综合治疗中心主任 Vice-Chairman & Secretary-General of PhIRDA Clinical Research on Cranial Nerve Drugs Specialty Committee, Director of Cancer Center, Beijing Tiantan Hospital, Capital Medical University	注射用绿原酸治疗复发胶质母细胞瘤 I/II 期临床试验进展汇报 Evaluation of Chlorogenic Acid for Injection in the Treatment of Recurrent Glioblastoma

项目简介

胶质瘤是中枢神经系统最常见的原发恶性肿瘤，其中，WHO 分级 IV 级的胶质母细胞瘤恶性程度最高，占所有胶质瘤的 46% 左右。胶质母细胞瘤预后极差，目前的标准治疗方案为手术 + 术后同步放化疗 + 替莫唑胺辅助化疗。据文献报道，新确诊的胶质母细胞瘤患者中位生存期仅有 14.6 个月，首次复发的胶质母细胞瘤患者中位生存期仅有 7-9 个月。本团队的试验药物绿原酸为首创 1 类原研药物，具有调节免疫及降低肿瘤恶性程度等广谱抗肿瘤作用，I 期试验已证实绿原酸安全性良好，且治疗后生存期明显超过既往文献结果，目前正在进行的 II/III 期临床试验的研究重点是受试者的生存期，本中心的中期数据分析令人满意。

Project Introduction

Glioma is the most common primary malignant tumor in the central nervous system. Among them, glioblastoma (WHO grade IV) has the highest malignant degree, accounting for about 46% of all gliomas. Glioblastoma has a very poor prognosis, and the current standard treatment is surgery + postoperative concurrent chemoradiotherapy + temozolomide adjuvant chemotherapy. According to the literature, the median survival time of newly diagnosed glioblastoma patients was only 14.6 months, and the median survival time of first recurrent glioblastoma patients was only 7-9 months. Chlorogenic acid as the first class of original drugs, has broad spectrum antitumor effects such as regulating immunity and reducing the degree of tumor malignancy. The phase I trial demonstrated that chlorogenic acid is safe and has a significantly longer post-treatment survival than previously reported. The ongoing phase II/III clinical trial focuses on the survival of the subjects, and the interim data from our center are satisfactory.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
胡超苏 HU Chaosu	复旦大学附属肿瘤医院主任医师、教授、博士生导师 Chief Physician, Professor, Doctoral Supervisor, Fudan University Shanghai Cancer Center	派安普利单抗治疗前线化疗失败鼻咽癌的多中心 II 期注册临床研究 A Multicenter, Phase II Trial of Penpulimab in the Treatment of Metastatic Nasopharyngeal Carcinoma after the Failure of Previous Chemotherapy

项目简介

派安普利单抗是目前唯一基于人免疫球蛋白 G1（IgG1）亚型设计的 PD-1 单抗，在保留 IgG1 稳定性好优点的同时，通过彻底的 Fc 段改造，完全去除了 ADCC，ADCP 和 CDC 效应，降低了 ADCR 效应。 AK105-202 (NCT03866967) 为一项多中心、单臂注册临床研究，纳入了 130 例至少经过二线化疗失败的转移性鼻咽癌患者，研究达到了其主要终点，客观缓解率（ORR）为 29.7%，中位生存期（mOS）可达 18.63 个月，为目前同类研究公布的最长 mOS，安全性良好，研究中 3 级及以上治疗相关不良事件发生率仅 8.5%。本研究数据目前已递交 NMPA 用于申请派安普利单抗在复发转移鼻咽癌相关适应症。

Project Introduction

Penpulimab is a monoclonal antibody that targets directly on programmed cell death-1 (PD-1). Penpulimab is the only PD-1 inhibitor that was designed based on the IgG1 subtype. Through the reconstruction of Fc domain, penpulimab was stable and with no ADCC, ADCP and CDC effect and less ADCR effect. Immunotherapy has brought nasopharyngeal carcinoma (NPC) patients with new promising approach of treatment. AK105-202 (NCT03866967) is a multicenter, single-arm, open-label study involved in 130 patients to evaluate the efficacy and safety of penpulimab in patients with metastatic nasopharyngeal carcinoma progressed after ≥2 prior lines of therapy including platinum-containing chemotherapy. The study reached its primary endpoint with the ORR of 29.7%. Long term survival benefit was observed that the median OS was 18.63 months, which was the best mOS data in all published data till now. Treatment with penpulimab was safe and tolerable that the incidence of grade 3 or worse TRAE was only 8.5%. Based on these results, penpulimab has been applied to NMPA for the approval of treatment to NPC.

马建华 MA Jianhua	南京医科大学附属南京医院内分泌科主任、主任医师，教授，博士生、博士后导师 MD, PhD, Professor. Advisor of Doctoral and Postdoctoral Research. Director of Department of Endocrinology, Nanjing First Hospital	全球首创糖尿病在研新药 Dorzagliatin 糖尿病缓解 DREAM 研究结果 Dream Study Result Release for the First Time, First-In-Class Antidiabetic Investigational Drug Dorzagliatin's Lasting Effect in Diabetes Remission

项目简介

Dorzagliatin 为一款在研的全球首创双作用的葡萄糖激酶激活剂，旨在通过恢复 2 型糖尿病患者的血糖稳态来控制糖尿病渐进性退变性疾病发展。通过修复葡萄糖激酶的葡萄糖传感器功能的缺陷，Dorzagliatin 具有恢复糖尿病患者受损的胰岛 β 细胞功能的潜力，有望作为该疾病源头治疗的基石药物。Dorzagliatin 已成功完成单药治疗 SEED 研究和与二甲双胍联合用药 DAWN 研究，并在完成 SEED 研究的部分血糖控制达标患者中开展研究者发起的 DREAM 研究，以评估 Dorzagliatin 在药物治疗结束后，对糖尿病患者血糖的持续控制效果和糖尿病缓解或临床治愈情况。DREAM 研究的结果将在本次大会上首次公布。

Project Introduction

Dorzagliatin is an investigational first-in-class, dual acting glucokinase activator, designed to control the progressive, degenerative nature of diabetes by restoring glucose homeostasis in patients with Type 2 diabetes. By addressing the defect of the glucose sensor function of glucokinase, dorzagliatin has the potential to restore the impaired pancreatic β-cell function and serve as a cornerstone therapy targeting the root cause of the disease. Both Dorzagliatin monotherapy study (SEED) and combination therapy with metformin study (DAWN) were completed successfully. The investigator-initiated DREAM study was conducted in part of the patients who achieved glycemic control after monotherapy with Dorzagliatin from SEED study, to evaluate Dorzagliatin's lasting effects in diabetes remission. The DREAM study result will be released for the first time in the world at this conference.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
秦志杰 QIN Zhijie	武汉禾元生物科技股份有限公司首席医学官 CMO, Wuhan Healthgen Biotechnology Corp.	幼儿轮状病毒感染急性腹泻新药 HY1002 的 I 期临床试验结果 Phase I Clinical Trial Results of HY1002, A New Generation of Acute Diarrhea Caused by Rotavirus Infection in Children

项目简介

轮状病毒是全球 <5 岁儿童重度胃肠炎和死亡的主要病原。中国 <5 岁儿童腹泻死亡中 RVGE 导致的死亡占 35%。目前还无特效药物治疗轮状病毒引起的儿童急性腹泻。人乳铁蛋白是一种具有多种生物学功能的蛋白质，母乳中丰度很高。乳铁蛋白具有促进肠道铁的吸收、广谱抑菌、抗病毒、抗癌、免疫调节、促进对营养物质的吸收。人溶菌酶能杀死肠道腐败球菌，增加肠道抗感染力。乳铁蛋白对溶菌酶的活性有协同作用。人乳铁蛋白是稀缺资源；植物源重组人乳铁蛋白溶菌酶口服液 HY1002 可为临床提供安全、绿色的医药产品。该产品已经完成健康成人受试者 I 期临床试验，安全耐受性良好。

Project Introduction

Rotavirus is one of the major pathogens to cause gastroenteritis (RVGE) in children under the age of 5. In China, 35% of the total mortality of diarrhea in children under 5 years old was contributed by RVGE. At present, there is no specific treatment against Rotaviral gastroenteritis yet, and the standard of care of this viral infectious diarrhea including rehydration, electrolyte balancing, and acid-base equilibration. Human lactoferrin (hLF) is one of the major proteins in human milk with multiple functions including broad spectra anti-bacteria, anti-virus, anti-cancer, immune balancing, and enhancement of nutrients absorption. Lysozyme (LYZ) shows activities as a bactericide and improves the defense to bacterial infections, and there is a synergistic effect with hLF. However, there are limited supplies for human lactoferrin. The OrsHLF will satisfy the clinical demands of safe, green anti-Rotavirus drugs. At present, the Recombinant Human Lactoferrin and Lysozyme Oral Solution (HY1002) has finished its Phase I clinical trials, and their safety and tolerability are promised.

刘利平 LIU Liping	深圳君圣泰生物技术有限公司 创始人兼首席执行官 Founder&CEO, Shenzhen HighTide Biopharmaceutical Ltd.	HTD1801 改善二型糖尿病合并脂肪肝患者心血管代谢的临床 2 期试验结果 Phase 2 Trial Results of HTD1801 Improving Cardiometabolic Risk Factors in Subjects with Type 2 Diabetes and Fatty Liver Diseases

项目简介

2 型糖尿病合并代谢相关脂肪性肝病患者是心血管疾病的高危人群。HTD1801 是君圣泰开发的具有多靶点协同作用的新分子实体，具有对复杂代谢疾病的综合治疗能力。在一项随机、双盲、安慰剂对照临床 2 期研究中，HTD1801 显著降低 2 型糖尿病合并脂肪肝患者的肝脂水平；并改善糖、脂代谢。在受试者维持原控糖治疗的基础上 HTD1801 显著降低 HbA1c 水平，空腹血糖指标亦有降低趋势；HTD1801 高剂量组体重显著降低，LDL-c 水平呈现降低趋势；HTD1801 低剂量和高剂量组的 TG 水平得到改善。 试验结果显示 HTD1801 可改善多个心血管疾病风险指标，有望为此类患者带来临床获益。

Project Introduction

Patients with type 2 diabetes mellitus (T2DM) and metabolic associated fatty liver disease (MAFLD) are the population with high risk of cardiovascular disease (CVD). HTD1801 is a multifunctional new molecular entity. In a randomized, double-blinded, placebo-controlled, 18-week Phase 2 study of HTD1801 in subjects with T2DM and MAFLD, HTD1801 treatment significantly improved liver fat content and other markers of glucose and lipid metabolism. There were significant decreases in HbA1c in both HTD1801 treatment groups relative to placebo, and there was a trend for reduced fasting glucose with HTD1801. A significant decrease in weight was observed with HTD1801 high dose compared to placebo. Treatment with HTD1801 high dose was associated with a reduction in LDL-c compared to placebo. Both HTD1801 doses resulted in improvements in triglycerides compared to placebo. Treatment with HTD1801 was associated with improvements in the markers of CVD risk. The multifaceted effects demonstrated in this study support the further development of HTD1801 to treat metabolic disorders in patients with T2DM and MAFLD.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
王庆华 WANG Qinghua	国家特聘专家，上海银诺医药技术有限公司董事长兼 CEO State Specially Recruited Experts, CEO & General Manager of Innogen Pharmaceutical Technology Co., Ltd. ;	糖尿病创新药苏帕鲁肽的 I 期 II 期临床数据汇报 Pharmacokinetics, Pharmacodynamics and Clinical Efficacy of Supaglutide, a Novel Weekly Dosing GLP-1 Based Therapy

项目简介

苏帕鲁肽是一种新型 GLP−1 类似物，用于治疗 T2D。我们进行随机、双盲、安慰剂对照、单剂量和多剂量递增研究，以调查健康受试者和 T2D 患者的安全性、耐受性、PK、PD 和降糖疗效。在健康和 T2D 受试者中，Supa 在 53.8 和 71.9 小时达到药物峰值，平均 T1/2 分别为 119.6 和 207.4 小时。单次剂量递增研究表明，Supa 表现出线性药代动力学特征，在所有受试剂量（高达 9.0 mg）下，其耐受性良好，不良反应轻微。给药 7 周后，T2D 受试者平均 HbA1c 降低 1.30%/mg（1.0mg），平均体重降低 1.88kg（4.0mg）。在干预期间，很显著的大多数接受苏帕鲁肽治疗的受试者以剂量和时间依赖性方式实现 HbA1c 小于 7%。这项研究支持苏帕鲁肽作为一种长效注射药物用于血糖控制和减肥。

Project Introduction

Supaglutide (Supa) is a novel GLP-1 analogue developed for type 2 diabetes (T2D). We conducted randomized, double-blind, placebo-controlled, single and multiple dose-escalation studies to investigate the safety, tolerability, PK, PD and hypoglycemic efficacy in healthy subjects and T2D. Supa reached drug peak at 53.8 and 71.9 hrs with mean T1/2 of 119.6 and 207.4 hrs respectively in healthy and T2D subjects. Single dose-escalation studies demonstrated that, while supa showing linear pharmacokinetic characteristics it was well tolerated in all doses tested (dosing up to 9.0 mg), with AEs which were minor such as gastrointestinal symptoms. After 7 weeks of dosing, mean HbA1c reductions were 1.30% with supa 1.0mg, and mean weight reductions was up 1.88kg (4.0mg) in T2D. Significantly more subjects treated with supa achieved HbA1c<7.0% in a dose- and time-dependent fashion during intervention period. This study supported supaglutide as a long-acting injectable medication for glycemic control and weight loss.

王　敏 WANG Min	瑞石生物医药公司创始人兼首席执行官 Co-Founder & CEO of Reistone Biopharma	SHR0302 JAK1 抑制剂治疗斑秃的 II 期临床试验结果 Positive Topline Phase 2 Results for SHR0302, a Selective JAK1 Inhibitor, for Treatment of Patients with Alopecia Areata

项目简介

其在研国内首创、具有自主知识产权的高选择性 JAK1 抑制剂 SHR0302 获得成人斑秃 II 期临床研究成功的结果。试验中，两种剂量（8 mg 和 4 mg）的 SHR0302 均可显著改善斑秃患者的 SALT 评分（一项脱发严重程度评分工具）。斑秃是一种自身免疫性疾病，临床表现为不明原因的局部性或全身性脱发，易对患者造成自卑感，同时造成巨大的精神负担。全球约 2% 的人患有斑秃，仅在中国就约有高达 400 万名患者，且 70−80% 的患者是青壮年发病（40 岁之前发病）。目前，全球还尚未有获批针对斑秃的治疗药，是一个亟待解决的临床难题以及研究热点。

Project Introduction

Positive topline results from a Phase 2 study evaluating the safety and effectiveness of once-daily SHR0302 in adults with alopecia areata (AA). Two doses (8 mg and 4 mg) met the primary endpoint, demonstrating statistically significant and clinically relevant percentage change of SALT score versus placebo. Treatment was well tolerated, and safety was consistent with other JAK1 inhibitors. AA is an autoimmune disease that causes hair loss in patches or sometimes complete hair loss, leading to high psychological burden. Currently, there are no U.S. Food and Drug Administration (FDA)-approved medications for the treatment of AA. The primary endpoint was assessed through the Severity of Alopecia Tool (SALT) score at week 24, defined by the percent change from baseline. Primary endpoint in 8 mg and 4 mg groups were met with statistically significant percentage change from baseline in SALT score versus the placebo group. SHR0302 8mg and 4mg groups also met the secondary endpoint of absolute change in SALT score at week 24.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
张　虹 Helena ZHANG	甫康药业首席医学官 Chief Medical Officer, Convalife	PI3K β/δ 双重抑制剂 CVL237 在 B 细胞淋巴瘤患者的 1 期临床试验和布鲁顿酪氨酸激酶耐药的潜在治疗 First in Human Phase I Study of PI3K Dual β/δ Inhibitor CVL237 in Patients with B Cell Lymphoma and Potential Treatment for Bruton Tyrosine Kinase Resistance

项目简介

CVL237 是一个独特的和高度选择性的 PI3K β/δ 双重抑制剂。I 期临床在美国 MD 安德森癌症中心进行的开放标签、单臂研究，目的在于根据剂量限制毒性确定最大耐受剂量，并评估复发难治性 B 细胞淋巴瘤患者的抗肿瘤疗效。试验对 21 例患者进行了安全性评估，结果表明，其安全性和药物依从性均优于已批准的同类药物。其中 19 例患者在推荐临床 2 期剂量以上时 ORR 为 50%。 同时，双重选择性 PI3K−β/δ 抑制剂 CVL237 治疗显著降低了伊布替尼耐药 DLBCL 的活力，并阻断了 AKT/mTOR 轴的激活，这表明 PI3K−β 和 PI3K−δ 是伊布替尼耐药 DLBCL 中 AKT/mTOR 轴信号传导和细胞存活的关键节点。

Project Introduction

CVL237 is a unique and highly selective PI3K dual β/δ Inhibitor. The phase I, open-label, single arm study conducted at MD Anderson Cancer Center, determine the maximum tolerated dose based on dose limiting toxicity and assess preliminary anti-tumor activity in pts with R/R B-cell lymphoma. 21 pts were evaluated for safety assessment. The results show its safety and medication compliance are better than approved agents in this class. ORR is 50% in 19 patients starting at doses at or above RP2D, including 4 CR and 2 PR. Responses were observed across lymphoma subtypes including DLBCL, FL, CLL and MCL. Treatment with the selective dual PI3K-β/δ inhibitor CVL237 significantly reduced ibrutinib-resistant DLBCL viability and blocked the activation of the AKT/mTOR axis, suggesting that PI3K-β and PI3K-δ are the key nodes underlying AKT/mTOR axis signaling and cell survival in ibrutinib-resistant DLBCL. Also, ibrutinib-resistant cells do not lose their resistance to ibrutinib upon pretreatment with CVL237. The treatment with the selective PI3K-β/δ dual inhibitor CVL237 reduced both tumorigenic properties and survival-based PI3K/AKT/mTOR signaling of these ibrutinib-resistant cells.

贾正虎 JIA Zhenghu	贝罗尼集团副总裁 Vice President of Beroni Group Limited	晚期实体肿瘤新药 PENAO 的首个人体 I 期临床试验 The First-in-Human Phase I Clinical Trial of PENAO in Advanced Solid Tumors

项目简介

PENAO 是一种新型的、特有的、用于抗癌的首创化合物，可穿过血脑屏障发挥作用。PENAO 靶向 ANT 抑制线粒体能量产生，限制癌细胞增殖。我们在澳大利亚完成了 26 例晚期实体瘤患者的 PENAO 首个人体 I 期临床，以评估其安全性和毒性。持续静脉输注 PENAO 的耐受性良好，高达 9 mg/m^2/ 天，仅有 1 个剂量表现出剂量限制毒性。虽未观察到明确疗效，但一名间变性星形细胞瘤患者接受 6 mg/m^2/ 天治疗后病情稳定 7 个月（ 10 个剂量周期 ）。此外，PENAO 表现出的半衰期明显长于动物模型的预测，因此未来可考虑间断给药。我们计划在中国开展 PENAO 间歇给药的临床 I 期研究，目前正在向 NMPA 提交 IND 注册申请。

Project Introduction

PENAO is a novel, proprietary “First in-Class” anti-cancer and anti-mitochondrial compound that can cross the blood brain barrier, it contains an active arsenic molecule. PENAO targets the adenosine nucleotide translocase (ANT) to suppress mitochondrial energy production and thereby limit cancer cell proliferation. Under the Australian TGA, we have completed an Australian First in-Human phase I clinical trial of PENAO in 26 patients with advanced solid tumors to evaluate safety and toxicity of PENAO. PENAO by continuous intravenous infusion was well tolerated up to 9 mg/m2/day, with only 1 dose-limiting toxicity. Whilst, no objective responses (efficacy) were observed, we observed a patient with anaplastic astrocytoma treated at 6 mg/m2/day had stable disease for 7 months (10 dose cycles). Unfortunately, the half-life of PENAO was significantly longer than predicted by animal models and therefore supports intermittent administration in future studies. We are currently submitting an IND to the NMPA for a phase I study of intermittent administration of PENAO in China, which builds upon the phase I trial already completed in Australia.

路演项目介绍 »»»
Introduction of Roadshow Projects

云路演专场
Virtual Roadshow

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
Hugh Davis	CEO of Biosion	立足全球、面向全球：新一代抗体药物研发引领者 In Global and For Global: Pioneering Next Generation Biologics

项目简介

博奥信生物技术（南京）有限公司 (Biosion, Inc.) 是一家专注于创新抗体药物发现与临床开发的生物技术公司，凭借其专有 H^3 抗体技术平台 (High−Throughput High−Content High−Efficiency Antibody Technology Platform) 和协同抗体技术 (SynAb™ Antibody Technology Platform)。博奥信致力于深度开发性能卓越、差异性丰富、临床应用多样化的创新性抗体药物分子，聚焦肿瘤和自免领域未被满足的临床需求，目前已拥有十多个新型肿瘤免疫治疗抗体项目组成的丰富研发管线，其中已有多个项目进入临床开发阶段。

Project Introduction

Biosion is a global biotechnology company focusing on the discovery and clinical development of innovative biologicals for global unmet medical needs. Leveraging our proprietary H^3 (High-throughput, High-content, High-efficiency) antibody platform and SynAb™(Synergistic antibody) technology, Biosion is able to undertake a deep discovery of antibody drug candidates with superior properties, multiple differential choices, and diversified clinical applications. Based on its integrated antibody discovery engine and fueled by our corporate motto of "Innovation for Cures", Biosion is committed to bring next generation innovative drugs to patients around the world

Ricardo Garcia	CEO of Oncoheroes Biosciences Inc.	儿科肿瘤学的新疗法 New Therapies for Pediatric Oncology

项目简介

儿童癌症被认为是一种罕见的疾病，但全世界每年有 30 万新病例，9 万病儿因此死亡。尽管如此，只有 5 种癌症药物被专门设计和批准用于治疗儿童及青少年，而针对成人的则有 200 种之多。

Oncoheroes Biosciences 是一家总部设在波士顿的生物技术公司，百分百专注于开发治疗儿童和青少年癌症的新疗法。为了满足对专门的儿科肿瘤药物的高需求，Oncoheroes 正利用其在科学界的联系，建立一个多样化的儿童肿瘤候选药物组合，为患者和投资者创造价值。我们有 4 个开发中的药物资产，主要资产已准备好进入临床 Ib/II 期试验（预计 2026 年批准）。我们正在筹集 4000 万美元的 A 轮投资来推进这 4 项资产。

Oncoheroes 的优势之一在于创始人的专注，有两人是患癌病儿的父亲，团队其他成员有超过 20 年的药物开发经验。Oncoheroes 已经得到了历史悠久的癌症基金会和非营利组织的认可，这些组织在过去 40 年里支持儿童癌症研究的资金超过 3 亿美元。

Project Introduction

Childhood cancer is considered a rare disease that accounts for 300,000 new cancer cases and 90,000 will die every year worldwide. Despite, only 5 cancer drugs have been specifically designed and approved to treat children and adolescents versus more than 200 in adults.

Oncoheroes Biosciences is a Boston-based biotech 100% focused on discovering, developing and commercializing new therapies for children and adolescents with cancer. To fulfill the high demand for specifically designed oncology drugs for children, Oncoheroes is leveraging its established connections within the scientific community to build a diversified portfolio of pediatric oncology drug candidates and generate value for patients and investors. With 4 assets in the pipeline, our lead asset is ready to enter a Phase Ib/II clinical trial (expected approval 2026). We are currently raising a SERIES A of $40M to advance the 4 assets.

One of the Oncoheroes' strengths is the commitment of the founders, two of them fathers of children who suffered cancer, and the rest of the team with more than 20 years of experience in drug development. Oncoheroes has received endorsement from well-established cancer foundations and non-profit organizations that supported childhood cancer research with +$300M in the last 40 years.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
马克思·施耐德 Max Cynader	CEO of Primary Peptides	利用蛋白质调控领域的创新平台技术开发新的治疗多肽 Developing novel therapeutic peptides using innovative platform technologies in Protein Manipulation

项目简介

Primary Peptides 是一家来自加拿大的临床阶段的生物技术公司，是两个药物开发领域的先驱：1) 蛋白 – 蛋白相互作用干扰；2) 蛋白质靶向降解。

通过使用我们的平台技术，我们正在研究那些被认为是不可成药的药物靶点。我们已经与 3 家中国公司签订了区域性合作伙伴关系，分别是亚宝药业、先声药业和青岛普美圣。我们与亚宝药业合作的针对脑中风的化合物计划于 2021 年下半年在脑中风患者中开展临床 1b 期试验。

我们正在以下两个领域寻求合作：1) 我们在心血管、肿瘤和神经疾病领域现有的化合物；2) 利用我们的平台技术为合作伙伴开发新的多肽化合物。

Project Introduction

Primary Peptides is a clinical stage company from Canada and is a pioneer in two transformational areas of therapeutic development:

1) Protein-protein interaction blockade which prevents specific disease-causing proteins from interacting with each other

2) Protein degradation which harnesses the body's own natural processes to destroy disease causing proteins

Using our platforms, we are expanding the scope of new targets for drug development, by unlocking the untapped pool of targets that are considered undruggable.

We have signed regional partnerships with 3 Chinese companies, Yabao Pharmaceutical, Simcere Pharmaceutical and Qingdao Primedicine. Our most advanced asset in stroke, which is partnered with Yabao, is entering a Phase 1b in stroke patients in Q4 2021.

We are seeking partnerships and collaborations for:

1) Our targets in CVD (Stroke & Heart Attack), Oncology (Prostate & Liver Cancer) and Neurodegeneration (Parkinson's Disease).

2) Leveraging our platform to develop peptides for targets of interest by partners.

Christoph Ladel	CSO of Biobone BV	骨新生：专注于骨科疾病创新疗法 Biobone BV: Focus on providing innovative therapy in bone diseases

项目简介

BioBone 是一家致力于开发骨疾病创新疗法的生物技术公司，以帮助改善骨病患者的病情和生活质量，特别是骨性关节炎患者，与目前的缓解症状治疗不同，我们的目标是开发疾病修饰型骨关节炎药物 (DMOAD)。目前，公司的产品线包括 8 项创新资产，即 2 项临床阶段的 DMOAD(疾病修饰骨关节炎药物) 疗法、2 项临床阶段的骨生物材料品种和 4 项临床前资产。进展最快的化合物为 BBT01，可诱导软骨细胞增殖和增加细胞外基质 (ECM) 的产生，具有促进软骨生长和修复软骨的潜力。BBT01 首个适应症为膝关节骨关节炎，目前已完成 II 期临床，正准备启动 III 期。

Project Introduction

BioBone BV is a biotech company committed to developing innovative therapeutics to help improve the lives of patients with bone disorders, especially with osteoarthritis. Unlike current alleviate symptom treatments, we aim to development of Disease Modifying OsteoArthritis Drug (DMOAD). The company's pipeline consists of eight innovative assets: 2 clinical stage DMOAD (Disease-Modifying Osteoarthritis Drug) therapies, 2 clinical stage revolutionary bone biomaterial and 4 pre-clinical assets. Its' leading compound BBT01, thought to induce chondrocyte proliferation and increased extra-cellular matrix (ECM) production, with the potential of promoting cartilage growth and repair. BBT01 is in clinical phase III development to investigate its potential as a treatment for OA in the knee. Robust efficacy was demonstrated in the Phase ll study showing cartilage repair, generating large excitement in the OA expert community.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
Guy Yachin	Board Member of Stromatis Pharma	开发创新的癌症靶向免疫疗法 Developing Innovative Targeted Immunotherapies for Cancer

项目简介

Stromatis Pharma 由一批经验丰富的创业科学家及企业家创立，并得到了全球著名的肿瘤学家 Dan Von Hoff 博士的指导。Stromatis 已经为癌症免疫治疗的已验证靶点开发了数种创新型单克隆抗体（moabs）。重点产品为抗体药物偶联物（ADC）和嵌合抗原受体（CAR−T）：CART 细胞疗法解决了实体瘤中导致 T 细胞失活的问题，以提高疗效。109 moab 靶点为 CEACAM6，具有多种性质（肿瘤靶向性、检查点抑制和防止 T 细胞失活，这些均为肿瘤生存所必需的特性），并具有一种新型共刺激结构域 CD2，可增强 T 细胞持久性并防止 T 细胞衰竭。由于 CEACAM6 在 PaCa 肿瘤中过度表达，而这种表达与生存率低相关，因此创新型 CAR 设计极具价值，可以解决实体瘤 CAR−T 细胞方法中的障碍。

Stromatis 已与一家上市公司就 109CART 进行了一项关于预付款、里程碑和特许权使用费的 License 许可计划，内容包括使用 S38 有效载荷的三个 ADC，均针对热门癌症特异性靶点 CEACAM5、CEACAM6 和 Nectin−4。

Project Introduction

Stromatis Pharma was founded by an experienced group of entrepreneurial scientists and business members with the guidance of the world-renowned oncologist- Dr. Dan Von Hoff. Stromatis has developed several innovative monoclonal antibodies (moabs) to validated targets for immunotherapy of cancer. Lead product will be in Antibody Drug Conjugate (ADC) and Chimeric Antibody ReceptorT (CAR-T) format:

- CART cell therapy approach that increases the efficacy of CART therapy by overcoming the barriers in solid tumors that cause T cell inactivation. 109 moab targets CEACAM6, with multiple properties (tumor targeting, checkpoint inhibition, and prevention of T cell inactivation - all of which are obligatory for tumor survival) and a novel designed co-stimulatory domain, CD2, that enhances T cell persistence and prevents T cell exhaustion. As CEACAM6 is over-expressed in PaCa tumors and its expression correlated with poor survival, this novel design of the CAR has high potential to overcome obstacles/barriers encountered during previous CAR-T cell approaches in solid tumors.

Stromatis has executed a licensing plan with a public company for 109CART with upfront, milestones, and royalties payments.

- Three ADC using S38 payload to cancer-specific targets CEACAM5, CEACAM6 and Nectin-4 that are greatly sought after

Takashi Asahi	Corporate Director of CMIC	日本成立最早最大 CRO 公司分享肿瘤学解决方案的重要性 Sharing the importance of the Oncology Solutions by the First and Largest CRO in Japan

项目简介

CMIC 集团是日本成立最早，也是日本最大的 CRO 公司，我们开发了独特的“药物价值创造者”（PVC）商业模式，目前正在为制药公司、医疗器械制造公司、科研机构、生物企业提供全方位服务，包括药物研发和制造、临床试验运行、临床试验中心管理、销售和营销等业务。CMIC 集团已经为日本近 80% 的新药开发和备案提供了服务。CMIC 集团拥有独特的肿瘤学相关团队，协助战略发展规划，为希望发展肿瘤学领域的公司提供包括监管互动、临床研究实施及上市后推广的服务业务。特别在实体瘤和血液系统恶性肿瘤领域，我们拥有资深权威的关键医学专家 (KOL) 联络网，将使您的肿瘤项目在从开发到市场营销的整个流程中受益。我们的肿瘤学专家团队将根据日本特定及不断更新的法律法规和独特的地域环境，提供最佳研发解决方案，灵活地配合客户的市场进入战略。我们致力于在肿瘤学领域为客户提供克服监管障碍的解决方案，并加速临床试验进程。

Project Introduction

CMIC Group, the first and largest CRO in Japan, developed its unique “Pharmaceutical Value Creator” (PVC) business model and now offers full services, including drug development and manufacturing, clinical trial, clinical site management, sales, and marketing, to pharmaceutical companies, medical device manufacturers, academia, bio-ventures, etc. Today, CMIC Group is involved in close to 80% of new drug development and filing in Japan.CMIC Group’s specialized oncology staff assists with strategic development planning, including regulatory interaction, conducting clinical studies and post-marketing promotion for companies that wish to enter into the field of oncology. Our resources, with an established network of Key Opinion Leaders (KOLs) in solid tumors and hematologic malignancies, will benefit your oncology project from development to marketing. Our oncology experts will help you determine the best strategy in accordance with Japan-specific changing regulations and unique environment, working flexibly with your company’s plans for market entry. We will navigate the regulatory hurdles and accelerate your clinical trials by making the right connections in oncology field.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
杨敦杰 Jay Yang	Business Development Manager of Twist Bioscience	运用新型抗体文库开发针对几乎所有靶点的治疗药物 Developing Therapeutics Against Virtually Any Target with New Antibody Libraries

项目简介

单克隆抗体已成为癌症、感染性疾病、炎症和自身免疫性疾病以及其他疾病的首选治疗方法。

Twist Bioscience 旗下的 Twist Biopharma 积极支持并推进该项工作，开发了囊括多个针对诸多高价值靶点的预先构建且经过验证的「文库组合」，科学家们可以利用这些文库，构建一个全面而强大的抗体发现平台。

在此，我们为您介绍 1）Twist Biopharma 如何凭借 DNA 合成能力和领先的生物信息学专业知识，为先导抗体的鉴定和优化提供了独特的优势；2）Twist Biopharma 创新的「文库组合」是如何开辟新的序列空间，特别针对难度高的靶标进行治疗开发；3）「文库组合」的两个成员：超免疫文库和 VHH 文库。

Project Introduction

Monoclonal antibodies have become the preferred therapeutic modality for cancer, infectious diseases, inflammatory and autoimmune disorders, and other conditions.

Twist Biopharma, a vertical within Twist Bioscience, is on a mission to support this work, offering a Library of Libraries containing multiple pre-constructed and validated libraries against many high-value targets with which scientists can build a comprehensive and robust antibody discovery platform.

Here, please let us introduce 1) how Twist Biopharma leverages DNA synthesis capability and advanced bioinformatics expertise to provide unique advantages for lead antibody identification and optimization, 2) how Twist Biopharma's innovative "Library of Libraries" creates new sequence space for therapeutic development, specifically for hard-to-drug targets, 3) two members of the "Library of Libraries": Hyperimmune Library and VHH Library

国际云路演专场 -- 丹麦 »»»
Virtual International Roadshow--Denmark

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
Anne R. Scordt	CEO of PokeAcell	PokeAcell—针对实体瘤的新型多靶点 T 细胞疗法 PokeAcell- Breaking Solid Tumor Escape-with ImmPACT

项目简介

PokeAcell 开发了针对实体瘤的新型多靶点 T 细胞疗法，以共享、病毒和新抗原为目标。通过我们的 ImmPACT 平台，我们将血液中的多靶点 T 细胞扩展到异质性实体肿瘤，并将患者的覆盖范围扩大到 TIL 和普通 HLA TCR 之外。

PokeAcell 有三个正在开发的产品，第一个用于转移性黑色素瘤的产品正在招募临床 I 期。另外两个针对梅克尔细胞癌和高突变癌症（如肺癌和膀胱癌）的产品将于 2023 年提交 IND 和开始临床试验。

PokeAcell 由一个经验丰富的领导团队创立，并得到世界领先的顾问的支持。

Project Introduction

PokeAcell develops novel multi-targeted T cell therapies to solid tumors targeting shared, virus and neoantigens. With our ImmPACT platform, we expand multi-targeted T cells from blood to target heterogeneous solid tumors and expand the patient reach beyond that of TIL and common HLA TCRs. PokeAcell have three products in development with the first product for Metastatic Melanoma recruiting for phase I now. Two additional products for Merkel Cell Carcinoma and high mutational cancers like lung and bladder cancer aim for IND submission and clinical testing in 2023. PokeAcell is founded by an experienced leadership team and supported by world leading advisors.

Stig Lofborg	CEO of Meabco	Meabco—通过治疗—连接生命 Meabco- Access to Treatment- Access to Life

项目简介

Meabco 是一家丹麦拥有独特技术平台的专业化公司，通过基于专利保护的系列多酚（BP−Cx−1），成功开发出多款产品。目前主要专注于两大领域：肿瘤和癌症的辅助治疗。

Project Introduction

Meabco is a private Danish company with a unique technology platform based on a patented coplex of polyphenols (called BP-Cx-1) being the basis for multiple products. Currently with the focus on two potential target areas Medical Oncology and Supportive Care.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
Torsten M. Madsen	CEO of Hoba Therapeutics	治疗慢性疼痛和听力障碍的不同方法 A Different Approach to Treating Chronic Pain and Hearing Loss

项目简介

霍巴医疗公司的重心是研发用于治疗神经性疼痛和听力障碍的新型疗法。HB−086 和 HB−097 是治疗性蛋白质，也是最近发现的神经生长因子中唯一的成员。我们的研究表明，这些分子对感觉神经元及其周围的支持细胞具有独特的作用。

Project Introduction

Our focus at Hoba Therapeutics is the development of novel therapeutics for the treatment of neuropathic pain and hearing disorders. HB-086 and HB-097 are therapeutic proteins and the only members of a family of recently discovered neurotrophic factors. Our research indicates that these molecules have unique actions on sensory nerve cell and their surrounding support cells.

Claus Elsborg Olesen	CEO of Initiator Pharma	Initiator—治疗勃起功能障碍 (ED) 的全新治疗方案 Initiator- A Novel Treatment Paradigm for the Treatment of Erectile Dysfunction (ED)

项目简介

Initiator Pharma 是一家临床阶段的制药公司，致力于开发安全调节单胺类神经递质水平的药物，作为一系列医疗适应症的治疗手段。IPED2015 和 IP2018 的临床 II 期针对原发性和精神性勃起功能障碍（ED）的新疗法。Initiator Pharma 的 IPED2015 和 IP2018 新治疗方法旨在治疗一大批对现有治疗方法有抵抗力的勃起功能障碍患者。此外，Initiator Pharma 正在推进神经性疼痛项目计划，即针对三叉神经痛的 IPTN2021。

Project Introduction

Initiator Pharma is a Clinical stage pharmaceutical company focused on developing drugs that safely modulate the monoamine neurotransmitters levels as therapy for a range of medical indications. The IPED2015 and IP2018 Phase 2 programs constitute new treatments for erectile dysfunction (ED) of organic and psychogenic origin, respectively. Initiator Pharma's new treatment methods with IPED2015 and IP2018 is intended to treat a large group of patients suffering from erectile dysfunction who are resistant to current treatment methods. In addition, Initiator Pharma is advancing the Neuropathic pain program, IPTN2021 targeting Trigeminal Neuralgia.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
Alexander Hovard Sparre-Ulrich	CEO of Antag Therapeutics	Antag Therapeutics——一种治疗肥胖症的新方法 Antag Therapeutics- A Novel Treatment for Obesity

项目简介

肥胖是一种全球性的流行病，有超过 6.5 亿人被正式列为肥胖，19 亿人被认为超重。肥胖症会导致严重的并发症，如心血管疾病、中风、癌症、非酒精性脂肪肝（NAFLD）和 2 型糖尿病（T2D）。令人满意的减肥的安全和耐受性良好的药物疗法的市场机会是巨大的，预计到 2024 年全球肥胖症治疗市场将达到 156 亿美元。

Antag Therapeutics 是一家丹麦生物技术公司，正在开发一种协助肥胖患者减肥的新型疗法。该公司的技术基于哥本哈根大学霍尔斯特小组数十年来对增殖素生理学的研究，该中心是一个卓越的糖尿病研究中心，在建立两个新型药物类别，即二肽基肽酶 4（DPP−4）抑制剂和胰高血糖素样肽 −1（GLP−1）模拟物方面起到了关键作用。最近，他们的研究导致发现了一种新型的 GIP（一种参与人类能量平衡的激素）内源性拮抗剂，随后的人体研究已经证明了这种新型治疗策略的生物学证据。

Antag 公司目前的主要候选药物 AT673 和 AT706 已经过优化，可以实现每周一次的皮下注射，并在为期 6 周的非人类灵长类肥胖症研究中证明了诱导减肥的功效。基于这些发现，用 AT673/706 治疗肥胖患者有望诱导减肥，改善血糖控制，并降低血浆脂质。重要的是，这种治疗方法的目标产品特征与 GLP−1 激动剂高度兼容。

迄今为止，Antag 公司已经从 Novo Holdings、Broadview Ventures 和丹麦成长基金等经验丰富的投资者那里共筹集了 6500 万元人民币。该公司目前正在启动一期启用的毒理学研究，并正在组建 A 轮银团，预计在完成 Ib 临床期后退出。

Project Introduction

Obesity is a global epidemic with over 650 million people formally classified as obese, and 1.9 billion considered overweight. Obesity leads to significant co-morbidities with poor outcomes such as cardiovascular disease, stroke, cancer, nonalcoholic fatty liver disease (NAFLD) and Type 2 diabetes (T2D). The market opportunity for a safe and well-tolerated pharmaceutical therapy that induces satisfactory weight loss is significant, with the global market for obesity treatments projected to reach $15.6B by 2024.

Antag Therapeutics is a Danish biotech company developing a novel therapeutic to induce weight loss in obese patients. The company's technology is based upon decades of research into incretin physiology from the Holst Group at the University of Copenhagen, a center of excellence for diabetes research that played a pivotal role in the establishment of two novel drug classes, namely dipeptidyl peptidase 4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) mimetics. More recently, their research has led to the discovery of a novel endogenous antagonist of GIP (a hormone involved in human energy homeostasis), where subsequent human studies have demonstrated proof-of-biology for this novel treatment strategy.

Antag's current lead candidates, AT673 and AT706, have been optimized to enable once-weekly subcutaneous administration and have demonstrated efficacy in inducing weight loss in a 6-week non-human primate obesity study. Based on these findings, treatment of obese patients with AT673/706 is expected to induce weight loss, improve glycemic control, and decrease plasma lipids. Importantly, the target product profile for this therapeutic approach is highly compatible with GLP-1 agonists.

To date, Antag has raised a total of ¥65M RMB from experienced investors such as Novo Holdings, Broadview Ventures, and the Danish Growth Fund. The company is now initiating Phase-I-enabling toxicology studies and is assembling a Series A syndicate with the expectation to exit following the completion of Phase Ib.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
吴劲梓 WU Jinzi	歌礼制药有限公司创始人、 董事会主席兼首席执行官 Founder, Chairman and CEO of ASCLETIS PHARMA INC.	歌礼制药新药研发管线介绍与 肿瘤脂质代谢最新研发进展 update for the pipeline of Ascletis Pharma Inc. and the interoduction of Patients with Recurrent Glioblastoma

项目简介

歌礼是一家在香港证券交易所上市（1672.HK）的创新研发驱动型生物科技公司。致力于以下四大疾病领域创新的研发和商业化，满足国内外患者临床需求：1、非酒精性脂肪性肝炎：针对 FASN、THR-ß 及 FXR 的处于临床阶段的候选药物及三种联合用药疗法。2、肿瘤（脂质代谢与口服检查点抑制剂）：在肿瘤脂质代谢中起关键作用的脂肪酸合成酶口服抑制剂管线以及新一代检查点抑制剂－口服 PD-L1 小分子抑制剂管线。3、病毒性肝炎：(i) 乙肝：以皮下注射 PD-L1 抗体 ASC22 及派罗欣 ® 为基石药物的联合治疗方案。(ii) 丙肝：两个 1 类新药戈诺卫 ® 和新力莱 ® 组成全口服丙肝治疗方案。4、艾滋病：ASC22 是一种免疫疗法，用于艾滋病特异性免疫重建，最终实现艾滋病感染者的功能性治愈。

Project Introduction

Ascletis was established in 2013, and is listed on the Hong Kong Stock Exchange since 2018 (1672.HK) and committed to developing and commercializing innovative drugs in the areas as below to address unmet medical needs both in China and globally:1. NASH: three clinical stage drug candidates against three different targets – FASN, THR-beta and FXR, and three fixed-dose combinations. 2. Cancer lipid metabolism and oral checkpoint inhibitors: focus on a pipeline of oral inhibitors targeting FASN which plays a key role in cancer lipid metabolism and a pipeline of oral PD-L1 small molecule inhibitors as the next generation checkpoint inhibitors. 3. Viral hepatitis: (i) Hepatitis B: focus on breakthrough therapies for HBV clinical cure with subcutaneously injected PD-L1 antibody - ASC22 and Pegasys® as cornerstone drugs. (ii) Hepatitis C: successfully launched all oral regimen of ASCLEVIR® and GANOVO® combination (RDV/DNV regimen). 4. HIV/AIDS: ASC09F is a FDC treatment of HIV targeting protease.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
杨　亮 Allen YANG	绿叶制药投资者关系与公共关系副总裁 Vice President of Investor Relations and Public Relations of Luye Pharma	研发、合作多点突破， 创新产品线价值显现 Various Breakthroughs in R&D and Cooperation, Innovative Efforts Start to Generate Value

项目简介

绿叶制药是致力于创新药物的研发、生产和销售的国际化制药公司。绿叶制药在中国、美国和欧洲设有研发中心，拥有超过 30 个中国在研药物和 10 多个海外在研药物，在中枢神经和肿瘤领域已有多个创新制剂和创新药在全球开展注册及临床研究。绿叶制药在微球、脂质体、透皮释药等先进药物递送技术领域达到国际先进水平，并在生物抗体、细胞治疗、基因治疗等领域进行了积极布局和开发。绿叶制药深度布局全球供应链体系，已在全球建有 8 大生产基地，超过 30 条生产线，并建立了与国际接轨的 GMP 质量管理和控制体系。公司现有 30 余个上市产品，产品覆盖肿瘤、中枢神经、心血管、消化与代谢等治疗领域；业务遍及全球 80 多个国家和地区。

Project Introduction

Luye Pharma Group is an international pharmaceutical company dedicated to the R&D, manufacturing and sale of innovative medications. The company has established R&D centers in China, the U.S. and Europe, with a robust pipeline of over 30 drug candidates in China and more than 10 drug candidates in other international markets. Along with a number of new drugs and new formulations in the central nervous system and oncology therapeutic areas under study in the U.S. Europe and Japan, Luye Pharma has reached high-level international standards in novel drug delivery technologies including microspheres, liposomes, and transdermal drug delivery systems, as well as actively making strategic developments in the fields of biological antibodies, cell therapies and gene therapies, among others. Luye Pharma is developing a global supply chain of 8 manufacturing sites with over 30 production lines in total, establishing GMP quality management and international standard control systems. With more than 30 products covering the central nervous system, oncology, cardiovascular, metabolism and other therapeutic areas, business is conducted in over 80 countries and regions around the world.Luye Pharma is developing a global supply chain of 8 manufacturing sites with over 30 production lines in total, establishing GMP quality management and international standard control systems. With more than 30 products covering the central nervous system, oncology, cardiovascular, metabolism and other therapeutic areas, business is conducted in over 80 countries and regions around the world.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
陈　力 CHEN Li	华领医药董事长、首席执行官、 创始人、首席科学官 Executive Director, Chief Executive Officer, Founder and Chief Scientific Officer of Hua Medicine	华领医药未来研发管线展望 Introduction of future pipeline——Hua Medicine

项目简介

华领医药的全球首创糖尿病新药 Dorzagliatin 已完成两项三期临床研究，2021 年 4 月 23 日 NDA 申请已获国家药品监督管理局（NMPA）新药审评中心（CDE）受理，并有望在 2022 年获批上市。在积极推进联合用药相关试验的同时，华领也对未来的研发管线做了布局。凭借扎实的研发功底，华领有信心在首创新药领域为中国医药界再添新枝。

Project Introduction

Dorzagliatin, an investigational first-in-class dual acting glucokinase activator, completed two phase III clinical studies. The NDA application was accepted by Center for Drug Evaluation (CDE) of National Medical Products Administration (NMPA) on April 23, 2021, and is expected to be approved in 2022. While promoting the combination therapy with other drugs, Hua has also made new layout pipelines. With solid research and development background, Hua is confident to develop first-in-class drugs for Chinese medical industry.

郭晓宁 GUO Xiaoning	赛生药业控股有限公司副总裁， 研发负责人兼首席医学官 Vice President, Head of R&D and CMO of SciClone Pharmaceuticals (Holdings) Limited	新赛生，新动能 A New SciClone with New Momentum

项目简介

赛生药业控股有限公司（港交所上市公司，股份代号 6600）是一家拥有产品开发和商业化集成平台的生物制药公司，战略上专注于在中国规模较大、增长迅速且存在巨大未被满足医疗需求的治疗领域，包括肿瘤科及重症感染。凭借赛生药业的产品开发及商业化实力，公司在重点治疗领域开发优质的上市产品及具有较佳潜力的在研产品并对其进行商业化。公司已建立起了均衡的、国际品质的产品组合，包括多款 First-in-class 与 Best-in-class 产品。自有产品日达仙为中国首个品牌胸腺法新药物。代表性在研产品主要包括小分子肿瘤免疫药物 CD-47/SIRPα 拮抗剂 RRx-001 和小分子偶联药物 PEN-866。

Project Introduction

SciClone Pharmaceuticals is a biopharmaceutical company with an integrated platform for product development and commercialization. SciClone Pharmaceuticals strategically focuses on some of the largest and fast-growing therapeutic areas with unmet medical needs in China, primarily including oncology and severe infection. With its product development and commercialization strength, SciClone Pharmaceuticals has established a good track record in terms of balanced and high-quality products on the market in key therapeutic areas and in developing and commercializing portfolios of pipeline products with better potential. SciClone has several First-in-class and Best-in-class products. Our self-developed product Zadaxin is the first branded thymalfasin drug. Our in-licensed products consist of Angiomax, Zometa and a number of pipeline products. Key products under development include RRx-001 and PEN-866. RRx-001 is a small molecule immunotherapeutic that targets the CD47-SIRPα axis. PEN-866 is a small molecule drug conjugates product.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
吴灵犀 WU Lingxi	贝达药业股份有限公司 董事长助理兼董事会秘书 Chairman Assistant & Board Secretary of Betta Pharmaceuticals Co., Ltd.	贝达的创新与发展 From One to Unlimited: Betta's Innovation and Development

项目简介

贝达是一家专注于创新药开发、生产及商业化的生物制药公司。我们专注于肺癌治疗的创新药物发现、研发及商业化，也将管线产品扩展至其他恶性肿瘤治疗领域。我们的埃克替尼是中国首款自主研发的小分子靶向抗癌药，是目前中国肺癌治疗领域的畅销创新药品牌，在临床中广泛应用于携带 EGFR 突变的局部晚期或转移 NSCLC 一线、二线治疗以及术后辅助治疗。我们的第二款靶向药物恩沙替尼于去年 11 月获得国家药监局批准上市，是中国第一款自主研发的用于治疗携带 ALK 突变的晚期 NSCLC 创新药。我们的管线产品旨在解决关键治疗靶点，采用有效机制治疗多种适应症，不仅具有单药治疗的潜力，更有希望通过联合用药策略产生突破性疗效。

Project Introduction

Betta is a biopharmaceutical company focused on the development, manufacture and commercialization of innovative therapies for lung cancer, as we have strategically expanded our pipeline to now cover a variety of other malignant cancers. Icotinib, our first marketed drug, is China's first domestically-developed innovative small molecule targeted anti-cancer drug and currently one of the best-selling innovative drug brands. It has already been widely used in the clinic as a first- and later-line treatment for locally advanced or metastatic NSCLC with EGFR mutation, as well as a postoperative adjuvant treatment of early-stage NSCLC patients. Ensartinib is our second marketed drug which approved by the NMPA in November 2020. It's the first Category 1 new drug to be independently developed by a Chinese company for the treatment of advanced NSCLC with ALK mutation. Our pipeline products are designed to address critical therapeutic targets and employ diverse validated mechanisms for the treatment of a broad spectrum of cancer indications, and can be utilized both as potent monotherapies and in combination with other therapies that together may unleash potentially breakthrough efficacy.

杨大俊 YANG Dajun	中国药促会药物研发专业委员会主任委员、 亚盛医药董事长兼 CEO Chairman of PhIRDA Drug R&D Specialty Committee、Chairman of the Board & CEO of Ascentage Pharma	亚盛医药 专注细胞凋亡研发创新药物 Ascentage Pharma Group-Advancing Therapies That Restore Apoptosis

项目简介

亚盛医药是一家立足中国、面向全球的处于临床开发阶段的原创新药研发企业，致力于在肿瘤、乙肝及与衰老相关的疾病等治疗领域开发创新药物。亚盛医药拥有自主构建的蛋白－蛋白相互作用靶向药物设计平台，处于细胞凋亡通路新药研发的全球最前沿。公司已建立拥有 8 个已进入临床开发阶段的 1 类小分子新药产品管线，包括抑制 Bcl-2、IAP 或 MDM2-p53 等细胞凋亡路径关键蛋白的抑制剂；新一代针对癌症治疗中出现的激酶突变体的抑制剂等，为全球唯一在细胞凋亡路径关键蛋白领域均有临床开发品种的创新公司。目前公司正在中国、美国、澳大利亚及欧洲开展 40 多项 I/II 期临床试验。

Project Introduction

Ascentage Pharma (6855.HK) is a globally focused biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B, and age-related diseases. Ascentage Pharma focuses on developing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. The company has built a pipeline of eight clinical drug candidates, including novel, highly potent Bcl-2, and dual Bcl-2/Bcl-xL inhibitors, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors (TKIs). Ascentage Pharma is also the only company in the world with active clinical programs targeting all three known classes of key apoptosis regulators. The company is conducting more than 40 Phase I/II clinical trials in the US, Australia, Europe, and China.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
周　超 Frank ZHOU	远大医药健康控股有限公司行政总裁 Chief Executive Officer of China Grand Pharmaceutical and Healthcare Holdings Limited	远大医药 – 打造国际一流的肿瘤核素诊疗创新平台 GP(HK) builds up a world-leading innovation platform for oncology diagnosis and treatment

项目简介

远大医药（HK.00512）是一家科技创新型国际化医药企业，以患者未被满足的需求为核心，深度布局肿瘤、心脑血管及重症领域全球首创诊疗产品及器械。肿瘤板块在精准介入内放射治疗、放射性核素偶联药物（RDC）赛道进行差异化布局，着力打造创新核药科技龙头。钇 [90Y] 树脂微球作为唯一一款 FDA 批准的针对肝脏恶性肿瘤的内放射核素微球产品，获得 NCCN、ESMO、NICE 等权威指南推荐，中国 NDA 申请已获受理，上市在即。 RDC 药物整合精准靶向和强力杀伤两种治疗需求，产品管线丰富，覆盖多个癌种，将为肿瘤患者带来差异化诊疗手段。同时积极布局经营资质、核素原料，全球销售渠道和开发渠道，建立全产业链布局。

Project Introduction

China Grand Pharmaceutical and Healthcare Holdings Limited (HK.00512) is an international innovative pharmaceutical enterprise, focusing on the unmet needs of patients, with a deep layout of the first-in-class diagnostic and treatment products and instruments in the fields of oncology, cardiovascular and cerebrovascular diseases and critical diseases. The oncology segment has differentiated layout in the precision interventional radiotherapy and Radionuclide Drugs Conjugates (RDC), and strives to become the innovative nuclear medicine technology leader. SIR-Spheres® Y-90 resin microspheres, as the only FDA approved endoradionuclide microspheres for liver malignant tumors, have been recommended by NCCN, ESMO, NICE and other authoritative guidelines. The NDA application in China has been accepted and it will be commercialized soon. RDC drugs combine the needs of both precise targeting and powerful killing. Our rich product pipeline covers multiple cancer types, and brings differentiated treatments to cancer patients. The company actively layout business qualifications, nuclide raw materials, global sales channels and development channels, to establish a whole industrial chain layout.

任德林 Derek REN	维亚生物执行董事兼总裁 Executive Director and President of Viva Biotech (Shanghai) Co., Ltd	维亚生物 全球创新药研发及生产一站式平台 Viva Biotech, One-stop Platform for Global Innovative Drug R&D and Production

项目简介

凭借在基于结构的药物发现（SBDD）领域的技术优势，维亚生物（01873.HK）向全球生物医药创新者提供领先的 CRO 药物发现服务，及贯穿药品全生产流程的 CMC/CDMO 服务。同时，我们专注于发现、投资高潜力生物医药初创公司，以 EFS（服务换股权）的形式解决未满足的临床医学需求，持续构建生物医药创新的开放式合作平台和共赢生态圈。我们始终秉持“成为全球创新型生物科技公司的摇篮”的使命，通过赋能全球生物医药初创公司及中大型药企，希冀早日惠及更多患者。

Project Introduction

Leveraging the technical advantages in the field of Structure-based Drug Discovery (SBDD), Viva Biotech (01873. HK) provides world-leading CRO drug discovery services and CMC / CDMO services throughout the entire drug production process to global biopharmaceutical innovators. At the same time, we focus on digging up and investing in high potential biotech start-ups, so as to solve the unmet clinical medical demands though EFS (service for equity), and continue to build an open cooperation platform and win-win ecosystem.We always adhere to the mission of "Becoming the cradle of innovative biotechnology companies from around the world", and hope to benefit more patients as soon as possible by empowering global biotech start-ups, as well as large and medium-sized pharmaceutical enterprises.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
李鑫磊 Gino LI	上海复宏汉霖生物技术股份有限公司 首席财务官兼副总裁 Chief Financial Officer and Vice President of Shanghai Henlius Biotech,Inc.	可负担的创新 值得信赖的品质 Reliable Quality, Affordable Innovation

项目简介

复宏汉霖致力于为全球患者提供可负担的高品质生物药，产品覆盖肿瘤、自身免疫疾病、眼科疾病等领域，高质量的产品管线，涵盖 20 多种创新单克隆抗体，并全面推进基于自有抗 PD-1 单抗斯鲁利单抗的肿瘤免疫联合疗法。继国内首个生物类似药汉利康 ®（利妥昔单抗）、中国首个自主研发的中欧双批单抗药物汉曲优 ®（曲妥珠单抗，欧盟商品名：Zercepac®）、公司首个自身免疫疾病治疗产品汉达远 ®（阿达木单抗）相继获批上市，创新产品斯鲁利单抗 MSI-H 实体瘤的上市注册申请已纳入优先审评审批程序，HLX04 贝伐珠单抗及 HLX01 利妥昔单抗类风湿关节炎新适应症的上市注册申请也正在审评中。公司已建立完善高效的全球研发中心，位于上海徐汇的生产基地已获得中国和欧盟 GMP 认证。

Project Introduction

Henlius has pro-actively built a diversified and high-quality product pipeline covering over 20 innovative monoclonal antibodies (mAbs) and has continued to explore immuno-oncology combination therapies with proprietary serplulimab (anti-PD-1 mAb) as backbone. Apart from the launched products 汉利康 ® (rituximab), the first China-developed biosimilar, 汉曲优 ® (trastuzumab, Zercepac® in the EU), the first China-developed mAb biosimilar approved both in China and in the EU and 汉达远 ® (adalimumab), the Company's first product indicated for autoimmune diseases, the NDA of innovative product serplulimab indicated for MSI-H solid tumors has been granted priority review, and the NDAs of HLX04 (bevacizumab) and HLX01 (rituximab) for the treatment of rheumatoid arthritis are also under review. It has established global R&D centres and a Shanghai-based manufacturing facility certificated by China and the EU Good Manufacturing Practice (GMP).

Henlius has pro-actively built a diversified and high-quality product pipeline covering over 20 innovative monoclonal antibodies (mAbs) and has continued to explore immuno-oncology combination therapies with proprietary serplulimab (anti-PD-1 mAb) as backbone. Apart from the launched products 汉利康 ® (rituximab), the first China-developed biosimilar, 汉曲优 ® (trastuzumab, Zercepac® in the EU), the first China-de

陈　洪 CHEN Hong	成都苑东生物制药股份有限公司 研发中心总经理 President of R & D Center of Chengdu Easton Biopharmaceuticals Co., Ltd	苑东生物创新和国际化之路 Easton Biopharma Pursuing Innovation and internationalization

项目简介

成都苑东生物制药股份有限公司成立于 2009 年，是一家集化药、生物药研发、生产、销售于一体的高新技术企业，有 1000 余人（研发人员约 30%），2020 年 9 月在上海证券交易所科创板挂牌上市。具有一支强大和国际视野的研发团队：聚焦肿瘤麻醉镇痛领域并兼顾心血管、糖尿病和儿童用药领域大品种；集中布局小分子、大分子创新药、改良型新药平台；国际化新药布局：现有 1 个制剂和 1 个原料的国际化制造工厂。已实现 26 个化学药制剂和 17 个化学原料药产品的产业化。现有 50 多个化学创新药、高端仿制药及原料药研发项目，其中 10 多个自主研发 1 类新药将先后进入临床前，IND，I， II，III 期临床，5 个高端制剂将申报美国 FDA。

Project Introduction

Chengdu Easton Biopharmaceutical Co., Ltd. is established in 2009,a high-tech enterprise integrating chemical and biological drug research and development, production and sales. It has more than 1,000 employees .It was listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange in September 2020.It has a strong R&D team with international perspective: mainly focusing in the field of cancer, anesthesia and analgesia, and take into account the large varieties of cardiovascular, diabetes and pediatric drugs.It has main focus on the development of small and large molecules, innovative drugs, improved new drug platforms and international new drug layout.There is an internationally approved manufacturing plant for manufacturing of raw materials (API's).There are totally 26 pharmaceutical dosage forms and 17 API's have been manufactured and commercialized.Currently there are more than 50 chemical innovative drugs, high-end generic drugs and API R&D projects are being developed, which more than 10 independently developed NDA will successively enter in pre-clinical, Phase I, II, III clinical studies, and 5 high-end formulations will be submitted to the FDA.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
奚 浩 Ronnie Ede	信达生物制药集团执行董事兼首席财务官 Executive Director and Chief Financial Officer of Innovent Biologics	信达：打造全球化的创新生物制药企业 Innovent: the strategy of global Innovation and globalistaion

项目简介

信达生物成立于 2011 年，致力于开发、生产和销售用于治疗肿瘤、自身免疫、代谢疾病等重大疾病的创新药物。2018 年 10 月 31 日，信达生物制药在香港联合交易所有限公司主板上市，股票代码：01801。信达生物坚持全球创新与全球化的发展战略，力争成为国际一流的生物制药公司。

Project Introduction

Inspired by the spirit of "Start with Integrity, Succeed through Action," Innovent's mission is to develop, manufacture and commercialize high-quality biopharmaceutical products that are affordable to ordinary people. Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines for the treatment of cancer, autoimmune, metabolic and other major diseases. On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801. HK, with market cap over HKD100bn as of today.

邵 奇 SHAO Qi	前沿生物药业（南京）股份有限公司 高级副总经理、首席财务官 SVP and CFO of Frontier Biotechnologies Inc.	前沿生物 – 抗病毒新药的自主创新与国际化 Frontier-Independent innovation and internationalization of new antiviral drugs

项目简介

前沿生物是一家覆盖研发、生产和销售全产业链的创新型生物医药公司，是一家在抗 HIV 创新药领域具有国际竞争力的本土企业。公司自主研发的国家 1 类新药艾可宁，全球首个长效 HIV 融合抑制剂，为初始治疗失败的 HIV 感染者，提供高效低毒的两药组合，已在中国及其他发展中国家实现商业化。抗 HIV 在研产品 FB1002，为长效、注射、双靶点融合抑制剂，拟每 2 周 −4 周给药一次。中、美双报在研项目。 抗新冠病毒在研产品 FB2001，小分子新药，蛋白酶抑制剂，是基于冠状病毒主蛋白酶三维结构设计合成的拟肽类化合物，目前在美国开展一期临床试验。

Project Introduction

Frontier Bio is an innovative biopharmaceutical company covering the entire industry chain of R&D, production and sales. It is a local company with international competitiveness in the field of innovative anti-HIV drugs. The company's self-developed national class 1 new drug - Aikening, the world's first long-acting HIV fusion inhibitor, provides high-efficiency and low-toxicity two-drug combinations for HIV-infected patients who have failed initial treatment. It has been commercialized in China and other developing countries. The anti-HIV product - FB1002, is a long-acting, injectable, dual-target fusion inhibitor. It is planned to be administered once every 2 to 4 weeks, the China-USA Double News Research Project. The anti-new coronavirus product - FB2001, a new small molecule drug, and a protease inhibitor, is a peptide compound. It is being done phase I clinical trial in the United States Currently.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
申华琼 Joan SHEN	天境生物科技（上海）有限公司首席执行官 CEO of I-Mab Biopharma.Co.Ltd	根植免疫，创新超越 Immunology and Innovation for Transformational Medicines

项目简介

天境生物是一家处于临床阶段的创新生物药公司。公司聚焦肿瘤免疫和自身免疫疾病领域创新生物药的早期发现，药物开发和商业化，以填补尚未满足的重大医疗需求。公司的使命愿景是“持续开发创新生物药，真正改变患者生活”。为抓住机遇，履行使命，天境生物在“快速产品上市”和“快速概念验证”的双轮策略驱动下，通过自主研发和全球合作等多元化模式，聚焦于开发肿瘤免疫和自身免疫性疾病两大治疗领域临床前和临床阶段的创新生物药。通过自主研发，全球项目引进，迅速建立起拥有十多个具有全球竞争力的创新药管线，其中三个自主研发项目已在美国及中国进入临床一期试验，四个项目在中国分别处于临床二期和三期试验。

Project Introduction

We are a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. Our mission is to bring transformational medicines to patients through innovation.To achieve our mission and capitalize on these commercial opportunities, we have developed a business model built on two pillars. The first is a fast-to-market China approach, and the second a fast-to-PoC (proof of concept) global approach. Reflecting these two approaches, we have established a China Portfolio and a Global Portfolio of novel or highly differentiated clinical and preclinical assets in the most exciting therapeutic areas of immuno-oncology and immuno-inflammation. Through our internal research and development efforts, and in-licensing arrangements with global pharmaceutical and biotech companies, we have built an innovative pipeline of more than ten assets in clinical and preclinical stages of development. We are currently running three Phase 1 clinical trials in the US and China, and a further four trials, mostly Ph2 or 3 in China.

苏慰国 SU Weiguo	和黄医药（中国）有限公司 执行董事、首席科学官 Executive Director & Chief Scientific Officer of HUTCHMED (China) Limited	和黄医药：以临床需求为导向的新药研发策略 HUTCHMED : R&D strategy focused on clinical needs

项目简介

和黄医药（纳斯达克 / 伦敦证交所：HCM；香港交易所：13）是一家处于商业化阶段的创新型生物医药公司，致力于发现、全球开发和商业化治疗癌症和免疫性疾病的靶向药物和免疫疗法。超过 1,400 人的专业团队已将自主发现的 11 个候选癌症药物推进到在全球开展临床研究，其中首三个创新肿瘤药物现已获批上市。

Project Introduction

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. A dedicated organization of over 1,400 personnel has advanced eleven cancer drug candidates from in-house discovery into clinical studies around the world, with its first three oncology drugs now approved and marketed.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
陈颖颖 CHEN Yingying	和铂医药控股有限公司 CFO CFO of Harbour BioMed	创新技术平台引领差异化优势产品线 Highly Innovative Technology Platform Drives Differentiated Product Portfolio

项目简介

和铂医药专注于肿瘤及免疫领域创新药开发，致力于开发全球首创及同类最优的产品，依托强大的核心技术平台，已打造了兼具高度创新和差异化的产品管线。公司拥有高效创新技术平台，Harbour Mice® 平台能够产生拥有两条重链和两条轻链的全人源抗体（H2L2）以及全人源重链抗体（HCAb）。基于 HCAb 开发了免疫细胞衔接器平台（HBICE®）来开发新一代双特异性抗体，以实现传统的药物联合疗法无法达到的抗肿瘤疗效。公司基于技术平台开发多个 first-in-class, best-in-class 的单抗及双抗产品，目前已有十多个产品在临床开发或即将进入临床开发。

Project Introduction

Harbour BioMed is a global clinical-stage biopharmaceutical company committed to discovering and developing first-in-class and best-in-class antibody therapeutics in oncology and immunological disease areas. We have built a robust portfolio and differentiated pipeline by leveraging on our unique and highly effective technology platforms. Harbour Mice, our proprietary antibody technology platforms, generate fully human monoclonal antibodies in the classical two heavy and two light chain (H2L2) format, as well as heavy chain only (HCAb) format. Building upon our HCAb antibodies, the HACb-based immune cell engagers (HBICE) are capable of delivering tumor killing effects unachievable by combination therapies. Our antibody discovery engine is highly productive and efficient to drive innovation and sustainable growth of the company.

大数据 + 智慧医疗专场 »»»
WIT-MED + Big Data Roadshow

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
邹瑞阳 ZOU Ruiyang	觅瑞私人有限公司首席技术官、联合创始人 & 中国区总裁 CTO, Co-Founder & President of China of MIRXES PTE LTD	miRNA 技术平台以及机器学习算法在癌症早筛领域的应用 Combing miRNA Detection Platform and Machine-learning Methods for Cancer Early Detection

项目简介

MIRXES(觅瑞)，一家专注于 miRNA 领域的创新型生物科技公司，是全球领先的微小核酸（miRNA）检测技术的领导者和开拓者，在新加坡、中国、日本、美国都设有办公室。依托于高效血液 miRNA 检测平台技术，重点布局在癌症、心脑血管疾病等领域的临床级诊断应用，已完成过数万例各类疾病人群的血液 miRNA 图谱分析。核心产品 GastroClear 血液 miRNA 胃癌早筛产品，已经经过前瞻性多中心临床，在新加坡以及欧盟获批。其他核心管线包括肺癌、乳腺癌、结直肠癌、肝癌等高发癌症以及心脏病检测的产品。致力利用过机器学习算法，通过 miRNA 健康监测，完成疾病全生命周期管理。

Project Introduction

MIRXES, an innovative biotechnology company focusing on miRNA, is the global leader and pioneer in miRNA detection technology. MiRXES has offices in Singapore, China, U.S., and Japan. Relying on high-efficiency blood miRNA detection platform, we focus on diagnostic applications in cancer and cardiovascular diseases and completed the miRNA blood profiling for more than 20000 subjects. Our core product GastroClear – the world's first blood miRNA kit for gastric cancer early detection, was approved in Singapore and Europe. Other pipelines include lung cancer, breast cancer, CRC, liver cancer and heart failure detection kit. Company aims to develop miRNA health monitoring tools with machine learning methods for life cycle disease management.

陈　航 Michael CHEN	北京星亢原生物科技有限公司联合创始人 &CEO Cofounder & CEO of neoX Biotech	基于人工智能与生物物理的大分子和多特异性分子药物理性设计与开发 Macromolecule and Multispecific Molecules' Rational Design by AI and Biophysics

项目简介

星亢原将人工智能（AI）和生物物理以及高通量实验有机结合，进行生物大分子和多特异性分子药物研发。星亢原已经打造了“AI+ 生物物理 + 高通量实验”三位一体的新药研发平台，通过研究蛋白质与蛋白质之间相互作用，从多维度探寻药物研发的底层逻辑，实现创新药物的理性设计和开发。

Project Introduction

By integrating artificial intelligence (AI), biophysics with high-throughput experiments, neoX focuses on the research and development of macromolecular drugs and multi-specific drugs. Through an in-depth characterization of protein-protein interaction (PPI), neoX has developed a highly transferable and sophisticated platform for early drug discovery.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
刘立宇 LIU Liyu	生命奇点（北京）科技有限公司 CEO CEO of Gennlife (Beijing) Technology Co., Ltd.	数据智能赋能医疗健康创新 Healthcare Innovation Driven by Data Intelligence

项目简介

生命奇点自 2015 年创立以来，一直致力于医疗数据智能技术的研发和创新。公司研发了行业领先的中文医学自然语言处理引擎，积累了超过 1 亿人千亿级数据项的处理经验。 目前公司的合作网络覆盖了数百家医疗机构、医保机构、公共卫生疾控机构。在 2020 年支持武汉市医保局在国家医保局技术专家组对 30 个 DRG 试点城市测评中获得第一名。2020 年中标国内第一个省级的智慧化多点触发预警平台。

Project Introduction

Since its establishment in 2015, Gennlife is continually focused on healthcare innovation driven by data intellligence. It developed the industry-leading NLP of medical science in Chinese and accumulated processing experiences for more than 100 million person as well as more than 100 billion data. By now, Gennlife has served for several hundred of medical institutions, medicare administrations and pubulic disease control and prevention centers. In 2020, Wuhan Healthcare Security Administration, with the assistance of Gennlife, was rewarded No.1 award in the test of 30 cities by technical experts from National Healthcare Security Administration. In the same year, Gennlife also won the bid of a provincial Intelligent multi-point trigger early warning platform which is the 1st one in China.

夏　平 XIA Ping	翼帆数字科技（苏州）有限公司 董事长兼首席科学家 Chairman & CSO, Clippers DigiTech, Co., Ltd.	隐私计算赋能智慧医疗，推动医药数据生态建设 Privacy Computing Enable Smart Medicine, Promote Eco-System of Digital Medicine

项目简介

隐私已经成为大数据和人工智能在医疗领域中应用的最大障碍。从价值挖掘角度，大量的临床数据被锁定在一个个数据孤岛中，而无论药企还是 AI 公司，均饱受数据缺乏之苦；横亘在这之间的，是日趋严格的隐私保护。从提供服务角度，云架构已经成为数字服务商的首选，而当数据明文输入，隐私与安全成为云计算的最大隐患。翼帆翼必达 ® 系列产品融合了差分隐私、同态加密和多方安全计算等多种技术，从模型训练、模型推断、到模型保护，提供“雾到云”的一体化解决方案。使用翼必达 ® 平台，数字化医疗产品如 AI 辅助诊断、临床实验智能化、药物重定位策略等，可以替代单独平台建设或采购安装的传统模式，而通过更高效、订阅服务的方式实现。

Project Introduction

Privacy has become the biggest obstacle for the advancement of Big Data and AI in the field of medicine. In view of data mining, a big chunk of clinical data is locked down in various silos. On the other hand, the pharmaceuticals and AI firms are in dire need of first-hand data. In between lies the privacy which is growing rigorous ever. In view of service offering, Cloud Computing has become a major force. Nevertheless, data security & privacy is a major concern. We, at the Clippers DigiTech, have developed a pipeline of products, in the form of Fog and Cloud computing architecture, that integrate technology such as differential privacy, homomorphic encryption, and secure multiparty computing, apply from model training, model inference to model protection. With our product, digital medicine offerings such as AI assisted diagnosis, clinic trial efficiency, drug repositioning, etc., can substitute the traditional paradigm of individually built system with more efficient, cloud-based subscription service.

非上市公司专场 »»»
Non-Listed Company Roadshow

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
齐念民 QI Nianmin	上海泉生生物科技有限公司董事长 Chairman, Asia Stem Cell Regenerative Pharmaceutical Co., Ltd.	亚洲干细胞 TM 干细胞药物研发、注册申报及转化应用 Stem Cell Drug Research, Development, Registration, Application and Transformation Application

项目简介

上海泉生生物科技有限公司是一家专业从事干细胞制剂研发、新药注册申报及产业化的生物医药研发企业。公司在上海建立了符合国家 ISO9001 和 GMP 标准的临床级细胞制剂制备车间，具备完善的制备过程质量控制体系，实现产品可追溯、工程参数实时监控。公司主要产品是人脐带间充质干细胞，该产品已通过中检院和武汉伽创双重检测，结果显示其符合国家相关质量标准和要求。除 hUC-MSCs 外，公司在研产品有人脂肪间充质干细胞、iNK-Car、hES-OPC、hiPS-NPC 等产品。与国内多家临床机构合作的 4 个干细胞临床研究项目通过国家卫健委 / 中央军委后勤保障部卫生局备案。2021 年 9 月将向 CDE 提交 3 项新药 PreIND 申请，未来 10 个月我公司预计约有 10 项新药临床试验 I 期阶段。另外，公司计划于 2022 年赴港交所上市。

Project Introduction

Asia Stem Cell Regenerative Pharmaceutical Co., Ltd. , specilizing in research and development of stem cell preparations, new drug registration and industrialization, is a high and new enterprise founded in 2016. Based in Shanghai, the company has established a clinical-grade cell preparation platform in Shanghai which conforms to the national ISO9001 and GMP standards. Moreover, it has a complete quality control system for the preparation process to achieve product traceability and real-time monitoring of engineering parameters. As a main product, hUC-MSCs has passed the duplex tests of the China National Inspection Institute and Wuhan Jiachuang. And the results show that it meets the relevant national quality standards and requirements. In addition to hUC-MSCs, other products including hADMSCs, iNK-CAR, hES-OPC, and hiPS-NPC, etc, are under research and development. Four stem cell clinical research projects in cooperation with a number of domestic clinical institutions have been filed by the National Health Commission/Central Military Commission Logistics Support Department Health Bureau. 3 new drug PreIND applications will be submitted to the CDE in September, 2021. And in next 10 months, 10 new drugs are expected to be in Phase I clinical trials. Furthermore, the company plans to list on the Hong Kong Stock Exchange in 2022.

程云锋 Jerry CHENG	杭州维坦医药科技有限公司 创始人 & 首席执行官 Founder & CEO, Hangzhou Westan PharmTech Co., Ltd.	针对呼吸系统及相关疾病的 FIC 小分子原创新药研发 R&D of FIC Small Molecue Drugs for Respiratory System and Related Disease

项目简介

杭州维坦医药成立于 2019 年，是一家以临床需求为导向、聚焦呼吸系统及相关疾病诊疗创新的研发驱动型初创企业，2020 年中国创新创业大赛浙江省和全国生物医药行业第一名（初创组）获得者。核心成员包括浙大、斯坦福等高校教授学者，全球前 10 药企研发高管、知名 CRO 公司技术骨干等。公司基于 AI+ 创新药特色研发技术和合理药物设计平台，聚焦国际前沿新靶点，针对临床迫切需求的适应症开发 FIC 小分子原创新药。现有研发管线包括针对难治愈型慢性咳嗽、哮喘等适应症的十余个原创新药项目，代表性产品相较国际竞争对手具有全新化合物母核结构、全新作用机制、更好体内外活性及安全性等一系列优势，预计 2022 年陆续取得临床许可。

Project Introduction

Hangzhou Westan PharmTech, a clinical demand-oriented R&D-driven start-up company focusing on the innovation of diagnosis and treatment of respiratory system and related diseases, was established in 2019. It is the first prize winner of 2020 China Innovation & Entrepreneurship Competition (BioMed Startup Group). The core members include professors and scholars from Zhejiang University and Stanford, R&D executives of the world's top 10 pharmaceutical companies, and core technical members of well-known CRO companies. Based on AI+ innovative drug characteristic research and development technology and a rational drug design platform, the company focuses on international cutting-edge new targets and develops FIC small molecule drugs for indications that are urgently needed in clinical practice. The existing R&D pipeline includes ten projects for refractory chronic cough, asthma, and other indications. Compared with international competitors, the representative products have a series of advantages, including new core structures, new mechanism of action, better in vivo and in vitro activity and safety. These products are expected to advance to IND and clinical trial in 2022.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
李铭曦 LI Mingxi	上海湃隆生物科技有限公司总裁 President, GT Apeiron Therapeutics	下一代 CDK 抑制剂： 高选择性 CDK7 抑制剂的研发 Next Generation CDK Inhibitors: Development of A Highly Selective CDK7 Inhibitor

项目简介

湃隆生物总部位于上海，正开发一系列下一代细胞周期蛋白依赖性激酶（CDK）抑制剂。GTAEXS617 是一种高效、高选择性、可口服的小分子 CDK7 抑制剂。CDK 家族其中一员的 CDK7，是一种转录激酶，在癌细胞生存增殖的两个过程中起着核心作用：促癌基因表达增加和细胞周期进展失控。CDK7 活性与一系列实体瘤相关。利用我们的战略合作伙伴 Exscientia 的人工智能药物发现平台，我们发现了多个高效、高选择性的小分子 CDK7 抑制剂。其中，GTAEXS617 在低纳摩尔药物浓度的三阴性乳腺癌（TNBC）和卵巢癌细胞系中诱导强烈的肿瘤生长抑制效应和细胞周期阻滞，并在 CDX 模型中，单药观察到肿瘤完全消退。

Project Introduction

GT Apeiron Therapeutics, a biotech located in Shanghai, is building a portfolio of next generation cyclin-dependent kinase, or CDK, inhibitors. GTAEXS617 is a highly potent and selective small molecule CDK7 inhibitor that can be administered orally. CDK7, a member of the CDK family, is a transcriptional kinase that plays a central role in the two processes that cancer cells use to survive and thrive: increased expression of cancer-promoting genes, and uncontrolled cell cycle progression. CDK7 activity has been implicated in a range of solid tumors. Leveraging our strategic partner Exscientia's AI drug discovery platform, we have generated several potent and selective small molecule CDK7 inhibitors. GTAEXS617 induced robust tumor growth inhibition effects and cell cycle arrest in triple-negative breast cancer (TNBC), and ovarian cancer cell lines at low nanomolar drug concentrations, with apoptosis, or cell death, demonstrated in cancer cells but not in non-cancerous cells. GTAEXS617 significantly impacted tumor growth in vivo, with complete regressions observed with GTAEXS617 as a single agent in multiple TNBC and ovarian CDX models at doses way below the maximum-tolerated dose.

马伟伟 MA Weiwei	北京卓凯生物技术有限公司总经理 General Manager, Beijing Joekai Biotechnology Co., Ltd.	治疗阿尔兹海默症的新概念、新机制、新结构的小分子化合物 50561 A Novel First in Concept Small Molecular 50561 for Treatment of Alzheimer's Disease

项目简介

开发阿尔兹海默症的有效药物具有巨大的市场价值和社会效应，而最新的研究认为突触可塑性和突触退行是疾病修饰的重要靶点，多种突触相关的小分子处于各期临床试验钟，但尚未有直接针对认知障碍的突触靶点在研。卓凯着眼于多种病因导致认知障碍的汇集点，开发全球首个通过抑制遗忘，完全挽救多模型认知缺陷，又具有疾病修饰能力的 1.1 类小分子新药 50561，预期能改善多种因素导致的痴呆症状。50561 已于 2021 年获得中国临床批件，目前已经在宣武医院开展 I 期临床研究。公司的愿景是成为涵盖研发和临床的生物技术公司，致力于研发神经系统新药。

Project Introduction

The development of effective drugs for Alzheimer's disease has great market value and social effects. The latest studies suggest that synaptic plasticity and synaptic degeneration are important targets for disease modification. A variety of synaptic related small molecules are in various clinical trials, but there are no synaptic targets for cognitive impairment. Zhuoke focuses on the convergence point of cognitive impairment caused by various causes, and develops the world's first class 1.1 small molecule drug 50561, which can completely save multi model cognitive impairment by inhibiting forgetting and has the ability of disease modification. It is expected to improve the symptoms of dementia caused by various factors. 50561 has obtained Chinese clinical approval in 2021, and has carried out phase I clinical research in Xuanwu Hospital. The company's vision is to become a biotech company covering R & D and clinical research, dedicated to the development of new nervous system drugs.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
陆满晴 John LUK	艾贝乐医药科技有限公司首席执行官 CEO, Arbele Limited	用于治疗消化道癌的 CDH17/CD3 双特异性抗体新药和 mRNA 非病毒 CDH17 CAR-NK/T 治疗方法的研发和产业化（商业化） Development and Industrialization (Commercialization) of New CDH17/CD3 Bispecific Antibody (BsAb) Drug and mRNA non-viral CDH17 CAR-NK/T Therapy for the Gastrointestinal Cancer

项目简介

本团队在早期研究中发现，CDH17 分子在消化系统癌中的表达水平极高。基于此，本项目创新性在于将 CDH17 作为靶点，开发具有自主知识产权的人源化 CDH17/CD3 双特异性抗体药物和 mRNA 非病毒 CDH17 CAR-NK/T 细胞治疗方法。本项目具有“原始创新”的特质，故 CDH17-CD3 双特异性抗体新药和 mRNA 非病毒 CDH17 CAR-NK/T 治疗方法均有成长为“同类首创”新药的潜力。

Project Introduction

In our earlier studies, we found that the expression level of CDH17 molecules in gastrointestinal cancer is extremely high. Based on this, this project innovatively uses CDH17 as the target to develop humanized CDH17/CD3 bispecific antibody drugs and mRNA non-viral CDH17 CAR-NK/T cell therapy with independent intellectual property rights. The characteristic of this project is "Original Innovation", so the new CDH17-CD3 bispecific antibody drug and mRNA non-viral CDH17 CAR-NK/T treatment have the potential to grow into "first-in-class" drugs.

杜小波 DU Xiaobo	重庆勉弈生物技术有限公司联合创始人 Cofounder, Chongqing mianyi Biotechnology Co., Ltd.	一种可协同调动 NK、DC、T 细胞的全新的肿瘤免疫疗法 A New Immunotherapy Which Can Harness NK, DC and T Cells Synergistically

项目简介

CTF025 采用了全新的机制设计，将几种免疫分子融合在一起，利用它们作用于免疫细胞时的协同作用，合理地调动 NK、DC、T 细胞等多种免疫细胞。进而完成肿瘤细胞杀伤，肿瘤抗原释放，抗原递呈细胞捕获并递呈肿瘤抗原，肿瘤特异性 T 细胞活化，肿瘤特异性 T 细胞杀死肿瘤这一完整的抗肿瘤免疫应答流程，并且能够形成长期的免疫记忆。CTF025 主要组分为人内源蛋白，大幅降低耐药性问题。理论上，这个它能够广谱的应用于各种肿瘤，小鼠模型和宠物临床试验结果和理论推测一致。上述试验中，疗效显著优于 PD1/PDL1 抑制剂在同种模型或宠物临床上的疗效。同时，它显示出了很高的安全性。这是一个在疗效和安全性上都有革命性突破的产品。

Project Introduction

CTF025 is a fusion protein composed of several cytokines. Its mechanism is different from other existing antitumor drugs. Depending on the synergistic action of these immune molecules on immune cells, it can harness NK, DC and T cells. These cells perform the complete anti-tumor immune response process of tumor cell killing, tumor antigen releasing, antigen presenting, specific T cell activation. And can establish long-term immune memory. The main component of the drug is human endogenous protein, which greatly reduces the risk of drug resistance. In theory, the indication may be the vast majority of solid tumors. The results of mouse model and pet clinical trials are consistent with the theoretical speculation. In the above trials, the efficacy was significantly better than that of PD1 / PDL1 inhibitor in the same animal model or pet clinic. At the same time, the drug showed a very reliable safety. Compared with the existing drugs, this is a breakthrough product in terms of efficacy and safety.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
周　意 ZHOU Yi	苏州澳宗生物科技有限公司 总经理 / 首席执行官 General Manager/CEO, Suzhou Auzone Biological Technology Co., Ltd.	澳宗生物：CNS 药物研发拓荒者 Auzone: Pioneer of Central Nervous System (CNS) Drugs

项目简介

AAV-p75ECD-FC 是“First-in-Class”1 类创新生物药，拟用于治疗 AD。项目由南澳大学周新富教授团队和第三军医大学王延江教授团队联合攻关，发表论文 40 多篇，研究成果达到国际领先水平。已完成初步的药学和药理学研究，正在准备一项评价其治疗 AD 的安全性和有效性的研究者发起的临床（IIT），预计 2 年内进入临床研究。 依达拉奉口服制剂是应用特有的专利技术开发的 2.2+2.4 类改良型新药，与注射剂比较，具有更好的顺应性和便利性，拟用于治疗 AIS、ALS、AD 和 NASH 等。澳大利亚 I 期临床研究已完成，国内 I 期临床试验申请已于 2021 年 3 月获得 CDE 默示许可，预计 2022 年底提交 NDA。

Project Introduction

AAV-p75ECD-FC, a first-in-class biological product, was developed for Alzheimer’s disease(AD) with new mechanisms of action. This project was jointly researched by Professor Xin-Fu Zhou from University of South Australia and Professor Yan-Jiang Wang from The Third Military Medical University, with more than 40 papers published in world-famous journals. The primary CMC and pharmacology studies have been completed, an investigator-initiated trial (IIT) is being designed to evaluate the safety and efficacy of AAV-p75ECD-Fc in the treatment of AD. It is expected to enter the clinical stage within 2 years. Edaravone injection is approved for treatment of acute ischemic stroke (AIS) or amyotrophic lateral sclerosis(ALS). We have made a breakthrough to develop the only oral edaravone in the world which dramatically improved the bioavailability with better compliance and convenience. A Phase 1 clinical trial has completed in Australia in 2020 and an IND has granted an implied licence from CDE in March 2021. It is expected to submit NDA application in 2022. In conclusion, the two drug candidates mentioned above are both innovative with obvious clinical advantages.

王正旺 David WANG	北京海洁海斯健康科技有限公司总经理 G.M, BEIJING H&H	新型干眼症药物 New Drug for Dry Eye Disease

项目简介

在此之前，所有的干眼症治疗方案都需要同时结合多种治疗手段，没有一个单一的治疗方案可以解决这种不适；在此之前，所有的干眼症治疗方案 都伴随 明显的副作用，包括烧灼感、刺痛等 。我们尝试提供一种新型的、更早期的、针对 NO-MGD 干眼症的干预和治疗方法，我们的目标是兼顾药效同时成为干眼症领域副作用最少的单品。 干眼症是一种普遍的、慢性的、渐进性的疾病。未来市场巨大。我们认为：MGD 是直接或间接导致大多数干眼症的最主要原因，同时对 NO-MGD 有独特理解和认知。 传统干眼症治疗出现很多问题，甚至无效 HYPER052 提供一种新型的、更早期的、针对 NO-MGD 干眼症的干预和治疗方法，我们的目标是兼顾药效同时成干眼症领域副作用最少的单品。

Project Introduction

Before that, all treatments for dry eye need to combine multiple treatments at the same time, and no single treatment can solve the discomfort. Before that, all the treatments for dry eye had obvious side effects, including burning sensation and tingling. We try to provide a new and earlier intervention and treatment method for NO-MGD dry eye disease, our goal is to give consideration to both efficacy and become the single product with the least side effects in the field of dry eye disease. Dry eye is a common, chronic and progressive disease. The future market is huge. We believe that MGD is the most important cause of most dry eyes directly or indirectly based on unique understanding and cognition of NO-MGD. Traditional treatment of dry eye has many problems, even ineffective. Hyper052 provides a new, more early intervention and treatment method for NO-MGD dry eye. Our goal is to give consideration to the efficacy and become the single product with the least side effects in the field of dry eye! At present, Restasis and Xiida are the two most important dry eye drugs in the world, with annual sales of more than US $1 billion. The patient costs about $5000 a year.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
李季男 LI Jinan	深圳瑞健同壹生物技术有限公司首席科学家 CSO, Shenzhen Ruijian Tongyi biotech company Co., Ltd.	一种治疗脊髓性肌萎缩症（SMA）的创新药物候选物 An Innovative Drug Candidate for the Treatment of Spinal Muscular Atrophy (SMA)

项目简介

肌萎缩侧索硬化症（ALS）与脊髓性肌萎缩症 (SMA) 同属运动神经元障碍病（MND)。SMA 是由于运动神经元存活基因的缺失或突变引起运动神经元死亡、肌肉萎缩，甚至死亡。 我们以 SMA 和 ALS 转基因模型小鼠为研究对象，研发出全球领先的治疗 SMA 的创新药。 结果显示，候选药物能够有效延长 SMA 小鼠生存时间和改善运动能力，减少神经细胞死亡，促进神经损伤和肌肉萎缩的修复，改善肺部损伤。此外，研究者发起的 20 余位 I 型和 II 型 SMA 的临床志愿者参加的临床研究结果显示候选药物高度安全，可以迅速改善患者的运动和呼吸功能等，并延长生存期。 目前药物的全球专利已经申报 / 获批，中试工艺开发已经完成，正在申报临床试验。

Project Introduction

Amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA) are both motor neuron disorders (MND). SMA leads to motor neuron death, muscle atrophy, and even death, due to the deletion or mutation of the motor neuron survival (SMN) gene. We have used SMA and ALS transgenic mouse models to develop a novel drug candidate for the treatment of SMA. Current results show that the drug candidate effectively prolongs the survival time and improves the motor ability of SMA mice, reduces neuron death, promotes the repair of nerve damage and muscle atrophy, and improves lung impairment. In addition, after ethical committee approval, the results from an Investigator Initialed Trial involving more than 20 clinical volunteers with type I and type II SMA showed that the drug candidate is highly safe and can rapidly improve patients' motor and respiratory functions, and prolong the survival. Global patent applications for the drug has been filed/approved, the large-scale manufacturing process have been developed and currently IND is being applied.

丁　强 DING Qiang	上海璃道医药科技有限公司副总经理（生物药理总监） Vice-general manager (Director of Biological Pharmacology), Shanghai Leado Pharmatech Co., Ltd.	靶向离子通道治疗纤维肌痛的无成瘾性创新药物研发 The Development of Non-Addictive Drug for the Treatment of FibromyAlgia by Targeting Ion Channels

项目简介

纤维肌痛以全身广泛性疼痛和躯体不适为主要特征，常伴有睡眠障碍、晨僵和抑郁、焦虑，全球患病率 2%-3%，临床上存在巨大的未满足需求。LDS 是我们自主研发的 1 类小分子化药，通过靶向离子通道 TRPA1 通道用于肌纤维痛的治疗。TRPA1 是确定的镇痛新靶点，可克服阿片类药物的滥用倾向，且无非甾体抗炎药的安全限制。LDS 镇痛药效强，在多种动物模型中镇痛活性均优于临床一线用药；同时具有口服给药方便、制剂工艺稳定、药代性质优秀、毒副作用可控等优势。目前 LDS 的临床申报已完获得 CDE 受理，预计 8 月底前获得临床默示许可。LDS 有望开发成为 First in class 的纤维肌痛治疗药物，具有极高的临床价值和商业价值。

Project Introduction

Fibromyalgia is characterized by generalized pain and physical discomfort throughout the body, and often accompanied by sleep disorders, morning stiffness, depression and anxiety. The global prevalence rate is between 2% and 3% with huge unmet clinical needs. LDS, a class 1 small molecule drugs, was developed by Leado completely targeted ion channel TRPA1 for the treatment of fibromyalgia.TRPA1 is an identified new analgesic target, which can overcome the tendency of opioid abuse and does not have the safety limitation of NSAIDs. LDS has a strong analgesic effect, which is superior to that of first-line clinical drugs in various animal models. At the same time, it has the advantages of convenient oral administration, stable preparation technology, excellent pharmacokinetic properties and controllable toxic and side effects. At present, the clinical application has been accepted by CDE, expecting the approval of clinical study by the end of August.LDS has the potential to be developed as the First-in-class drug for the treatment of fibromyalgia, which will have high clinical and commercial value.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
丁　栋 DING Dong	江苏领航生物科技有限公司药理总监 Director of Pharmacology Department, Jiangsu Linghang Bio-technology Co., Ltd.	改良型制剂 LH1037 的项目介绍 Introduction of the optimized formulation LH1037

项目简介

江苏领航生物科技有限公司是一家以临床需求为导向，聚焦肿瘤领域中美双报新药研发的公司，主要专注于创新改良型制剂，提高药物溶解性和稳定性，打造以特色平台技术为核心的高端制剂产业。领航生物进展最快 LH1037 是 SBECD 包合的白消安注射液项目已经申请 IND 并获得美国 FDA 的人体临床豁免，后续将尽快启动 NDA 相关工作，拟 2022 年按照 505(b)(2) 途径提交新药上市申请（NDA），争取成为江苏省首个美国 505(b)(2) 的注射液。SBECD 包合的白消安可最大程度地提高给药安全性，同时改善活性药物成分（API）的溶解度和稳定性，并且不再需要使用 N，N 二甲基乙酰胺（DMA）作为助溶剂，值得一提的是，用于 SBECD 助溶延长了白消安的使用时间，简化其临床使用及输液管理，极大提高用药顺应性。SBECD 作为注射液辅料已经在 FDA 申请多个药物，像注射用伏立康唑、胺碘酮等，在多个药物的使用足以说明 SBECD 在注射制剂的安全性和相容性

Project Introduction

Jiangsu Linghang Biotechnology Co., Ltd. is a company that is clinically demand-oriented and focuses on the research and development of oncology new drugs that will be declared in both China and US. The company mainly focuses on the innovation of optimized formulations, improving the solubility and stability of drugs, and establishing a high-end formulation industry with proprietary technology platform. The fastest progressing project LH1037 is SBECD-included Busulfan injection, which has been applied for IND and obtained the human clinical exemption by FDA. We are planning to submit the new drug application (NDA) according to the 505(b)(2) route in 2022, expecting to be the first 505(b)(2) Injection approved by FDA in Jiangsu Province. The safety of Busulfan can be maximized by included by SBECD, meanwhile the solubility and stability of the active pharmaceutical ingredient (API) will be improved, and the N, N dimethyl acetamide (DMA) will no longer be necessary as the cosolvent. It is worth mentioning that the use of SBECD-aided dissolution prolongs the effective time of Busulfan, which can simplify the clinical use and infusion management, and also greatly improves the medication compliance. Multiple drugs with SBECD as an injection excipient has been approved by FDA, such as injection voriconazole, amiodarone, etc. These cases fully prove the safety and compatibility of SBECD in injection formulation.

顾祥巨 Justin GU	来凯医药首席科学官 Chief Scientific Officer, Laekna Therapeutics	来凯医药——专注于肿瘤与肝病领域的突破性新药研发 Laekna Therapeutics—— Focus on Developing New Ground-Breaking Innovative Therapies to Treat Cancer and Iiver Diseases

项目简介

作为活跃于中国“张江药谷”和美国新泽西的一家医药新锐公司，来凯医药专注于肿瘤与肝病领域的突破性新药研发，目前已经完成三轮融资。来凯获得诺华授予的 4 项一类候选新药的全球独家研发、生产、市场和销售权利，其中两款抗肿瘤候选新药的临床试验已经处于包括中国在内的全球临床 II 期阶段。公司还开展了另外四项 I 期临床，覆盖乳腺癌、卵巢癌、前列腺癌等多个癌种领域。

其中 LAE002（afuresertib），属于新一代小分子泛 AKT 激酶强效抑制剂，预期将于 2022 年获得临床试验终点。在研新药 LAE001 是全球首个 CYP17A1 和 CYP11B2 双靶点抑制剂，属于新一代雄激素合成抑制剂。来凯医药将在会上汇报两个新药在卵巢癌和前列腺癌等领域的最新研究结果。

Project Introduction

Laekna Therapeutics is an innovative biotech company focused on developing breakthrough new drug and innovative therapies to treat cancer and liver diseases. In addition to China R&D facility in China’s “Zhangjiang Pharma Valley” , Laekna also operates in New Jersey, USA. To date, Laekna has completed three rounds of financing from the world renowned investors.

Laekna has obtained the exclusive global rights of four new drug candidates from Novartis, of which two are anti-tumor drug candidates and have already advanced to global phase II clinical trials, including in China. Laekna also conducted another four phase I clinical trials to study the new treatments for breast cancer, ovarian cancer and prostate cancer.

Among the above 4 candidates, LAE002 (afuresertib) is an oral, small molecule pan-AKT kinase inhibitor. Laekna is conducting a phase 2 registration MRCT trial in China and the US, and expect to have the readout for the primary endpoints in 2022. LAE001 is the first and the only CYP17A1/CYP11B2 dual inhibitor in the global development. Laekna will present the results from clinical studies on the treatment of ovarian cancer and prostate cancer at the meeting.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
徐英霖 Mark XU	徐诺药业（南京）有限公司 董事长兼首席执行官 Chairman & CEO, Xynomic Pharmaceuticals (Nanjing) Co., Ltd.	徐诺药业——专注于开发抗肿瘤靶向创新药 Xynomic Pharmaceuticals——Developing Innovative Targeted Anti-Tumor Therapeutics

项目简介

徐诺药业专注于同类最优肿瘤治疗方法，在全球授权引进、开发和商业销售抗肿瘤新药。领导团队由行业资深人士管理，世界一流的科学 / 医学顾问提供支持。与包括 Pharmacyclics / AbbVie，Boehringer Ingelheim 和 Janssen 等知名跨国药企合作。 徐诺药业目前的产品管线主要包括三款候选药物，艾贝司它、 XP−105 和 XP−102。公司拥有这些药物的全球独家开发、生产和商业化权益。其领先的候选药物艾贝司他正在进行治疗肾细胞癌（与培唑帕尼联用）全球关键 3 期临床试验和单药治疗非霍奇金淋巴瘤的中国关键 2 期临床试验。另外艾贝司他已获得 2 项美国 FDA 快速通道。

Project Introduction

Xynomic Pharmaceuticals is a clinical stage best-in-class oncology therapeutics biopharmaceutical company. Xynomic Pharma focus on in-licensing, developing and commercializing oncology drug candidates in China, US, and rest of the world. Partnerships with MNCs including Pharmacyclics/AbbVie, Boehringer Ingelheim and Janssen. Its current pipeline mainly consists of 3 drug candidates; Xynomic owns global exclusive development, manufacturing and commercialization rights to each of these. Its lead drug candidate abexinostat is in global potentially pivotal clinical trials against renal cell carcinoma (in combination with pazopanib) and non-Hodgkin's lymphoma (as a single agent). Abexinostat has granted 2 Fast-Track designations from FDA. Xynomic's XP-105 (BI 860585) is a Phase 2 ready, ATP-competitive mTORC1/2 inhibitor against solid tumors. Xynomic's XP-102 (BI 882370) is a Phase 1 ready pan-RAF inhibitor.

李永国 LI Yongguo	广州嘉越医药有限公司董事长、首席科学官 Chairman & Chief Scientific Officer (CSO), Guang Zhou JOYO Pharma Co., Ltd.	嘉越医药——创新实现临床价值 JOYO Pharma——Create Unmet Needs Through Innovation

项目简介

嘉越医药致力于创新药研发，聚焦临床转化医学，不断创新实现临床价值和社会价值。 现有研发管线共有 8 个创新药项目，全部为新化学实体（NCE）的创新药，正在进行的临床研究包括 4 个 II 期，3 个 I 期，和 1 个 IND 申报，1 个临床前研发。公司已完成三轮融资，总融资额 5 亿元 人民币。有一支 70 人的年富力强的研发团队。

临床 II 期包括：

1、抗肿瘤项目，PI3K/mTOR 双靶点抑制剂，first-in-class, 正在进行 2 个 II 期临床试验；

2、降血脂项目，小分子 PCSK9 抑制剂，first-in-class, 正在进行 II 期临床试验；

3、耐药肺结核项目，接近完成 II 期临床。

Project Introduction

JOYO Pharma make our endeavors on the innovative drug, and focus on the translational medicine and clinical development. Currently, in total 8 programs in the pipeline, including ongoing clinical such as 4 phase II, 3 phase I, 1 in IND filing, and 1 in preclinical development. All of them are the New Chemical Entities (NCE) with the potential first-in-class, first-in-disease and/or best-in-class. JOYO Pharma got the 80 million USD investment.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
胡海迪 Eddy WU	极目峰睿（上海）生物科技有限公司创始人、首席执行官及董事 Founder, CEO & Board Director, Arctic Vision (Shanghai) Biotechnology Co., Ltd.	眼科创新药企的“双引擎”战略定位思考 "Dual-Engine" Strategic Positioning of Innovative Ophthalmic Company

项目简介

极目生物是一家总部位于中国、专注于眼科创新疗法的生物技术公司，拥有覆盖从早期发现阶段到商业化阶段的一系列突破性眼科治疗技术产品组合。公司的愿景是，通过在中国、亚洲乃至全球提供创新疗法，解决眼科疾病领域未满足的临床需求，惠及广大眼科患者群体。极目生物在顶级生命科学投资方的支持下创立，并由一支拥有丰富的全球眼科产品研发和商业化经验的行业精英团队管理。

Project Introduction

Arctic Vision is a China-based ophthalmic biotech focusing on breakthrough therapies, with a leading portfolio covering from pre-clinical stage to commercial stage products. Our vision is to provide innovative therapies in China, Asia and globally to address unmet clinical needs and benefit ophthalmic patients at large. Arctic Vision is supported by top-tier life sciences investors and led by an elite team of ophthalmic industry veterans with substantial regional and global experiences in R&D and commercialization of ophthalmic products.

姜　华 Sammy JIANG	山东博安生物技术股份有限公司首席执行官 CEO, Shandong Boan Biotechnology Co., Ltd.	博安生物——全球化生物药创新企业 Boan Biotech——Global Innovative Biopharmaceutical Company

项目简介

山东博安生物技术股份有限公司（博安生物）是绿叶制药集团的控股子公司，于 2013 年成立，专业从事治疗用抗体的开发和生产，拥有全整合型产业链布局。公司依托自建的全人抗体转基因小鼠及噬菌体展示技术平台、双特异 T-cell Engager 技术平台、抗体药物偶联（ADC）技术平台三大技术平台，专注于肿瘤科、自身免疫疾病、疼痛和内分泌疾病等领域。目前，博安生物已构建了 10 多个拥有国际知识产权保护的创新抗体以及 8 个生物类似药的产品组合。此外，公司亦围绕前沿技术积极布局，储备有新一代通用型及可调控 CAR-T 产品的在研项目。除了在中国烟台和南京，博安生物在美国还设有研发基地，驱动全球业务发展。

Project Introduction

Established in 2013 as a holding subsidiary of Luye Pharma Group, Shandong Boan Biotechnology Co., Ltd. (Boan Biotech) is a fully integrated biopharmaceutical company. It specializes in therapeutic antibody development and manufacture with a focus on oncology, immunology, pain, and endocrine diseases. Boan Biotech's antibody discovery work is based on three technology platforms: Human Antibody Transgenic Mouse and Phage Display Technology, Bispecific T-cell Engager Technology, and ADC Technology. Through leveraging its efficient and innovative capabilities, the company has developed more than 10 innovative antibody product candidates with international intellectual property protection, and 8 biosimilar products. In addition, the company is investing in further cutting-edge technologies. Its CAR-T products focus on late-stage solid tumors and will be manufactured by a non-lentiviral platform. The company continues to develop cutting-edge technologies including novel off-the-shelf CAR-T and regulatable CAR-T, meaning safer and more affordable treatments for patients. Outside of China, Boan Biotech also pursues biopharmaceutical development in the US and European markets.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
王　鹏 WANG Peng	南京宁丹新药技术有限公司首席执行官 CEO, Neurondawn Pharmaceutical Co., Ltd.	宁丹新药——中枢神经领域 创新药研发引领者 Neurondawn Pharmaceutical——Leading CNS Drug Discovery and Development

项目简介

南京宁丹新药技术有限公司于 2020 年注册成立，专注于脑卒中等神经系统疾病领域的新药自主研发和产业化，已吸引专业投资机构及知名药企的投资。公司创始团队具有深厚的神经系统新药研发积淀，曾成功开发上市 1 个 1 类新药，并有新药国际开发经验。宁丹研发管线有 8 个创新药项目，其中 2 个进行临床试验阶段，包括阿尔茨海默病治疗药物 Y-1 和脑卒中治疗药物 Y-2，同时卒中及卒中后抑郁治疗药物 Y-3、脑小血管病药物 Y-5、用于脑卒中后的修复的 Y-6 等将陆续递交 IND 申请。

Project Introduction

Neurondawn Pharmaceutical was founded in Nanjing, China in 2020, focusing on the independent development and industrialization of new drugs in the field of stroke and other neurological diseases, and has attracted investment from professional investment institutions and well-known pharmaceutical companies. The company's founding team has deep experience in neurological drug research and development, having successfully developed and marketed one new class 1 drug, and has experience in international drug development. Neurondawn has 8 innovative drug projects in its R&D pipeline, 2 of which are in clinical trials, including Y-1 for Alzheimer's disease and Y-2 for stroke, while Y-3 for stroke and post-stroke depression, Y-5 for cerebral small vessel disease, and Y-6 for post-stroke repair will be submitted for IND application one after another.

李　染 Emma LI	亿一生物制药（北京）有限公司高级财务总监 Senior Finance Director, Evive Biotech (Beijing) Co., Ltd.	亿一生物的国际化创新之旅 Evive's Global Journey

项目简介

亿一生物是一家专注研发革命性创新疗法，布局全球、服务国际的生物制药公司，通过专有的技术平台推动开发针对肿瘤、炎症和代谢疾病的一系列创新候选药物。公司成立于 2004 年，员工遍及美国、新加坡和中国。作为首个开辟国际化直通专线的创新生物制药企业，亿一生物拥有一支全球视野、洞察全球市场监管标准的顶尖团队，采用全面的方法进行药物开发，将卓越的研究和商业化能力与世界一流的全球监管专业知识相结合。通过与行业、医生和监管机构的合作，亿一生物致力于打通革命性创新疗法国际市场，持续为未满足的患者需求创造可能，为全世界的患者和他们的家庭带来真正和持久的改变。

了解亿一生物更多信息，请访问 www.evivebiotech.com

Project Introduction

Evive Biotech is a global biologics company devoted to developing a portfolio of novel biological therapies for patients worldwide. We leverage our proprietary technology platforms to advance a series of innovative drug candidates for oncology, inflammatory and metabolic diseases. Founded in 2004, we currently have operations in the US, Singapore, and China. As the first biopharmaceutical company to build a platform bringing innovative therapies from China to the world, Evive adopts a holistic approach to drug development, combining exceptional research and commercialization capabilities with our world-class in-house regulatory expertise and extensive international management experience. Through partnerships with industry, physicians, and regulatory authorities, we strive to bring revolutionary remedies to the global market quickly and efficiently to address unmet medical needs, making a real and lasting difference to patients and their families worldwide.

To learn more about Evive Biotech, visit www.evivebiotech.com.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
陈永奇 CHEN Yongqi	深圳瑞思普利生物制药有限公司董事长 Chairman, Shenzhen Resproly Bio-Pharmacy Co., Ltd.	吸入制剂技术在呼吸系统给药领域的研究和产业化 Research and Industrialization of Inhalation Preparation Technology in the Field of Respiratory Drug Delivery

项目简介

据不完全统计，国内大约有将近五千万哮喘病患者、一亿的慢性病患者，对疾病的认知不足，用药率低。目前，我国吸入制剂长期被国际巨头垄断，吸入制剂国产化是市场发展的必然。瑞思普利是国内外极少数掌握干粉吸入给药系统平台技术的高科技公司，公司的发展是站在 Vectrua 肩上，实现多个重磅吸入产品的国内首次仿制成功，接着我们将勇于创新，成为中国乃至全球吸入制剂领域的领导企业。

Project Introduction

According to incomplete statistics, there are about 50 million asthma patients and 100 million chronic disease patients in China, with insufficient awareness of the disease and low drug use rate. At present, inhalation preparations in China have been monopolized by international giants for a long time, and the localization of inhalation preparations is the inevitable development of the market. Responly Inc. is one of the few domestic and high-tech companies that master the technology of dry powder inhalation drug delivery system platform. The development of Responly Inc. is on the shoulder of Vectrua. We are determined to achieve the first domestic imitation of multiple blockbuster inhalation products.We will be able to innovate and become a leading enterprise in the field of inhalation preparations in China and even the world.

陈育新 CHEN Yuxin	江苏普莱医药生物技术有限公司董事长 Chairman, Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd.	源头创新多肽抗感染抗肿瘤药物研发 Source Innovation R&D of Anti-Infective and Anti-Cancer Drugs

项目简介

江苏普莱医药生物技术有限公司是一家以多肽类抗感染、抗肿瘤 first-in-class 创新药物的研究、开发与生产为主的高科技生物医药企业。公司承担了包括国家科技部国家“十二五”、“十三五”重大新药创制专项、科技部中小企业技术创新基金等各类科研项目 30 余项。公司产品管线有 12 个不同适应症的多肽创新药在研，在无锡江阴设有占地面积近 100 亩的产业基地，已建成国际首条多肽喷雾剂生产线及多肽栓剂中试生产线。公司秉承源头创新理念，建立了全球领先的抗菌肽药物从头设计平台及多肽药物创新制剂研发平台。普莱医药在 2020 年已完成 C 轮融资，目前进行 D 轮融资，预计 2022 年启动科创板上市申报。

Project Introduction

Jiangsu ProteLight Pharmaceutical & biotechnology Co., Ltd. is a high-tech pharmaceutical enterprise focusing on the R&D and manufacture of first-in-class anti-infective and anti-cancer peptide drugs. ProteLight has borne over 30 national and local science and technology projects, including the National Major Scientific and Technological Project for “Significant New Drugs Development” during the twelfth and thirteenth five-year plans, and SME Technology Innovation Fund of the Ministry of Science and Technology of China, etc. ProteLight’spipeline has 12 peptide innovative drugs with various indications under R&D. It has set up a production line of peptide spray and a pilot line of peptide suppository,which are the first in the world. Takingthe source innovation idea, ProteLight has founded the leadingplatforms of de novo designof antimicrobial peptides and creative peptide preparations. It has completed the round C fund-raising in 2020, and the round D financing is ongoing. The company plans to initiate the list declaration of SSE STAR market in 2022.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
李清源 LEE Chingyuan	贝尔克斯生技股份有限公司商务长 Chief Business Officer, BELX Bio-Pharmaceutical Corporation	慢性乙型肝炎新合并疗法： 植物新药 BEL-X Novel Combination Treatment for Chronic Hepatitis B: Botanical New Drug BEL-X

项目简介

目前慢性乙型肝炎之治疗停药后复发率极高，药物治疗后乙型肝炎病毒抗原转阴率低，造成病患疗程长，而慢性乙肝带原者为高风成为险肝癌、肝硬化患者，不仅对患者医疗花费同时对国家医疗系统造成一定的负荷。目前研究发现：治疗慢性乙肝药物植物新药 BEL-X 与已上市之抗病毒药合并使用，将加速增加患者血清 e 抗原转阴率、大幅缩短患者服药时间、且可降低停药后病毒复发率。故植物新药 BEL−X 若成功开发，不仅对慢性乙型肝炎患者为重大福祉，也能降低医疗系统之负担。植物新药 BEL-X 已建立 六大核心技术，包含：(1) 药材符合 GACP 规范之栽种，(2) 药材基源鉴定，(3) 药材活性分子鉴定，(4) 符合 cGMP/PIC/S 规范原料药及药品生产技术，(5) 药物前临床试验（药理及毒理试验）以及 (6) 临床试验申请与执行等，拥有全球近 50 项专利申请，其中 41 项已获核准，且已在完成 FDA/TFDA 人体临床一期试验。在当今国际经贸冲突的险峻情势下，开发植物新药特别具有战略之优势，从药材栽种、采收，到药品制造及销售，可形成完全在地化的之整体供应链，符合国家医药安全之战略需求。

Project Introduction

The high viral rebound of chronic hepatitis B after stopping drug treatment and low HBeAg seroconversion of anti-HBV treatment have been obtained. Both factors result in extending medication and increasing cost not only for patients but also for national healthcare. The botanical new drug BEL-X (BEL-X), when combined with anti-HBV drugs, can significantly shorten the duration of patients' medication and further reduce the viral rebound after treatment by increasing the HBeAg seroconversion rate in patients. Thus, if successfully developed, the botanical new drug BEL-X will not only benefit hepatitis B patients, but also reduce the burden on the healthcare system. Six core technologies have been established around BEL-X, including: (1) GACP plantation, (2) species identification, (3) identification of active compound, (4) cGMP/PIC/S-compliant API and drug production technologies, (5) pre-clinical trials (pharmacological and toxicological), and (6) clinical trial application and execution, etc. BEL-X has completed a Phase I clinical trial in Taiwan.

黎志良 Julius LI	苏州欧赛微科生物医药科技有限公司联合 CEO Co-CEO, Suzhou OSWK Bio-Pharm Co., Ltd.	活体生物药（LBPs）开发及 卷曲乳杆菌临床研究 Live Biotherapeutic Products (LBPs) Development of Lactobacillus Crispatus

项目简介

阴道乳杆菌活菌胶囊注册分类为 1 类：创新型生物制品。作为活体生物药（Live Biotherapeutic Products，LBPs），所选菌株为女性阴道最优势菌 ---- 卷曲乳杆菌（Lactobacillus crispatus，代号 Lc262−1），筛选自中国健康育龄妇女阴道菌群。该产品治疗领域为女性生殖泌尿道感染，首个临床适应症为细菌性阴道病 (BV)，目前已经进入 III 期临床试验研究。I 期临床试验显示其具有良好的安全性和耐受性。II 期临床试验表明，治疗组较安慰剂对照组疗效差异显著，治疗组显著降低细菌性阴道病 (BV) 复发率（$P < 0.01$）。

Project Introduction

Lactobacillus crispatus capsule, classified as a live biotherapeutic products（LBPs）, contains the strain Lc262-1 of Lactobacillus crispatus, the predominant species of vaginal lactobacilli in healthy Chinese women of childbearing age. Phase I trial showed that the live Lactobacillus therapeutic is safe and well tolerated when administrated to vagina of healthy women. Currently, results from Phase II trial indicated that the new combination regimen, e.g., simultaneously adminstration of both oral metronidazole and vaginal live Lactobacillus capsule to BV patients, is safe and resulted in a significantly lower incidence of recurrence of BV than placebo after 3 month post treatment（$P<0.01$）.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
陈兆荣 Rong CHEN	百奥赛图（北京）医药科技股份有限公司 副总经理兼临床部首席医学官 Deputy General Manager and Chief Medical Officer, Biocytogen Pharmaceuticals (Beijing) Co., Ltd.	创新思维更好满足临床需求 Innovative Thinking to Better Meet Medical Needs

项目简介

百奥赛图的“千鼠万抗”计划能够快速地发现具有更好安全性和有效性的候选药物，从而更好满足临床需求。YH001（CTLA-4 单抗）在临床前试验及临床研究中展示出很好的安全性和抗肿瘤活性。在一项 YH001 联合 PD1 单抗治疗晚期实体瘤 I 期剂量递增研究中（n=17），未发现≥ 3 级不良事件、未观察到 DLT、没有与研究药物相关的 SAE 或导致的治疗中断。同时，表现出不错的抗肿瘤活性（PR=1，SD=8）。同样，在一项 CD40 单抗 YH003 联合 PD1 单抗治疗晚期实体瘤 I 期剂量递增研究中（n=18），显示了良好的安全性，并表现初步的抗肿瘤活性（PR=2，SD=3）。在临床前和临床研究中均未发现同类产品报道的肝毒性。

Project Introduction

Tumor immunotherapy is developing rapidly, but some targets, such as CTLA-4 and CD40, have serious side effects. Biocytogen has established a unique, in vivo target discovery, antibody screening system (Project Integrum), which can quickly identify candidates with good safety and efficacy, and therefore to better meet medical needs.

YH001 is a CTLA-4 mAb. In preclinical trials, YH001 demonstrated better safety and antitumor activity than ipilimumab. In a phase I dose escalation study of YH001 combined with toripalimab in the treatment of advanced solid tumors (n = 17), the combination showed very good safety profile. No grade 3 AEs, no DLT, no SAE related to the study drug were reported. At the same time, it showed promising anti-tumor activity (PR = 1, SD = 8).

Similarly, in a phase I dose escalation study, YH003, a CD40 mAb, combined with toripalimab in the treatment of advanced solid tumors (n = 18), showed good safety and preliminary anti-tumor activity (PR = 2, SD = 3). No hepatotoxicity reported by similar products was found in preclinical and clinical studies.

Sunny WANG	启德医药科技（苏州）有限公司首席商务官 & 知识产权副总裁 CBO & VP, IP Management of GeneQuantum Healthcare (Suzhou) Co., Ltd.	启德医药 —— 创新生物偶联药物的开拓者 GeneQuantum —— A Pioneer in Innovative Bioconjugate Drug Development

项目简介

启德医药科技（苏州）有限公司（简称启德医药）是一家聚焦于 ADC 药物为代表的新一代生物偶联药物开发的高科技公司。启德医药通过跨学科差异化创新，自主开发了国际领先的智能化连续偶联平台技术（iLDC），该创新平台技术颠覆了现有化学偶联技术和批次生产工艺，攻克了生物偶联药物领域非特异连接、工艺繁杂、放大难等一系列痛点问题。启德医药颠覆性的 iLDC 研产平台可有效整合抗体药物、小分子药物、核酸药物、放射性核素等多种类型的药物资源，进一步提升包括免疫治疗在内的肿瘤现有治疗的效果，完善生物偶联药物产业链，通过自主开发以及全球范围内的广泛合作，孕育更多 First-in-class 及 Best-in-class 生物。

Project Introduction

GeneQuantum Healthcare (Suzhou) Co., Ltd. is a high-tech biopharmaceutical company dedicated to the development of innovative biotherapeutics. The company is focused on the development of a new generation of bioconjugate therapeutics to meet the unmet medical needs of cancer patients globally. GeneQuantum's pipeline portfolio includes not only potential blockbuster ADCs with validated targets (BEST-IN-CLASS), but also drug candidates with novel mechanisms of action (FIRST-IN-CLASS).

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
秦续科 Steve CHIN	科望（上海）生物医药科技有限公司首席医学官 CMO, Elpiscience Biopharma Co., Ltd.	聚焦冷肿瘤向热肿瘤转换 开创新一代癌症免疫治疗 Revolutionizing Cancer Therapy by Turning "Cold" Tumors into "Hot" Tumors with A Systemic Immuno-Oncology Approach

项目简介

科望医药是一家专注于肿瘤免疫治疗，致力于引领新一代肿瘤免疫治疗创新研发的临床阶段生物医药公司。科望医药的产品管线覆盖广泛，现有针对各类靶点的创新产品在研，其中重点布局将“冷”肿瘤转变为“热”肿瘤，以期开发出更有效的新一代肿瘤免疫治疗药物。目前，除 ES002 之外，ES101、ES102 和 ES104 已在临床试验阶段。科望医药可持续发展的管线布局构成了发展下一代更有效的肿瘤免疫疗法的坚实基础。科望医药由生物医药业界资深人士领导管理，由有声望的国际国内顶级投资人（包括礼来亚洲基金、高瓴资本、汇鼎投资、大湾区共同家园发展基金、鼎晖投资、Cormorant Asset Management、Superstring Capital）出资背书。“科望智造，一年一分子”展示了科望团队的决心：每年会将至少一个具有世界创新性的候选药物带入临床，最终造福全球癌症患者。

Project Introduction

Elpiscience is a clinical stage biopharmaceutical company focusing on innovating and developing the next generation of cancer immunotherapy. Elpiscience has developed a pipeline of globally innovative molecules, covering a wide range of targets with a particular focus on turning "cold" tumors "hot". In addition to ES002, the company has three assets in clinical stage (ES101, ES102 and ES104). Elpiscience's sustainable pipeline forms a strong cornerstone for developing the next generation and more effective immunotherapies. Founded and managed by seasoned executives in the biopharma industry, Elpiscience is backed by renowned investors such as Lilly Asia Ventures, Hillhouse Capital, Hyfinity Investments, Greater Bay Area Homeland Development Fund, CDH, Cormorant Asset Management and Superstring Capital. Elpiscience endeavors to advance at least one world-class molecule into the clinic each year, providing clinical benefits to cancer patients worldwide.

周　毅 ZHOU Yi	辉诺生物医药科技（杭州）有限公司 首席科学官 CSO, Phaeno Therapeutics Co., Ltd.	下一代抗感染新药的研发 Develop the Next Generation of Anti-Infectious Drugs

项目简介

辉诺生物医药是一家处于临床阶段专注于抗感染新药研发的创新型公司，拥有领先突破性抗感染产品组合，立足中国，具全球竞争力。公司愿景是引领抗感染新疗法，呵护大众健康。在国内知名生物医药投资方支持下，荟萃经验丰富的行业精英。在团队带领下，已建立了从药物靶标发现到临床前评估，临床设计和执行，药品生产等方面的强大内部研发能力。 辉诺致力于打造国际一流、国内领先抗感染新药开发平台，专注于严重威胁人民生命健康和生活质量的感染疾病，包括病毒感染和细菌感染。抗病毒感染管线包括抗人巨细胞病毒感染（HCMV）、抗单纯性疱疹病毒感染（HSV）、抗流感病毒（IFV）等药物；抗细菌感染方向产品主要针对抗多重耐药细菌感染药物。

Project Introduction

Phaeno Therapeutics is a China based clinical-stage biotech company, focusing on the research and development of breakthrough therapies against infectious diseases. We are dedicated to the research and development of novel drugs to meet unmet medical needs, and improve quality of lives of those infected. With the support of our top-tier life science investors, Phaeno has established an experienced management team, with the capabilities of discovery, preclinical and clinical development. Phaeno's pipeline covers both viral and bacterial infections, including anti-human cytomegalovirus (HCMV), anti-herpes simplex virus (HSV), anti-influenza virus (IFV) infection, and anti-multidrug resistant bacterial infection programs.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
金文卿 Adam JIN	江苏新元素医药科技有限公司执行副总裁 Executive Vice President, Jiangsu Atom Bioscience & Pharmaceutical Co., Ltd.	具有全球商业价值的痛风和其它创新药物的研发 Development of A Potent and Safe Gout Drug ABP-671 and Other Programs

项目简介

新元素医药主要从事代谢和抗癌创新药物研发。公司已完成 4 轮融资，总融资额近 3 亿元人民币，投资方包括红杉资本、丽珠医药、凯泰资本、优选资本、达晨资本、中钰资本等，并计划于 2022−2023 年递交 IPO 申请。 公司拥有多种项目组合，其中拥有自主知识产权 1 类抗痛风创新药 ABP−671 以全球市场为目标，正开展 2 期临床研究。从已有的临床数据看，ABP−671 对受试患者的血尿酸下降率优于预期：在很低剂量给药下，体现出极佳的疗效和安全性，远优于市场药物。全球痛风患者超过 5500 万；而现有药物有十分严重的毒副作用。全球痛风市场存在着巨大的、未满足的临床需求。Nash 及抗癌药物预计将在 2022 年进入全球临床研究。

Project Introduction

Atom Bioscience mainly focused on new drug discovery and development on metabolic diseases and anti-cancer. Atom Bioscience has completed around $45 million USD financing. Atom Bioscience develops several pipelines. Among them, a novel compound ABP-671 for gout treatment showed a great inhibition of hURAT1. Gout has over 55 million patients worldwide. The current medications do not meet the requirement of treatment of gout due to the severe side effects of these drugs. ABP-671 demonstrated great efficacy in the animal models, excellent safety profiles, good PK and several other good characteristics in its pre-clinical studies. ABP-671 is currently under Phase 2 clinical trials in and outside China. It shows superior lowering serum uric acid, which is much better than current gout drugs. ABP-671 may become a most potent and safe drug for the treatment of gout and hyperuricemia worldwide. Besides ABP-671, ABP-6016 showed remarkable potency for the treatment of NASH with a good safety profile. ABP-431 is under investigation for the treatment of gastric cancer, colon cancer, and breast cancer. Both compounds will enter the clinical trials in 2022.

夏　钢 XIA Gang	浙江新码生物医药有限公司首席科学官 CSO, Novocodex Biopharmaceuticals Co., Ltd.	基于非天然氨基酸插入定点偶联技术的创新药研发先行者 R&D Pioneer of Innovative Drug Based on Unnatural Amino Acid-Introduced Site Specific Conjugation Technology

项目简介

浙江新码生物致力于非天然氨基酸定点偶联大分子药物的研发和生产。首个项目 NCB001（又名 ARX788，抗 HER2-ADC）在 I 期临床研究中表现出良好的安全性和疗效。入组的 69 例 HER2 阳性晚期乳腺癌受试者中有 33 例 PR，31 例 SD，4 例 PD，使用 II/III 期的推荐剂量（1.5mg/kg）≥ 3 级药物相关毒性低的前提下，ORR 达到了 65.5%（19/29）。该项目的胃癌 I 期临床研究总体 ORR=44.4%（12/27）。NCB001 已获得突破性治疗药物认定，并获得 FDA 孤儿药资格认定和快速审评通道资格认定。

Project Introduction

Zhejiang NovoCodex Biopharmaceuticals Co., Ltd. was established in January 2017. The company is committed to the discovery and development of macromolecular drugs based on unnatural amino acids-introduced site specific conjugation. The two phase I clinical studies of the leading project, NCB001 (or ARX788, an anti-HER2 ADC), for breast cancer (BC) and gastric cancer(GC) will be completed soon. NCB001 showed good safety and efficacy in subjects with advanced BC or GC. Among 69 enrolled BC subjects, there were 33 best response of PR, 31 SD and 4 PD. The ORR of 1.5 mg/kg group (recommended dose of phase II/III clinical study) was 65.5% (19/29) with few cases of grade 3 or above drug related adverse events. Encouraged by the good outcome of NCB001 in BC Phase I study, the phase II/III clinical study of NCB001 has been initiated in 56 sites. In the Phase I clinical study of GC with 30 subjects were enrolled, an overall ORR is 44.4%(12/27) . NCB001 have been granted as Breakthrough Therapy Designation, Orphan Drug Designation(FDA) and Fast Track Designation(FDA). The company has several innovative site-specific conjugated macromolecules that are in the IND or pre-IND development stages.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
杨选明 YANG Xuanming	上海隆耀生物科技有限公司首席科学家 Chief Scientist, Shanghai Longyao Biotech Co., Ltd.	不依赖抗原的 OX40 信号可以改善 CAR−T 细胞的持久性和细胞毒性 Antigen-Independent OX40 Signaling Improves the Persistence and Cytotoxicity of CAR-T Cells

项目简介

上海隆耀致力于研发针对癌症的免疫细胞药物，目前拥有国内第一款获批 IND 的 CD20 靶点 CAR−T 药物。隆耀自主知识产权的独特 OX40 共刺激信号设计被证明可以提高 CAR−T 细胞对于肿瘤的杀伤效能，减少细胞毒性以及改善 CAR−T 在体内和体外的留存。我们 CD20−CART−OX40 产品针对难治复发的淋巴瘤的研究者发起的临床试验已经证明这一设计在临床上的价值，临床试验达到了 100% 的客观有效率和 40% 的完全缓解率。我们的发现提供了优化 CAR−T 以攻克实体瘤的一种思路。

Project Introduction

Shanghai Longyao BIotech is dedicated to developing immune cell therapeutics for tumours, with the first CD20 targeted CAR-T with IND approval in China. Our patented unique OX40 costimulatory design has been proven to increase the effacacy CAR-T cells against tumours, reduce the cytotoxicity and improves the retaining of CAR-T in vivo and in vitro. IIT cases of CD20-CART-OX40 for r/r lymphoma patients have proven the clinical value of of this design, with 100% ORR and 40% CR. Our findings provide an alternative option for CAR-T optimization with the potential to overcome the challenge of treating solid tumors.

王奎锋 WANG Kuifeng	勤浩医药（苏州）有限公司创始人 &CEO Founder & CEO, Suzhou Genhouse Bio Co., Ltd.	利用组合技术平台 开发全球新一代的抗肿瘤小分子药物 Utilizing Integrated Technology Platforms to Develop Next-Generation Cancer Therapeutics

项目简介

勤浩医药坐落在人文荟萃、集聚创新的医药企业发展热土——苏州工业园区，是一家专注于全球领先的小分子抗肿瘤新药开发的生物科技公司。公司管理层拥有多年企业管理、新药研发、临床医学研究经验，致力于突破“难以成药”靶点，聚焦原始创新。 勤浩医药着力打造独具特色的创新药物研发体系，建立了基于结构生物学的构效关系研究平台，基于靶点研究的早期药物筛选平台以及涵盖药效、代谢和安全性研究的临床前评价平台，形成了以靶向抗肿瘤品种为核心的产品管线。 得益于自身完整的创新药物研发战略规划及实施能力，勤浩医药与国际生物创新药企沪亚生物国际成功签署 SHP2 抑制剂 GH21 的海外权益转让，让中国的创新药物拥抱全球市场。

Project Introduction

Genhouse Bio is a clinical-stage biotech company focusing on the development of global next-generation anti-cancer therapeutics, headquartered in the Suzhou Industry Park . The senior management team of Genhouse has multiple years of experience in new drug development, clinical research and corporate management. Genhouse has a clear focus on original innovation and overcoming those “undruggable” targets. Genhouse has established intergrated in-house drug development platforms. With these platforms, Genhouse has started to build a highly innovative anti-cancer pipeline and out-licensed the ex-China rights of its SHP2 inhibitor GH21 to HUYABIO , an international biotech company. Genhouse will continue to advance more innovative pipeline programs into global development.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
卢安邦 Pony LU	维昇药业 CEO CEO, VISEN Pharmaceuticals	创新点亮生命——维昇药业 TransCon 技术平台产品研发进展 Innovation Brings Light to Life——VISEN Pharma Innovative Pipeline Development Leveraging TransCon Technology

项目简介

维昇药业是专注于内分泌相关治疗领域的创新型生物医药公司，致力于以人性化的创新疗法，让内分泌患者享有更好的治疗过程与疗效，以实现向往的生活。维昇药业以患者需求为先，力求提供同类首创或同类最佳的内分泌疾病产品和治疗方案。治疗领域包括成人内分泌、儿童内分泌以及内分泌罕见病。维昇持续汇聚国际化背景的资深专业人才，以及全球创新前沿的技术和资源，深入布局中国市场，已在上海、北京、香港、台北设立办公室，并在苏州设立大中华区研发制造基地，落实从研发、生产到商业化的内分泌创新药领域的全链条布局，让更多的中国内分泌患者更早地受惠于全球前沿可靠的治疗方案。

Project Introduction

VISEN Pharmaceuticals is a clinical-stage biopharmaceutical company specialized in developing and commercializing paradigm-shifting endocrine therapies in the Greater China markets. We aim to bridge global innovation to bring life-saving and life-changing endocrine therapies to Chinese patients. Leveraging our expertise in local markets and our elationships with global healthcare companies, we are developing drug candidates with first-in-class or best-in-class potential to address significant unmet medical needs while maximizing the full value of our innovative pipeline. We strive to build an “end-to-end” platform that integrates research and discovery, clinical development, manufacturing and commercialization capabilities for endocrine therapies.

邵　辉 SHAO Hui	依生生物首席执行官 CEO, YishengBio	皮卡佐剂在创新性疫苗中的应用 Application of PIKA Adjuvant in Innovative Vaccines

项目简介

依生生物是一家综合性的生物制药公司，专注于发现、开发、制造及商业化针对传染病和抗癌领域的新一代疫苗及治疗性生物制品。公司拥有全球独创的皮卡免疫调节技术平台，开发出创新型疫苗和治疗性生物大分子产品。公司的皮卡技术和疫苗产品三次获得“国家新药创制项目”的支持。公司在中国、新加坡、和美国设有分公司，员工人数超过 600 人。 皮卡（PIKA）免疫调节技术平台被国家科技部和卫健委列为“国家重大新药创制项目”，用于开发新一代抗病毒和抗肿瘤产品，提升现有的治疗方案和解决未满足的医疗需求。皮卡技术基于我公司自主研发的双链 RNA（dsRNA）大分子复合物和 GMP 生产工艺，在 40 多个国家获得 70 多项专利。

Project Introduction

YishengBio is a fully integrated biotechnology platform. We discover, develop, manufacture and commercialize new generations of vaccines and therapeutic biologics for infectious diseases and cancer. We have developed in-house our PIKA immunomodulating technology platform through which we empower and nurture a diverse pipeline of vaccines and therapeutic biologics with better efficacy and safety potential to address the unmet medical needs in infectious disease and cancer fields. The company has branches in China, Singapore, and the United States with more than 600 employees. PIKA technology consists of synthetic biologic complex that is originated from our research and synthesized based on our proprietary GMP manufacturing technology. Through TLR3, RIG-I and MDA-5 signaling pathways, PIKA molecule can induce a prompt production of interferon, cytokines, chemokines and costimulatory factors.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
包　骏 BAO Jun	英派药业总裁兼首席执行官 President & CEO, Impact Therapeutics	英派药业——小分子，大影响：打造全球领先的合成致死机制产品组合 IMPACT Therapeutics——Small Molecule, Big Impact: Building Leading Global Synthetic Lethality Product Pipeline

项目简介

英派药业致力于研发具有自主知识产权的靶向抗癌创新药，专注于合成致死作用机制。公司以 DNA 损伤修复通路（DDR）自主研发产品为基础，构建了全球生物医药公司中覆盖面最广的 DDR 产品组合之一，并且逐步拓展到更多全新的合成致死靶点。公司产品管线包括 PARP 抑制剂（senaparib/ IMP4297）、Wee1 抑制剂（IMP7068）以及多个其他 DDR 靶点抑制剂。自创立以来，公司获得包括战略投资人君实生物以及礼来亚洲基金在内的多家知名机构的投资。

Project Introduction

IMPACT Therapeutics is a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality. IMPACT Therapeutics has assembled one of the most comprehensive DNA damage response (DDR) global pipeline of novel drug candidates generated by in-house discovery efforts and is expanding to other novel synthetic lethality targets to broaden its pipeline. IMPACT pipeline products include PARP inhibitor (senaparib/IMP4297), Wee1 inhibitor (IMP7068), and other novel DDR pathway inhibitors. The company has received investment from recognized venture capital firms, including strategic investor JunShi Biosciences and Lilly Asia Ventures.

李　俊 LI Jun	苏州方德门达新药开发有限公司总经理 General Manager, Suzhou Fundamenta Therapeutics Inc.	基于膜蛋白胞内滞留技术的通用型 CAR−T：平台技术开发及临床探索 Allogeneic CAR-T Platform Based on Intracellular Retention of Membrane Proteins: Technology Development and Clinical Investigation

项目简介

CAR−T 细胞药物是近年肿瘤免疫治疗领域的一个重大医学突破，即用型（off−the−shelf）是 CART 领域的主攻方向。我司成功开发的 ThisCART 通用型 CART 平台技术，采用具有自主知识产权的膜蛋白胞内滞留技术，它不仅从根本上避免了基因编辑的脱靶风险，制备工艺上还与自体 CART 几乎完全一致（“秒变”），利用单一病毒载体即可同步实现 CAR 的表达和 GvHD 的消除。ThisCART 平台技术是对目前通用型 CAR−T 细胞开发路线的一个巨大创新，突破了主流制备技术面临的安全性和工艺瓶颈，有望率先实现通用型 CART 的临床应用，造福广大的晚期肿瘤患者。

Project Introduction

While Chimeric antigen receptor (CAR) T cells are advancing rapidly in the field of individuallized immunotherapy, off-the-shelf CAR-T cell therapy becomes a new development focus. Our company has successfully developed an proprietary allogeneic CAR-T platform technology, named ThisCART (TCR and/or MHC-I intracellularly sequrested CAR-T). This platform employs intracellular retention of membrane proteins methods to generate off-the-shelf CART cell, with several major advantages. Firstly, it avoided the risk of genomic off-target effects. Secondly, the expression of CAR and elimination of graft-versus-host disease (GvHD) effect are simultaneously achieved with a single lentiviral vector. Lastly, its manufacturing process readily replicates the common one for autologous CAR-T cells in addition to a removal step of TCRalphabeta cells. ThisCART cells targeting CD19 (ThisCART19) is being investigated in reflactory and relapsed NHL patients with promising safety and clinial responses observed. ThisCART allogeneic platform technology represents an unique promise to bring both clinical value and affordability to advanced cancer patients besides the gene-editing ones.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
宫丽崑 GONG Likun	中国科学院上海药物研究所 课题组长，教授 PI, Professor, Shanghai Institute of Materia Medica	COVID−19 表位肽疫苗 CoVac501 研发 Development of CoVac501, A Multiple Epitope Peptide Vaccine for COVID-19

项目简介

本项目新冠病毒表位多肽疫苗是利用人工智能预测 S 蛋白抗原表位，加入新型佐剂制备的表位多肽疫苗。该疫苗具有全化学合成抗原，性质稳定可常温保存和安全高效的特点。攻毒试验结果显示，表位多肽疫苗免疫接种食蟹猴后，可抵抗新冠病毒入侵；并且可以耐受 delta 等多种突变，有望成为引人注目的安全、有效疫苗。

Project Introduction

Safe, effective and economical vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are needed to achieve adequate herd immunity and end the pandemic. We have constructed a novel SARS-CoV-2 vaccine which contains multi-immunodominant peptides screened from receptor-binding domain (RBD) and is fully chemically synthesized. And the vaccine has been formulated in an optimized nanoemulsion formulation and can keep stable at room tempreture.In non-human primates (NHPs), this vaccine elicited high and persistent titers of protective neutralizing antibodies against multiple mutations, SARS-CoV-2 wild strains and variants (alpha, beta and delta etc). Meanwhile, It elicited the increase of memory T cells, antigen-specific CD8+ T cell responses and Th1-biased CD4+ T cell immune responses in NHPs. Notably, at an extremely high challenge dose of 1×107 TCID50, our vaccine provided near-complete protection for the upper and lower respiratory tracts of cynomolgus macaques.

张类波 Angela ZHANG	北京无疆脑智科技有限公司首席运营官 COO, Beijing Infinite Brain Technologies	无疆科技——专注于脑科学研究和中枢神经疾病干预的数字疗法 Beijing Infinite Brain Technologies——Aims to Provide Digital Curative Solutions for Central Nervous System (CNS) Diseases

项目简介

无疆科技（北京无疆脑智科技有限公司），是专注于脑科学研究和中枢神经疾病干预的数字疗法高科技企业。以产业化数字疗法为己任，以成为全球深受信赖的脑科技公司为目标。与国家认知神经科学重点实验室开展紧密科研合作，与国家顶级精神和神经科医院进行临床实验研究，包括北医六院、天坛医院、儿研所、深圳儿童医院等。无疆致力于打造多维度产品线，通过数字化手段覆盖各类中枢神经相关疾病的诊疗，涉及疾病包括儿童多动症、孤独症、精神分裂症、卒中后认知障碍等。基于神经重塑技术通过人工智能和深度学习技术，无疆为客户和用户提供了“筛查 – 诊断 – 治疗 – 管理 – 科研”中枢神经全流程数字疗法解决方案。

Project Introduction

Beijing Infinite Brain Technologies (IBT) is a leading medical technology company that aims to provide digital curative solutions for central nervous system (CNS) diseases. By leveraging the advanced brain sciences and cutting-edge computational technologies, IBT is committed to improving the process of screening, diagnosis, treatment and management for a wide range of CNS diseases, such as ADHD, autism, schizophrenia, and post stroke cognitive impairment. The company conducts long-term scientific and clinical research, developing and providing proprietary digital therapeutic products that have been clinically validated, by partnering with national key laboratories and top research hospitals in China. Bearing the difficulties of patient and family firmly in mind, IBT strives to level up patient care with products with higher efficacy and lower cost.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
仲为栋 ZHONG Weidong	宁波圣健生物医药科技有限公司商务总监 Business Development Director, Ningbo Shengjian Biopharmaceutical Tech. Co., Ltd.	用于治疗复发难治多发性骨髓瘤及其他多种肿瘤的新一代蛋白酶体抑制剂的研发 Development of A New Generation of Proteasome Inhibitors for the TreatMent of Relapsed and Refractory Multiple Myeloma and Other Tumors

项目简介

宁波圣健生物成立于 2013 年，是一家专注于蛋白酶体抑制剂研发的创新药企业。蛋白酶体是细胞内蛋白质降解的主要途径，对蛋白酶体位点的选择性抑制，可以对不同类型的肿瘤发挥抗肿瘤作用。目前国际上有第一代产品（硼替佐米）和第二代产品（卡非佐米）。圣健自主研发的新一代靶向药 CX13−608，提高了分子靶向性，改进了疗效和安全性，在复发难治多发性骨髓瘤患者中已进入 IIb 期临床研究。根据（RRMM) I 期临床的数据，进一步开展淋巴瘤、白血病、肺癌等临床研究。圣健在不同领域拥有多项专利。其核心团队由具有全面药物开发经验的专家组成，包括新药发现、临床前、临床、监管（美国 FDA 工作经验）等，专门从事抗肿瘤药开发。

Project Introduction

Proteasome is the main pathway of protein degradation in cells, and selective inhibition of proteasome sites can exert anti-tumor effects on different types of tumors. Established in 2013, Ningbo Shengjian Biopharmaceutical Technology Co., Ltd. is an innovative biotech focusing on the research and development of proteasome inhibitors. Currently there are first-generation products (bortezomib) and second-generation products (carfilzomib) in the world market. The new generation of multiple myeloma targeted drug candidate, CX13-608, independently developed by Shengjian, improves the targeting of drug molecules to specific sites, further enhances efficacy, and reduces side effects. It has entered phase IIb trial in patients with relapsed and refractory multiple myeloma. It's also approved for clinical trial in lymphoma, leukemia, lung cancer. Shengjian holds multiple patents in different fields. Its core team members have comprehensive drug development experience, including early stage research and development, pre-clinical, clinical and regulatory (US FDA working experience). It specializes in oncology, cardiovascular, and autoimmune disease drugs developments.

罕见病专场 »»»

Rare Diseases and Orphan Drugs Roadshow

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
袁鹏飞 YUAN Pengfei	博雅辑因首席技术官 CTO, EdiGene	基因编辑疗法在罕见病领域的发展现状和潜力 The Development and Potential of Gene Editing Therapies for Rare Diseases

项目简介

自 2012 年 CRISPR 技术被发现以来，基因编辑技术正在被开发为针对包括罕见病在内的多种疾病的疗法。基因编辑疗法能够在基因层面治疗疾病，从而带来一次性治愈的可能。近年来，针对罕见病的基因编辑疗法临床试验，无论是体内还是体外疗法，都有相关安全性和有效性数据发布。在博雅辑因，我们也正在开发相关疗法。例如，在体外疗法上，我们针对输血依赖型 β 地中海贫血的基因编辑疗法产品 ET-01 的多中心 I 期临床试验正在开展；在体内疗法上，我们正在基于 “LEAPER” 新型 RNA 单碱基编辑技术研发相关疗法。虽然基因编辑疗法的开发仍处于早期阶段，且还有许多挑战需要应对，但是目前行业取得的成果已经展现基因编辑疗法的潜力。

Project Introduction

Discovery of CRISPR in 2012 has triggered exponential growth of research and translation activities in the field of gene editing technologies. In the therapeutics arena, translational potential has been made for different patient populations, including the ones suffering from rare diseases. The majority of rare diseases are thought to be genetic. Gene editing therapies can directly correct the root cause of the disease instead of treating its symptoms and provide potential one-time cure. In recent years, preliminary clinical data from gene-editing trials, both ex vivo and in vivo, have been published. At EdiGene, we have been exploring such potentials as well. Ex vivo, autologous gene-edited hematopoietic stem cell therapy is being developed to treat transfusion-dependent β-thalassemia. In vivo, LEAPER, a non-CRISPR RNA base editing system, is being developed to convert critical point mutations in disease-causing genes back to wild type in order to treat selected genetic diseases. While still in early stages and facing many challenges, progress by us and others in the field have pointed to significant and transformative potential of gene-editing therapies.

韦沂均 WEI Yijun	成都惠泰生物医药有限公司首席执行官 CEO, Chengdu Huitai Biomedical Co., Ltd.	单靶点全球首创新药开发：通过靶向 TSP-1 阻断 TGF-β 激活 Developing Single-Target First-in-Class Treatment Through Blocking TGF-β Activation By TSP-1 Technology

项目简介

HTPEP-001 是惠泰开发的一款全新靶点多肽类创新药，该药物能够解决两大世界级医学难题：抗纤维化的临床治疗；以及 TGF-β 及超家族蛋白成药性难题。这是一款以 TSP-1 为靶点的 TGF-β 激活抑制剂，能在病理条件下选择阻断 TGF-β 的激活过程。HTPEP-001 给药途径包括静脉和雾化吸入两种途径，在三种动物模型上均能特异性阻断组织病理纤维化进程，优于现有的已批准药物，并达到一百倍的安全窗口。HTPEP-001 临床前数据多次被美国胸科学会（ATS）和美国临床肿瘤学会（ASCO）接收并在年会上公开展示，同时获得美国相关领域多位临床指南撰写人的高度评价。

Project Introduction

Our first product HTPEP-001, a global first-in-class novel drug suppressing active TGF-β1 production and SMAD signaling through targeting TSP-1, we made HTPEP-001 available for both intravenous drip and aerosol inhalation. Previous data shows promise as an effective anti-fibrotic agent that can be used in the treatment of Idiopathic Pulmonary Fibrosis, and without systemic side effects of TGF-β inhibition or side effects of blocking physiological fibrosis. TSP-1 can modulate the pathway of TGF-β1, with specific high expressions in IPF patients. This promising medicine can prominently block pathological fibrosis compared with the nintedanib and pirfenidone in vivo at a much lower dosage, and the identified NOAELs provided exposure margins of 1-to 100-fold compared to effective dose. You can find more therapeutic data at ATS and ASCO International Conferences.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
谢生荣 Ron XIE	上海柯西医药科技发展有限公司总经理 General Manager, Shanghai Cauchy Medical Technology Development Co., Ltd.	以患者为中心的中国孤儿药研发策略 Research and Development Strategy of Patient Centered Orphan Drugs in China

项目简介

“以患者为中心的中国孤儿药研发机遇”的主题演讲，将重点探讨中国孤儿药临床研发的机遇与挑战。 孤儿药行业的先行者，应立足中国数据，布局全球市场。要有科学引领商业的意识，要具备面向全球研发和商业化的策略，医生、患者要与社会组织、患者组织、慈善机构、福利基金会共同合作，需要政府政策在税收、医保、科研支持，并要与传媒和政府相关部门保持良好的沟通。

Project Introduction

The keynote speech of "patient centered opportunities for R&D of orphans in China" will focus on the opportunities and challenges of clinical research and development of orphan drugs in China. The pioneers of orphan medicine industry should base on Chinese data and lay out the global market. To have a scientific awareness of leading business, to have a strategy for global R&D and commercialization, doctors and patients should cooperate with social organizations, patient organizations, charities and welfare foundations, and government policies should be supported by tax, medical insurance and scientific research, and good communication with media and relevant government departments should be maintained.

向　宇 Shawn XIANG	琅钰集团首席执行官 CEO, RareStone Group	以患者为中心，探索“药品 + 科技”的中国罕见病商业模式 Drug+Technology: a Patient-Centric Business Model for Rare Disease in China

项目简介

琅钰集团 (RareStone Group) 致力于成为中国最领先的罕见病企业，通过打造中国首个罕见病生态系统，为受罕见病影响的患者和家庭提供全方位且可持续的支持。琅钰集团旗下目前有两家子公司：专注罕见病药品解决方案的“琅铋医药 (Citrine Medicine)”和为广大罕见病患者和家庭提供医疗科技解决方案的“子昂健康 (Zircon Health)”。琅钰集团由全球领先的医疗基金斯道资本、F-Prime 资本和维梧资本共同创办，并于 2020 年 7 月完成 8000 万美元的 A 轮融资。

Project Introduction

RareStone Group is dedicated to building the first rare disease ecosystem in China, to improve the lives of patients and families impacted by rare diseases with comprehensive and sustainable solutions. RareStone Group consists of two business subsidiaries: Citrine Medicine and Zircon Health. RareStone Group was founded by Eight Roads Ventures, F-Prime Capital, and Vivo Capital in 2019, and closed a USD80 million Series A financing in July 2020.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
郝景辉 Oliver HAO	香港维健医药集团有限公司联席首席执行官 Co-CEO, Hongkong WinHealth Pharma Group Co., Ltd.	罕见，但不罕治： 管控式供药，我们在路上 Winhealth Pharma, Bringing Real Impact to the Rare

项目简介

博鳌乐城维健罕见病临床医学中心于 2020 年 4 月 10 日创立于中国海南博鳌乐城国际医疗旅游先行区，维健投资（香港）有限公司、乐城管理局、博鳌未来医院中心三方共建，并由维健投资（香港）有限公司投资建立。 博鳌乐城维健罕见病临床医学中心，以与全球同步的速度，将最先进的罕见病产品导入中国市场，给中国及周边国家和地区的罕见病患者及家庭带来前所未有的希望。

Project Introduction

BO'AO WINHEALTH RARE DISEASE MEDICAL CENTER was jointly established on April 10th, 2020 in Bo'ao Lecheng international medical tourism pilot zone in the province of Hainan in China, by Win Health Investment (HK) Limited, Le Cheng Administration, Ruida Medicell International Medical Center, and was invested by Win Health Investment (HK) Limited. Bo'ao Winhealth Rare Disease Medical Center is introducing the most advanced rare disease medical products into Chinese market at a pace synchronized with the world, bringing unprecedented hope to patients with rare disease in China and neighboring countries and regions.

蒋　鑫 JIANG Xin	北京科信必成医药科技发展有限公司创新总监 Director, Pipeline&Strategy of CoSci Med-Tech Co., Ltd.	罕见病患者长期用药依从性的解决办法 Compliance Plays Key Role in Long-Term Medication of Rare Diseases

项目简介

罕见病大多数为单基因遗传病，患者通常需要长期用药。由于研发成本、周期、技术，和企业商业模式选择等多种因素的影响，罕见病用药往往在给药方式、剂量、用药管理等用药依从性和安全性方面研究的并不充分，患者和其家庭往往会面临用药不方便，服药剂量大、频次多，药物剂型、味道、口感都很差，患者厌恶吃药、甚至产生逆反心理等问题，对罕见病患者的健康管理造成巨大障碍。科信必成从制剂角度做出技术突破，实现了更加适合罕见病特殊患者长期使用的药物，让用药不再痛苦，使患者、家庭及社会同时获益。

Project Introduction

Rare Diseases often result in long-term medication of the patient, majority of which shall take medicines for their whole life. In the contrast, due to the cost, RnD capabilities, marketing choice and regulatory considerations, most of the existing drugs on Rare Diseases are insufficient in terms of compliance performance, such as taste, dosing reigm, way of administration, dosing strength and so on. As a result, patients are not willing to take the pills as demanded to, which certainly cause mistake or even failure in the treatment. CoSci has been focusing on designing and developing proper dosage forms for long-term use, in order that the patient is willing to and is able to take the medicines on time as instructed, which is expected to bring better cure and care to the illness.

人工智能与生物医药专场 »»»
Artificial Intelligence (AI) + BioMed Roadshow

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
谭文康 Ronald Tam	深圳晶泰科技有限公司首席财务官 CFO, xtalpi.inc	以 AI 先进技术赋能药物研发创新 Advanced AI Technology Enables Drug Research and Development Innovation

项目简介

回溯晶泰科技本身发展历程，介绍目前正对外提供的针对新药发现以及药物固体形态的独特解决方案，以及晶泰科技独特的药物研发模式和平台。

Project Introduction

Reviewing XtalPi's development history, introducing unique solutions for new drug discovery and drug solid-state which we are currently providing, as well as XtalPi's unique drug development paradigm and platform.

沈倩诚 SHEN QIancheng	上海宇道生物技术有限公司首席执行官 CEO, Nutshell Biotech (Shanghai) Co., Ltd.	First-in-Class 变构小分子研发平台与管线布局 First in Class Allosteric Molecules: Platform and Pipeline in Drug Discovery

项目简介

本项目自 2009 年以来长期聚焦于变构机制小分子药物研发领域，并开发了具有国际领先水平的变构药物计算发现平台，包括一系列从变构位点识别到变构分子优化相关的计算工具，该平台为使用变构技术克服难成药靶点打下了基础。同时，使用该自主研发的计算平台并经过一段时间的积累， 本项目已针对多个难成药靶点和全新靶点开发了具有变构机制的药物先导分子，目前进度最靠前的分子已经进入了临床前研究阶段，在多个肿瘤相关的适应症中表现出了良好的动物水平活性药效。

Project Introduction

This project has been long focusing on the innovative research of small molecular drugs with allosteric mechanisms since 2009. A globally well-known allosteric drug discovery platform is developed and continue to be updated, this includes a series of computational tools and databases from allosteric site recognition to allosteric molecular optimization. The platform is the foundation for the use of allosteric technology to reach out traditionally non-druggable targets. At the same time, by utilizing the platform, we have gradually generated our own drug pipeline with allosteric mechanisms for multiple new targets, and the most advanced project is close to the pre-clinical candidate stage. This first in class (FIC) molecule has shown good efficacy in animal models for multiple tumor-related indications.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
刘磊峰 LIU Leifeng	苏州青云瑞晶生物科技有限公司创始人 &CEO Founder & CEO, ReadCrystal Technology Co.	基于 MicroED 的结构 +AI 计算新药发现平台 MicroED based AI+Structure Drug Discovery Platform

项目简介

基于微晶电子衍射 MicroED 的结构 + 计算新药发现平台，集合了 MicroED，量子化学计算和 AI 算法。针对 GPCR，激酶、转录因子等主要的药物靶点，快速设计出有效的创新药分子。与传统技术相比，该平台能够将新药发现的成功率由 4% 提升至 8%−20%，周期由 15 年下降至 8−10 年，由此带来单个药物的研发成本由 25 亿美元，下降至 3−5 亿美元。 MicroED 技术能够将蛋白 − 分子结构表征时间缩短为 1/50，业界认为 MicroED 是一项在化学合成，生物制药等领域的颠覆性技术。权威杂志 Science 杂志将 MicroED 评选为 2018 年全球十大科技突破科技。

Project Introduction

The Structure + AI based new drug discovery platform integrates MicroED (Microcrystal Electron Diffraction), quantum chemical calculation and AI technology. For most undruggable target. Like GPCRs, kinases, transcription factors, our platform can help quickly design or find a new drug compound. Without the crystallization process, MicroED only need nano-size crystals to determine the key structure for drug discovery, like protein-ligand cocrystal structure. People believes that MicroED should have a profound impact on fields ranging from the synthesis and discovery of new pharmaceuticals to the design of molecular probes to study and track diseases. MicroED was selected as TOP 10 BREAKTHOUGH of the year 2018 by.

吴国胜 WU Guosheng	康龙化成（北京）新药技术股份有限公司 副总裁 Vice President, Pharmaron	基于人工智能的药物分子设计： 潜在价值和目前的问题 AI-based Drug Design: Potential Values and Current Issues

项目简介

近几年来，基于人工智能的药物分子设计（AIDD）已经成为新药发现领域的一个新兴技术。但是，现有的文献中并没有看到很多对照研究，使得和传统的计算机辅助药物设计（CADD）方法相比，不太清楚 AIDD 到底有多少优势。本报告中，我们将选择一些成熟的药物靶点，根据 AIDD 和 CADD 得出的计算结果进行一些对比，希望可以帮助阐明 AIDD 的潜在价值，以及这一领域目前还可能存在的问题。

Project Introduction

In the last a few years, AI-based drug design (AIDD) has becoming an emerging technology for drug discovery. However, it seems very limited number of interesting compound structures have been disclosed by AIDD for targets where one could compare different approaches easily. In this presentation, we would like to analyze some computational results through AIDD and traditional CADD head-to-head for some well-studies drug targets, hoping to illustrate the potential values for AIDD, as well as practical issues at this stage.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
吴 军 WU Jun	香港生物节律研究院有限公司中国区首席执行官 CEO, Mainland China, HK Bio-rhythm R&D Company Limited	香港生物节律研究院有限公司 –– 高发癌症 居家早筛 HK Bio-Rhythm R&D Company Limited -- Home-based Pre-screening of Cancer

项目简介

成立于2019年的香港生物节律研究院有限公司是一家创新生物科技研发企业，专注于进行居家疾病早筛设备和分析系统的研究及开发。基于多个曾诺贝尔生物医学奖的基础理论研究，以及异常细胞代谢热机理，我们研发并推出了“乳腺生物节律监测系统”及监测设备。该系统拥有 AI 大数据支持，已通过国家级权威机构检测，可用于乳腺癌居家预警，填补了“细胞释热节律” 波形居家辅助自我筛查的国际市场空白。目前正通过与保险公司、体检中心等合作的方式进行商业化推广。 香港节律将继续进行产品研发和临床试验，推动产品纳入国家医保。我们的目标是建立中国最大的生物节律数据库，成为国际肿瘤居家筛查领域的领导者和标准制定者。

Project Introduction

Founded in 2019, HK Bio-rhythm R&D Company Limited is an innovative biotech R&D company, focusing on the research and development of home-based illness pre-screening equipment and data analysis systems. Based on several Nobel Prizes awarded physiological theories, and our research in the thermal mechanism of abnormal cell metabolism, we developed the "Breast Bio-Rhythm Monitoring System" and monitoring equipment. The system is supported by big data and AI technologies. It has passed the test of national authorities and can now be used for home-based early warning of breast cancer. We are commercialzing our product and services in B2B model co-operating with business partners like insurance companies and body check centers. HK Bio-Rhythm R&D Company Limited will continue conducting product R&D and clinical trials. We aim to get our product and services included in the national medical insurance catalog, build the largest biorhythm database in China and become a leader and standard-setter in the field of international oncology home screening.

张宏波 ZHANG Hongbo	北京望石智慧科技有限公司 CEO 助理 & 药化总监 CEO Assistant & Director of Medicinal Chemistry, Beijing StoneWise Technology Co., Ltd	AI 时代的小分子创新药设计与开发 Novel Drug Design in The AI Era

项目简介

本次路演将重点介绍本土小分子药物研发创新升级所带来的机遇和挑战、AI 技术在小分子药物研发中的技术应用逻辑、以及推动相关技术成熟和应用落地的实践方法。

望石智慧致力于技术驱动药物研发，其受到国内顶级科技和医药投资机构的青睐。近期也在美国 ACS 作为业界首次实现了基于电子云密度表征的 3D 口袋生成技术。

Project Introduction

We will discuss the opportunities and challenges brought by the ever growing domestic R&D upgrade and the accompanying needs for innovation, the adoption of AI technologies, as well as real world practices.

Stonewise is dedicated to enabling novel drug R&D with innovative technology, backed by leading tech and bio investors in China. In the recent ACS, Stonewise has first in the industry to realize 3D pocket generation technology using representation by electron density.

创新研发服务专场
R&D Service Company Roadshow

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
闻丹忆 WEN Danyi	上海立迪生物技术股份有限公司 董事长兼 CEO President & CEO, Shanghai LIDE Biotech. Co., Ltd.	MiniPDX® 赋能精准医疗和新药研发 MiniPDX® for Precision Medicine and New Drug R&D

项目简介

精准医疗 2.0 版是功能性诊断，最据代表性的是类器官和 PDX。安可唯 ® MiniPDX® 小鼠体内 7 天药敏检测，作为体内版的类器官，在肿瘤个性化精准医疗和创新药研发中发挥日益重要的作用。 MiniPDX® 将从新鲜的活检或手术样本、或胸腹水中制备的肿瘤细胞，放在中空纤维的三维立体胶囊中，植入小鼠体内，连续 7 天系统给药后，取出胶囊做定量分析，适合检测靶向药，细胞毒类药物，抗血管生成类药物，前药，ADC， PROTEC 等大分子和小分子类药物，免疫版的 MiniPDX 也在开发中。目前已检测各类肿瘤样本 2500 例，与临床结果总相关 >80%。 MiniPDX 也广泛用于临床适应症的探索和病人分层。

Project Introduction

Functional Diagnosis is 2.0 Version of Precision Medicine, Organoid and PDX are the two major representatives. OnceVee MiniPDX®, a 7 days in vivo drug efficacy test, is an in vivo version of the Organoid. It is getting more and more wildly used in personalized oncology and new drug R&D. MiniPDX®: fresh prepared cell suspension (from biopsy, surgery or hydroxy) were sealed into a holly fiber mini-capsule, implemented into mice. Drug were given systemically for 7 days. Capsules were taken out for quantitively analysis after 7 days systemic dosing. MiniPDX is suitable for testing targeted drug, chemo, angiogenesis, pro-drug, ADC, PROTEC. Imuno-Oncology version of the MiniPDX is also under development. 2500 samples have been tested with over 80% corresponding rate to clinical end point. MiniPDX mouse trial is also widely used for identifying clinical indication and patient stratification in new drug R&D.

闫　慧 Angela YAN	缔脉生物医药科技 (上海) 有限公司 中国区总裁 China President, dMed Biopharmaceutical Co., Ltd.	助力中国国际化创新 Advance China's Internationalization Innovation

项目简介

中国已经由“创新元年”进入“出海元年”。“创新出海”可以让中国药企融入全球创新的生态圈，更好地吸纳人才和技术，充分与国际接轨。同时，也可实现企业经济的最大化和进一步可持续发展。

当代中国医药创新已经开始重新定义世界，CRO 也将以中国分量来重新定义未来，助力中国创新的国际化。未来的 CRO，应当具备的三个条件：真正的全球化网络，能在全球范围内开展高质量临床试验；深耕中国，拥有深厚的资源和知识，深刻理解中国客户（尤其是 Biotech）的需求；“大脑 + 四肢”功能健全，包括具备丰富且前沿的医学知识和药物开发经验。合格的 CRO 要以强烈的主人翁精神和高度的责任心，成为创新药企的临床开发伙伴。

Project Introduction

China has entered the "First Year of Innovation" into the "First Year of Going Overseas ". "Innovation going to sea" can enable Chinese pharmaceutical companies to integrate into the ecological circle of global innovation, better absorb talents and technologies, fully be in line with international standards. At the same time, it can also maximize the enterprise economy and further sustainable development.

When Chinese pharmaceutical innovation has begun to redefine the world, CROs will also use China's power to redefine the future and advance internationalize Chinese industry innovation. The future CROs should have three features: a truly global network that can carry out high-quality clinical trials worldwide; strongly positioned in China, with deep resources and knowledge, and a profound understanding of the needs of Chinese clients (especially Biotech); and sound function of "brain + limbs" including rich and cutting-edge medical knowledge and drug development experience. Qualified CROs should have a strong sense of ownership and a high sense of responsibility to be reliable clinical development partners of innovative pharmaceutical companies.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
赵建民 ZHAO Jianmin	国信医药科技（北京）有限公司副总裁 兼首席统计官 VP, GX Pharma Technology (Beijing) Co., Ltd.	真实世界研究中的生物统计师 Biostatiscian in Real World Study

项目简介

传统临床试验设计强调控制混杂因素，从而优化数据质量。人们笃信 RCT 是检验效果的金标准，是反映因果关系最有效的手段。生物统计师的价值体现在实验设计，数据分析，量化决策等几方面。

《真实世界证据支持药物研发与审评指导原则（试行）》的发布，被业界与学界评价为一个里程碑式的事件。真实世界研究多数以非干预观察性研究为主。相较于 RCT 研究，真实世界研究中的因果推断需要特别注意对混杂效应的调整，需要用到相对较复杂的统计模型和分析方法。

生物统计师不是魔法师，不能因为想得到某种统计结论就采取有偏倚的统计方法，否则得出的所谓真实世界证据就不是客观准确的。

Project Introduction

Traditional clinical trial design emphasizes the control of confounding factors to optimize data quality. People firmly believe that RCT is the gold standard for testing effects and the most effective means of reflecting causality. The value of biostatistician is embodied in several aspects such as trial design, data analysis, and quantitative decision-making.

The release of "Guidance for Drug Development and Evaluation Supported by Real World Evidence (Trial)" was treated as a milestone by industry and academia. Most real world studies are non-interventional observational ones. Compared with RCT research, causal inference in real world study requires special attention to the adjustment of confounding effects, and requires the use of relatively complex statistical models and analysis methods.

Biostatisticians are not magicians, as they cannot choose biased statistical methods just because they want to obtain certain statistical conclusions, otherwise the so-called real world evidence obtained will not be objective and accurate.

戴学东 DAI Xuedong	上海美迪西生物医药股份有限公司 国际研发服务部执行副总裁 Executive Vice President Head of International Discovery Service Unit of Shanghai Medicilon Inc.	CRO 如何助力药企的国际化发展策略 How CRO Assist Strategical Globalization and Development of Pharmaceutical Companies

项目简介

药企的目标是能发现新的药物并让新药成功进入市场。CRO 能提供一站式服务，从药物发现到临床前研究，助力 IND 申报。IND 申报不限于中国 NMPA，还包括了美国 FDA、澳洲 TGA 和欧洲 EMA，是在筹备国际化发展的药企的必经之路。 1. 合作模式 –FTE 类型合作：从先导化合物开始，得到临床候选化合物并申报进入临床测试。 – 项目整体外包合作：从 API 到制剂再到临床前研究。工艺的优化和后续安全性的优化。 2. 国际服务部 – 为国际客户提供更优质的服务，为客户从新药发现至新药申报整个过程中产生的任何问题提供解决方案。

Project Introduction

The aim for any pharmaceutical company is to discovery new drugs and to enter the market successfully. CRO provides a one-stop shop service, from discovery to preclinical researches to aid IND registration. IND registration is not limited to NMPA in China, but also includes FDA (U.S), TGA (Australia) and EMA (Europe), which are unavoidable routes for a pharmaceutical company preparing for globalization. 1. Collaboration models -Integrated services/FTE: from HTS leading compound to obtaining clinical candidate compounds and to have these candidates enter the clinical testing phase. -Project outsourcing: from API to formulation and preclinical studies. Optimization of process development and safety of the candidate. 2. International Discovery Service Unit (IDSU) -to provide high quality for our international clients or international projects of clients. To solve any problems encountered during the whole process from drug discovery to IND registeration.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
熊金城 Jason XIONG	润东医药研发（上海）有限公司商务发展负责人 BBD, Rundo International Pharmaceutical Research & Development Co., Ltd.	临床 CRO 的技术创新赋能药物研发 Innovation of Clinical CRO Empowering Drug Development

项目简介

润东医药研发（上海）有限公司成立于 2004 年，致力于为客户提供符合 ICH-GCP 和 NMPA 相关法规、专业规范的一站式临床研究全程服务。润东医药是行业内首家通过 ISO9001:2008 质量管理体系并结合 CRO 行业规范认证，在成立的 17 年里，累积执行完成超过 1400 项临床试验，其中 60% 以上是创新药项目。作为中国国内领军的临床 CRO 公司，润东医药是中国 CRO 联盟（CROU）的主要发起者和推动者，现为 CROU 的理事长单位，中国医药质量管理协会 CRO 分会的会长单位，同时也在探索创新模式和数字化技术，不断转型成为创新型、综合型 CRO 公司。

Project Introduction

Rundo International Pharmaceutical Research & Development (Shanghai) Co., Ltd. was founded in 2004, dedicating in providing One-stop full CRO service to our clients in compliance with ICH-GCP and NMPA regulations and professional standard, services includes Regulation Affairs, Medical Affairs, Project Management, Clinical Operations, Biometrics, Pharmacovigilance, SMO, etc. Rundo is the first domestic CRO accredited with ISO9001: 2008 Quality Management System and CRO Industry Standard Certification. Within 17 years of service, Rundo has completed more than 1400 clinical studies, of which over 60% are innovative drug studies. As one of the leading CROs in China, while being the main founder and facilitator of the Chinese CRO Union (CROU), and current chair of CROU, Rundo is continuously exploring innovative models and digital technologies to facilitate the transformation into an innovative and comprehensive CRO.

付　萌 Amanda FU	锐得麦医药创始人兼首席执行官 Founder & CEO, Redbud Medicine Co., Ltd.	为创新药出海赋能，国际多中心临床的全球战略合作伙伴 Next Generation Global Clinical CRO- Strategic Partner with Emerging Biotech Companies

项目简介

立足先驱者，探索无界，锐得麦医药，以前瞻的国际视野开辟一条崭新道路，基于全球视野的临床试验及 AI 驱动的数据管理技术，深入扎根中美全球重要的两个新药研发市场，秉持着“资源共享，共生共赢”的服务理念，链接全球顶尖医药资源及一流科研实力，致力于成为中国创新药企业迈向全球市场的战略合作伙伴；

汇生命科技，聚共赢生态，以创新药开发为核心，优化临床试验流程，从早期产品立项入手，加快多国家多地区，临床开发策略的拓展，基于 AI 驱动的智能数据库及全球一流的科研人才团队，不断连接更新更广的服务空间；从注册事务到医学策略，从靶点验证到生物标记物开发，从临床运营到数据管理和统计分析服务，锐得麦以强大的专业资源和全面的业务服务，与中国创新药企携手迈向中国医药新高度。

Project Introduction

Redbud Medicine is a global clinical development strategic partner CRO rooted in China and U.S., top two new drug R&D markets globally. By applying intelligent technologies, Redbud optimizes and accelerates every single process within clinical trials, and ultimately lower the operation cost and accelerate the clinical study process. Redbud runs a broad network of world-wide well-known principle investigators and experts. The physician database enables Redbud be able to execute fast clinical trials with top quality of data.

Currently, The China domestic market has a lack of China-rooted global clinical CRO being able to run global clinical studies with compliance in ICH guideline. While global CROs in China lack of attention on small biotech companies need, trials conducted overseas need intensive communication with local language.

Redbud Medicine is founded to fill this gap with global clinical operation team based in US and China. The founders of Redbud have years of global experience in new drug development, operation, and interactions with regulatory agencies. Redbud Medicine is designated to minimize clinical development risks, unify drug submissions internationally, and push forward commercialization process.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
董正伟 Harvey DONG	厦门艾德生物医药科技股份有限公司 业务拓展部高级总监 Senior Director of Business Development, Amoy Diagnostics Co., Ltd.	伴随诊断助力肿瘤新药研发 Companion Diagnostics Facilitate Development of Innovative Oncology Therapeutics

项目简介

厦门艾德生物医药科技股份有限公司由国家特聘专家郑立谋教授于 2008 年回国创办，聚焦在肿瘤精准医疗分子诊断领域，专注于科技惠民的技术创新，致力为患者提供合规、高品质的诊断产品和服务，让患者从精准医疗中真正获益。公司产品覆盖具备精准医疗条件的各大癌种，多个产品为目前 NMPA 独家获批产品，除了在国内三甲医院大规模应用外，部分产品在日本、韩国获批上市并进入当地医保，开创了我国肿瘤伴随诊断海外获批的先例。公司瞄准行业创新源头，以伴随诊断赋能原研药物临床，是阿斯利康、强生、安进、礼来、默克、卫材、恒瑞、百济等国内外顶级药企肿瘤药物开发的战略合作伙伴，共筑肿瘤精准医疗的未来。

Project Introduction

Amoy Diagnostics Co., Ltd. (AmoyDx) is an R&D based diagnostic company, focusing on molecular diagnostics for oncology precision medicine. With completely independent intellectual property rights of ADx-ARMS®, Super-ARMS®, ddCapture® and ADx-HANDLE® technologies, AmoyDx has a market-leading portfolio of molecular diagnostic assays. Based on multiple technology platforms including PCR, NGS, FISH and IHC, AmoyDx's core product categories include but not limit to single gene testing kits, multi-gene testing panels, NGS panels and NGS analytical systems. In the past years, more than 20 diagnostic kits have been approved by the Chinese authorities, the NMPA and in Europe (CE mark). In several External Quality Assessment (EQA) programs, including EMQN and PQCC, AmoyDx is the NO. 1 testing kit supplier for years and always achieves the highest accuracy rates.

孔令洁 KONG Lingjie	苏州博腾生物制药有限公司首席技术官 CTO, Porton Biologics Ltd.	端到端的 CDMO 服务助力基因细胞治疗药物研发 End-to-end CDMO Services Help Gene Cell Therapy Drug Discovery

项目简介

细胞和基因疗法（CGT）不仅改变了人类治疗遗传疾病和疑难杂症的方式，同时也正在颠覆整个制药生态圈。目前，全球共推出超过 28 种 CGT 产品，据预测，全球 CGT 市场规模有望在 2025 年超过 119.6 亿美元。CDMO 可为 CGT 在研发生产流程中各阶段提供产能支持，帮助药企选择适合的细胞或载体并进行优化从而减少试错成本、提高研发成功率，其丰富的生产平台和严格的质检措施也可以帮助药企削减商业化生产成本和时间。博腾生物专注于基因与细胞治疗 CDMO，充分利用团队的丰富经验和合规的 GMP 设施为客户提供从质粒、病毒载体和细胞类产品的开发、GMP 生产及分析到质量控制的优质服务。

Project Introduction

Cell and gene therapy (CGT) is not only changing the way we treat genetic and difficult diseases, it is also upending the entire pharmaceutical ecosystem. At present, more than 28 CGT products have been launched worldwide, and it is predicted that the global CGT market size is expected to exceed 11.96 billion US dollars by 2025. CDMO can provide production capacity support for CGT in all stages of R&D and production process, and help pharmaceuticals companies to select and optimize suitable cells or carriers to reduce the cost of trial and error and improve the success rate. Its flexible production platforms and strict quality control system can also help drug companies to reduce the cost and time of commercial production.

Here at Porton Biologics, we provide know-how of our experienced teams and our industrial facilities for gene and cell therapy to our customers. Our services include process development, GMP manufacturing, analytical and quality control of plasmid DNA, viral vectors and cell therapy products.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
陈晋宇 Wayne TAN	北大未名（合肥）生物制药有限公司首席执行官 CEO, Peking University V-Ming (Hefei) BIologics Co., Ltd.	北大生物——为您打入欧美日市场的生物大使 Peking University Biologics——"Biologics Ambassador" to China, Japan, USA, and Europe
张安雷 Alan CHANG	泰宏科学有限公司首席执行官兼创始人 CEO & Founder of Taron Solutions Limited	

项目简介

北大生物拥有多年的生物制药规模化，优化和技术转让经验，专注于生物药物从基因开发到 CMC 准备，IND 申报等。我们的管理团队在药物开发，GMP 生产和监管方面积累了多年的经验 (NMPA, FDA, EMA, PMDA 等) 以帮助药物开发公司满足监管要求。 我们有经验并有能力将您的药物开发从中国推向国际市场，满足相应机构的监管要求，获得 IND 批准，进行临床试验，获得药证，商业化生产至销售 (特别是在日本市场), 而无需在各自的国家“实际”设立和运营。 北大生物是您在国际医药市场的“生物大使”！

Project Introduction

Peking University Biologics has many years of biopharmaceutical scale-up, optimization, and technology transfer experience focuses on biologic drugs from gene development to CMC readiness, IND submission, etc. Our management team has accumulated years of experience in drug development, GMP production, and regulatory experience (NMPA, FDA, EMA, PMDA, etc.) to help drug development companies fulfill regulatory requirements. PKU Biologics complements and enhances the work done by academia and drug development company, by bringing commercial value to their innovation and advancing their drug product to the international market. We are experienced and capable to bring your discovery drug from China to the international market, meeting the respective agency regulatory requirement, obtaining IND approval, conducting clinical trials, getting your drugs approved, and ever generating sales revenue (especially in the Japanese market) without the necessity for your company to set up and operate “physically” at the respective countries. Peking University Biologics is your “Biologics Ambassador” to the international pharmaceutical market!

李原强 LI Yuanqiang	浙江九洲药业股份有限公司首席科学官 CSO, Zhejiang Jiuzhou Pharmaceutical Co., Ltd.	创新药大环境下 CDMO 企业的机遇和挑战 Opportunities and Challenges of CDMO Enterprises under the Environment of Innovative Drugs

项目简介

首先介绍 CDMO 行业背景， 其次详细介绍九洲药业 CDMO 业务 。

九洲药业 CDMO 事业部 (浙江瑞博制药) 是中国领先的 CDMO 企业，十多年来向全球跨国药企和新药研创公司提供全面的委托研发和定制生产服务，服务涵盖新药临床前药学研究、临床及各阶段原料药工艺研发和生产、到商业化生产的全业务链。瑞博制药拥有瑞博台州、瑞博杭州、瑞博苏州和瑞博美国四个基地，研发团队有合成研发和分析研发高层次研发人才 400 多名，团队由国际顶尖人才领衔，成功交付 1000 个项目，含中美双报项目。瑞博制药的研发团队在手性合成、氟化学和生物催化等技术领域拥有专利核心技术，能够为客户提供最专业的新药研发解决方案。

Project Introduction

Firstly introduce the background of CDMO industry, then introduce the Business profile of Jiuzhou CDMO.

Jiuzhou CDMO BU (Zhejiang Raybow Pharmaceutical Co., Ltd) is committed to providing “One-Stop Service” to global partners, covering the stages from new drug preclinical research all the way to commercial production, has more than 2000 global employees. Raybow Pharma has two production sites (Raybow Suzhou, Zhejiang Raybow) and three R&D centers (Zhejiang Raybow, Raybow Hangzhou, Raybow US). ZhejiangRaybow is committed to the research and development of new pharmaceutical technology, especially in the area of high-end fluorine chemistry, asymmetric synthesis, glycosides, high potency synthesis, and biological enzyme technology. This reflects Raybow’s high level of technical research and development strength.

The company has passed official audits of the FDA, NMPA and AIFA/PMDA many times and passed EHS audits by multinational companies on a regular basis. At present, Raybow Pharma is the only CDMO enterprise in China contract manufacturing APIs for blockbuster drugs by multinational pharmaceutical companies.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
罗　敏 LUO Min	广州百暨基因科技有限公司总经理 CEO, Guangzhou Bio-gene Technology Co., Ltd.	广州百暨——引领全球 AML 细胞治疗 Guangzhou Bio-gene leads the world in AML cell therapy

项目简介

CAR−T 赛道尤为火热，下一个 CAR−T 突破的领域会是什么？在 2021 年 ASCO 口头报告上，我们披露了百暨 BG1805（anti−CLL1 CAR−T）在治疗复发 / 难治性多发性骨髓瘤（R/RMM）的 IIT 临床研究的数据。初步统计 11 例 AML 患者的总体有效率（ORR）达到 82%，完全缓解率（CR）为 73%。安全性方面，患者仅发生 1−2 级 CRS，无免疫效应细胞相关神经毒性综合征（ICANS）。除了进展较快的 BG1805（CLL1 CAR−T），百暨基因的基于 γδT 的通用型细胞平台（UCAR−γδT）在近期也取得了积极的研究进展。

Project Introduction

What will be the next breakthrough area for CAR-T? In our 2021 ASCO oral presentation, we presented data from the IIT clinical study of BG1805 (anti-CLL1 CAR-T) in the treatment of relapsed/refractory multiple myeloma (R/ RMM). The overall response rate (ORR) and complete response rate (CR) of 11 AML patients were 82% and 73% respectively. In terms of safety, the patient developed only grade 1-2 CRS and no immunoeffector cell associated neurotoxic syndrome (ICANS). In addition to BG1805 (CLL1 CAR-T), which has been developed rapidly, a general-purpose cell platform based on γδT (UCAR-γδT) has also been developed recently.

廖玉华 LIAO Yuhua	武汉华纪元生物技术开发有限公司运营总监 Director of Operations, Wuhan Huajiyuan Biotechnology Development Co., Ltd.	创新治疗性降压疫苗 Innovative Therapeutic Antihypertensive Vaccine

项目简介

HJY−ATRQβ−001 治疗性降压疫苗是廖玉华团队正在研发的国家生物一类新药候选药，是目前国际上领先的高新科技成果，本公司拥有国际首创自主研发的专利 11 项。公司目前已经掌握多肽治疗性疫苗关键 know−how 技术，完全自主掌握制剂制备技术工艺、质量评价标准、动物实验评价模型等产业化必备平台技术。目前，公司已经与国内知名的 CRO/CDMO 公司签订 IND 申报研究开发合同，正式进入 HJY−ATRQβ−001 治疗性降压疫苗产业化临床前研发阶段。

Project Introduction

HJY-ATRQβ-001 therapeutic antihypertensive vaccine is a national biological first-class new drug candidate being developed by Yuhua Liao's team, and is currently a leading high-tech achievement in the world. The company has 11 internationally first patents independently developed. At present, the company has mastered the key know-how technology of polypeptide therapeutic vaccine, and fully mastered the necessary industrialization platform technology of preparation technology, quality evaluation standard, animal experimental evaluation model and so on. At present, the company has signed an IND application research and development contract with a well-known domestic CRO/CDMO company, and officially entered into the pre-clinical development stage of HJY-ATRQβ-001 therapeutic antihypertension-vaccine industrialization.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
贺小宏 HE Xiaohong	南京北恒生物科技有限公司董事长 CEO, Nanjing Bioheng Biotech Co., Ltd.	免疫细胞疗法于肿瘤治疗未来之路 Immune cell therapy in the future of tumor therapy

项目简介

免疫细胞治疗针对血液相关肿瘤取得瞩目疗效，现已上市产品及各机构在研产品以自体型 CART 细胞疗法开发为主。由于其个性化制备的特殊性，导致免疫细胞治疗药物可及性及高昂价格使其应用受到限制。对于未来免疫细胞疗法下一步出路，依然重点是在解决其商业化及针对更广阔市场的实体瘤方面，期待通过不同形式的通用型免疫细胞疗法及实体瘤有效性方面的突破，使免疫细胞疗法更具有市场性及服务更多患者。

Project Introduction

Immunocell therapy has achieved remarkable efficacy for hematogenous tumors, and the products currently on the market and under development by various institutions are mainly self-shaped CART cell therapy. Due to the particularity of its personalized preparation, the availability and high price of immune cell therapy drugs restrict its application. As for the next step of immunocell therapy, the focus is still on the commercialization and solid tumors targeted at the broader market. We expect to make immunocell therapy more marketable and serve more patients through breakthroughs in the effectiveness of different forms of universal immunocell therapy and solid tumors.

肖　凯 Carl XIAO	泰励生物科技有限公司副总裁 VP, Tyligand Bioscience	FIC 肿瘤免疫双靶点小分子和多靶点激酶的开发 Development of FIC Immunoncology bispefic small molecue and muti-spefic kinase inhitor

项目简介

泰励生物科技于 2018 年成立于上海张江药谷， 团队立足于合成化学探索新的分子空间的能力，综合对生物靶点特别是蛋白磷酸酶的独特科学洞见和丰富的药物设计经验， 致力于针对肿瘤的自主创新药物研发和核心知识产权的创造， 目前有 7 个小分子在研项目全速推进。其中多激酶抑制剂 TSN084，具有针对 CDK8/19 的优异活性和 1st in Class 潜力，适应症包括三阴性乳腺癌及前列腺癌。预计 2021 年中向中美两国药监机构递交临床试验申请文件。业界首创肿瘤免疫 1st in Class 双靶点抗肿瘤免疫激动剂 PCC 也进入临床前开发阶段，预计 2022 年初向中美两国药监机构递交临床试验申请文件。

Project Introduction

Tyligand Bioscience was established in Shanghai Zhangjiang in 2018. The team is based on the ability of medicinal chemistry to explore new molecular spaces, combining unique scientific insights and rich drug design experience on biological targets, especially protein phosphatase, and is committed to the development of in-house innovative drugs for oncology and the creation of core intellectual property rights, there are currently 7 small molecule research projects advancing at full speed. Among them, the multi-kinase inhibitor TSN084 has excellent activity against CDK8/19 and 1st in Class potential. The indications include triple-negative breast cancer and prostate cancer. It is expected that the clinical trial application documents will be submitted to NMPA and FDA in mid-2021. The industry's first tumor immune 1st in Class Bispecific anti-tumor immune agonist PCC has also entered the preclinical development stage. It is expected to submit IND application NMPA and FDA in early 2022.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
李新燕 LI Xinyan	方拓生物科技（苏州）有限公司总裁 President, Frontera Therapeutics, INC.	AAV 基因治疗产品的研发和产业化 R&D and industrialization of AAV gene therapy products

项目简介

芳拓生物公司是一家由国际知名且实力雄厚的风投基金（泓元资本和奥博资本）投资创立的基因治疗公司，旨在研发和生产能够满足中国患者治疗需求、用得起的高质量基因治疗药物。公司创始人团队汇集了基因治疗领域全球知名的临床专家、病毒学家、基因专家、以及卓越的投资者，公司核心管理团队汇集了中美两地有创新药物研发、临床研究、注册和生产管理丰富经验的专业人员。公司现有员工近 70 人，已获融资 1.95 亿美元。 公司研发领域涉及眼科、血液病、神经肌肉和代谢系统疾病领域，2022 年将有项目进入临床试验阶段。 公司未来 3−5 年，将有近 10 款产品分别进入临床前、临床或者商业化阶段。

Project Introduction

Frontera Therapeutics is a gene therapy company founded by Creation Ventures and OrbiMed Advisors, both renowned funds in the biotech industry. Frontera is focused on developing and manufacturing high quality and affordable AAV based gene therapy products that meet the patient needs in China. The company's founders brings together world-renowned clinical experts, virologists, genetic experts, and outstanding investors in the field of gene therapy. The company's core management team is filled with experienced leaders in R&D, clinical research, registration and manufacturing in China and the United States. The company currently employs nearly 70 staff and has received a total of 195 million USD in financing. The company's research and development areas include ophthalmology, hematology, neuromuscular and metabolic diseases, and its leading program is expected to start clinical trial in 2022. In the next 3-5 years, the company will move nearly 10 products into preclinical, clinical and commercialization stages.

姜宝红 JIANG Baohong	中科院上海药物研究所研究员 Professor, Shanghai institute of material medica	抗缺血再灌注损伤新药 SR-01 New drug SR-01 against ischemia-reperfusion injury

项目简介

SR−01 是源于传统中药开发的化药 I 类新药，先后得到“重大新药创制”科技重大专项 (2013ZX09103002−024)、国家自然科学基金（81573646）、上海市科委科技支撑项目（16401901800）、中科院科技促进发展局（ZSTH−011、 KFJ−BRP−008）等纵向经费支持近千万。发表 SR−01 相关 SCI 研究论文 20 余篇，申请多项发明专列，全面维护 SR−01 的成药性进程。

Project Introduction

SR-01 is a new chemical medicine developed from traditional Chinese medicine. The research of SR-01 was supported by the National Science & Technology Major Project for “Key New Drug Creation and Manufacturing Program” (2013ZX09103002-024), the National Natural Science Foundation of China Grants (81573646), the Shanghai Science and Technology Development Foundation (14401900900, 21S21901900) and the Biological Resources Programme, Chinese Academy of Sciences (No. KFJ-BRP-008). There are more than 20 SCI publications and patents based on SR-01.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
黄成钢 HUANG Chenggang	中科院上海药物研究所研究员 Researcher, Shanghai Institute of Materia Medica, Chinese Academy of Sciences	抗抑郁 1.1 类化学创新药 The 1.1 class of chemically innovative medicine of antidepressant

项目简介

本项目系从动物口服中药后进入脑组织的成分中发现抗抑郁活性化合物。从中药提取该成分为先导化合物，进行半合成制备新结构衍生物。采用社交失败抑郁等多种慢性和急性动物模型，发现候选分子 YY−23 具有显著抗抑郁作用，起效时间快于氟西汀（百忧解）。安评预试（小鼠急毒和一个月连续给药）未见异常。机制研究显示，该化合物靶向 NMDA 受体，通过激活 mTOR 通路快速重塑皮层神经突触的结构和功能，起到快速抗抑郁作用。其作用靶点和机制不同于单胺类重摄取抑制剂药物（SSRIs）。目前已完成成药性评价，正在进行抗抑郁 1.1 类化学创新药的正式临床前研究。该项目获得国家新药重大专项资助。已申请中国、美国、欧洲和日本发明专利。

Project Introduction

The antidepressant is derived from the compounds entering the brain after orally administrated Chinese medicines. We extracted the compound as lead compound for structural modification, followed by the semi-synthetic structural derivatives. Pharmacodynamics using chronic and acute models, such as social failure , showed the candidate YY-23 had significant antidepressant effect, and the onset time is faster than fluoxetine (Prozac). Safety pre-test (acute toxicity in mice and continuous administration for one month) showed no abnormalities.Mechanism studies demonstrated that YY-23 activats mTOR pathway by targeting NMDA receptors, and rapidly reshaped the structure and function of cortical synapses, causing rapid resistance.This differs from traditional monoamine reuptake inhibitor (SSRIs). At present, the druggability evaluation of YY-23 has been completed, and the formal preclinical research of 1.1 class of chemically innovative medicine is underway. This project were funded by National Major Special Funding for New Drugs, and the invention patents in China, the United States, Europe and Japan were applied.

医疗器械专场
Medical Devices Roadshow

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
牛 伟 NIU Wei	长沙迈吉尔医疗科技有限公司 联合创始人及商务副总裁 Co-Founder & Commercial VP of Changsha Magill Medical Technology Co., Ltd.	新一代可视喉罩系统及高精度多功能便携输液泵 Next Generation Video Laryngeal Mask System and High Accuracy Multi-function Ambulatory Infusion Pump

项目简介

长沙迈吉尔医疗器械有限公司是一家专注于麻醉，重症和输液治疗领域的创新型医疗器械公司。目前已经开发出全球首创的可视喉罩系统及高精度便携输液泵，获得多项中国及国际发明专利。气道管理是手术麻醉中风险最高的环节之一，30% 的麻醉严重事故是由不当的气道管理引起。迈吉尔医疗 SafeLM® 可视喉罩系统，很好的解决了现有喉罩对位不准的问题，被国内外专家评为“全球首款第三代喉罩”。输液泵是临床最常用的医疗设备，全球市场规模约 70 亿美元。迈吉尔医疗 MP1000 高精度便携输液泵，采用专利的驱动结构，输液精度为同类产品中全球第一。MP1000 还具有小巧便携，输液速度高的优势，能够更好的满足未来输液设备需求。

Project Introduction

Changsha Magill Medical Co., Ltd. is an innovative medical device company, focusing on anesthesia, ICU, and infusion therapy. Magill Medical has developed a first-in-class video laryngeal mask system and a high accuracy ambulatory infusion pump. Both got Chinese patents and PCT. They have passed TUV testing and are going to get CE approval. Airway management is one of the riskiest processes in anesthesia. 30% of serious anesthesia adverse accidents are caused by failed airway management. Magill Medical SafeLM® video laryngeal mask system significantly decreases the malposition risk of the existing laryngeal mask. SafeLM® is regarded as the First 3rd Generation Laryngeal Mask by top anesthetists globally. Infusion pump is the most common medical device with 7 billion US dollar mark size. Magill Medical MP1000 is the world's highest accuracy ambulatory pump with innovative patent driving mechanism. It has also high infusion speed and compact size. MP1000 can best meet the infusion needs in the future.

杨 劼 YANG Jie	贝罗尼集团精准医疗国际研究中心副总裁 Vice President of International R&D Center for Precision Medicine of Beroni Group	贝罗尼黄病毒四联鉴别诊断试剂盒 CII-ArboViroPlex rRT-PCR assay Beroni’s Flavivirus Detection Kit -- CII-ArboViroPlex rRT - PCR assay

项目简介

目前虫媒病毒尤其是黄病毒感染的发病率不断提升，感染后果严重且无特效药，其中寨卡病毒感染孕妇会导致胎儿小头畸形，因此急需更有效、快速、准确的产品检测和鉴别常见黄病毒。贝罗尼黄病毒四联鉴别诊断试剂盒 CII-ArboViroPlex rRT-PCR assay 由贝罗尼集团联合美国哥伦比亚大学 Walter Ian Lipkin 教授实验室研发，是全球唯一利用 rRT-PCR 方法同时检测寨卡、登革热、基孔肯雅和西尼罗河病毒并获得 FDA 的 EUA 和欧盟 CE 认证的产品，已获得 4 项国际发明专利和东南亚等国家的意向订单。基于此项目，贝罗尼集团已建成感染与免疫中心及病原微生物发现平台，打造病原微生物快速诊断的技术高地。

Project Introduction

In recent years, the incidence of arbovirus, especially flavivirus, has increased year by year. After infection, the patient’s condition is serious and there is no specific medicine. Among them, Zika virus infection in pregnant women will cause fetal microcephaly. So a more efficient, faster, and more accurate method to detect and identify common flavivirus is needed urgently. Beroni’s CII-ArboViroPlex rRT - PCR assay developed by Beroni Group and Prof. Walter Ian Lipkin’s lab of Columbia University is a multiplex assay that can simultaneously test, detect and differentiate the Zika virus (ZIKV), Dengue virus (DENV), Chikungunya virus (CHIKV) and West Nile virus (WNV) by means of multiple rRT-PCR, and is approved for emergency use by US FDA and is CE certified. At present, it has filed 4 international invention patents. We have received intention orders from 4 countries including Malaysia and Indonesia. Based on that, Beroni Group has established an Infection and Immunity Center and a Pathogenic Microorganism Discovery Platform for rapid diagnosis of pathogenic microorganisms.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
李笑微 LI Xiaowei	艾康特医疗科技有限公司 创始人及首席执行官 Founder & CEO of VisionX	眼视光全套创新医疗器械解决方案 VisionX - An emerging leader in China's vision care devices market

项目简介

艾康特医疗科技，致力于眼科眼视光领域医疗器械全套解决方案的研发和生产，公司拥有在医疗器械的生产、质量和设计开发具有丰富经验的专业团队；目前在上海、珠海、杭州、温州等地拥有配置完备的医疗器械生产和研发设施。目前公司研发和生产五个产品系列：1）青少年近视防控产品，包括 OK 镜和多焦点角膜接触镜；2）成人不规则角膜视力矫正产品，包括巩膜镜以及特殊设计角膜接触镜；3）眼视光检查设备；4）眼科接触镜全套护理产品系列；5）软性隐形眼镜产品系列等。以上多个产品系列均为三类医疗器械，并已正在开展上市前多中心临床试验阶段。除此之外，公司已启动立项干眼疾病领域等新产品管线的研发。

Project Introduction

VisionX is a China-based eye care devices company dedicated to bringing innovative ocular health products to children and adults. Established in 2018, we aim to provide the widest array of vision care offerings in China with products including 1) advanced myopia management products (Ortho-K lenses and RGP) for teenagers, 2) innovative vision correction products (scleral lenses and RGP) for adults, 3) disposable, reusable and color-enhancing contact lenses, 4) diagnostic instruments in eye clinics, 5) contact lens solutions, and 6) products for dry eye treatment. VisionX makes continuous R&D commitments to strengthen its comprehensive portfolio for vision care and routinely screens for external innovation opportunities worldwide to broaden its existing product offerings. We look forward to working with Chinese ophthalmologists and taking vision care to the next level to help more people see better and live better!

何 峰 Victor Ho	瑞脉医疗集团副总裁及董事 Vice President and Director of Sramek Group Inc.	无创智能心血管检测系统 Non-invasive hemodynamic system for cardiovascular screening

项目简介

最初，美国太空总署（NASA）将该项无创心功能技术用于宇航员心功能状态监测，用于宇航生理研究，开创了无创心功能技术的先河。其后由波特瑞默博士 (Dr. Bo Sramek), 升级为 TEBCO，一方面提高精准度，同時也利用 HOTMAN 软件进行数据分析。以胸腔阻抗法（TEB）为基础的无创心功能测定方法，为连续监测血流动力学变化和对心功能进行评价提供了一种新的方法。该方法具有安全无创、操作简便、准确可靠、重复性好等特点，而且可连续监测多个参数。自从 1998 年以来，对无创心功能的准确性进行了确认。多项国内外临床研究结果表明：与有创检测结果相比，该技术具有很高的相关性和精确性，因此在多个医疗领域有重要应用价值。

Project Introduction

Initially, the US National Aeronautics and Space Administration. (NASA) used this non-invasive hemodynamic technology for astronauts' cardiac function monitoring and physiological research. Later, Dr. Bo Sramek was upgraded to TEBCO, which improved accuracy on the one hand and also used HOTMAN software for data analysis. The non-invasive hemodynamic measurement method based on thoracic impedance method (TEB) provides a new method for continuous monitoring of hemodynamic changes and evaluation of cardiac function. The method is safe, non-invasive, easy to operate, accurate and reliable, and reproducible, and it can continuously monitor multiple parameters. The accuracy of non-invasive hemodynamics has been proven medically and obtained FDA clearance since 1985. Therefore, it is used in many medical insitutions and support preventive medicine.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
万颖瑜 Sean WAN	浙江瑞华康源科技有限公司首席技术官 CTO of Zhejiang Rivamed Science & Technology Co., Ltd.	瑞华康源智慧管理解决方案 Rivamed Intelligent management solutions

项目简介

随着医疗机构的不断升级，智慧医院建设过程中需要医院进行多维度的互联互通 . 医院人员、物资、信息的协同，医院各科室间的协同，以及不同角色如患者、医生、护士等的协同都需要以科学有效的方法提升医疗机构的管理能力。 以手术室为例，作为医院重要收入来源及最为复杂的平台科室，其人员结构、物资调拨及手术复杂程度都影响手术室整体运行效率。瑞华康源利用物联网、5G、大数据等技术，打造智慧管理整体解决方案，将医院的人、财、物数据进行追踪、采集、处理、分析。其平台化的智慧医院建设真正实现医疗生态圈中的云、大、物联相互协同的智慧医院。

Project Introduction

With the continuous upgrading of medical institutions, multi-dimensional connectivity of hospitals is required in the construction of Intelligent hospitals.The coordination of hospital personnel, consumable and information, the coordination of hospital departments, and the coordination of different roles such as patients, doctors and nurses all need to improve the management ability of medical institutions in a scientific and effective way. as an example for operating room, as an important source of income and the most complex platform department of the hospital, its personnel structure, consumable allocation and operation complexity all affect the overall operating efficiency of the operating room.Rivamed uses the IOT, 5G, big data technologies to create an overall solution for intelligent management, and track, collect, process and analyze the hospital's human, financial and consumable data.The construction of its platforming smart hospital truly realizes the interconnection of cloud, big data and IOT in the medical ecosystem.

徐　百 XU Bai	苏州纳生微电子有限公司董事长 Chairman of Suzhou Nasheng Microelectronics Ltd.	新型纳米晶片透皮技术的开发和产业化 Development of Novel Nanochip-based Transdermal Drug Delivery Technology and its Clinical Applications

项目简介

打针不是愉快的事，但许多大分子药物，包括疫苗，都需要注射给药，才能保持药物活性。我们用 18 年时间，率先开发了部分取代打针的新型透皮医疗器械——纳米晶片。纳米晶片只穿透对药物起屏障作用的角质层，不触及真皮层，实现透皮给药，避免了注射给药的疼痛，已形成以 38 项国内外授权专利为基础的自主知识产权体系，目标产品新型纳米给药器械已用于皮肤科疑难杂症等多种疾病的治疗，新型透皮导入的给药方式可减少对皮肤的刺激，精准控制药物渗透速度和渗透量，其成功推广将率先解决胰岛素等大分子药物需注射给药的难题。

Project Introduction

Most people dislike needles, however, needle injection is still the method of choice to deliver many medicines including vaccines. We have developed a novel transdermal nanochip delivery device that compromises stratum corneum only without touching the blood vessels and nerve ending in dermal layer. The company has 38 issued patents covering China, US and major industrialized countries. The device has been successfully used by dermatologists to treat difficult-to-cure skin conditions such as melasma, acne etc. Because of features like non invasive, no injection and more accurate dose control of this novel transdermal drug deliver method, it can be used to deliver large molecules such as insulin for diabetes care.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
张海川 ZHANG Haichuan	赛雷纳（中国）医疗科技有限公司 创始人 / 董事长 / 总经理 Founder/Chairman/CEO of Celula (China) Medical Technology Co., Ltd.	聚焦生殖健康，提供完整普惠的 IVD 产品 Highlight reproductive health, offer intact and inclusive IVD products

项目简介

赛雷纳（中国）医疗科技有限公司是一家拥有先进诊断技术的高新科技企业，于 2013 年在成都设立总部，并分别在上海、珠海横琴，北京和美国加利福尼亚州圣迭戈市设立分公司和办公室。企业拥有 5000 余平米完整的研发、产品转化、生产和服务基地，近百人的多学科技术和营销团队。通过多年在美国和中国的技术研发，已成功推出适合中国各级医疗机构的小型化 Sparrow 流式细胞仪，配套生殖，免疫等多项重大疾病的检测试剂盒。赛雷纳还拥有新一代靶向型无创产前基因检测（NIPT）技术，产品拥有检测更准确，更多检测内容和更低成本的明显优势，可在更早的孕周和更广的人群普及。

赛雷纳（中国）将持续进行技术创新，提供最完整、最惠普的诊断产品。

Project Introduction

Celula China Med-Technology Co., Ltd. is a high-tech enterprise with advanced diagnostic technologies. The company established headquarter in Chengdu 2013, and subsidiaries in Shanghai, Zhuhai/Hengqin, Beijing and San Diego. It has more than 5,000 square-meter facility for R&D, commercial operation and close to 100 employees with multidisciplinary technical background and commercial experiences. Through years of technology development in both US and China, the company has successfully launched miniaturized Sparrow flow cytometer and IVD reagent kits for reproductive health, immunology and other important diseases. The product is designed for all levels of hospitals and clinical laboratories in China. Celula China has also developed a novel NIPT technology based on targeted sequencing. Its product has advantages in higher accuracy, expanded test content and lower cost, which can be applied to all pregnant women in earlier gestational weeks.

Celula China will continue technology innovations, provide the most complete and cost effective IVD products.

尤其敏 YOU Qimin	杭州优思达生物技术有限公司 创始人 / 首席科学家 Foundr/Chief Scientific Officer of Ustar Biotechnologies (Hangzhou) Ltd.	分子 POCT 诊断技术平台的发展：我们需要什么？我们在做什么？ The development of molecular POCT diagnostic technology platform: what do we need? What are we doing?

项目简介

优思达（USTAR）是一家致力于创新型 POCT 分子诊断产品研发、生产和销售的高新生物科技公司。公司拥有多项自主知识产权和快速分子检测技术平台，截止目前全自动核酸检测设备已覆盖全国 2000 多家医院，和全球五十多个国家，公司致力于分子诊断新技术平台的开发：

1. 可用于基层的核酸家庭自检产品
2. 全自动、高通量的核酸检测产品
3. 多重检测
4. 点突变检测
5. 理想产品：POCT + 高通量 + 多重检测 + 点突变检测

我们致力于让分子诊断和检测不再依赖于昂贵的仪器和高要求的分子实验室，从而真正得到普及应用，落实到千家万户，让大众受益，即“分子诊断，随处可行”。

Project Introduction

USTAR is a high-tech biotechnology company dedicated to the development, production and sales of innovative POCT molecular diagnostic products. The company has a number of independent intellectual property rights and rapid molecular detection technology platforms. Up to now, fully automatic nucleic acid detection equipment has covered more than 2,000 hospitals across the country and more than 50 countries around the world. The company is committed to the development of new molecular diagnostic technology platforms:

1.Nucleic acid self-testing products that can be used at home
2. Fully automatic, high-throughput nucleic acid detection products
3. Multiple detection
4. Point mutation detection
5. Ideal product: POCT + high throughput + multiple detection + point mutation detection

We are committed to making molecular diagnostics and testing no longer dependent on expensive instruments and high-demand molecular laboratories, so that they can be truly popularized and applied to thousands of households to benefit the public, that is, "Molecular Testing,Anywhere!"

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
方彬彬 FANG Binbin	币冠（上海）生物科技有限公司首席执行官 CEO of Day6 Shanghai Biotech Co., Ltd.	新一代多重分子微流控即时诊断平台 Sample in- Result out ——the next generation of syndromic testing platform

项目简介

币冠生物历时数年研发可快速鉴别多种感染源的智能化分子诊断平台——IO 系列分子诊断一体机，采用高效固相侧流核酸提取、多重实时荧光 PCR、全集成式微流控及冻干技术，具有核酸提取效率和纯度高、检测灵敏高的特点，可在一次测试中半定量和定量地分析多达 72 项病原体分子靶标，不仅直接给出准确直观的检测结果，还能让用户看到原始扩增曲线和 Ct 值，为鉴别混合感染、定植菌、条件致病菌，提供准确可靠的证据，可广泛用于呼吸道、胃肠道、生殖道等传染病检测，全面覆盖已知常见致病微生物和耐药菌。

Project Introduction

Day6.io Versatile Multiple Assay Automaton Full automation from Sample Input to Result Output: sample preparation, NAT extraction, qPCR reactant mixing, thermocycling, optical readout, data analysis, cloud storage, mobile acces (sample-to-answer)

马　林 MA Lin	英赛诊断首席运营官兼总经理 Insightmatix Diagnosis COO & General Manager	基于机器学习的宿主免疫分析技术：诊断感染的新方法 Host immune analysis technology based on machine learning: a new method for diagnosing infections

项目简介

Inflammatix 是一家起源于美国斯坦福大学的创新型生物技术及人工智能技术公司，其开创性地将基于机器学习的宿主免疫分析技术与分子 POCT 技术相结合，研发出能够实现早期、快速诊断急性感染和脓毒症的突破性分子诊断技术 InSep。其已获得美国 FDA 的突破性医疗器械认定，可用于医院急诊及危重症监护住院病人在不同临床环境下（急诊室、ICU 重症监护病房）诊断（或排除）急性感染和脓毒症，并预测感染严重程度和后续风险。

Project Introduction

Inflammatix is an innovative biotechnology and artificial intelligence technology company that originated from Stanford University in the United States. It pioneered the combination of machine learning-based host immune analysis technology and molecular POCT technology to develop an early and rapid diagnosis tool for acute infections and sepsis - InSep, which has been certified as a breakthrough medical device by the U.S. FDA and can be used to diagnose (or rule out) acute infection and sepsis in hospital emergency and critical care inpatients in different clinical environments (emergency room, ICU), and predict severity of infection and subsequent risk.



会议品牌效应逐年凸显
The brand influence of CBIIC is more and more significant every year



参会企业名单 »»»

Participating Company List

参会企业名单（截至 2021 年 9 月 13 日）

齐鲁制药集团有限公司	上海药明康德新药开发有限公司
江苏先声药业有限公司	昆翎医药
上海复星医药（集团）股份有限公司	中国药科大学
中国医学科学院药物研究所	首都医科大学附属北京天坛医院
绿叶制药集团有限公司	武汉禾元生物科技股份有限公司
成都康弘药业集团股份有限公司	荣昌生物制药（烟台）股份有限公司
中国科学院上海药物研究所	正大天晴药业集团股份有限公司
江苏恒瑞医药股份有限公司	天境生物科技（上海）有限公司
天士力生物医药股份有限公司	深圳晶泰科技有限公司
上海医药集团股份有限公司	缔脉生物医药科技（上海）有限公司
北京协和医院	太极集团有限公司
百济神州	和铂医药
四川科伦药业股份有限公司	深圳君圣泰生物技术有限公司
信达生物制药	北京康辰药业股份有限公司
上海君实生物医药科技股份有限公司	成都苑东生物制药股份有限公司
深圳微芯生物科技有限公司	上海艾力斯医药科技股份有限公司
再鼎医药	药渡经纬信息科技（北京）有限公司
上海复宏汉霖生物技术股份有限公司	宝石花医药科技（北京）有限公司
歌礼制药有限公司	北京科信必成医药科技发展有限公司
前沿生物药业（南京）股份有限公司	科望（上海）生物医药科技有限公司
三生制药集团	深圳市高特佳投资集团
北海康成制药有限公司	亿一生物制药（北京）有限公司
北京泰德制药股份有限公司	苏州开拓药业股份有限公司
珐博进（中国）医药技术开发有限公司	上海立迪生物技术股份有限公司
南京圣和药业股份有限公司	上海艾迈医疗科技有限公司
中天（上海）生物科技有限公司	来凯医药
基石药业（苏州）有限公司	上海盟科药业股份有限公司
华领医药技术（上海）有限公司	润东医药研发（上海）有限公司
亚盛医药	厦门艾德生物医药科技股份有限公司
北京加科思新药研发有限公司	博远资本
和记黄埔医药（上海）有限公司	礼来亚洲基金
红杉资本	应世生物科技（上海）有限公司
倚锋资本	北京五和博澳药业股份有限公司
上海醴泽投资管理有限公司	亚宝药业集团股份有限公司

参会企业名单（截至 2021 年 9 月 13 日）

远大医药（中国）有限公司	上海华平投资咨询有限公司
嘉和生物	台州市椒江区人民政府驻京招商（引才）办
罗欣药业（上海）有限公司	台州市驻京联络处外联处
鲁南制药集团股份有限公司	台州市黄岩驻京招商办
德福资本	辉诺生物医药科技（杭州）有限公司
琅钰集团	重庆太极实业（集团）股份有限公司研究院
江苏亚虹医药科技股份有限公司	北京东方略生物医药科技股份有限公司
维昇药业（上海）有限公司	天津药物研究院有限公司
君合律所	澳大利亚维多利亚州政府
山东博安生物技术有限公司	海正药业
中山医诺维申新药研发有限公司	上海药明生物技术有限公司
北京神经外科研究所	四川辉阳生命工程股份有限公司
科伦药物研究院	北京步长新药研发有限公司
美柏医健	昆翎企业管理（上海）有限公司
美柏资本	北京无疆脑智科技有限公司
华东医药股份有限公司	艾社康（上海）健康咨询有限公司
深圳大学医学部	晖致医药有限公司
哈尔滨三联药业股份有限公司	双运生物医药科技苏州有限公司
西安美柏医疗科技有限公司	艾昆纬医药科技（上海）有限公司
浩悦资本	深圳红土医疗健康产业股权投资基金合伙企业
汉坤律师事务所	财达资本管理有限公司
国药中金（上海）私募股权投资管理有限公司	广州海汇投资管理有限公司
东曜药业有限公司	北京茂榕投资有限公司
领中资本	杭州三花弘道创业投资合伙企业
上海国际股权投资基金协会	杭州民生医药控股集团有限公司
海南海药股份有限公司	杭州民生药业股份有限公司
百试达（上海）医药科技股份有限公司	斯之道（上海）企业管理咨询有限公司
桥麦资本	科越医药
科睿唯安	NEJM 医学前沿
毕马威华振会计师事务所（特殊普通合伙）上海分所	中国医学科学院北京协和医学院药物研究所
复星恒利证券有限公司	迈威生物
上海枢境生物科技有限公司	合一生技股份有限公司
上海联新资本管理有限公司	绿叶生命科学集团
依生生物	广东粤港澳大湾区国家纳米科技创新研究院
毅达资本	信成基金
蚂蚁集团	中国医学科学院医药生物技术研究所
瑞脉医疗集团	湖南海捷投资有限公司
拜耳医药保健	默沙东研发（中国）有限公司

参会企业名单（截至 2021 年 9 月 13 日）

上海金景投资管理咨询有限公司	康龙化成（北京）新药技术股份有限公司
重庆市医药保健品进出口有限公司	美国华平投资集团
浙江新码生物医药有限公司	澳门大学
江苏高科技投资集团有限公司	江苏柯菲平医药股份有限公司
苏州工业园区元禾原点创业投资管理有限公司	上海泉生生物科技有限公司
北大未名（合肥）生物制药有限公司	瓴路药业（上海）有限责任公司
英派药业	南方科技大学
国寿股权投资有限公司	上海隆耀生物科技有限公司
百奥赛图（北京）医药科技股份有限公司	苏州方德门达新药开发有限公司
云南沃森生物技术有限公司	加拿大西安大略大学中国技术转移中心
上海科技创业投资（集团）有限公司	澳大利亚新南威尔士州政府贸易与投资办事处
西安力邦联盟医疗投资管理有限公司	锐得麦医药
郑州安图实业集团股份有限公司	广州汉光药业股份有限公司
杭州优思达生物技术有限公司	澳大利亚贸易投资委员会
礼新医药科技（上海）有限公司	上海遵理投资管理有限公司
华控基金	武汉华纪元生物技术开发有限公司
洲嶺资本	西班牙加泰罗尼亚自治区企业发展局北京办事处
北京华控投资顾问有限公司	四川三叶草生物制药有限公司
昆拓信诚医药研发（北京）有限公司	生命奇点（北京）科技有限公司
艾瑞嘉医药研发（上海）有限公司	应世汇康（北京）生物科技有限公司
北京普祺医药科技有限公司	博雅辑因
雷诺丽特北京医疗健康事业部	深圳瑞健同壹生物技术有限公司
赛生药业控股有限公司	国信医药科技（北京）有限公司
浙江汉博投资管理有限责任公司	香港维健医药集团有限公司
派格生物医药（苏州）股份有限公司	四川九章生物科技有限公司
赛雷纳（中国）医疗科技有限公司	北京星亢原生物科技有限公司
苏州纳生微电子有限公司	寻常投资
翼帆数字科技（苏州）有限公司	江苏苏中药业研究院有限公司
浙江瑞华康源科技有限公司	深圳市臻络科技有限公司
正大制药集团	江苏普莱医药生物技术有限公司
瑞石生物医药	曙方医药
荣盛（厦门）投资有限公司	诺华（中国）生物医学研究有限公司
北京银河吉星创业投资有限责任公司	长沙迈吉尔医疗科技有限公司
江苏秉华健康科技有限公司	上海创瑞投资集团
勤浩医药（苏州）有限公司	上海湃隆生物科技有限公司
上海银诺医药技术有限公司	上海碧博生物医药工程有限公司
北京厚新投资管理有限公司	成都埃微路新生物技术有限公司
中关村股权投资协会	苏州博腾生物制药有限公司

参会企业名单（截至 2021 年 9 月 13 日）

上海半洲企业管理咨询有限公司	杭州阿诺生物医药科技有限公司
江苏丰华生物制药有限公司	易贸医疗
艾康特医疗科技有限公司	易企说 17Talk
中国医药企业管理协会	每日经济新闻
天津贝罗尼生物科技有限公司	华夏时报社
艾贝乐医药科技有限公司	杭州科畅科技信息咨询有限公司
香港生物节律研究院有限公司	中国证券报
和医医药（中国）有限公司	财新传媒
北京海洁海斯健康科技有限公司	证券日报
深圳瑞思普利生物制药有限公司	时代周报
杭州维坦医药科技有限公司	杭州市萧山区投促局
苏州欧赛微科生物医药科技有限公司	万新医药科技
上海宇道生物技术有限公司	亿帆医药
宁波圣健生物医药科技有限公司	鑫智谷（上海）科技发展有限公司
极目峰睿（上海）生物科技有限公司	长安私人资本
南京市第一医院	南京鹰盟投资管理中心（有限合伙）
上海璃道医药科技有限公司	薄荷天使基金
苏州澳宗生物科技有限公司	施维雅（天津）制药有限公司
贝尔克斯生技股份有限公司	花旗银行（中国）有限公司上海分行
复旦大学附属肿瘤医院	无锡智康弘义生物科技有限公司
徐诺药业（南京）有限公司	横琴金投产业投资基金管理有限公司
南京宁丹新药技术有限公司	苏州协耀投资管理有限公司
江苏领航生物科技有限公司	知中投资
远大医药健康控股有限公司	泰合资本
北京卓凯生物技术有限公司	江苏建设集团
江苏新元素医药科技有限公司	昆药集团
浙江九洲药业股份有限公司	扬子江药业集团上海海尼药业有限公司
广州嘉越医药有限公司	和其瑞医药（南京）有限公司
成都惠泰生物医药有限公司	深圳信立泰药业股份有限公司
苏州青云瑞晶生物科技有限公司	苏州晶云药物科技股份有限公司
璧辰（上海）医药科技有限公司	苏州工业园区管委会
上海柯西医药科技发展有限公司	苏州维力医疗科创园
维亚生物（上海）科技有限公司	苏州工业园区科技招商中心
启德医药科技（苏州）有限公司	爱科百发
苏州聚明投资管理合伙企业（有限合伙）	甘李药业股份有限公司
招商局健康产业控股有限公司	上海美迪西生物医药股份有限公司
上海倍勘生物技术有限公司	呈益投资
财经网	复星医药产业发展有限公司

华泰证券

领先的科技驱动型证券集团

华泰证券是一家领先的科技驱动型证券集团，以领航业界的数字化平台，为个人和机构客户提供专业的财富管理、投资银行、投资管理等金融服务，主要财务和业务指标稳居中国证券业前列，致力于成为兼具本土优势和全球影响力的一流投资银行。

公司前瞻把握新经济崛起和注册制改革机遇，深度聚焦科技创新与实体产业，通过投行、投资、研究等全业务链联动和境内外一体化协作，为客户提供全产品、全周期、跨市场的综合服务，在大健康领域已形成鲜明品牌和广泛影响力。

投资银行业务领航业界

No.1
并购重组
2021年至今监管审核过会的并购重组交易数量及金额均位居行业**第一**

No.2
科创板
2021H1科创板受理及过会家数位居行业**第二**

No.3
股权主承销
2021H1股权主承销项目数量、规模均位居行业**第三**

No.3
债券主承销
2021H1债券主承销项目数量、规模均位居行业**第三**

打造市场标杆 与优质企业建立长期战略合作

药明康德A+H股两地上市及多次再融资
A股首例医疗健康行业中概股回归

迈瑞医疗IPO
A股医疗器械行业市值最高

爱尔眼科产业并购
先后助力爱尔眼科非公开发行收购9家眼科医院、发股收购30家眼科医院

华熙生物IPO
科创板生物科技行业市值第一

跨境一体化 面向全球整合资源

天境生物美股IPO
被纳入富时全球股票指数系列成分股的创新生物药公司

荣昌生物港股IPO
联交所18A章有史以来最大的生物科技公司IPO项目（不含二次上市）

沛嘉医疗港股IPO
中国经导管瓣膜治疗医疗器械市场及神经介入手术医疗器械市场中的领先国内参与者

海吉亚医疗港股IPO
国内最大肿瘤医疗服务集团

* 以上案例排序不分先后。

扫码了解华泰证券

先声药业 Simcere

让患者早日用上更有效药物

Providing Today's Patients with Medicines of the Future

先声药业（2096.HK）是一家正在快速向创新与研发驱动转型的制药公司，获科技部批准建设“转化医学与创新药物国家重点实验室”。公司聚焦肿瘤、中枢神经和自身免疫三大疾病领域，致力于让患者早日用上更有效药物。凭借优异的研发与商业化能力，其主要产品在中国保持领先的市场份额。自主研发与合作研发双轮驱动，与多家跨国公司和生物技术企业成为战略合作伙伴，促进全球生命科学成果在中国的价值实现。

拥有40+已上市产品组合

肿瘤疾病产品 ONCOLOGY PRODUCTS	恩度 ENDOSTAR	捷佰舒 Jepaso	培美纳 Pemetrexed	中人氟安 Sinofuan	EnLength 恩立施	
中枢神经系统疾病产品 CENTRAL NERVOUS SYSTEM PRODUCTS	先必新	必存	安可欣 盐酸曲唑酮片			
自身免疫疾病产品 AUTOIMMUNE PRODUCTS	Iremod 艾得辛	恩瑞舒	艾捷维	英太青		
心血管疾病产品 CARDIOVASCULAR DISEASES PRODUCTS	复傲坦	舒夫坦 Softan	欣他			
抗感染产品 ANTI-INFECTIVE PRODUCTS	安信 Newanti	再立克	也青	安奇	再林	再克	力宏
其他领域产品 OTHER THERAPEUTIC AREAS PRODUCTS	必奇	诺威	结敏	先声咳喘宁	法能 Alfacan	欧迪佳	顶安

声明：处方药需经专业医师处方指导使用。
产品详细信息一律以产品包装内附的说明书为准。

全球研发布局


南京研发中心


上海创新中心


波士顿创新中心


获国家科学技术部批准建设
转化医学与创新药物国家重点实验室

先声药业集团有限公司
Simcere Pharmaceutical Group Limited

No. 699-18, Xuanwu Avenue, Nanjing, 210042
+86 25 8556 6666
www.simcere.com

西安杨森制药有限公司
Xian Janssen Pharmaceutical Ltd.

西安杨森 xian janssen

西安杨森助力建设健康中国

作为最早进入中国的跨国制药公司之一，西安杨森始终践行改变人类健康发展轨迹的使命。我们的长期发展战略与**“健康中国”**战略完全一致，那就是为改善患者生命提供可及和全面的疾病解决方案，我们坚持关键要素：**一是对中国坚定不移的承诺，二是优先开展可及的创新。**

扎根中国

1. 我们致力于继续与中国的合作，助力中国转变为全球创新强国。

2019年6月，公司斥资约4亿美元在西安建设的创新供应链生产基地正式投产。

2.西安杨森大力支持健康中国-基层健康服务团队能力建设

2021年，西安杨森支持健康中国行动推进委员会办公室，实施扩大基层卫生服务队伍，支持基层医疗机构能力建设和常见病诊疗能力提升，改善服务质量，整合公共卫生服务资源，从而提高居民健康素养，延长居民预期寿命，助力实现“健康中国2030”规划。预计在2021年系列项目惠及基层卫生人员以及计生协工作者骨干会员等约**50000人**。该工作从2021年开始将在中国开展**10年**。

3. 吴阶平医学研究奖-保罗·杨森药学研究奖（简称“吴杨奖”）

1994年，西安杨森与国家卫生健康委国际交流与合作中心共同设立了“吴杨奖”。截至2020年，“吴杨奖”已组织二十一届评选，共有434位杰出学者获得这一荣誉，其中14位获得特殊贡献奖。“吴杨奖”已成为中国医药卫生领域最具影响力的奖项之一。

创新助力健康中国建设

我们致力于积极改变人类健康发展轨迹，利用尖端技术和设备以及世界一流的研发能力，加快中国的创新步伐，以满足患者迅速变化的需求。

1.西安杨森是中国抗击耐多药肺结核（MDR-TB）的坚定伙伴，支持中国实现“终结结核2035”的目标。2016年，我们向中国引进了一种创新的结核病解决方案，这是40多年来中国批准的第一款新型抗结核病药物。

- 我们还致力于帮助筛查饱受困扰的结核病患者。与多方力量合作，实施结核病新药引进和保护（NDIP）项目，以提高治疗的可及性，并帮助培训医务人员。

NDIP 新药引入和保护项目 New Drug Introduction & Protection

2.还致力于改善中国的精神卫生水平，这也是“健康中国”战略规划的一个重点。西安杨森自从1997年推出第一款治疗精神分裂症的产品以来，持续不断为中国患者带来各种创新的疾病解决方案。除了为精神分裂症患者提供创新的长效治疗方案（LAT）外，我们还支持创新LAT医院-社区综合治疗低自付模式，迄今为止，惠及超过8000名精神分裂症患者和他们的家庭。

3.我们一直致力于提供变革性疗法，解决中国患者未满足的医疗需求。近年来，我们在中国上市或获批了多种创新的药物和新适应症，用于满足中国急需的医疗需求。

4.我们从未止步，不断为患者提供更多的端到端服务，为患者定制解决方案，以优化患者在治疗过程中的体验。我们的患者支持计划（PSP）包括在线咨询和患者教育计划等。

5.乘着“互联网+医疗”战略的“东风”，以政府指导为“罗盘”，我们通过开展开放式创新来探索基于互联网的患者服务。通过合作，我们希望创建一个新的、灵活的、数字化的线上线下生态系统，让患者和医疗保健专业人士能够随时随地获得更好的医疗和疾病解决方案。

展望未来，西安杨森致力于与中国政府合作，助力落实“十四五”规划，强化卫生健康系统并提高创新和变革性技术的可及性，为中国人民带来更多健康福祉，助力全民健康，实现“健康中国2030”中国梦。

西安杨森制药有限公司简介

作为首批进入中国的跨国制药企业之一，西安杨森自1985年在华成立以来，始终致力于研发、引进和生产高质量的药品和创新健康解决方案，以满足中国不断增长的医药卫生需求。作为强生在华制药子公司，西安杨森聚焦能够为人类健康带来巨大改变的六大疾病领域：肿瘤学、免疫学、传染病和疫苗、神经科学、心血管与代谢以及肺动脉高压。

截至目前，我们已经在全国29个城市设有办事处，拥有员工近3000人，以公司信条和关爱精神为本，建立可持续的人才培养体系，帮助员工实现多元化价值和发展。

肿瘤学　免疫学　传染病与疫苗

神经科学　心血管与代谢　肺动脉高压

齐鲁制药
QILU PHARMACEUTICAL

齐鲁制药集团是中国大型综合性现代制药企业，主要从事肿瘤、心脑血管、感染、精神系统、神经系统、眼科疾病的制剂及原料药的研制、生产与销售，集团多年跻身中国医药工业百强榜十强。齐鲁制药集团始终秉持“大医精诚 家国天下”的核心价值观，坚持产业报国，大力实施“创新驱动”与“国际化”两大战略，坚定走高质量发展道路，不断满足临床未满足用药需求、提高药品可及性，为人类健康保驾护航。

创新驱动，用科技表达我们的爱

齐鲁制药集团始终坚持创新驱动战略，47个药物国内首家或独家上市，5个药物荣获国家科技进步二等奖。集团建立了中美联动的五大研发平台，持续开发“全球新”“全球好”药物，目前在研创新药物项目近60项，涵盖临床未被满足重大疾病治疗领域，未来数年内，将有多个创新药物研发上市。

全球五大创新中心分布图

国际视野，迈向世界医药产业价值链最顶端

齐鲁制药集团引进了国际一流的生产设备、检测仪器和技术，建立了与国际接轨的完善质量保证体系，是国内首家通过美国FDA、欧盟EDQM、英国MHRA无菌产品认证企业；产品出口全球80多个国家和地区；集团是国内唯一一家同时向欧、美、英、日、澳大利亚法规市场出口制剂的药企，18个产品在当地的市场占有率第一；是国内首家对日本出口商业化包装注射剂产品的企业，迄今实现17个制剂产品对美出口，10个产品出口欧洲；头孢系列、巴坦系列等12个人用原料药全球市场占有率第一。

8626亩 十大生产基地

12家 集团下设子公司

80多个国家和地区 产品出口全球

品质至上，做人类健康的坚实守护者

齐鲁制药集团产品结构科学完整，具有治疗领域广、产品系列化特点。30多个制剂产品国内市场占有率第一，在研产品200余个，涉及抗肿瘤、心脑血管、精神、神经系统等重大疾病领域。集团一致性评价获批数量、首家数量均位居行业第一位，87个已获批通过，其中37个为国内首家。每年全球约10亿患者使用齐鲁好药。



用科技表达我们的爱
CARING THROUGH SCIENCE & TECHNOLOGY

WARBURG PINCUS
华平投资

企业家成长伙伴

了解更多信息
请扫描二维码

华平投资是中国医疗健康产业最大、最活跃的投资机构之一，拥有近 20 年投资经验，已累计对中国 20 多家医疗健康企业投资超过 130 亿人民币。华平投资长期重点关注和布局创新药和医疗器械的技术创新、医疗服务升级以及分销和零售渠道整合等领域。

50+ 年	20 年	130+ 亿元	6000+ 亿元
全球医疗健康投资经验	中国医疗健康投资经验	中国医疗健康产业累计投资金额	被投企业总市值

所有数据更新于 2021年6月

医疗健康领域中国部分被投企业

锦欣生殖 JINXIN FERTILITY
HYGEIA 海吉亚医疗
amcare 美中宜和医疗集团
药明康德 WuXi AppTec
Insilico Medicine
海和药物 HaiHe Pharmaceutical
Abbisko 和誉
高视 GAUSH
伊美尔 EVER CARE
angelalign 时代天使
HTDK 华瑭大昌
CTBB 泰邦生物
乐普医疗 LEPU MEDICAL

www.warburgpincus.com.cn

bioBAY

创业人才 / 企业故事 / 政策解读 / 融资上市 / 精品会议

中国最具有创新力的生命科学故事，都在这里。

宝石花医药科技（北京）有限公司由宝石花医疗集团与安欣泰（北京）医院管理有限公司合资组建。

宝石花医疗集团旗下拥有全资及控股子公司38个，集团所属医疗机构共计174家，其中三级医院7家，二级医院18家，一级医院21家，社区卫生服务中心28家，社区卫生服务站、门诊部100家，总床位数10522张，年门诊量800万人次，年住院量30万人次。

安欣泰（北京）医院管理有限公司由中国科学院院士葛均波和中国医药创新促进会会长宋瑞霖创立，专家资源雄厚。

宝石花医药科技致力于打造全新、高效，以患者为中心，以数据为驱动，赋能人工智能机器学习的开放式一体化临床研究及成果转化综合服务平台。

业务板块

1

健康受试者研究--2个I期临床研究中心，5400㎡，178张床位

2

肿瘤早期研究--与上海东方医院建立战略合作，作为卫星中心参与

3

顶层研究设计--为创新药早期研究提供研究策略咨询服务

4

外院随访--基于宝石花所属医院地域优势为临床研究受试者提供外院随访

5

真实世界研究—基于宝石花医疗集团170多家医院数据资源优势开展各种类型研究

6

临床研究项目管理--为申办方协调各方资源、协助运营临床研究项目，保障项目的质量及进度

联系我们

地　　址：北京市东城区东四十条甲22号南新仓商务大厦A706

联系电话：010-67013860

业务联系：商务部总监 余耀武 18601301790